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ABSTRACT OF THE DISSERTATION 




Doctor of Philosophy in Biology and Biomedical Sciences 
Computational and Systems Biology 
Washington University in St. Louis, 2016 
Associate Professor Li Ding, Chair 
Cancers, including hematologic malignancies, arise as a result of the stepwise accumulation of 
mutations. Some early mutations that potentially initiate clonal expansion might exist in patients 
many years before they develop obvious disease symptoms. Therefore, identifying and 
characterizing these early mutations are critical to understanding the genetic basis of 
tumorigenesis. Here, we analyzed blood-derived DNA sequencing data from 2,728 individuals 
without apparent hematologic malignancies and identified 77 blood-specific mutations in 31 
cancer-associated genes. Importantly, 83% of all mutations occurred in 19 genes that have been 
previously linked to hematological malignancies, such as DNMT3A, TET2, JAK2, and ASXL1. 
By investigating these mutations in different hematologic diseases, we identified several 
recurrently mutated genes that may be disease initiators. To obtain more comprehensive profiling 
of genes and variants associated with clonal hematopoietic expansion, we processed an 
additional 3,221 normal blood samples from The Cancer Genome Atlas (TCGA) and developed 
a statistical approach to systematically identify blood-specific mutations in all human genes. 26 
genes were significantly mutated in human blood samples, including PPM1D. Functional 
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validation showed that PPM1D mutations suppressed the phosphorylation of TP53 at Ser15, 
suggesting that the blood-specific mutants in PPM1D retain its phosphatase activity in regulating 
TP53. We also characterized rare copy number variations (CNVs) in blood samples and 
discovered about half of the individuals examined carried rare somatic CNVs in their blood. 
Some of these CNVs were associated with genes involved in hematological malignancies, such 
as JAK2, ASXL1, and FLT3. In summary, we systematically identified early genomic alterations 
in normal blood cells by utilizing the large-scale sequencing data and further determined the 
functional impact of the mutations in the recurrently mutated gene. Our comprehensive analysis 
of blood-specific genomic alterations will shed light on understanding the complex mechanisms 
of hematologic malignancies and also facilitate the development of more efficient strategies for 





Chapter 1: Introduction to Cancer Genomics 
Cancer is a leading cause of death worldwide. According to the International Agency for 
Research on Cancer, there were 14.1 million new cancer cases and 8.2 million cancer-related 
deaths in 2012 [1]. Furthermore, as a result of the growing and aging human population, the 
number of annual cancer cases is expected to double in the next two decades [1]. The majority of 
cancer cases are sporadic, caused by exposure to various carcinogens, such as radiation, chemical 
mutagens, or viral/bacterial infections. However, approximately 5–10% of cancers are inherited 
[1].  
Cancer is “a disease of the genome.” Scientists first realized the role of the genome in cancer 
development in the early twentieth century when Theodor Boveri proposed that cancers are 
caused by chromosomal abnormalities [2]. This groundbreaking hypothesis was proven in the 
1970s by the discovery of the Philadelphia Chromosome and the identification of the BCR–ABL 
fusion gene in chronic myelogenous leukemia [3, 4].  
Because cancer is attributed to genomic alterations in cells, it is essential to identify the genes 
that tend to accumulate mutations during cancer development. Based on their effects on 
tumorigenesis, cancer-associated genes are classified into two categories: oncogenes and tumor 
suppressor genes. In 1979, src was identified as the first oncogene in a chicken retrovirus, which 
induces tumors in connective tissues, such as bone and muscle, of infected animals [5]. Five 
years later, the first tumor suppressor gene, RB1, was discovered in the retinoblastoma studies  
[6]. Unlike oncogenes, where a genetic alteration on a single allele can lead to cellular 
transformation, the inactivation of tumor suppressor gene requires genetic silencing of both 
alleles, which is so-called “two-hit hypothesis,” proposed by Knudson [7].  
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After decades of study, many important discoveries in cancer research have been achieved by 
traditional molecular analysis. However, due to the complex pathophysiology, it is very difficult 
to comprehensively study cancer progression by relying on traditional approaches alone. The 
Human Genome Project opened up new avenues for cancer research, leading biologists to realize 
that the complete sequencing of the cancer genome would be a superb way to systematically 
study genes and mutations involved in cancer development. Based on this idea, the first cancer 
genome from a patient with acute myeloid leukemia was decoded in 2008 [8]. Since then, the 
number of sequenced cancer genomes has grown exponentially. By 2015, more than 8,000 cases 
across various cancer types were sequenced and analyzed by TCGA, the majority of which are 
high-coverage whole exome sequencing data [9, 10]. The ubiquity of these data has spurred 
active research in multiple areas, including identification of novel pathogenic somatic mutations, 
detection of germline cancer susceptibility variants, and cancer evolution. These studies have 
provided significant insights into the characterization of the mutational landscape within the 
cancer genome and the understanding of the mechanisms underlying tumorigenesis. These 
advancements are expected to facilitate the development of novel strategies for cancer diagnosis, 
prevention, and treatment. Although cancer genomic studies have made remarkable progress, 
some key challenges still need to be addressed, as discussed below. 
1.1 Mutation landscapes in cancer genomes 
1.1.1 Mutational heterogeneity in cancer  
Although cancers are caused by the genomic mutations, the patterns of mutations are divergent, 
both mutation frequency and spectra varying substantially across cancer types, among 
individuals with the same cancer, and even within a single cancer genome, which indicates 
cancer heterogeneity [9-12].  
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First, mutation frequency varies in different cancer types, averaging from 0.1 events per Mb in 
pediatric cancers or adult leukemia to more than 10 events per Mb in melanoma and lung cancers 
[9, 10]. This difference can be partly explained by the divergent mutagenic mechanisms 
underlying each cancer type.  For example, pediatric cancers often occur in tissues that have 
fewer cell divisions. As a result, there is less time for mutations to accumulate. While melanomas 
and lung cancers are primarily induced by chronic exposure to well-known carcinogens, such as 
ultraviolet (UV) radiation and tobacco smoke, leading to extremely high mutation rates in skin 
and lung tissue.  
Mutation frequency also varies substantially among individuals with the same cancer type. 
Remarkable example can be seen in lung cancer and leukemia. In lung cancer, the median 
frequency of non-synonymous mutations varies by more than 1,000-fold across the entire lung 
cancer cohort, ranging from 0.1 to 100 mutations per Mb [10]. Similarly, although leukemia 
exhibits fewer mutations, the mutation frequency in the entire leukemia cohort also spans three 
orders of magnitude (from 0.01 to 10/Mb per individual), as lung cancer does [10].  
Moreover, at the single cancer genome level, the mutation frequency also appears to be divergent 
across the genome, correlated with transcription level and DNA replication timing [11, 12]. 
Specifically, late-replicating and low-expression regions, such as intergenic and non-coding 
regions, tend to have much higher mutation rates than the early replicating and actively 
transcribed regions due to depletion of the pool of free nucleotides and transcription-coupled 
repair, respectively [10-12].  
In addition to mutation frequency, mutation spectra also vary in different cancer types [9, 10]. 
Skin cancers show a distinct pattern of C->T mutations, which is caused by misrepair of UV-
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induced covalent bonds between adjacent pyrimidines [9, 10]. Lung cancer is the most common 
cancer caused by smoking.  Correspondingly, C->A transversion, a signature of tobacco smoking 
exposure, is dominant in lung cancer patients’ genomes [9, 10]. In addition, bladder, cervical, 
and head and neck cancers usually show frequent C->T or G->A mutations, possibly due to off-
target modification of DNA by the APOBEC family of cytidine deaminases [10, 13].  All of 
these observations suggest that the study of mutation spectra could facilitate understanding of 
specific tumor etiology.   
Mutational heterogeneity is a hallmark of cancer. To some extent, mutational heterogeneity 
reflects the diversity and complexity of cancer. Divergent mutation patterns conceal the key 
mechanisms underlying tumorigenesis and make it difficult to determine the potential targets for 
directed therapies. Large-scale cancer genome sequencing studies have provided an enormous 
amount of information on the genomic alterations in a variety of human cancers, which has 
sharply improved our understanding of the genetic basis for cancer. However, the unexpectedly 
large number of mutations detected in human cancers also dramatically increases the difficulty in 
identifying the critical genes or mutations that cause cancer initiation, progression, and 
metastasis.    
1.1.2 Passenger and driver mutations in the cancer development 
Cancer is caused by genomic alterations, but not all alterations present in the cancer genome 
promote tumorigenesis. According to their roles in tumor growth, alterations can be categorized 
as “drivers” or “passengers.” The majority of alterations in cancer genome are incidental 
“passengers”—they have no effect on tumorigenesis. On the other hand, the “driver” mutations 
are under positive selection during cancer progression and constantly confer a growth advantage 
to the cancer cells [9, 10, 14]. 
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In comparison to passenger mutations, the number of driver mutations is extremely small. It is 
estimated that 2 to 7 driver mutations are sufficient to convert a normal human cell to a 
malignant cell [9, 15-16]. Given the importance of driver mutations in cancer development, 
distinguishing them from passenger mutations has been a central goal of cancer research for 
years. At present, more than 600 genes have been discovered in several large-scale cancer 
genomic studies, with substantial evidence showing that their mutations are associated with 
cancer progression, and many of these genes are transcription factors, protein kinases, cell cycle 
regulators, or DNA/histone modifiers [9, 10, 17-19]. Some of these genes are commonly mutated 
in several cancer types. For example, TP53, an essential gene in the cell cycle regulation 
pathway, was mutated in about half of all cases in certain studies, especially in serous ovarian 
(95% of cases) and serous endometrial carcinomas (89% of cases) [9, 17]. Genes in the classical 
PI3K signaling pathway, including PIK3CA, PTEN, PIK3R1, TLR4, PIK3CG, and AKT1, are 
also frequently mutated in most cancer types, such as breast cancer, endometrial cancer, head 
and neck cancer, and glioblastoma multiforme [9]. Also, some drivers show tumor-type 
specificity. For example, APC is a well-known tumor suppressor gene, whose mutations 
predominate in the colon and rectal carcinoma [9], as well as VHL in kidney cancer [9, 17].  
The analysis of driver mutations is critical for understanding the molecular mechanisms of 
tumorigenesis and the identifying of therapeutic targets. However, the role of mutations as 
passengers or drivers is not immutable. Sometimes, due to cancer treatment or changes of 
microenvironment, a passenger mutation can become a driver mutation and confer resistance to 
the selective pressure, expanding at relapse or growing in new sites [20]. Therefore, the 
identification of driver mutations is still of primary importance for cancer genomic study.  
6 
 
1.2 The heritability of cancer 
1.2.1 Hereditary cancer syndromes 
The majority of cancer cases are sporadic, however, some common cancers, including breast, 
ovarian, colorectal, and prostate cancers, exhibit clear family aggregation patterns, showing 
cancer more frequently occurred in family members at an earlier age than in the general 
population [21-24]. Based on monozygotic twins studies, the family aggregation of cancer is 
believed to be primarily caused by inherited genetic factors instead of shared environmental 
factors [21, 22].  
It is estimated that at least 5%-10% of all cancers are inherited. Based on the two-hit hypothesis 
[7], a person with an inherited mutation obtain one copy of an abnormal gene passed from their 
parents, where another copy of the functional gene could be inactivated with a high chance 
during cell division by random processes, such as DNA mismatch, chromosome rearrangement, 
deletion, or insertion. Therefore, they are much more likely to develop cancer at an early age. 
However, for individuals without inherited mutations, two mutations, one in each allele of the 
gene, need to be accumulated in the same cell, and this process could take much longer. 
Hereditary cancers often show different features from sporadic cancers. First, several family 
members tend to have the same or similar cancers at an earlier age. Second, cancer is more likely 
to develop in more than one place in the body. For example, patients with germline pathogenic 
variants in BRCA1 or BRCA2 have high risk of developing breast and ovarian cancers, as well as 
the other cancer types, such as prostate, pancreatic, and melanoma at an earlier age [25-28]. 
Meanwhile, they also have much higher risk for cancer recurrence than the general population. 
This phenomenon is “hereditary breast and ovarian cancer syndrome (HBOC)”. For HBOC 
individuals, the lifetime risks for developing breast and ovarian cancers are 55%-85% and 25%-
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45%, respectively, while for the general population, the corresponding risks are much lower, 
only 12.3% and 1.3%, respectively [29, 30]. A similar phenomenon is also found in Lynch 
syndrome, often called hereditary nonpolyposis colorectal cancer (HNPCC) [31].  
1.2.2 Cancer predisposition genes and variants 
In the past 30 years, many inherited loci and genes have been identified as high-risk candidates 
associated with cancer predisposition by family-based studies and genome-wide association 
studies (GWAS) [32-42]. However, these candidates can only explain a small proportion of the 
cancer heritability, which leaves a door open for many more candidates to be discovered. 
Since GWAS primarily focuses on identifying common disease risk-associated variants, 
typically with a minor allele frequency (MAF) > 1%, it is reasonable that rare variants could 
have the potential to explain additional disease risk. On the other hand, based on the theory of 
evolution, disease-associated variants are likely to be rare as a result of negative selection. 
Therefore, the hypothesis that many more unknown rare variants may contribute to the missing 
heritability in cancer has been commonly accepted.  
Based on current studies, there are two types of rare variants associated with cancer 
predisposition. The first type of rare variant has high penetrance to disease, and their frequencies 
are very low in the population, most often less than 0.1%. Such would include, for example, 
pathogenic variants in BRCA1 [34], BRCA2 [35], APC [36], TP53 [37], and some mismatch 
repair genes, such as MSH2 [38], MLH1 [39]. Individuals with relevant variants in these genes 
have a much higher risk of developing cancer. Another type of rare variant, with frequencies 
ranging from 0.1% to 0.5%, have moderate penetrance to disease, but their combined effects can 
be sufficient to cause cancer progression. For example, genes in a common pathway (e.g., DNA 
damage checkpoint or repair pathways), such as CHEK2, BRIP1, and PALB2, have been reported 
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to carry moderate-effect rare variants that are associated with breast cancer predisposition [40-
42]. 
A rapidly growing number of publicly available deep-coverage exome sequencing data is a 
valuable resource for the study of rare germline cancer susceptibility variants [43-45]. Kanchi et 
al. analyzed 429 whole exome sequencing data from TCGA serous ovarian cancer patients and 
detected 3,635 high confident, rare (<1% MAF in the population and cohort) truncations and 
22,953 missense variants with predicted functional impact [45]. By comparing the frequency of 
germline variants with healthy control data, several novel candidate germline susceptibility 
variants in known ovarian genes (such as BRCA1, BRCA2, ATM [46], and PALB2), as well as 
several genes not previously associated with ovarian cancer (such as, ASXL1, RB1, NF1, 
CDKN2A and EXO1), were identified [45]. This investigation established a foundation for future 
susceptibility variants studies in other cancer types.  
Large-scale sequencing data hold great promise for rare cancer susceptibility variant discovery. 
However, to determine the effect of candidate variants and genes prioritized by sophisticated 
computational filtering strategies, the replication in additional datasets and extensive 
experimental functional validation are essential. 
1.3 The evolution of cancer  
1.3.1 Model of cancer evolution 
Cancer progression is a complex, dynamic, and cumulative process that involves stages of cancer 
initiation, invasion, and metastasis. The first landmark perspective on cancer progression took 
place in 1976 when Peter Nowell proposed that cancer is a clonal disease restricted by Darwinian 
evolution [47]. Based on this theory, the typical view of cancer progression can be characterized 
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as successive waves of clonal expansion, in which clones with the best growth advantage 
(evolutionary fitness) arise from a small subclone to become a dominant clone, giving rise to 
disease relapse and metastasis.  
Intra-tumor heterogeneity is central to cancer evolution, as it provides a pool of genetic variants 
that can be used for selection, increasing the probability of a subclone with a fitness advantage 
existing in the cell population. On the other hand, environmental factors, such as tumor 
microenvironment, carcinogenic exposures, and cancer treatments, provide selective pressures to 
guide the evolutionary process within a tumor and shape the clonal architecture.    
Several studies have already demonstrated clonal evolution in several common cancer types, 
such as renal carcinomas, acute myeloid leukemia, breast cancers, and glioblastoma [48-52]. 
Ding et al. studied the primary tumor and relapse samples from eight AML patients, and found 
two main clonal evolution patterns during AML relapse: either a founding clone in the primary 
tumor gained new driver mutations, or a subclone survived in cancer treatment gained additional 
mutations [48]. This study confirmed previous research on cancer evolution and enhanced the 
understanding of genetic changes acquired during AML progression and relapse.  
In another study, Nik-Zainal et al. analyzed tumor sequence data from 21 breast cancer patients, 
investigated the content of subclonal variations within the cancer samples, and examined 
mutation changes over time [51]. By reconstructing the dominant subclonal lineage during breast 
cancer development, they revealed the appearance of the most-recent common ancestor, which 
contains the full complement of somatic mutations found in all tumor cells. This study uncovered 
a new cancer evolution pattern, which is different from that observed in AML, and shed light on 
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the investigation of the mechanism of breast cancer development from breast organogenesis to 
carcinogenesis in adults. 
1.3.2 Clonal expansions in normal cells 
Current cancer genomic studies have already made substantial progress in our understanding of 
the temporal order of mutations or clonal architectures during cancer progression. However, 
many knowledge gaps still remain. For example, how normal cells obtain growth advantages 
progressively, how they initiate the clonal expansion, and how and when they break through the 
evolutionary bottleneck and eventually result in clonal dominance in the newly formed tumor. 
All of these questions remain largely unanswered.  
In adult epithelial tumors, about 5-7 driver mutations are required for cancer progression [9,14]. 
Although in hematopoietic malignancies, this number might be lower, at least two lesions are 
still needed, each belonging to a distinct allele [9, 53]. However, it is not so easy for a normal 
cell to acquire two spontaneous driver mutations on different alleles. One possible way to 
achieve that quickly is clonal expansion. When a normal cell acquires one driver mutation due to 
a random process, it obtains a growth advantage that triggers clonal expansion. Although this 
clonal expansion is not sufficient to cause cancer directly, it could expand the pool of mutated 
cell for further selection, thus increasing the chance for one mutated cell to obtain an additional 
driver mutation, and thereby contributing to cancer development when neither of them is 
sufficient to cause it alone. Therefore, measuring the genomic changes in normal tissues over 
time could help us quantify the extent of mutation and understand the dynamics of clonal 
expansion in the early stages of cancer development.  
There are two significant challenges in this study. First, based on the model of cancer evolution, 
a series of clonal expansions during cancer development is a long-term process, which usually 
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takes decades. Therefore, collecting sufficient sequencing data from normal tissues to monitor 
clonal expansion is a big challenge. Second, in the early stages of clonal expansion, the driver 
mutation is only present in a very tiny fraction of cells, making them very difficult to detect 
precisely.  However, recently, a wide variety of large-scale sequencing projects, including TCGA 
and ICGC, have generated a number of high coverage exome sequencing data in normal tissues, 
especially in blood samples, which makes the study of clonal expansion in noncancerous tissue 
feasible. Investigating clonal expansion in normal tissue will provide great insight into the 
dynamic change of genomic alterations from organogenesis to tumorigenesis, and allow us to 
better understand cancer initiation and progression. In addition, this study can also be translated 
into effective clinical strategies, helping us to promote targeted screening and preventive 
measures, and to monitor people’s health status and disease risk. 
In summary  
Cancer is a complex disease, and decades of detailed genetic research indicate that it is more 
complicated than we initially thought. Cancer genome studies so far have laid a foundation for us 
to better understand the genetic basis for cancer, which demonstrates the power of sequencing 
technology and genomic information for analyzing complex diseases.  However, we need to 
realize that the cancer study is a long path, and there is still a lot of unknown in cancer, just like 
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Chapter 2: Patterns and Functional 
Implications of Rare Germline Variants 
across 12 Cancer Types†  
2.1 Abstract 
Large-scale cancer sequencing data enable discovery of rare germline cancer susceptibility 
variants. Here we systematically analyze 4,034 TCGA cancer cases representing 12 cancer types. 
Rare germline truncations in 114 cancer-susceptibility-associated genes vary widely, from 4% 
(AML) to 19% (ovarian cancer), with a notably high frequency of 11% in stomach cancer. 
Burden testing identifies 13 cancer genes with significant enrichment of rare truncations, some 
associated with specific cancers (e.g. RAD51C, PALB2, and MSH6 in AML, stomach, and 
endometrial cancers, respectively). Significant, tumor-specific loss of heterozygosity occurs in 9 
genes (ATM, BAP1, BRCA1/2, BRIP1, FANCM, PALB2, and RAD51C/D). Moreover, our 
homology directed repair assay of 68 BRCA1 rare missense variants supports the utility of allelic 
enrichment analysis for characterizing variants of unknown significance. The scale of this 
analysis and the somatic-germline integration enable the detection of rare variants that may 
affect individual susceptibility to tumor development, a critical step toward precision medicine.  
2.2 Introduction 
At least 3% of all cancer cases are thought to have a strong hereditary component, with large 
variation being found across cancer types [1]. For example, it was recently estimated that up to 
20-25% of ovarian cancers are due to a germline loss-of-function variant in one of several genes 
that confer moderate to high risk [2, 3], while other cancer types (e.g. lung) have strong 
                                                
† Charles Lu*, Mingchao Xie*, Michael C. Wendl*, et al. "Patterns and functional implications of rare germline 
variants across 12 cancer types." Nature communications 6 (2015) (* contributed equally to this work) 
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environmental components with little evidence of genetic predisposition [4]. The absence of 
heritability in some cancers may be due to low or medium penetrance alleles [5]. Genome wide 
association studies (GWAS) have been instrumental in identifying hundreds of common low-
effect risk alleles across multiple cancer types [6]. The availability of large scale normal and 
tumor sequencing data from cancer cases now allows for discovery of rare variants influencing 
cancer susceptibility through analysis of both germline and somatic sequencing data. 
Tumorigenesis is a complex process that often involves close interactions between germline and 
somatic variants. Their cooperation is best exemplified by the “two-hit hypothesis” [7], in which 
a tumor suppressor gene is inactivated by the combination of an initial germline mutation of one 
allele, followed by the somatic inactivation of the other. Loss of heterozygosity (LOH), whereby 
the wild-type allele for a two-hit tumor suppressor is eliminated, has been implicated in many 
cancers [8, 9]. Advancing our understanding of cooperative germline-somatic dynamics and their 
implications for tumorigenesis requires large cohort studies using sequencing data from both 
germline and somatic tissues, as well as new tools to reliably detect allelic loss.  
We have previously reported that whole exome sequencing data can be successfully employed to 
identify both known high penetrance cancer genes in ovarian cancer, as well as new candidate 
predisposition alleles for downstream functional characterization [3]. Here, we extend this work 
to 12 cancer types with the goal of describing the landscape of germline variants (truncation and 
missense) and analyzing the effect of germline variants on somatic mutations using >4,000 
cancer cases. Our analysis shows a diverse set of genes potentially contributing to predisposition 
with variable frequencies and levels. Stomach cancer has a relatively high rate of rare germline 
truncations, in large part due to frequent PALB2 and ATM mutations. Genes and local hotspots of 
significant allelic enrichment within functional domains were discovered through integrating 
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germline and somatic data. Germline and somatic integration sheds insights on genes influencing 
somatic mutation frequencies and genes/pathways involved in the entire life history of individual 
tumors. Experimental validation of 68 BRCA1 variants, with 62 having previously unknown 
functional significance or not reported by the NHGRI Breast Cancer Information Core (BIC) 
database, identified 9 with complete or partial loss of homology directed repair (HDR) function, 
further supporting LOH analysis results. Such discovery of new cancer susceptibility genes and 
functional characterization of variant alleles will be an important step toward generating an 
actionable catalog for personalized treatment of cancer. 
2.3 Results 
2.3.1 Cancer types and sample characteristics 
We searched for candidate germline cancer predisposition variants in the exome sequence data 
from 4,034 cancer patients across 12 diverse cancer types: breast adenocarcinoma (BRCA), 
glioblastoma multiforme (GBM), head and neck squamous cell carcinoma (HNSC), kidney renal 
clear cell carcinoma (KIRC), acute myeloid leukemia (AML), low grade glioma (LGG), lung 
adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), ovarian carcinoma (OV), 
prostate adenocarcinoma (PRAD), stomach adenocarcinoma (STAD), and uterine corpus 
endometrial carcinoma (UCEC). The numbers of cases from each tumor type ranged from 178 
(PRAD) to 770 (BRCA) and are listed in Table 2.1. Of the 3,548 TCGA cases with available 
ethnicity information, 88.1% were Caucasian (n=3,125), 6.3% were African American (n=225), 
5.2% were Asian (n=183), and 0.4% (n=15) were American Indian/Alaska Native. Patients 
(n=3,827) were diagnosed between 10-90 years (mean 59.9 ± 13.2 years) with LUSC and LGG 
having the highest and lowest mean ages, respectively (Table 2.1). The sex distribution is 
generally consistent with U.S. general population cancer statistics for these malignancy types. 
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Age of onset distribution is bimodal for LGG, LUAD, and STAD, with some evidence of a 
bimodal distribution for OV, KIRC, HNSC, and GBM. Distinct age of onset populations may 
indicate discrete mutational or disease processes (Figure 2.1a).  
Sequencing data for an additional 1,627 TCGA cases were collected for 10 out of the 12 cancer 
types (AML and STAD not included) for validating findings from the discovery cohort. In the 
validation cohort, 1,388 TCGA cases had available demographic information, of which 1,173 
cases had ethnicity information, where 83.8% were Caucasian (983 out of 1,173), 12.79% were 
African American (150 out of 1,173), 2.98% were Asian (35 out of 1,173), and 0.4% (5 out of 
1,173) were American Indian/Alaska Native/Native Hawaiian or Other Pacific Islander. Patients 
(n=1,388) were diagnosed between 19-90 years (mean 59.8 ± 13.1 years), with LUAD and LGG 
having the highest and lowest mean ages, respectively (Figure 2.1a and Table 2.1).  
Sequencing data for samples from the National Heart Lung and Blood Institute (NHBLI) 
Women's Health Initiative Exome Sequencing Project (WHISP) were downloaded, processed, 
and used for comparison of genetic variants to TCGA cancer cases. After extensive quality 
checks (see Methods), 1,039 Caucasians with an average age of 63.7 ± 7.9 years (mean ± s.d., 
range 50-79) were selected as controls for downstream burden test analyses (Figure 2.1b). 
NHLBI variant calls for 6,503 samples (4,300 Caucasians and 2,203 African American) were 
also downloaded from the NHLBI Exome Variant Server (ESP6500SI-V2, 
http://evs.gs.washington.edu/EVS/) for additional comparative analyses.  
2.3.2 Landscape of germline truncation and missense variants 
Germline variant calling was conducted using VarScan [10], GATK [11], and Pindel [12] for 
TCGA discovery (4,034) and validation (1,627) samples and WHI (1,039) controls. False-
positive filters were applied to the intersected indel calls to ensure high quality for downstream 
21 
 
analyses. Missense variants were further analyzed by comparing to recurrent somatic mutation 
sites and IARC and ClinVar databases (Supplementary Note). Examination of coverages in the 
TCGA and WHI samples across the exome showed comparable depths, with averages of 115.3 
and 106.2, respectively (see Supplementary Table 2.1). Specifically, there is a high positive 
correlation (Pearson Correlation R= 0.98) of the percentage of coding regions with at least 30X 
coverage between WHI (70.8%) and TCGA (71.4%) samples across the 624 cancer genes 
selected based on several recent studies [13-17] (Supplementary Figure 2.1). 
We identified 2,089 truncation variants (splice site, frameshift indels, nonstop, and nonsense) in 
the TCGA discovery cohort in 624 cancer-associated genes (see Methods and Supplementary 
Table 2.2-2.4). We limited our analysis to variants whose minor allele frequency between our 
discovery dataset and that of NHLBI ESP 6,503 was ≤0.05%, based on the distribution of minor 
allele frequencies across BRCA1 and BRCA2 truncations detected (Supplementary Figure 2.2).  
After manual curation, we retained 838 truncation variants in 249 genes previously implicated in 
cancer (Supplementary Table 2.2); 69 of them with whole genome sequencing coverage have all 
been confirmed (Supplementary Table 2.4).  
We conducted a more stringent investigation of the distribution of the rare truncation variants 
(MAF ≤ 0.05%) across cancer types using 2 different gene sets: 114 well-known cancer 
susceptibility genes reported by Rahman et al. [1] and 47 DNA repair genes associated with 
Fanconi Anemia pathway [3], with 15 overlapping between the two sets (Figure 2.1c, and 
Supplementary Table 2.5 and 2.6). Examination of the 114 susceptibility genes revealed that 
ovarian (19%, 95% confidence interval (CI): 16%-23%) and stomach (11%, 95% CI: 8%-14%) 
cancers have the highest percentage of cases carrying rare truncation variants, while AML (4%, 
95% CI: 2%-8%) and GBM (4%, 95% CI: 3%-8%) have the lowest number of such events 
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(Figure 2.1c). Ovarian (17%, 95% CI: 14%-20%), prostate (8%, 95% CI: 4%-12%) and breast 
(8%, 95% CI: 6%-10%) cancers exhibit the highest percentage of cases harboring rare 
truncations when the 47 DNA repair genes associated with Fanconi Anemia pathway are 
included. Stomach cancer (8%, 95% CI: 5%-11%) in the Fanconi Anemia pathway-related genes 
also displayed relatively high truncation rates. Interestingly, LGG (2%, 95% CI: 1%-5%) and 
KIRC (3%, 95% CI: 2%-5%) have the lowest truncation rates in the Fanconi Anemia pathway-
related genes, consistent with the small numbers of somatic variants identified in these two 
cancer types.  
2.3.3 Genes significantly associated with cancer predisposition 
Out of 4,034 total discovery cases, 3,125 were identified as Caucasians based on reported 
clinical data. We performed burden analysis in Caucasians (3,125 cases vs. 1039 WHI Caucasian 
controls, see Supplementary Table 2.7) using well-established methods [18, 19] (see Methods). 
To obtain the most comprehensive information, we also performed comparisons between the 
TCGA 4,034 cases and ESP 6,503 (downloaded variant calls, see Supplementary Table 2.8). We 
searched for genes displaying significantly higher rare truncation variant frequencies than the 
background rate derived from WHI 1,039 control set (see Methods) and identified 13 significant 
genes (FDR ≤ 5%) using TFT calculations [19], 5 from cross cancer type analysis and an 
additional 8 from individual cancer type analysis, with BRCA1, BRCA2, ATM, BRIP1 and 
PALB2 as the top 5 ranked genes associated in the pan-cancer analysis, and other genes including 
CNKSR1, EME2, MRE11A, MSH6, PIK3C2G, RAD51C, RAD51D, and XRCC2 associated with 
specific cancer types (Figure 2.2a and 2.2b, and Supplementary Table 2.7). 
We detected 53 BRCA1 rare truncation variants across 7 cancer types and 50 BRCA2 rare 
truncation variants across 6 cancer types (Figure 2.2c). As expected, most variants were detected 
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in ovarian and breast cancer cases. However, 7 BRCA1 and 6 BRCA2 germline truncations (MAF 
≤ 0.05%) were detected in other cancer types (3 each in endometrial, stomach, and lung cancers, 
2 in kidney cancer, and 1 each in prostate and head and neck cancers). The average age at 
diagnosis of BRCA1 and BRCA2 germline truncation carriers vs. non-carriers was non-
significantly younger for endometrial (52.7 vs. 63.1), stomach (59.7 vs. 66.1), and lung (63.0 vs. 
66.1) cancers, providing support that these variants may contribute to younger onsets of these 
cancer types, though additional data is required for confirmation and to reach statistical 
significance. We also observed 32 truncations in BRCA1 and BRCA2 interacting proteins: 
PALB2 (n=12, 4 in stomach, 3 in ovarian, 2 in head and neck and each in breast, lung, and 
prostate cancers), BRIP1 (n=16, 3 each in breast, ovarian, and lung, 2 in stomach, one each in 
GBM, HNSC, KIRC, LGG, and UCEC), and BAP1 (n=2, in kidney), and BARD1 (n=2, 1 each in 
PRAD and BRCA). ATM, ataxia telangiectasia mutated, was the third most significant gene and 
the third highest in number of rare truncation variants; a total of 28 were found in ATM (23) and 
its homolog, ATR (5) (Supplementary Table 2.7). Our study bolsters evidence for previously 
claimed ATM/ATR associations with breast cancer with observations of 4 ATM and 4 ATR 
truncations in breast cancer cases. Notably, 19 ATM truncations were also detected in other 
cancer types, mostly in lung, stomach, and prostate cancers, the respective fractions of cases 
being 1.1% (5 out of 462 cases), 1.2% (4 out of 321 cases), and 3.4% (6 out of 178 cases). These 
fractions are all higher than the observed 0.5% in breast cancer. Both ATM and ATR are 
serine/threonine protein kinases that act upstream from cell cycle check point proteins CHEK2 
(6) and CHEK1 (1), respectively. The rest of the significant genes were linked to various DNA 
repair pathways.  For example, MSH6 (11) is a component of the mismatch repair pathway and 
XRCC2 (7), RAD51C (6), NBN (9) are all part of the DNA double strand repair pathway. ERCC1 
24 
 
(3) and ERCC2 (10) are involved in transcription-coupled nucleotide excision repair. Four rare 
truncations (2 in LGG) were also found in MUTYH (a mutY homolog), involved in oxidative 
DNA damage repair (Supplementary Table 2.7). 
We also sought to identify genes enriched for truncations that were significantly associated with 
single or a subset of cancer types. RAD51C was found to be significant in OV and significant and 
top ranked in AML, while PALB2 truncations were associated with STAD and OV (Figure 2.2b).  
PMS2, involved in colorectal [20] and endometrial cancer [21] predisposition, showed 
suggestive association with HNSC (TFT, FDR = 14%) and LGG (TFT, FDR = 10%) in the 
discovery set, but did not reach the 5% FDR threshold (Figure 2.2b).  Significant enrichment of 
MSH6 (6 were close to the C-terminus of the protein) and MRE11A truncations were found in 
UCEC. Other notable genes that were significant in a specific cancer type included EME1 in 
KIRC and FANCM in BRCA (Figure 2.2b and Supplementary Table 2.7). Notably, we observed 
several novel associations between specific cancer types and genes, including RAD51C in AML, 
ATM in PRAD, PALB2 and EME2 in STAD.    
To further evaluate these findings, we investigated rare truncations in those 13 significant genes, 
as well as an additional 21 suggestive genes having FDR ≤ 15% (TFT) using another 
independent set of 1,627 cancer cases from 10 of the 12 cancer types (see Methods). Our analysis 
showed that additional rare truncations (MAF ≤ 0.05%) were identified in 29 out of these genes 
in the validation set (Supplementary Table 2.3). The overall frequencies correlate positively 
(Pearson coefficient of 0.6167, Supplementary Figure 2.3). Notably, 10 rare PMS2 truncations 
were found in the validation set, with 4 from UCEC, 2 each from LUAD and LUSC, and 1 each 
from BRCA and PRAD; these observations confirm the significance of PMS2 in susceptibility 
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and broaden its role in cancer types not previously implicated. Another example is XPA detected 
as significant using the discovery cohort and confirmed by the identification of 2 additional rare 
truncations (E111* and V244fs) in prostate cancer using the validation cohort. Although 3 
additional ATM rare truncations were found in BRCA and GBM in the validation cohort, no 
events were detected in LUAD and PRAD, two cancer types with significant results in the 
discovery cohort. Overall, our results from the validation cohort strengthen provisional 
conclusions derived in the discovery phase, but also indicate that larger cohorts are required for 
accurately assessing frequencies of germline mutations as well as detecting low frequency events 
in individual cancer types. 
2.3.4 LOH analysis of rare truncation and missense variants   
While burden analysis can identify genes with significant enrichment of rare truncations, 
association studies have limitations, specifically with respect to inference about functional 
implications of specific variants. LOH analysis can uncover heterozygous germline variants that 
are under potential selection in the tumor, one of the key indications being increased VAF in the 
tumor sample. With no LOH, it would be expected that the VAF detected in tumor relative to the 
normal tissue derived DNA would be 1 while with complete LOH the VAF ratio would be 2. 
Because tumor samples are not completely free of normal tissue and can exhibit clonal 
heterogeneity, evidence for LOH is increasingly strong for VAF ratios approaching 2.  The 
combined use of burden tests that can narrow the search space for germline variants of functional 
importance with LOH analysis can solidify support for both putative genes and specific variants 
involved in cancer susceptibility. 
With respect to genes, we first tested the expanded list of 34 significant or nearly significant 
genes (known and likely oncogenes excluded) in burden analysis (see Methods) for evidence of 
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somatic loss of the wild-type allele. A total of 7 genes, BRCA1, BRCA2, RAD51D, PALB2, 
RAD51C, ATM, and BRIP1 were significant (FDR ≤ 5%) along with 2 genes (BAP1 and 
FANCM) near significance (Supplementary Table 2.9 and 2.10, and Figure 2.2 and 2.3a). 
Consistent with expectations, BRCA1 and BRCA2 had the highest percentage of significant 
variants demonstrating LOH (44 of 48 (92%) and 21 of 30 (70%), respectively). Other genes 
demonstrating variants with LOH include: PALB2, which functions in maintenance and repair 
and cooperates with BRCA2 [22] (5 significant truncation mutations of 11, 45%), ATM, which is 
activated by double-strand breaks (8 of 17 significant, 47%), BAP1, a transcriptional repressor 
involved in BRCA1-mediated cell growth suppression [23] (2 of 2, 100%), and FANCM, which 
plays a role in DNA repair [24] (3 of 9, 33%). In all, 99 of 264 (38%) truncation variants showed 
significant LOH. It is worth noting that although LOH in cases with BRCA1 and BRCA2 
truncations mutations were largely restricted to OV and BRCA, the majority of LOH truncations 
in other genes (e.g., ATM, PALB2, BAP1, FANCM) were found across cancer types (Figure 
2.3a). 
We further compared VAFs of missense variants in the 7 significant LOH genes above, finding 
that 4 in BRCA1, ATM, BRCA2, and RAD51C are significant. This underscores both our findings 
from rare truncation analysis (Supplementary Table 2.11 and 2.12, and Figure 2.3b) and the 
potential importance of missense events in cancer. The significant missense VAFs in these genes 
range from 13% to 23% (Figure 2.3b), while other genes average 9%. Of all individual missense 
events, 173 of 1170 (11%) showed significant LOH (FDR ≤ 1%) (Supplementary Table 2.12). 
Significant events for ATM and BRCA1 were concentrated in BRCA, HNSC, and OV, while 
RAD51C did not show preference (Figure 2.3b). Of note, our LOH analysis identified G245V in 
TP53 as highly significant (FDR = 1.18e-07) although no rare TP53 truncations were found.  
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To further investigate the effect of missense events on cancer susceptibility, we sought to 
determine whether there are any larger informative patterns associated with their LOH, 
specifically whether the significant instances of LOH spatially cluster in or near specific protein 
regions/domains. Indeed, analysis shows statistically significant difference in spatial clustering, 
further supporting the mechanistic roles of these variants in cancer (Figure 2.3c). For example, 
there is a strong grouping of variants (FDR = 0.34%) that overlaps both a kinase-like and a PIK 
kinase domain near the end of ATM, which participate in chromosome maintenance and repair. 
We also found clusters overlapping the BRCT (FDR = 5%) and RING domains (FDR = 0.39%), 
which participate in the DNA repair functionality of BRCA1. 2 BRCA2 clusters (FDRs = 6.5% 
and 8.9%) in the oligonucleotide/oligosaccharide binding motif (OB fold) domains, important in 
the DNA damage response, are near significant (Supplementary Table 2.13).  
2.3.5 Somatic and germline interactions and clinical associations 
We followed stringent filtering strategies for standardizing specificity across the Pan-Cancer 
somatic variant calls for 3,368 cases in this study [13] (Supplementary Table 2.14). We first used 
MuSiC [25] to search for genes demonstrating co-occurring or mutually exclusive germline and 
somatic mutations (Figure 2.4a,b and Supplementary Table 2.15,2.16).  Our pan-cancer analysis 
using 34 burden test genes of interest and 54 cancer-associated genes with recurrently mutated 
somatic variants (frequency ≥ 5 across cancer types), detected significant mutual exclusivity 
between BRCA1/BRCA2 germline truncations and IDH1 somatic mutations, which is likely 
confounded by cancer-type specificity: BRCA1/BRCA2 germline truncations were most prevalent 
in BRCA and OV, whereas IDH1 somatic variants are mostly found in AML, GBM and BLCA. 
To mitigate the cancer type specific effect, we investigated co-occurrence and mutual exclusivity 
within each cancer type (requiring recurrently mutated somatic variants with frequency ≥ 2 
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across cancer types) (Supplementary Table 2.16). Notably, ATM germline truncations were 
found to be mutually exclusive of TP53 somatic mutations in LUAD (permutation test, P = 
0.041), consistent with the paradigm that ATM activates TP53 to trigger apoptosis [26] and the 
need to disrupt only one gene to confer an anti-apoptotic effect. As expected, we also observed 
co-occurrence of BRCA1 germline truncations and TP53 somatic mutations in BRCA 
(permutation test, P = 0.012) [27], as well as mutual exclusivity between BRCA1/BRCA2 
germline truncations and PIK3CA somatic mutations in BRCA (permutation test, P = 0.01 and P 
= 0.03). BRCA1 germline truncations have previously been reported to be associated with the 
basal subtype breast cancer [28], which tends to exhibit a molecular profile similar to ovarian 
cancer [29]. Our findings are consistent with the association between basal subtype breast cancer 
and frequent TP53 and infrequent PIK3CA mutations [30]. Additionally, we also observed a co-
occurrence of BRCA2 germline truncations and TP53 somatic mutations in ovarian cancer, as 
expected. Our data suggest that the combinational effects of BRCA1/BRCA2 germline mutations, 
along with the high frequency of LOH events and somatic TP53 mutations result in aggressive 
basal subtype breast cancer and ovarian cancer. 
Interestingly, the distribution of BRCA1, BRCA2, and ATM rare germline truncations with their 
somatic mutations across cancer types varies with the high frequency of ATM in prostate, lung, 
and stomach cancers and BRCA1 and BRCA2 germline events in ovarian and breast cancers 
(Figure 2.5a and Supplementary Table 2.17). Collectively, these analyses show distinct 
combinations of germline and somatic mutations contribute to the development of individual 
cancer types.  
We also examined germline variants having significant impact on carriers’ somatic mutation 
frequencies. Analysis of the expanded 34 burden test genes revealed that patients with germline 
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BRCA1 and BRCA2 truncations had significantly higher somatic mutation frequencies than cases 
without such changes in both breast and ovarian cancers (Figure 2.5b and Supplementary Table 
2.18). Since the correlation between BRCA1/2 germline and higher somatic mutation rate may 
be characteristic of the basal subtype breast cancer, we compared the mutation frequency of 
basal cases with BRCA1/2 germline truncation to basal cases without BRCA1/2 germline 
truncation and found the former have significantly higher mutation rate (Supplementary Figure 
2.4, Wilcoxon rank-sum test, P = 9e-4). 
In addition, RAD51C and RAD51D germline truncations are positively correlated with increased 
somatic mutation frequencies in ovarian cancer. FANCM and EME1 germline truncations are 
positively correlated with increased somatic mutation frequencies in HNSC (Wilcoxon rank-sum 
test, P = 0.046) and KIRC (Wilcoxon rank-sum test, P = 0.027), respectively. In UCEC, MSH6 
germline truncations are found to be significantly associated with higher mutation frequencies, as 
expected (Wilcoxon rank-sum test, P = 0.014) (Figure 2.5b and Supplementary Table 2.18). 
Further, 81 cases carried MSH2 germline variants (MAF ≤ 0.05%, including 1 truncation 
variant), and they also showed higher somatic mutation frequency (Wilcoxon rank-sum test, P = 
3.63e-03). 
The joint analysis of all 12 cancer types including cancer type as a covariate identified BRCA1, 
BRCA2, and PMS2 as having strong correlations with a younger age of onset (P = 5.20e-07, 
2.04e-04, and 0.049, respectively; MuSiC GLM analysis, Figure 2.5c and Supplementary Table 
2.19). Analysis of individual cancer types revealed significant early onset for germline 
truncations of FANCA in HNSC, BRIP1 in LUSC, and ATM in STAD (Figure 2.5c and 
Supplementary Table 2.20).  Not surprisingly, we found that germline truncation variants in 47 
Fanconi Anemia genes and 114 cancer susceptibility reported in Rahman et al. were significantly 
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enriched in younger patients according to Wilcoxon rank-sum testing (P = 1.08e-03 and 1.38e-
04, respectively). 
2.3.6 Functional validation of BRCA1 missense variants  
To investigate the effect of missense variants on BRCA1 function and evaluate LOH analysis for 
missense variants, 68 variants were selected based on MAF and protein domains for functional 
validation using the HDR assay [31] (see Methods and Supplementary Table 2.21); 47 of them 
had previously been assigned as variants of unknown clinical importance in the NHGRI Breast 
Cancer Information Core (BIC) database and 15 variants were not reported at all in BIC. One 
known deleterious truncation mutation in the carboxyl-terminus of the BRCA1 protein Q1779fs 
and 3 other truncations, E1250*, E1415fs and E23fs discovered in UCEC, were also included in 
the experiment. We successfully introduced 68 missense variants and 4 truncation variants into 
full-length BRCA1 expression plasmid pcDNA-5’HA-BRCA1 for the in vitro HDR assay as 
previously described [31, 32] (Supplementary Table 2.21). All mutant constructs were confirmed 
by sequencing and protein expression (Supplementary Figure 2.5) and tested in triplicate using 
the in vitro assay. The percentages of cells showing GFP expression were normalized to 
homologous recombination levels observed in cells depleted of endogenous BRCA1 and rescued 
by transfection of the wild-type BRCA1 expression vector (see Methods). 
Among all tested variants, all 4 truncations (3 from UCEC) and 6 missense variants retained less 
than 30% of homologous recombination activities relative to wide-type (WT) BRCA1, and are 
therefore considered HDR-defective (Supplementary Table 2.22). These missense variants 
included C61G (observed in 4 cases), C64G (2 cases), T1685I (1 case), R1699W (2 cases), 
L1786P (1 case) and G1788V (1 case); all of them showed significant enrichments in the tumor 
samples based on LOH analysis (Figure 2.6a). Comparative analysis of RNA-seq data from 2 
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carriers and 4 non-carriers suggests C64G is in fact a variant affecting splicing (Supplementary 
Figure 2.6), consistent with a previous report [33], and our results suggest that should some of 
the C64G mRNAs be properly spliced, the protein is not active in DNA repair. Of particular 
interest, L1786P, identified and validated as HDR-defective in our study, has not been previously 
designated as pathogenic, despite observations in two previous studies [34, 35]. Our analysis of 
the crystal structure of the BRCT domain showed that the substitution of leucine with proline in 
L1786P will likely result in the termination of the alpha helix structure, which may cause the loss 
of BRCA1 HDR function. Interestingly, an additional 3 variants, A1708V, M1783T and R1835Q 
(from one patient each) consistently displayed less than 70% HDR function in comparison to WT 
BRCA1 (partial HDR-defective, Figure 2.6a); all three had previously been designated as variants 
of unknown significance (VUS) in the BIC database. It is worth noting that A1708V and 
R1835Q were found in male patients with kidney and stomach cancers, respectively; both 
developed cancers at age of 48. A1708V has previously been characterized as a low to moderate 
risk variant [36] and R1835Q has been identified in a Malay population of early-onset breast 
cancer patients with a personal or family breast cancer history [37]. One endometrial cancer 
patient harboring M1783T was diagnosed at age of 65. The BRCA1 protein harboring this 
variant was previously shown to possess enhanced protease sensitivity [38]. Further, our analysis 
shows that all 7 HDR-defective or partial defective missense variants from the BRCT domain are 
either positioned in the center of the structure or on the surface responsible for protein-protein 
interactions, while the 5 HDR-WT variants from the BRCT domain tested are mapped to the 
periphery of the structure (Figure 2.6b). In addition, these 9 HDR-defective (or partial HDR-
defective) missense variants are mutually exclusive to BRCA1 somatic mutations and germline 
truncation variants (Supplementary Table 2.14 and Supplementary Table 2.2).  
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Using the systematic BRCA1 missense variant validation data, we evaluated the prediction power 
of LOH analysis for identifying candidate variants of functional relevance. Without LOH 
analysis filtering, we observed a rate of 4.7% (3 of 64 validated), but BRCA1 validation of 
candidates filtered through LOH was 38.1% (8 of 21) (Supplementary Table 2.23). The 
significant difference (P-value = 0.0004, Fisher’s test) suggests LOH offers an effective sieve for 
candidates, which in this case gives an estimated enrichment factor of 8-fold.  
2.4 Discussion 
 
This study of over 4000 cancer cases is the largest integrated analysis of germline and somatic 
variants to date. Our systematic analysis indicated that an estimated 18% of cancer cases from 
the TCGA cohort had one or more rare truncations in 624 genes associated with cancer. Further, 
there was significant enrichment of rare truncation variants in 13 genes and suggestive evidence 
of increases in 21 more, comprising 8.3% (333 out of 4,034) of TCGA cancer cases.   
We observed several significant associations in specific cancer types: RAD51C in AML, ATM in 
PRAD, PALB2 in STAD. Across cancer types, a higher percentage of breast and ovarian cancer 
cases were identified as having rare truncation variants in cancer genes versus other cancer types, 
due predominantly to high frequencies in BRCA1/2. The percentage of breast and ovarian cancer 
cases carrying BRCA1/2 germline truncation variants in the TCGA cohort was 4.4% and 11.6%, 
respectively, consistent with previous reports [39-42]. Interestingly, stomach cancer has the 
second highest percentage of rare truncations in 114 genes previously reported [1], largely due to 
the contributions from ATM, BRIP1, PALB2, XRCC2, and others.  In contrast, for KIRC and 
GBM, truncation variants in the 34 associated germline genes were uncommon, identified in 
only less than 6% of cases (Figure 2.2d). These results contribute to our understanding of the 
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genetic architecture in cancers, complementing the known effect of common and tagged variants 
from array-based studies as well as the estimate of overall heritability from twin studies in 
multiple cancer types [43, 44]. 
Our results indicated that germline truncation and missense variants in several genes were under 
selection in the tumor, with ATM, BRCA1, BRCA2, and RAD51C determined as significant from 
both truncation and missense analyses and BAP1, BRIP1, FANCM, PALB2, and RAD51D from 
truncation analysis alone. As a proof of concept, we performed functional validation for 68 
BRCA1 missense variant sites using HDR assay; our experimental efforts identified 9 variants 
from 14 patients with complete or partial defective HDR function and validated our LOH 
analysis for effective enrichment of variants under functional selection (an estimated 8-fold 
enrichment in BRCA1).  
More importantly, our integrated germline and somatic study identified BRCA1, BRCA2, 
RAD51C, RAD51D, FANCM, EME1 and MSH6 germline truncations significantly associated 
with increased somatic mutation frequencies in specific cancer types, suggesting that germline 
defects in DNA repair expand to the somatic level. Further, our search for co-occurring or 
mutually exclusive germline truncation/somatic mutations across 12 cancer types revealed a 
number of important insights in terms of genes and pathways involved including: 1) the 
association between germline BRCA1/2 germline truncations and frequent TP53 and infrequent 
PIK3CA somatic mutations confirm breast cancer clinical subtype classification and 2) ATM as a 
bona-fide (3rd frequently truncated) susceptibility gene demonstrated by both burden and LOH 
analyses, is the only common gene highly mutated at both germline and somatic levels.  
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Although our study has been revealing at a genetic level, we are mindful of the limitations of the 
TCGA dataset, including the lack of detailed family history information that would further 
inform the potential pathogenicity of germline variants. Despite the large sample size overall, our 
inferences are limited for specific cancer types because of small case numbers. In addition, the 
vast majority of TCGA cases in our sample set were of Northern European background, 
emphasizing the need for the development of a reference source of genomic data on germline 
cancer predisposition variants from ancestrally diverse population groups. Nonetheless, this 
study is the largest to date that has integrated somatic and germline alterations to identify 
important genes across 12 major types contributing to cancer susceptibility and our results 
provide a promising list of candidate genes for definitive association and functional analyses. 
The combination of high throughput discovery and experimental validation should identify the 
most functionally and clinically relevant variants for cancer risk assessment.  
2.5 Methods 
2.5.1 Access and Inclusion 
Approval for access to TCGA case sequence and clinical data was obtained from the database of 
Genotypes and Phenotypes (dbGaP) (document #3281 Discover germline cancer predisposition 
variants).  We selected a total of 4,034 discovery cases and 1,627 validation cases with germline 
and tumor DNA sequenced by exome capture followed by next generation sequencing on 
Illumina or SOLiD platforms.  All cases met our inclusion criteria of 50% coverage of the 
targeted exome having at least 20X coverage in both germline and tumor samples.  
2.5.2 Control cohort 
NHLBI variant calls for 6,503 samples (2,203 African-Americans and 4,300 European-
Americans unrelated individuals) were downloaded from the NHLBI GO Exome Sequencing 
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Project (ESP), Seattle, WA (URL: http://evs.gs.washington.edu/EVS/; accessed on August 26, 
2013). For comparative analysis, all ESP variants were filtered for < 0.1% total MAF to 
minimize false positives. For the Women’s Health Initiative Sequencing Project (WHISP) 
sample set (N = 1039) as part of the NHLBI ESP cohort, we performed variant analyses using 
methods described in the following section. All variants were processed using the same tools as 
for the TCGA cohort. dbGaP accession id for NHLBI ESP is phs00281.  
2.5.3 Germline variant calling and filtering 
Sequence data from paired tumor and germline samples were aligned independently to NCBI 
Build 37 of the human reference using BWA v0.5.9 and de-duplicated using Picard 1.29.  
Germline SNPs were identified using Varscan (2.2.6 –min-var-freq 0.10 --p-value 0.1 --min-
coverage 8 –map-quality 10), and GATK (revision5336) in single-sample mode for normal and 
tumor BAMs.  For breast and endometrial cancer samples, we also used population-based 
methods, but found differences to be minimal.  Germline indels were identified using Varscan 
2.2.9 (--min-coverage 3 –min-var-freq 0.2 –p-value 0.10 –strand-filter 1 –map-quality 10) and 
GATK (revision5336, only for AML, BRCA, OV, and UCEC) in single sample mode.  We also 
applied Pindel (version 0.2.4x, May 8, 2013; --window-size 1) on each pair of tumor and 
germline sequencing data (for some samples, multiple normal files are used if available) for indel 
prediction.  For the analysis, we preset the insertion size to 500 if this information was not 
provided in the BAM header. 
For each cancer type, all variants were limited to coding regions as defined by ensemble 70.  In 
addition to the coding regions, the two base pairs flanking each exon to cover splice 
donor/acceptor sites were included.  SNVs were based on the union of GATK and VarScan.  
They were subsequently processed through our in-house false-positive filter (all default 
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parameters --min-homopolymer 10).  We required that indels were called by at least 2 out of 3 
callers (GATK, Varscan, Pindel) when all three callers were applied.  In addition we also 
included Pindel unique calls (at least 30X coverage and 20% VAF).  All combined indels were 
then processed through our false-positive-filter (all default --min-homopolymer 10 –min-var-freq 
0.2 --min-var-count=6). We then applied additional annotation and minor allele frequency filters 
as previously reported [45]. 
The predictions for 4,034 TCGA cases consist of 2,709,906 variants (1,655,391 missense, 
947,045 silent, 36,009 nonsense, 18,693 splice site, 2,041 nonstop/readthrough, 30,508 
frameshift indels and 20,219 in frame indels) with minor allele frequency ≤1% in 1000 
Genomes, ESP 6,503 dataset, Discovery 4,034 cohort, and additional annotation filters as 
previously reported [3]; of these, 1,842,459 variants were from 3,125 Caucasian TCGA cases. 
Using the same processing for the 1,039 WHI Caucasian controls, we identified 516,219 
variants, consisting of 319,698 missense, 176,862 silent, 6274 nonsense, 3541 splice site, 355 
nonstop/readthrough, 6101 frameshift indels, and 3568 in-frame indels. 
2.5.4 Cancer Associated Genes 
A total of 624 candidate cancer-associated genes were compiled from nine sources, including 
recently published large-scale cancer studies, publicly available screening panels, and 
unpublished preliminary analysis of publicly available data sources. We retained 204 genes 
shared across at least two of the nine sources and a literature search was conducted to identify 
evidence supporting inclusion of any remaining unique genes. A subset of 518 genes originated 
from recent publications, including 294 genes from Frampton et al. [17], 125 from Kandoth et al. 
[13], 212 from Lawrence et al. [15], 194 from Pritchard et al. [16], 114 from Rahman [1], and 
124 from Vogelstein et al [14]. Thirty-nine additional genes were included based on the analysis 
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of driver mutations in publicly available TCGA data, the published guidelines for return of 
results of the American College of Genetics and Genomics [46], and 18 novel cancer driver 
genes identified in recently published large-scale studies. 
2.5.5 Germline sites overlapping with recurrent somatic mutations 
Recurrent somatic mutations were extracted from the high confidence filtered set of somatic 
mutations [13] and germline variants overlapping them were further filtered to remove those 
having a reported global MAF < 0.5% in the NHLBI Exomes (ESP6500SI-V2).  Remaining 
variants were filtered to remove artifacts due to ambiguous alignments, simple repeats, reference 
sequence errors, putative somatic mutations in adjacent normal tissue, somatic mutations 
associated with clonal expansion in blood [47], and variants with a VAF<10% in tumor or 
normal.  No germline mutations were found to overlap somatic mutations in the same individual. 
In addition to sites described in the main text, several rare germline variants overlapping somatic 
mutations in genes associated with toxin metabolism were also identified.  This included three 
cases carrying CYP2D6   (H352R) as well as one carrier of ABCC2   (E943K; rs3740065). 
Variants in both genes have been reported to be associated with poor outcome in post-
menopausal women treated with tamoxifen but their association with cancer predisposition 
remains undetermined [48, 49]. Additionally, a germline variant at somatic R423Q site was 
found in the CARD11 oncogene [50] and another germline variant S650L in PDGFRB was 
identified. Interestingly, a FLT3 germline variant (R387Q) was identified to have an overlapping 
somatic mutation in endometrial cancer. 
2.5.6 Identifying significant genes using burden tests 
We determined the MAF cutoff for rare variants as 0.05% based on balancing the inclusion of 
possible false-positives versus the loss of possible true-positives in subsequent burden test and 
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LOH analysis. For example, if one presumes that p-values <0.01 have a reasonable possibility of 
being retained as significant in a multiple hypothesis test, the 0.05 threshold only excludes 2 
such points out of a total of 47 for BRCA1 and 1 such point out of a total of 52 for BRCA2. 
Conversely, it excludes 24 points in the MAF range up to 1% that are very unlikely to show 
significance. Points having MAF > 1% are likewise not likely to be of interest (Supplementary 
Figure 2.2). 
Burden test analysis was performed by comparing the frequency of rare germline truncation 
mutations in cancer associated genes from the Pan-Cancer 12 germline dataset (from 12 cancer 
types) (cohort size = 4,034) with WHI 1,039 control samples and those downloaded from the 
NHLBI Exome Sequencing Project (ESP 6,503 including 2,203 African-Americans and 4,300 
European-Americans unrelated individuals).  Variant calling on the TCGA and WHI dataset was 
done as previously described in the methods section.  Variants for the ESP 6,503, along with 
their minor allele frequency were downloaded from http://evs.gs.washington.edu/EVS/).  The 
truncation variants (nonsense, splice_site, and frameshift indels) from both groups were limited 
to a list of genes previously associated with cancer (See Cancer Associated Genes section).  
Further filtering includes retaining variants with < 1% minor allele frequency from 1000 
Genomes Project, and < 1% cohort frequency in each cancer type.  A pooled minor allele 
frequency (the average minor allele frequency of each variant between the test and control 
group) was calculated for each variant and only those whose pooled minor allele frequency was 
less than 0.05% were kept for burden analysis. We excluded events having insufficient numbers 
of observations, defined here as fewer than 3 in the combined cases and controls for the ESP 
cohort and fewer than 2 in the WHI cohort. We subjected the data to the Total Frequency Test 
(TFT), evaluating the one-tailed P-value in each case (observations significantly greater than 
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controls). For reference, we also evaluated the data using the Cohort Allelic Sum Test (CAST), 
although these results were not carried forward for analysis, because they correlate with TFT. 
The TFT probabilities were then ranked by the standard False Discovery rate (FDR). This 
procedure was performed for each cancer type vs. the control group.  In addition an overall 
burden test was performed for Pan-Cancer 12 germline dataset vs. the control group.  A FDR 
cutoff of 10% for the Pan-Cancer 12 germline dataset was used. 
2.5.7 Statistical Methods of Loss of heterozygosity  (LOH) Analysis 
Next-generation sequencing provides direct read counts of reference and variant alleles and each 
pair of counts comprises an observational sample of the actual variant allele fraction (VAFs) at 
its site. We devised several statistical procedures using these counts to test for AI at sites within a 
subset of genes hypothesized to be relevant across cancer types and, moreover, to test the genes 
themselves for significant content of such sites. This is one component of a larger method to 
assess loss of function alleles in these genes. 
The evaluation at each tumor variant site (truncation or missense) is based on two 
complementary aspects related to its VAF: (1) whether it is significantly higher than the VAF at 
its corresponding site in the matched normal sample and (2) whether it is significantly higher 
than the characteristic VAF in the general population of genes having somatic mutations. The 
first aspect was implemented using Fisher’s exact test [51] on a 2X2 table of allele type 
(reference and variant) vs. sample type (tumor and normal). For the second test, we permuted all 
combinations of reference counts and variant counts of the somatic events for all other genes, 
thus obtaining a null distribution that can be used for computing tailed p-values. 
Each of these 2 calculations uses some component of unique information not available to the 
other: they are essentially independent tests of the same hypothesis. We used a standard 
40 
 
transformation method from the mathematical statistics literature to combine these values into a 
single, overall result [52]. The list of p-values for the entire complement of tested sites was then 
corrected for multiple hypothesis testing bias and ranked using the standard Benjamini-Hochberg 
False Discovery Rate (FDR) calculation [53].  
For the second type of test at the gene level, we took the following approach for truncation 
events. All mutated sites for the candidate gene were cataloged, as were all sites outside of that 
gene, the latter representing the mutation “background”. The statistical difference between the 
two sets was then calculated using a standard difference-of-means t-test on the tumor variant 
allele fractions of the 2 groups, where the number of degrees of freedom is 2 less than the total 
number of sites in the test. This procedure was repeated for each gene of interest, after which 
multiple testing correction was again applied in the context of FDR. With respect to missense 
events, we found this procedure was not sufficiently sensitive, so we used an alternative test 
based on comparing the fraction of missense sites within each gene that showed significant LOH 
on the individual level to the corresponding fraction in a background set consisting of the genes 
from burden testing that did not show significant LOH for truncations. To minimize noise, we 
adopted somewhat strict criteria for this particular test: to be tallied as LOH, a site must have had 
a maximum of 1% FDR in the site test and we only tested genes that satisfied the following 
inclusion criteria: a minimum difference of fractional values of 2 percentage points and at least 3 
events showing LOH at the 1% FDR level. We then applied Fisher’s exact test on 2X2 tables of 
missense type (significant LOH and no discernable imbalance) vs. cohort (test gene and 
background population), after which FDR was once again applied to the result. 
An important aspect of the above methods is pre-conditioning of inputs. Previous studies [54] 
have discarded sites based on their inability to attain a significant P-value under the test being 
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used, pointing out incidentally that excluding sites directly improves FDR. The latter observation 
is undoubtedly true, but this view misses the importance of the confidence level associated with a 
VAF estimate, as determined by the size of the sample used for its computation. Because of 
depth variations both between samples and within samples, the reliability (confidence) of VAF 
estimates as calculated from read counts varies from site to site. A specified confidence interval 
for each VAF furnish is a rigorous metric upon which reliability can be assessed and low-
reliability points subsequently excluded from analysis. Because VAFs can approach the extremes 
of 0 and 1 and are also sometimes based on only 10 or 15 reads, the standard interval from 
sampling theory is not particularly useful. Instead, we used Wilson’s interval [55], which does 
not suffer appreciably in these circumstances. We chose an interval of 90% confidence (Z-score 
of approximately 1.65), removing events whose larger distance (above or below the calculated 
VAF) exceeded 12%. The remaining “high-quality” data were then used in the tests described 
above. Results having FDR ≤ 20% were prioritized as significant. 
2.5.8 LOH analysis of germline truncations and missense variants 
We applied our LOH analysis method as a refinement step to the burden analysis. Specifically, 
we tested all sites (and by extension the genes containing those sites) that burden testing 
identified as being significant, either in a Pancancer context or as associated with a specific 
cancer type. Here, we used a FDR of 15% to capture the widest set of genes that could be 
significant. In a sense, we used our LOH method as a “confidence filter” situated on top of 
burden analysis to eliminate false positives. With oncogenes removed, the list of candidates at 
this stage consisted of 32 genes, including ATM, BRCA1, BRCA2, BRIP1, MSH6, and RAD51C 
(the “burden test genes”). We also separated missense from nonsense alterations, the latter 
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typically resulting in truncated, non-functional protein products, and analyzed these sets 
separately.  
The statistical procedure outlined above is straightforward, but can be applied in various ways. 
For assessing the burden test genes, we selected each one individually and constructed the 
corresponding null distribution from all remaining non-burden test genes. That is, we excluded 
from the null all those genes for which there was already some evidence of possible significance. 
The same principle applied to testing individual sites: no variants from burden test genes were 
included in the null distributions. 
2.5.9 Calculation of hotspots of significant LOH 
The calculation method for LOH discussed above identifies instances where the observed VAF 
in the tumor is higher than what is attributable to chance. Building on this, we now describe a 
subsequent calculation that identifies groups of such instances that are clustered spatially. These 
groupings are so-called “hotspots of significant LOH” and signal likely biological relevance. The 
null hypothesis is that instances of LOH, whether statistically significant or not, are distributed 
randomly. Since we are primarily interested in discovery, test regions are implemented as 
unbiased “sliding windows” rather than as specific domains, linkers, etc. A relevant LOH 
observation must satisfy 2 conditions: 
condition A: the LOH is statistically significant, as described above 
condition B: the LOH resides within the current test window 
Status and spatial placement are independent of one another, meaning that the Bernoulli 
probability of a single LOH observation can be calculated as 
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!! = ! ! ∩ ! = !! ∙!!! + !! ∙ ! !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!(1) 
where W and L are the sizes of the test window and protein, respectively (in units of amino acids) 
and Ds and Dn are the total numbers of significant and non-significant LOHs observed for the 
protein. This expression indicates observations are of greater weight to the degree that the 
significant LOHs are more rare (as compared to non-significant LOHs) in the test set and that 
they cluster within tighter regions. LOHs are independently and identically distributed under the 
null hypothesis, meaning the mass probability of k observations of significant LOH within the 
window is then 
! ! = !! + !!! ∙ !!! ∙ 1− !! !!!!!!! !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!(2) 
and the significance (test) probability of k observations within a test window is 
!! = !! ! + ! ! + 1 +⋯+ ! !! + !! !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!(3) 
Since pb is constant over a given protein for a given window size, appreciable caching can be 
used to economize the calculation. We use a slide-step of 1 amino acid and scan window sizes 
from 30 to 200, taking regions of significance to be characterized by their smallest PS. The 
software automatically merges overlapping significant regions. Standard FDR analysis, as 
described above, is then performed on the resulting list of hotspots. 
2.5.10 Functional validation of BRCA1 variants 
Variants were incorporated into a full-length BRCA1 expression plasmid, pcDNA-5’HA-
BRCA1, using Q5 site-directed mutagenesis kit (New England BioLabs). Primer sequencesare 
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available in the Supplementary table 2.21.  All of the desired variants were confirmed by 
sequencing. 
HeLa-DR cells, a stable derivative of HeLa cells containing the genomic integration of the 
recombination substrate vector, pDR-GFP were used for the homology-directed recombination 
assay. Co-transfection of HeLa-DR cells with the BRCA1 expression plasmid containing the test 
variant and siRNA targeting the 3’-UTR of the BRCA1 gene to deplete endogenous BRCA1 
expression was performed. Two days later, cells were transfected again with the siRNA, BRCA1 
expression plasmid, and the I-SceI expression plasmid. After 3 days, cells were harvested by 
trypsinization and the fraction of GFP-positive cells was determined using a FACScalibur flow 
cytometer (BD Biosciences model E1202). The plasmids and cell line used in this study have 
been described previously [31].  
All BRCA1 variants were tested in triplicate and the percentage of cells with GFP expression was 
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Table 2.1:  Case numbers from individual cancer types and basic clinical features for cancer 












Other Asian African 
America 
Caucasians NA Alive Deceased NA 
BRCA Discovery 770 58.2 ± 13.2 1.0 99.0 1 50 53 578 88 682 88 0 
 Validation 217 59.5 ± 12.8 0.5 99.5 0 6 64 124 6 189 11 0 
GBM Discovery 267 59.6 ± 14.0 60.9 39.1 0 4 21 237 5 89 176 1 
 Validation 124 61.0 ± 12.4 62.7 37.3 0 3 3 107 5 36 81 1 
HNSC Discovery 291 60.9 ± 12.4 71.3 28.7 1 4 26 223 7 153 108 0 
 Validation 222 60.3 ± 11.3 73.4 26.6 0 5 9 174 4 155 37 0 
KIRC Discovery 452 60.7 ± 12.1 64.8 35.2 0 7 20 419 6 306 146 0 
 Validation 42 58.5 ± 12.2 76.9 23.1 0 1 7 31 0 27 12 0 
AML Discovery 200 55.0 ± 16.1 54.5 45.5 0 2 15 181 2 67 133 0 
LGG Discovery 223 43.0 ± 13.5 57.7 42.3 0 0 9 209 2 169 51 0 
 Validation 240 43.5 ± 13.5 51.9 48.1 1 4 6 167 3 167 14 0 
LUAD Discovery 462 65.2 ± 9.9 46.3 53.7 1 5 23 297 61 294 93 0 
 Validation 94 66.7 ± 9.5 46.1 53.9 0 1 3 67 5 51 25 0 
LUSC Discovery 193 67.7 ± 9.3 74.8 25.2 0 0 4 113 22 93 46 0 
 Validation 183 66.1 ± 8.4 78.4 21.6 0 6 3 79 51 103 36 0 
OV Discovery 429 59.4 ±11.8 0 100 2 15 19 370 23 207 218 4 
 Validation 68 61.2 ± 10.3 0 100 1 3 2 58 4 40 27 1 
PRAD Discovery 178 60.4 ± 6.9 100 0 0 2 6 130 10 147 1 0 
 Validation 157 60.4 ± 6.7 100 0 0 0 1 9 118 127 1 0 
STAD Discovery 321 66.0 ± 10.7 61.1 38.9 0 81 4 175 46 281 25 0 
UCEC Discovery 248 63.1 ± 11.1 0 100 10 13 25 193 7 231 17 0 
 Validation 280 64.7 ± 11.3 0 100 3 6 52 167 19 221 26 0 
TOTAL Discovery 4034 59.9 ± 13.2 39.3 60.7 15 183 225 3125 279 2719 1102 5 
 Validation 1627 59.7 ± 13.1 44.1 55.9 5 35 150 983 215 1116 270 2 
 





Figure 2.1: Characteristics of the data. Data are distributed by age, cancer, cohort, and carrier 
frequency. (a) Age of onset by cancer type. Age varies on average across cancer types, from 43 
yr in LGG to 67.7 yr in LUSC. Note that LGG, LUAD, and STAD show clear bimodal 
characteristics. (b) Age distributions for discovery, validation, and control cohorts.  (c) 
Comparison of cancer gene truncation carrier frequencies across 12 cancer types.  The 
distribution of rare germline truncation variants for 12 cancer types (represented as the percent of 
cases in each cancer type with rare germline truncation mutation) in 2 different groups of cancer 
associated genes (labeled on top of each bar plot): 114 cancer susceptibility genes from Rahman 
et al [1] and 47 genes associated with the DNA repair (Fanconi Anemia) pathway.  There are 15 
genes common to both groups. The total number of unique genes from these 2 groups is 131. 
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Figure 2.2: Burden analysis reveals distinct set of cancer susceptibility genes across 12 
cancer types. A total of 34 genes of interest were identified by burden analysis by comparing the 
frequencies of rare truncation variants in Caucasian cancer cases (n = 3,125) vs. their frequencies 
in the WHI control population (n = 1,039). Two oncogenes (ABL2 and BCR) were omitted. (a) 
Significant genes across Pan-cancer types. Data were analyzed with the Total Frequency Test 
(TFT) followed by False Discovery Rate (FDR) ranking. Dark horizontal line indicates the 5% 
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FDR threshold, which is satisfied by 5 genes, including BRCA1, BRCA2, ATM, BRIP1, and 
PALB2. Inset shows closer visual resolution. (b) Significant genes for specific cancer types. Each 
plot shows the top tested genes, by FDR, from the same TFT analysis procedure for all 12 
individual cancer types. 8 genes in addition to the 5 shown in (a) are significant at the 5% FDR 
level from cancer type specific analysis. (c) Cohort frequencies of genes. Bubble plot shows 
frequency of rare truncation mutation as a percentage of cases in each cohort (all 4,034 cases 
included for frequency calculation). The x-axis denotes the test group of a specific cancer type, 
the Pan-Cancer discovery cohort (4,034), and the validation cohort (1,627). Genes found to be 
significant at 5% FDR using the Pan-Cancer discovery cohort are labeled in boldface. Grey rings 
indicate genes that are significant (TFT, FDR ≤ 5%) for a particular cohort on the x-axis. (d) 
Percentage of cases carrying rare truncation in the 34 genes of interest across 12 cancer types in 






Figure 2.3: Analysis of loss of heterozygosity in rare truncation and missense variants. (a) 
Bar plot shows individual truncations from 9 genes (FDR shown) with lengths representing 
ratios of tumor to normal variant allele fractions (i.e. the fraction of reads containing the variant 
allele). Statistically significant events, defined as FDR ≤ 5%, are shaded boldly, while non-
significant events are muted, with colors corresponding to genes. Cancer source of each 
truncation is shown underneath, for example most BRCA1 variants occur in ovarian and breast 
cancers and all BAP1 variants in KIRC. (b) Bar plot for individual missense variants from 4 
genes having elevated frequencies of such variants that show very significant LOH, i.e. at the 1% 
FDR level. (c) Dot plot shows individual missense variants where abscissa and ordinate are 
amino acid position and ratio of tumor to normal variant allele fraction. Blue and red indicate 
significant (FDR ≤ 5%) and non-significant events, respectively, with size of blue dots 
proportional to negative log of the FDR. Annotated domains from the PFAM database are 
aligned with position, while shaded areas indicate “hotspot” regions where variants having 
significant LOH cluster more than the rate explainable by chance. Plots are shown for ATM, 





Figure 2.4: Molecular interactions between rare germline variants and somatic mutations 
within and across cancer types. (a) Heatmap demonstrates the significance of interactions 
between 34 burden test significant genes and 54 cancer-associated genes (only 30 were shown) 
with recurrently mutated somatic variants across cancer types. Red-white color scale and blue-
white color scale depict the negative log of P-value for mutual exclusivity and co-occurrence, 
respectively. Both are based on the MuSiC permutation test (n=10,000). (b) Abacus plot displays 
the distribution of significant, mutually-exclusive rare germline variants and somatic mutations 
across all 12 cancer types. Unique combinations of germline and somatic variants contribute to 
the development of individual cancer types. Bigger dots indicate recurrent genes across cancer 





Figure 2.5: Germline variants correlate with somatic mutations and age at diagnosis. Panel 
(a) illustrates the distribution of BRCA1, BRCA2, and ATM somatic and germline mutations 
across cancer types. Panels (b) and (c) display genes significantly correlated with somatic 
mutation frequency and younger age of onset in different cancer types and in Pan-Cancer. The 
width of the shape indicates the density, and the horizontal line indicates the median. P-value is 






Figure 2.6: Functional validation of BRCA1 missense and truncation variants. (a) 68 rare 
missense and 4 truncation variant sites were tested by HDR assay. All samples were depleted of 
endogenous BRCA1 by transfection of a siRNA targeting the 3’-UTR. Indicated in the legend 
are the plasmids transfected to test for rescue of BRCA1 activity. “pcDNA3” is empty vector, 
and “WT” represents wild-type BRCA1 plasmid. The y-axis denotes the relative HDR activity to 
the wild-type BRCA1 protein. Error bars depict standard deviations from the mean. Dots on the 
x-axis represent LOH statuses, each dot corresponding to one case. Blue, red, dark gray, and 
light gray denote statistical significance, non-significance, unknown LOH (due to lack of 
sufficient coverage), and untested, respectively. Variants in different functional domains are 
tagged with different colors as follows: orange=RING domain; green=nuclear localization signal 
(NLS); blue=DNA binding region; purple=a SQ/TQ cluster domain (SCD), and red=BRCA1 C-
Terminal domain (BRCT). All the HDR assays were tested in triplicate. (b) Crystal structure of 
the BRCA1 RING (left) domain in complex with the BARD1 RING domain (labeled in gray) 
and BRCT domain (right panel) are displayed, with HDR-defective variants labeled in red and 





Chapter 3: Age-related Cancer Mutations 
Associated with Clonal Hematopoietic 
Expansion‡ 
3.1 Abstract 
Several genetic alterations characteristic of leukemia and lymphoma have been detected in the 
blood of individuals without apparent hematological malignancies. TCGA provides a unique 
resource for comprehensive discovery of mutations and genes in blood that may contribute to the 
clonal expansion of hematopoietic stem/progenitor cells. Here, we analyzed blood-derived 
sequence data from 2,728 individuals from TCGA and discovered 77 blood-specific mutations in 
cancer-associated genes, the majority being associated with advanced age. Remarkably, 83% of 
these mutations were from 19 leukemia/lymphoma-associated genes, and nine were recurrently 
mutated (DNMT3A, TET2, JAK2, ASXL1, TP53, GNAS, PPM1D, BCORL1 and SF3B1). We 
identified 14 additional mutations in a very small fraction of blood cells, possibly representing 
the earliest stages of clonal expansion in hematopoietic stem cells. Comparison of these findings 
to mutations in hematological malignancies identified several recurrently mutated genes that may 
be disease initiators. Our analyses show that the blood cells of more than 2% of individuals (5–
6% of people older than 70 years) contain mutations that may represent premalignant events that 
cause clonal hematopoietic expansion. 
3.2 Introduction 
Blood cells are continuously regenerated by hematopoietic stem/progenitor cells (HSPCs). 
Human HSPCs divide only rarely (estimated at once a month), but have self-renewal properties 
                                                
‡ Mingchao Xie*, Charles Lu*, Jiaying Wang*, et al. "Age-related mutations associated with clonal hematopoietic 
expansion and malignancies." Nature medicine 20, 1472-1478 (2014) (* contributed equally to this work) 
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that sustain survival for decades. As HSPCs divide, they accumulate rare, random mutations that 
generally do not affect function [1]. However, some mutations confer advantages in self-renewal 
and/or proliferation, resulting in clonal expansion of the affected cells. Although these 
“initiating” mutations do not lead directly to disease, they can cooperate with subsequent 
mutations to cause hematopoietic malignancies. For example, BCR-ABL and BCL2 translocations 
have been found in blood cells of individuals without overt hematological malignancies [2-4]. 
The frequency of such events appears to increase with age, with a similar trend being found for 
somatic structural changes in the nuclear genomes of blood cells [1, 5]. Single nucleotide 
polymorphism array analysis from large genome-wide association study cohorts showed ~2–3% 
of normal individuals of advanced age (70s and 80s) harbor leukemia-associated copy number 
changes that include genes such as DNMT3A (encoding DNA (cytosine-5-)-methyltransferase 
3α) and TET2 (encoding tet methylcytosine dioxygenase 2) [6, 7]. More recently, somatic 
recurrent TET2 mutations were detected in the blood of elderly women without overt 
hematological malignancies [8], and DNMT3A mutations were reported in nonleukemic cells [9]. 
These findings have collectively led to the hypothesis that certain genetic mutations may confer 
advantages to affected HSPCs, resulting in enhanced cell renewal, clonal expansion or both. 
However, it is unclear whether the effect involves only a small number of genes or many more 
genes related to leukemia and lymphoma and whether their participation in promoting clonal 
expansion necessarily leads to clones resembling cancer cells. Here, we address the former 
question by analyzing variations in 2,728 blood samples in TCGA. We observed many 
individuals with age-related hematopoietic clonal mosaicism and concurrent presence of over 60 
mutations in 19 leukemia- and/or lymphoma-associated genes. Our study identified not only 
genes but also specific mutations, associated with the clonal expansion process. Additional 
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statistical analysis identified low-level (2–10% VAFs) recurrent leukemic mutations in a 
substantial number of cases, possibly in the early stages of clonal expansion. Moreover, our 
analysis suggests that DNMT3A, TET2, JAK2 (encoding Janus kinase 2), ASXL1 (encoding 
additional sex combs–like transcriptional regulator 1), SF3B1 (encoding splicing factor 3b, 
subunit 1) and TP53 (encoding tumor protein p53) have distinct and overlapping roles in the 
development of myeloproliferative neoplasm (MPN), myelodysplastic syndrome (MDS), chronic 
lymphocytic leukemia (CLL) and/or acute myelogenous leukemia (AML). Finally, these results 
also incidentally highlight the need for caution when using blood as a reference for a surrogate 
‘germline’ genome, especially in older individuals. 
3.3 Results 
3.3.1 Cancer types and sample characteristics 
We searched for variants present in the blood normal controls across 2,728 cancer patients 
(Supplementary Table 3.1) from 11 diverse cancer types: breast adenocarcinoma (BRCA), 
glioblastoma multiforme (GBM), head and neck squamous cell carcinoma (HNSC), kidney renal 
clear cell carcinoma (KIRC), brain low grade glioma (LGG), lung adenocarcinoma (LUAD), 
lung squamous cell carcinoma (LUSC), ovarian carcinoma (OV), prostate adenocarcinoma 
(PRAD), stomach adenocarcinoma (STAD), and uterine corpus endometrioid carcinoma 
(UCEC). The numbers of cases from each tumor type range from 57 (KIRC) to 673 (BRCA) and 
are listed in Supplementary Table 3.2. Patients were diagnosed between 10–90 years (mean 59.5 
± 13.1 years) and 22.1% were deceased at the time of TCGA sample procurement 
(Supplementary Table 3.2). TCGA collects clinical data regarding diagnosis and prior treatment 
of neoplasms during the sample submission process. To ensure that our dataset was comprised 
only of individuals having first-time primary cancers and having had no treatment with radiation 
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and/or chemotherapy, we excluded those having reported histories of these events as identified at 
https://tcga-data.nci.nih.gov/annotations/ and all clinical data (July 30th, 2014). However, five 
patients with synchronous tumors not associated with blood were included, since these 
synchronous tumors would be unlikely to affect variant analysis in corresponding blood samples.  
3.3.2 Variant calling and filtering strategies 
Variants in the 2,728 blood normal controls were identified with VarScan (single nucleotide 
variant and indel), GATK (single nucleotide variant and indel), and Pindel (indel) (see Methods). 
False-positive filters were subsequently applied prior to downstream analysis and interpretation 
(see Methods). Out of the 49,317,027 variants (previously reported OV counts [10] were not 
included here) that passed false positive filters, 1,622,485 with minor allele frequency of <1% in 
the 1000 Genomes reference and in each cancer cohort were retained for further analysis; this 
consists of 1,025,632 missense, 529,505 synonymous, 19,663 nonsense, 10,976 splice site, 926 
nonstop/readthrough, 20,275 frameshift indels, and 15,508 in frame indels (Supplementary Table 
3.3). We used a stringent filtering strategy described previously [11] for standardizing specificity 
across the Pan-Cancer somatic variant calls for available matched tumor samples 
(Supplementary Table 3.4). 
3.3.3 Variants contributing to hematopoietic clonal expansion 
The collection of both tumor and matched blood normal exome data by TCGA provides a unique 
comparative resource for identifying those somatic variants in blood that contribute to clonal 
expansion. We set out to identify both rare truncation variants (RTV), that is, those having <1% 
MAF in both the 1000 Genomes collection and the cohort data, and variants overlapping with 
recurrent somatic mutations (also called Known Hotspot Variants (KHV)) found in the analysis 
of 12 TCGA cancer types (see Methods and Supplementary Table 3.5 and 3.6). Subsequently, 
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1,598 RTVs in 556 cancer-associated genes based on several recent studies [11-15] (see Methods 
and Supplementary Table 3.7) were manually reviewed to remove false positive calls and 136 
KHVs in the same set of cancer genes were identified. The resulting list was further filtered to 
remove polymorphisms present in 1000 Genomes (see Methods) and having greater than 0.1% 
MAF as reported in the current Exome Variant Server data release (ESP6500SI-V2, 
http://evs.gs.washington.edu/EVS/) from 6,503 samples drawn from multiple NHLBI Exome 
Sequencing Project (ESP) cohorts. We focused on those mutations found in blood normal 
samples, but not present or present only at very low levels in either the tumor samples or tumor 
adjacent normal samples, as this pattern is highly suggestive of somatic mutation in HSPCs 
introduced by the clonal expansion process. Inflammatory lymphocytes/macrophages/neutrophils 
will infiltrate different tumors to different extents. Therefore, the hematopoietic mutations do not 
have to be completely absent in the tumor sample. 
Our analysis of RTVs and KHVs in 556 selected cancer-associated genes identified 70 blood-
specific mutations in 58 individuals. We further performed comparative analysis of blood versus 
tumor samples for these 58 individuals, with the goal of detecting all blood-specific 
nonsynonymous mutations in the 556 cancer-associated genes; this analysis identified seven 
additional events (those that were likely loss of heterozygosity related to copy number alterations 
in the tumor were not included), yielding a final list of 77 blood-specific mutations in 58 cases 
(Table 3.1 and Supplementary Table 3.8). For five of those 58 cases that also had adjacent 
normal tissue analyzed, blood variants were absent in the adjacent normal tissue. Interestingly, 
among the 31 genes harboring these events, 19 have already been linked to hematological 
malignancies (Figure 3.1a). More strikingly, 64 out of the total 77 events (83%) were in these 19 
genes, examples as follows: DNMT3A [16] (18 cases), TET2 [17] (9 cases), JAK2 [18] (8 cases), 
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ASXL1 [19, 20] (6 cases), TP53 [21] (4 cases), SF3B1 [22] (2 cases), BCORL1 [23] (2 case), 
ASXL2 [24] (1 case), and SH2B3 [25] (1 case) (Table 3.1 and Figure 3.1a). The overall frequency 
of blood-specific mutations increased with age (logistic regression analysis, P = 2.38e–08), for 
example, 0.9% of the cases were in their 40s, 1.0% in their 50s, 1.8% in their 60s, 5.3% in their 
70s, and 6.1% in their 80s (Figure 3.1b). The blood-specific mutations were found in all 11 
cancer types (Figure 3.1b). Frequencies of individual TET2, DNMT3A, ASXL1, and SF3B1 
mutations also show association with age, (all FDR values <0.034, logistic regression). 
Interestingly, TET2, ASXL1, and SF3B1 mutations were predominantly found in the oldest age 
groups (70s and 80s) and DNMT3A mutations in 60s to 80s. In contrast, JAK2 mutations, which 
did not achieve significance, trended in both younger (40s and 50s) and older age groups (70s) 
(Figure 3.1c). 
The average age of the 54 individuals with blood-specific mutations in the 19 leukemia or 
lymphoma-associated genes was 70.0 ± 9.9 years, significantly higher than that of the larger 
TCGA cohort used in this study (difference of means test, P = 3.4e–10) (Figure 3.2a). Notably, 
the six individuals having two blood-specific mutations in the nine recurrently mutated genes are 
relatively older, with ages of 64 (DNMT3A: R882H; 36% VAF; TET2: H863fs; 12% VAF), 72 
(JAK2: V617F; 73% VAF and TET2: T229fs; 19% VAF), 75 (DNMT3A: Y584fs; 38% VAF and 
TET2: Q764fs; 33% VAF), 76 (JAK2: V617F; 42% VAF and ASXL1: R548fs; 35% VAF), 83 
years (TET2: F381fs; 50% VAF and TET2: Q888*; 20% VAF), and unknown age (BCORL1: 
G883E; 17% VAF and TP53: Q136*; 18% VAF), respectively (Table 3.1 and Supplementary 
Table 3.8). We also compared the distribution of variant allele fractions for these 64 events 
versus inherited sites identified in the same sample set; we observed a clear shift towards lower 
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VAFs in the blood-specific sites (Figure 3.2b), suggesting the majority are present in only a 
fraction of the blood cells.  
Although GNAS mutations have been found in leukemia [26], activating gain-of-function 
mutations in GNAS are best known for their involvement in polyostotic fibrous dysplasia and 
McCune-Albright syndrome [27]. Interestingly, previous studies showed that activating mosaic 
GNAS mutations could affect various tissue types and the non-mosaic state for activating GNAS 
mutations may be lethal for the embryo [28-30]. This is consistent with our finding of mosaic 
GNAS R202H in transcript ENST00000354359 (also known as R201H in transcript 
ENSP00000360126) in the three blood samples of TCGA cases (11.5%, 14.4%, 21.4% VAFs, 
respectively). It is also worth noting that two blood-specific truncation mutations were detected 
in PPM1D, a gene recently found to be associated with breast and ovarian predisposition with 
mosaic signatures [31], but not with hematological malignancies.  
Due to the fact that the blood-specific variants were present in only a fraction of the blood cells, 
we postulated that certain low level variants associated with clonal expansion were not captured 
by the variant detection tools. Therefore, we performed read count-based analysis for a set of 
known hotspot variants, including R882 in DNMT3A, R132 in IDH1, R172/R140 in IDH2, V617 
in JAK2, K700 in SF3B1, and S34 in U2AF1 for the entire TCGA cohort. We compared the 
distributions of VAFs between tumor and blood normal samples and found that the strongest 
differences were at R882 in DNMT3A and V617 in JAK2 (Figure 3.3 and Table 3.1). We devised 
a statistical procedure (see Methods) to identify additional “low VAF” sites significantly above 
the background error rate. Our analysis identified 14 blood samples having low-level hot spot 
variants (12 of them are not part of the 58 cases identified), including eight in DNMT3A, four in 
JAK2, one in both SF3B1 and IDH2, but none in IDH1 or U2AF1. The average age for these 14 
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cases is 64.0 ± 14.9 years, again higher than the entire TCGA cohort studied (Supplementary 
Table 3.9). We performed deep sequencing for five selected low-level hot spot variants (two 
R882C and one R882H sample sites in DNMT3A, one V617F in JAK2, and one K700E in 
SF3B1) to evaluate our detection approach. We achieved more than 450,000x average coverage 
for each site and all of the five variants were validated as bona fide low-level blood specific 
mutations (Supplementary Table 3.10 and see Methods). By including low VAF events, the 
overall frequencies of blood-specific mutations in different age groups are: 1.2%, 1.3%, 2.2%, 
6.1%, and 6.8% in their 40s, 50s, 60s, 70s, and 80s, respectively (Supplementary Figure 3.1). 
Collectively, we estimate that approximately 2% and 3.5% of individuals over the ages of 40 and 
60, respectively, and without overt hematological malignancies carry blood-specific mutations 
that are associated with hematological malignancies. 
3.3.4 Known Hotspot Variants in NHLBI exome sequencing project control 
cohort 
To confirm that these mutations are also present in an independent set of normal blood samples, 
we examined the NHLBI exome sequencing project (ESP) control cohort. We searched for RTVs 
and KHVs in 6,503 ESP samples, focusing on four AML-associated genes discovered in the 
TCGA set (DNMT3A, TET2, JAK2, and ASXL1). When we applied a 0.1% MAF threshold in 
ESP (to focus on rare variants and to prevent potential false positives), we identified 8 RTVs and 
13 KHVs in DNMT3A, 13 RTVs in TET2, and 7 RTVs in ASXL1, and 3 KHVs in JAK2 
(Supplementary Table 3.11). For a subset of ESP samples (n = 557 WHISP), we re-aligned reads 
and performed variant analysis using the same process applied for the TCGA cohort. This 
allowed us to confirm RTVs and KHVs detected by the pipeline, and also to detect low VAF 
KHVs potentially missed by variant detection tools. Our pipeline detected one RTV each in 
DNMT3A, TET2, and ASXL1, four DNMT3A R882H mutations, and two JAK2 V617F mutations. 
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Careful analysis of recurrent hotspot sites (described in the previous section) using the 557 
WHISP samples identified an additional three DNMT3A R882, one JAK2 V617, one GNAS R202 
and two SF3B1 K700 variants with VAFs ranging from 2% to 10% (Figure 3.3 and 
Supplementary Table 3.12). Based on these analyses, over 2% of the 557 WHISP cases contain 
mutations in these five selected genes. However, sequencing of matched non-blood samples from 
these cases would be required to prove that they are truly blood-specific mutations.   
3.3.5 Mutations in TCGA blood samples and patients with hematological 
malignancies 
We next compared the mutation frequencies in 25 genes frequently mutated in at least one of the 
five following cohorts: TCGA 58 blood samples, 151 myeloproliferative neoplasm (MPN) cases 
reported by Nangalia et al. [32], 150 myelodysplastic syndrome (MDS) cases reported by Walter 
et al. [33], 160 chronic lymphocytic leukemia (CLL) by Landau et al. [34], and 200 TCGA AML 
cases [21]. DNMT3A, TET2, ASXL1, TP53, and SF3B1 were found to be consistently mutated in 
at least four groups, while JAK2 was more specifically mutated in 58 TCGA blood samples and 
MPN patients (Figure 3.4a). No mutations were found in TCGA blood samples in genes such as 
IDH1, NRAS, RUNX1, and PHF6, which are significantly mutated in AML and frequently 
mutated in MPN and/or MDS. Several genes showed cohort specificity: GNAS was mutated only 
in TCGA blood samples and CEBPA, WT1, PTPN11, KIT, SMC1A, and SMC3 were preferably 
mutated in the AML cohort. We reasoned that common mutations among the cohorts (e.g., in 
DNMT3A, TET2, ASXL1, SF3B1, JAK2, and TP53) may be relevant for initiating HSPC clonal 
expansion, and are also likely to be early, initiation events for hematological malignancies, such 
as MPN, MDS, CLL, and AML. On the other hand, genes specific for MPN, MDS, and/or AML 
(e.g., NRAS, RUNX1, NPM1, and FLT3) are more likely to be subsequent, cooperating mutations 
that are involved in the progression of these diseases. These observations also show both distinct 
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and common connections among these five cohort groups, suggesting that the TCGA cohort 
consists of a combination of precursor mutations that may sometimes evolve to MPN, MDS, 
CLL, and/or AML, although subsequent, collaborating mutations are clearly required 
(Supplementary Figure 3.2). Finally, we compared the average number of mutations among these 
4 cohorts (not including MDS) in 556 selected cancer-associated genes; this showed TCGA 
blood samples having the fewest mutations, MPN and CLL cohorts having intermediate numbers 
of mutations, and AML patients harboring the highest number of mutations (Figure 3.4b). 
3.4 Discussion 
We identified age-related hematopoietic clonal expansion and the concurrent presence of 
leukemia/lymphoma-associated mutations in about 2% of individuals studied, who did not have 
reported hematological malignancies; this frequency reaches 5–6% for individuals who are at 
least 70 years of age. Our investigations of 2,728 TCGA blood samples identified 64 mutations 
in 19 genes known for their roles in hematological malignancies with VAFs above 10%, and an 
additional 14 mutations with lower VAFs (2 to 10%) when site-specific analysis was conducted. 
While many of these genes (e.g., DNMT3A, JAK2, ASXL1, and TET2) are established drivers for 
hematological malignancies, others (e.g., PPM1D) have not yet been implicated. The wide range 
of VAFs is indicative of the different stages of clonal expansion among individuals. Our finding 
also supports the hypothesis that mutations in genes such as DNMT3A, JAK2, ASXL1, TET2, 
GNAS, and others are likely to be initiating events for MPN, MDS, CLL, and/or AML, while 
epigenetic changes have also been previously implicated [35, 36]. Importantly, the lack of 
detectable mutations in IDH1, RUNX1, NRAS, NPM1, and FLT3 in both TCGA blood samples 
and WHISP cases supports the idea that these mutations are usually cooperating mutations that 
are important for disease progression.  
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These data suggest that extra care is required when using blood as a surrogate reference for the 
germline genome, especially in elderly individuals. First, there is an obvious risk of blood-
specific variants in individuals without overt hematological malignancy being mistaken as 
germline variants. Secondly, germline alleles in cancer samples could be mistaken as tumor-
specific variants when comparing to blood samples. Lastly, connections were made between 
mosaic PPM1D mutations in lymphocytes and the predisposition to breast and ovarian cancers 
[31]. While the influence of the immune system on tumorigenesis is well known, it is also 
possible that the blood-specific mutations are independent, unrelated events that are simply 
associated with the clonal expansion of HSPCs. 
Our unbiased mutational analysis using sequencing data of relatively high depth (average of 
107.5x coverage, Supplementary Table 3.13) allowed us to detect hot-spot mutations down to 2–
3% VAFs; we discovered that 5–6% cases with advanced age (over 70 years) carry blood-
specific mutations known to be involved in hematological malignancies. Some of these 
individuals may be undergoing hematopoietic clonal expansion (Figure 3.5), but most probably 
do not progress to overt disease, since the incidence of myeloid malignancies in the elderly is 
less than 0.1% [37]. Participants providing specimens to TCGA are de-identified/coded, so it is 
not feasible to determine whether a participant with a leukemia-associated mutation actually 
progressed to a malignant hematologic disease (Supplementary Figure 3.2). Using SNP array 
data from GENEVA study cohorts (melanoma, lung health, prostate cancer etc.), Laurie et al. 
showed roughly 2–3% of elderly individuals (over 70 years) have chromosomal anomalies in 
blood samples [7]. We therefore suggest that our estimate of frequency may be conservative, 
since other types of alterations (such as gene fusions and copy number alterations) were not 
included in our study. Regardless, these data clearly show that the elderly often acquire clonal 
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“skewing” in their hematopoietic compartments and that this may represent a contributing factor 
to the development of hematologic malignancies.  
3.5 Methods  
We analyzed the peripheral blood sequence data from 2,728 individuals having had first-time 
primary cancer and no radiation or chemotherapy treatment. Exome data were aligned to human 
reference build 37 using BWA [38] and variants were identified using VarScan [39], GATK 
[40], and Pindel [41], with stringent downstream filtering to standardize specificity. Variant 
annotation was based on Ensembl release 70_37_v5. The list of 556 cancer-associated genes was 
compiled from publicly available screening panels, published studies, and preliminary analysis 
of publicly available data sources [11-15, 42]. Read count analysis was performed with our bam-
readcount tool, available at https://github.com/genome/bam-readcount. Low level blood-specific 
events were discovered using a two-stage process including pre-filtering candidate non-mosaic 
samples using Bayes’ Rule and then the detection of high probability mosaic sites using Fisher’s 
exact test.  
3.5.1 Variant calling and annotation strategies 
Exome sequencing data were aligned to NCBI Build 37 of the human reference using BWA 
v0.5.9 and de-duplicated using Picard 1.29.  Single nucleotide variants were identified by 
Varscan (version 2.2.6: –min-var-freq 0.1 –p-value 0.1 –min-coverage 8 –map-quality 10), and 
GATK (revision 5336: –T UnifiedGenotyper –R GRCh37-lite –et NO_ET –l INFO –U ALL –
validation_strictness SILENT). Indels were identified using Varscan (version 2.2.9: –min-
coverage 3 –min-var-freq 0.2 –p-value 0.1 –strand-filter 1 –map-quality 10), GATK 
(revision5336: –T IndelGenotyperV2 –R GRCh37-lite –window_size 300 –et NO_ET –U ALL), 
as well as Pindel (version 0.2.4x, May 8, 2013: –window-size 1). For Pindel analysis, we preset 
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the insertion size to 500 if this information is not provided in the BAM header. SNVs were based 
on the union of GATK and VarScan.  They were subsequently processed through our in-house 
false-positive filter (–min-homopolymer 10).  We required that indels were called by at least 2 
out of 3 callers (GATK, Varscan, Pindel). In addition we also included Pindel unique calls (at 
least 30X coverage and 20% VAF). All combined indels were then processed through our false 
positive filter (–min-homopolymer 10 –min-var-freq 0.2 –min-var-count 6). We then applied 
additional annotation and minor allele frequency filters as previously reported [10]. 
Variant transcript annotation is based on all human transcripts obtained from Ensembl Release 
70_37_v5. The reference alleles and positions were derived from the sequence and coordinates 
of GRCh37. All transcripts were annotated and a single representative was selected for each 
somatic mutation based on the significance of the predicted functional effect of each mutation, 
ordered from most significant to least significant as follows: nonsense, frameshift, splice site, in 
frame, missense, no stop (nonstop/readthrough), synonymous, and RNA. Splice site mutations 
were restricted to substitutions, deletions, or insertions overlapping the 2bp intronic sequence 
defined as the canonical splice donor or splice acceptor. RNA mutations were restricted solely to 
transcripts without an annotated open reading frame. Mutations affecting 3'UTR, 5'UTR, intronic 
sequence, and intergenic sequence were discarded for the purposes of downstream analysis. 
3.5.2 Recurrent somatic mutations in 12 cancer types 
We collected extensively filtered somatic variants in 3,355 TCGA samples from 12 cancer types 
(Supplementary Table 3.5), and selected recurrent mutations appearing more than once at a given 
genomic position (Supplementary Table 3.6). 
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3.5.3 Compiling cancer-associated gene list 
A total of 556 candidate cancer-associated genes were compiled using nine sources, including 
recently published large-scale cancer studies, publicly available screening panels, and 
unpublished preliminary analysis of publicly available data sources. The 204 genes shared across 
at least two of the nine sources were retained and a literature search was conducted to identify 
evidence supporting inclusion of any remaining unique genes. A subset of 518 genes originated 
from recent publications, including 294 genes from Frampton et al [15], 125 genes from Kandoth 
et al [11], 212 genes from Lawrence et al [13], 194 genes from Pritchard et al [14], and 124 
genes from Vogelstein et al [12]. Thirty-nine additional genes were included based on the 
analysis of driver mutations in 20 TCGA cancer types (unpublished), recommendations in 
accordance with the standards and guidelines of the American College of Genetics and 
Genomics [42], and 18 novel cancer driver genes identified in recently published large-scale 
studies (Supplementary Table 3.7). 
3.5.4 Readcount analysis and statistical approaches for identifying significant 
low level variants 
Read counts for variants were determined using our internally developed tool bam-readcount 
(https://github.com/genome/bam-readcount). For sites to be included in the downstream 
statistical test, we require greater than 30X coverage for both blood normal and matched tumor 
samples. We assessed the false-discovery rate (FDR) using a two-stage process. The first step is 
a purpose-specific pre-filter to eliminate candidates that can be confidently identified as having 
originated from non-mosaic samples, as these identically fail the inclusion criterion for 
significance testing. It targets deeply covered sites whose apparent variant reads actually 
represent base-calling errors. Take the sample space for blood classification as consisting of two 
mutually exclusive, collectively exhaustive (MECE) statuses, “normal”, S=N, and “mosaic”, 
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S=M, and let the candidate blood site data, D, consist of T spanning reads, of which V and T-V 
report variant and reference counts, respectively. If we presume that the rate of mosaicism (the 
fraction of altered cells, assumed as roughly 2%), ρ, is much larger than the Phred-determined 
likelihood of base-calling error for any single read, ε, i.e. ρ/ε>>1, then the conditional 
probabilities are binomial, , where  is the number of combinations of T 
objects chosen V at a time and p=ε for S=N and p=ρ for S=M. Given a prior estimate of 
P(N)=0.999, we can formulate P(N|D) directly from Bayes’ Rule, from which additional 
algebraic manipulation and suitable asymptotic approximation show 
  . 
Candidates are culled as non-mosaic if this probability exceeds 95%, though in practice most 
cases actually removed have P(N|D)>99.5%. The remaining set of events is subsequently passed 
to the second step, which is a traditional Fisher exact (table) test for association between sample 
type and variant allele fraction followed by standard Benjamini-Hochberg FDR assessment. We 
report events having ≤20% FDR with at least 3 supporting reads and greater than 2% variant 
allele fraction. 
3.5.5 Analysis of NHLBI ESP data 
NHLBI variants calls for 6,503 samples were downloaded from the NHLBI Exome Variant 
Server http://evs.gs.washington.edu/EVS/. All variants were processed using the same tools as 
for the TCGA cohort. For comparative analysis, all ESP variants are filtered for < 0.1% total 
MAF to minimize false positives. The Women's Health Initiative Exome Sequencing Project 
(WHISP) is part of the National Heart, Lung, and Blood Institute’s (NHLBI), Grand Opportunity 
Exome Sequencing Project (https://www.fhcrc.org/en/labs/phs/projects/cancer-
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P N |D( )= 1
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prevention/projects/whisp.html). WHISP data for 614 samples were downloaded from dbGaP, 
verified for file integrity, and then imported as BAM files into our data warehouse. Alignment to 
the reference genome GRCh37-lite was carried out using BWA v0.5.9 with parameters –t 4 –q 5 
and marking of duplicates by Picard v1.46. Variant calling was performed as described in the 
“Variant calling and annotation strategies”. For quality control purposes, we included WHISP 
samples with read mapping rates greater than 80%, duplication rates less than 40%, and at least 
10,000 SNVs detected in the target region. The 557 Caucasian WHISP samples selected for this 
study, on average, had mapping rates of ~95%, duplication rates of ~9%, and ~18,000 SNVs 
called in the target region. 
3.5.6 Deep sequencing validation 
Five candidate low-level variants (two R882C and one R882H sample sites in DNMT3A, one 
V617F in JAK2, and one K700E in SF3B1), 5 positive controls, and 4 negative controls were 
selected for validation using deep sequencing (Supplementary Table 3.10). Primer pairs tailed 
with sample-specific indexes were designed for individual target sites and further used for PCR 
amplifications. Indexed libraries were made for tumor and blood pools respectively. We then 
generated sequencing data using 1 lane of MiSeq run with read length of 2x250. Custom 
references were created by including specific primer and index sequences. MiSeq reads were 
aligned to the custom references using BWA (bwa aln –t 8; bwa sampe). Allelic counts for the 
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Table 3.1: Blood-specific mutations in 9 recurrently mutated genes identified in TCGA 
cases. Asterisks indicate nonsense mutations. VAF represents variant allele fraction. 11 cancer 
types were investigated in this study: BRCA (breast adenocarcinoma), GBM (glioblastoma 
multiforme), HNSC (head and neck squamous cell carcinoma), KIRC (kidney renal clear cell 
carcinoma), LGG (brain low grade glioma), LUAD (lung adenocarcinoma), LUSC (lung 
squamous cell carcinoma), OV (ovarian carcinoma), PRAD (prostate adenocarcinoma), STAD 






Type Age VAF Type Age VAF 
DNMT3A 
p.R882C 
GBM 81 15.79% 
JAK2 p.V617F 
GBM 57 21.52% 
STAD 60 18.29% GBM 72 73.39% 
STAD 69 12.17% KIRC 59 28.57% 
p.R882H 
BRCA 62 21.43% LGG 45 15.87% 
GBM 64 35.56% LUAD 72 27.62% 
LUSC 76 31.91% LUAD 76 41.62% 
e13+1 
KIRC 79 15.94% UCEC 59 35.90% 
LUAD 76 11.11% UCEC 74 42.92% 
p.E469* GBM 72 20.60% 
ASXL1 
p.Q575* LUAD 75 20% 
p.F851fs BRCA 64 34.88% p.Q733* LUAD 72 14.29% 
p.K577fs HNSC 72 24.14% p.Q733fs UCEC 81 27.27% 
p.N516fs LUSC 71 33.33% p.R548fs LUAD 76 35.03% 
p.S770* STAD 75 16.03% p.Y591* STAD 65 17.88% 
p.W314* UCEC 74 22.06% p.Y591fs LUSC 56 29.70% 
p.Y584fs GBM 75 38% 
TP53 
p.C275Y OV 52 14.29% 
e12-1 PRAD 60 35.79% p.Q136* LUAD null 18% 
e21-2 GBM 76 11.81% p.Q144* STAD 62 15.96% 
e22-1 UCEC 77 33.85% p.R273L LUAD 70 34.62% 
TET2 
p.F381fs GBM 83 50% 
GNAS p.R202H 
GBM 76 14.44% 
p.H863fs GBM 64 11.67% HNSC 59 11.54% 
p.K889* OV 85 15.09% LUAD 69 21.43% 
p.Q531* KIRC 48 11.90% 
PPM1D 
p.Q520* BRCA 79 35.42% 
p.Q644* UCEC 89 16.78% p.S468* UCEC 49 21.23% 
p.Q764fs GBM 75 33.01% 
BCORL1 
p.G883E LUAD null 16.67% 
p.Q831fs LUAD 75 26.42% p.S264* PRAD 56 22.45% 
p.Q888* GBM 83 20.39% 
SF3B1 p.K700E 
GBM 89 13.86% 
p.R550* LUAD 76 16.25% KIRC 77 43.04% 
p.T229fs GBM 72 19.05% 





Figure 3.1: Blood-specific mutations identified in 58 out of 2,728 TCGA cases from 11 
cancer types. (a) Rose chart illustrating the distribution of blood-specific nonsynonymous 
mutations in 31 genes. The variant allele fractions (VAF) of the 77 mutations are indicated in the 
center. (b) Rose chart illustrating the age distribution of samples with blood-specific mutations. 
Higher frequencies of blood-specific mutations are found in older age groups (60s, 70s, and 80s) 
versus younger ones (40s and 50s). The cancer type distribution is shown in the center. (c) 
Distribution of blood-specific mutations in DNMT3A, TET2, JAK2, ASXL1, SF3B1, and GNAS in 
different age groups. Total includes all blood-specific mutations in 556 cancer associated genes 





Figure 3.2: Blood-specific mutations and their association with age. (a) Box plot showing 
positive correlation between blood-specific mutations in leukemia/lymphoma genes and age. 
Age information is not available for one of the 58 cases with blood specific mutations. (b) The 
wide spectrum and lower average variant allele fractions in blood-specific mutations, compared 





Figure 3.3: Low VAF blood-specific, hotspot mutations identified in the TCGA and 
WHISP cohorts using a readcount based approach. Blood-specific mutations identified by 
the variant detection pipeline are in blue. An additional 14 blood-specific events (13 shown in 
green) with VAFs between 2% and 10% were identified in the TCGA samples and their positive 
associations with older ages were confirmed. 13 hotspot variants were identified in WHISP 
samples (n = 557) and seven (in green) have variant allele fractions ranging from 2% to ~10%. 
One JAK2 V617F identified in a TCGA sample was not shown due to a VAF higher than 50%. 








Figure 3.4: Comparison of mutation frequencies in blood samples from 58 TCGA cases 
with mutations in cancer-associated genes in 151 MPN, 150 MDS, 160 CLL, and 200 AML 
cases. (a) Mutation frequencies of major genes involved in hematological malignancies. (b) The 
average number of non-synonymous mutations found in TCGA blood normal cases, MPN, MDS, 






Figure 3.5: Clonal expansion model. The distinct roles of a set of genes including DNMT3A, 
ASXL1, TET2, GNAS, JAK2, PPM1D, IDH1, NRAS, NPM1, and FLT3 in the initiation of 




Chapter 4: Genome-wide Pre-existing 
Genomic Alterations in Noncancerous Blood 
Associated with Clonal Hematopoietic 
Expansion  
4.1 Abstract 
Cancer development is a prolonged process. Mutations that initiate clonal expansion could exist 
in patients many years before disease symptoms are apparent. It is essential to identify and 
characterize these early mutations in order to understand the genetic basis of tumorigenesis. 
Here, I processed 5,949 normal blood samples from participants in TCGA and developed a 
statistical approach to systematically identify blood-specific mutations across all human genes. 
13,345 blood-specific mutations in total were discovered, and they were significantly enriched in 
cancer and AML-associated genes. Blood-specific mutations were significantly distributed 
across 26 genes, including well-known hematologic malignancy associated genes (e.g., 
DNMT3A, ASXL1, TET2, JAK2, IDH2, and SF3B1), as well as previously unreported genes, 
including PPM1D. All blood-specific PPM1D truncation mutations identified in our study were 
located in the C-terminal regulatory domain, and functional validation showed that they 
suppressed phosphorylation of p53 at Ser15 in vitro. Lastly, I also identified blood-specific 
CNVs associated with genes related to clonal expansion. This comprehensive analysis of 
genomic alterations in noncancerous blood samples sheds light on the complex origins of 
hematologic malignancies and could facilitate the development of strategies for early detection 




Blood cells are generated by the proliferation and differentiation of a very small population of 
pluripotent HSPCs, which have the ability to replenish themselves by self-renewal [1]. To ensure 
genomic stability and retain their capability, HSPCs rarely divide so as to avoid mutation 
occurrence and accumulation in the genome [2]. However, mutations are inevitable during cell 
division, and some of them have the potential to cause clonal hematopoietic expansion in 
“healthy” individuals before they develop severe disease symptoms.  What such mutations are 
and how they drive clonal hematopoietic expansion are still unclear so far. 
Recently, a few research groups have investigated these questions using large-scale sequencing 
data derived from individuals without overt hematologic disorders [3-5]. Two groups used blood 
samples alone to identify somatic mutations and found that the frequency of somatic mutations 
leading to clonal hematopoietic expansion increased with age and that about 10% of individuals 
older than 65 years carried these high-risk mutations in genes associated with myeloid and 
lymphoid cancers [3, 4]. These studies preliminarily provided insights into the connection 
between aging and the initiation of hematologic cancer. However, due to the lack of appropriate 
control samples from the same individual, the accuracy of somatic variant detection is 
concerning.  
In a previous study, we analyzed blood-derived sequence data from TCGA and assessed the 
incidence of specific mutations within 556 cancer-associated genes by comparing variant allele 
fractions between blood and matched tumor tissues [5]. We found that the majority of somatic 
mutations identified in blood samples occurred in leukemia/lymphoma associated genes, 
including DNMT3A, TET2, JAK2, ASXL1 and so on. However, since this study was limited to 
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candidate genes recurrently mutated in cancer, more comprehensive investigation of all human 
genes is needed. 
Furthermore, structural variants, particularly copy number alterations, associated with 
hematologic malignancies were also observed in normal blood samples [6-8]. 2-3% of persons 
older than 70 years of age carried large chromosomal abnormalities involving genes associated 
with hematologic cancers [7, 8]. However, precisely identifying blood-specific somatic structural 
variants and characterizing their roles in the clonal hematopoietic expansion remains a challenge.   
Here, I studied 5,949 whole exome sequencing data from TCGA, and systematically investigated 
blood-specific genomic alterations, including SNVs, small indels, and copy number variants 
(CNVs) across all human genes. To precisely determine somatic events, the matched tumor-
adjacent normal tissue or tumor tissue from the same individual has been processed in the 
identical way such that it effectively can serve as a control. In this study, we showed a 
comprehensive genomic alteration profile within noncancerous blood cells and investigated the 
association between these alterations and hematologic cancer, and this study will benefit our 
understanding of hematologic cancer progression and future investigation for clinical 
applications. 
4.3 Results 
4.3.1 Exome-wide discovery of pre-existing mutations in blood 
To identify blood-specific somatic mutations, I analyzed whole exome sequencing data 
generated from peripheral blood cells of 5,949 TCGA participants with no reported overt 
hematological malignancy. Samples represented 21 diverse cancer cohorts (Table 4.1). The 
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average age of these participants was 59 years old (ranging from 10 to 90), 3,639 were women 
(57.4%), and 4,738 were Caucasian (75.2%).  
Variant calling in blood samples was conducted using previously described methods [5, 9]. The 
final set of variants was composed of 1,071,919 missense, 26,423 nonsense, 25,803 frame shift 
indels, 13,215 splice site mutations, and 1,202 nonstop mutations. By performing read count–
based statistical analysis for all of the variants identified in copy number neutral regions (see 
Methods), 29,232 missense variants (2.7%) and 1,704 truncation variants (2.6%; nonsense, frame 
shift indel, nonstop, and splice site mutations) were classified as blood-specific somatic 
mutations. To capture potentially pathogenic missense mutations, further analysis was restricted 
to the set of missense mutations occurring in highly conserved sites (UCSC conservation score = 
1.0; 11,641 missense variants remained).  
The average variant allele fraction (VAF) of these mutations is 23.4% in blood samples and 
2.6% in control samples (tumor or adjacent normal samples). Compared to the germline 
mutations identified in the same cohort, whose average VAF should be 50%, blood-specific 
mutations were only present in a small subset of the cells from which we obtained DNA for 
analysis, suggesting the presence of an early stage of clonal expansion (Figure 4.1a).  
In addition, I detected well-known acute myeloid leukemia (AML) hotspot mutations in these 
5,949 individuals using methods described previously [5] and identified a set of deleterious 
mutations that were significantly enriched in normal blood samples, including DNMT3A/R882 
(28 cases), JAK2/V617F (19 cases), IDH2/R140Q (11 cases), SF3B1/K700E (6 cases), and 
GNAS/R202H (6 cases) (Supplementary Table 4.1).  
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4.3.2 Significantly mutated genes associated with clonal hematopoietic 
expansion 
In all of the detected blood-specific mutations, 944 were present in 351 cancer-associated genes, 
selected based on several recent studies [10-14], and 628 mutations occurred in 176 genes that 
were recurrently mutated in de novo AML (Supplementary Table 4.2) [15]. Considering the 
small fraction of cancer and AML-associated genes in the human genome, blood-specific 
somatic mutations were significantly enriched in these two gene groups (p < 2.2e-16, 
respectively, Fisher’s exact test) (Figure 4.1b). This result indicates that the mutations observed 
in blood samples were not randomly distributed, but rather, those associated with hematologic 
malignancy appear more likely to be retained. 
A total of 181 genes were truncated in at least 2 individuals, including 26 cancer-associated or 
AML-associated genes. By combining the highly conserved missense mutations and AML 
hotspot variants, I performed the significantly mutated gene (SMG) test using the Mutational 
Significance in Cancer (MuSiC) suite of tools [16]. This analysis yielded 26 genes with a higher-
than-expected mutation prevalence [false discovery rate (FDR) < 0.01], including genes with 
well-known relevance to hematologic malignancies (e.g., DNMT3A, ASXL1, TET2, JAK2, IDH2, 
and SF3B1), genes that have been implicated in the pathogenesis of hematologic diseases (such 
as EPHB2 [17], PTN [18], TIE1 [19], GNB1 [20], and ASH1L [21]), as well as the genes that 
have not been reported in leukemia/lymphoma studies, such as PPM1D, SPOP, MYH4, EMID2, 
FRG1, FRG1B, PCMTD1, TMEM196, ZNF318, EPPK1, GBAS, MORC2, SLC9A4, ZKSCAN4, 
and TMC1 (Figure 4.2, Supplementary Table 4.3).  
DNMT3A, TET2, ASXL1, and JAK2 were the top four most frequently mutated genes in our 
study, identified in 149 individuals, accounting for about 2.5% of the entire discovery cohort. 
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Remarkably, approximate 60% of DNMT3A mutations were potentially deleterious (26 
truncation mutations and 29 R882 hotspot mutations), while for ASXL1, TET2, and JAK2, the 
ratio of potentially deleterious mutations was 100%, 86.4%, and 88.2%, respectively. The 
existence of these putative driver mutations associated with hematological malignancies 
suggested that a premalignant state was common in asymptomatic persons.  
Besides, TP53 and NRAS were also significantly mutated in the normal blood samples (FDR = 
0.014 and 0.015, respectively), suggesting that they were likely to be involved in the process of 
early clonal hematopoietic expansion as well. In addition, a few leukemia/lymphoma-associated 
genes, such as KDM6A, MLL3, and ATM, did not pass the SMG test, but were recurrently 
mutated in the normal blood samples. For instance, 4 individuals had KDM6A mutations, 11 
individuals carried ATM mutations, and 13 cases observed with MLL3 mutations. Although these 
genes were frequently mutated in normal blood samples, more evidence is needed to determine if 
they are involved in the initiation of clonal expansion.  
4.3.3 Identification of somatic CNV from blood samples using whole exome 
sequencing data 
Chromosomal deletions and amplifications are often found in patients with AML and 
myelodysplastic syndromes [22, 23]. To investigate if the hematologic malignancy associated 
CNVs are present in noncancerous blood samples, I characterized the blood-specific CNV events 
from the same cohort using a statistical toolset, XHMM [24], which is specifically designed for 
detection of exon-resolution CNVs using whole exome sequence data (see Methods).  
After systematically removing the individual, batch, and target effects by principal-component 
analysis of XHMM, I identified 143,455 CNVs from 5,456 individuals. Since common CNVs 
usually do not confer much advantage for diseases, I restricted the analysis to rare CNVs with a 
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minor allele frequency (MAF) of less than 0.5% by filtering out common instances in more than 
55 individuals. Due to technical concerns, only CNVs on autosomal chromosomes were retained 
for the following analysis. To identify the high-confidence somatic CNVs in blood, I compared 
the genotyping quality scores of each rare CNV called in blood samples to the relevant target 
region in the control samples, such as tumor sample or adjacent normal sample from the same 
individual, and only those whose genotype in control were determined to be diploid with high 
certainty (quality score ≥ 60) were categorized as blood-specific somatic CNVs.  
Using this method, 13,522 rare CNVs in autosomal chromosomes (about 22.9% of all well-
defined, rare CNVs detected in the blood samples) were categorized as blood-specific. 
Duplication events were much more common than deletions, with 8,584 duplications (median 
length of 14.5 kb, ranging from 0.07kb to 3.6 Mb) and 4,938 deletions observed (median length 
of 18.5 kb, ranging from 0.12 kb to 3.7 Mb) (Figure 4.3a). About half of individuals (2,407, 
44.1%) were detected to have rare blood-specific CNVs, with 881 individuals (16.1%) carrying 
only one rare CNV and 396 individuals (7.2%) carrying more than 10 (Figure 4.3a). On average, 
each individual carried 5.6 blood-specific rare CNVs (3.58 duplications and 2.05 deletions). The 
average age of individuals carrying blood-specific CNVs is 60.1 years old, which is significantly 
older than the average age of the individuals without blood-specific CNV (57.3 years old, p-
value = 9.647e-13, student t-test) (Figure 4.3b).     
4.3.4 Somatic CNVs associated with clonal hematopoietic expansion  
The rare blood-specific CNVs observed in this cohort affected 8,329 unique autosomal genes. Of 
these genes, 58 were previously well-defined cancer-associated genes [12], including 25 
oncogenes observed in copy number duplication regions, and 18 tumor suppressor genes in copy 
number deletion regions, in 154 individuals (Figure 4.4a, Supplementary Table 4.4).  16 of these 
93 
 
genes occurred in more than one sample, such as KIT (2 cases), MET (2 cases), ACVR1B (2 
cases), RB1 (2 cases), SMARCA4 (2 cases), CTNNB1 (3 cases), ERBB2 (3 cases), FLT3 (3 cases), 
MLL3 (4 cases), MLL2 (5 cases), MSH6 (5 cases), JAK2 (5 cases), PIK3CA (5 cases), EGFR (7 
cases), CASP8 (7 cases), and NOTCH2 (9 cases) (Figure 4.4a). Importantly, most of these genes 
were associated with hematological malignancies.  
In addition, several genes that were previously reported as clonal expansion-related genes were 
also affected by blood-specific CNVs. For example, ASXL1 was entirely deleted in an 88-year 
old individual (Figure 4.4b), and CREBBP was partially deleted in another 68-year old 
individual. GNAS, IDH2, and SF3B1 were found in the CNV duplication region from older 
individuals as well (88, 76, 81 years old, respectively) (Supplementary Table 4.4).  Although 
DNMT3A and TET2 were recurrently mutated in normal blood samples, no blood-specific CNVs 
were found to be associated with them, even though they were amply covered by data across all 
samples (Supplementary Figure 4.1).  
4.3.5 Somatic gain-of-function PPM1D mutations in normal blood samples 
We identified one novel recurrently mutated gene, PPM1D, with significant enrichment of 
somatic mutations in blood samples. The average VAF of PPM1D mutations in the discovery 
cohort was even higher than that of DNMT3A, TET2, or ASXL1, suggesting that PPM1D has the 
potential to play an important role in clonal hematopoietic expansion. However, besides its 
association with breast and ovarian cancer predisposition [25], PPM1D has not been reported in 
any hematologic malignancy study.  
To confirm that PPM1D mutations are also present in an independent set of normal blood 
samples, I examined the ExAC (The Exome Aggregation Consortium) database and found 17 
PPM1D rare truncation mutations in 60,706 unrelated individuals (Supplementary Table 4.5). 
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All of these mutations occurred in the C-terminus, and 16 of them were located in the exon 6, 
which is consistent with our TCGA discovery cohort (Figure 4.5a).  
PPM1D functions as a phosphatase that dephosphorylates and inactivates many DNA damage 
response mediators such as TP53 [26]. It has been reported that PPM1D truncating alterations in 
the C-terminus could enhance the ability of PPM1D to hinder activation of DNA damage 
response proteins [27]. To examine the functional consequences of the PPM1D blood-specific 
mutations identified in our study, I assessed the impact of 3 truncation mutations, C478*, Q520* 
and K549fs, as well as 2 missense mutations, Q404E and R599K, on TP53 phosphorylation by 
introducing them into HEK293T cells, which carry wild-type TP53. As controls, I also 
introduced wild-type PPM1D, a phosphatase-dead D314A PPM1D mutant, and vector alone into 
HEK293T cells, respectively. Expression of the PPM1D mutants decreased the level of 
phosphorylation of TP53 at Ser15 after 10 Gy of irradiation (Figure 4.5b). This effect was also 
achieved by expressing wild-type PPM1D but not as strong as PPM1D mutant. These results 
demonstrated that blood-specific PPM1D mutants retained phosphatase activity against TP53, 
and suggested that PPM1D mutations were potentially involved in the cell proliferation 
regulation, stopping the cells from apoptosis after DNA damage. However, to fully evaluate the 
impact of PPM1D mutations in cell proliferation and clonal hematopoietic expansion, more in 
vivo experiments are needed.  
4.4 Discussion  
We observed that blood-specific somatic mutations were commonly present in healthy 
individuals, and the frequency of potential driver mutations (truncation mutations in cancer-
associated genes) in the general population is consistent with previous studies [3-5]. While taking 
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highly conserved missense mutations into consideration, the fraction of people carrying 
mutations in cancer genes increases to 7.9% in their 50s and 16.6% in 70s.  
I identified 26 SMGs with blood-specific somatic mutations in this study, including 6 established 
drivers for hematologic malignancy, such as DNMT3A, ASXL1, TET2, JAK2, IDH2, and SF3B1. 
Approximate 3.0% of individuals carried blood-specific mutations in these 6 genes. Of the 
remaining SMGs, 4 genes appear to be involved in leukemia/lymphoma. EPHB2 (Ephrin type-B 
receptor 2) was found to play important roles in colon cancer development and glioma cell 
invasion [28, 29]. It was recently reported that EPHB2 was strongly expressed in CD133+ cells 
and half of CD34+ cells, suggesting that it might play a role in HPSC function through regulatory 
effects on cell adhesion, migration, and differentiation [17]. GNB1 [Guanine nucleotide binding 
protein (G Protein), beta polypeptide 1] is involved in the PI3K-Akt signaling pathway, and 
recurrent GNB1 mutations conferred cytokine-independent growth in IL-3 dependent lymphoid 
cells and promoted myeloid dendritic cell neoplasms in vivo [20]. PTN (Pleiotrophin) is an 
angiogenic factor during tumor growth and promotes invasion and metastasis in different tumor 
types [30, 31]. PTN was highly expressed in CD19+ B cells from B-cell acute lymphoblastic 
leukemia (ALL) and B-cell chronic lymphocytic leukemia (CLL) patients, which suggests that it 
could be involved in the development of lymphocytic leukemia [18]. Tie1 (tyrosine kinase with 
immunoglobulin-like and EGF-like domains 1) was expressed in the very early stages of 
hemopoietic and endothelial cell development, and it might be associated with the initial stage of 
B-cell CLL [19]. 
In this study, I found PPM1D truncation mutations were enriched in blood samples, and all of 
these truncation mutations were located in the protein’s C-terminal regulatory domain. In vitro 
validation experiments demonstrated that these mutations increased PPM1D function on the 
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regulation of TP53 phosphorylation after DNA damage, suggesting that PPM1D blood-specific 
mutations might have regulatory effects on cell proliferation. Considering similar mutations 
found in ExAC, PPM1D has the potential to be involved in the early stages of clonal 
hematopoietic expansion.  
In addition, I found that blood-specific CNVs were commonly present in healthy individuals. At 
least 58 cancer-associated genes were affected by these CNVs. Some of the somatic CNVs were 
associated with clonal expansion related genes, such as JAK2, FLT3, ASXL1, CREBBP, IDH2, 
SF3B1, MLL3, and GNAS. All of these results suggested that CNVs might be an important 
contributor to the clonal hematopoietic expansion. Although DNMT3A and TET2 were 
frequented mutated in normal blood samples, no CNV events were found so far associated with 
these two genes. It could be due to the small sample size, or limitation of CNV detection using 
exome-sequencing data, but it also could indicate that point mutations and short indels are two 
major alteration forms for these two genes, but not CNVs. To fully explain that, additional 
sequencing data, especially whole genome sequencing data, or SNP-array data might be crucial.   
In summary, this study provides a comprehensive profile of genomic alterations in noncancerous 
blood samples. It reveals that genomic alterations associated with clonal hematopoietic 
expansion are commonly present in older individuals, suggesting a potential risk of pre-
malignancy in asymptomatic persons. This study provides numerous potential targets for novel 





4.5.1 Variant calling and annotation strategies 
Whole exome sequencing data from blood samples were aligned to NCBI human reference Build 
37 using BWA v0.5.9 and then de-duplicated using Picard v1.29. SNVs were detected by 
VarScan (v2.2.6) and GATK (revision 5336: −T UnifiedGenotyper). Only the SNVs called by 
both GATK and VarScan and passing our in-house false-positive filter (−min-homopolymer 10) 
were retained for the following analysis. Indels were identified using VarScan (v2.2.9), GATK 
(revision5336: −T IndelGenotyperV2), and Pindel (0.2.4x). We required that indels were 
detected by at least 2 out of 3 software (GATK, VarScan, Pindel). In addition, Pindel unique 
calls (minimal 30× coverage and 20% VAF) were also included. Moreover, then, all combined 
indels were processed through the false-positive filter (–min-homopolymer 10 −min-var-freq 0.2 
−min-var-count 6). Additional annotation and minor allele frequency filters were applied as 
previously reported [5, 9]. 
Variant transcript annotation is based on all human transcripts obtained from Ensembl Release 
70_37_v5. All transcripts were annotated and one single representative was selected for each 
variant based on the significance of the predicted functional effect, ordered as follows: nonsense, 
frame shift indels, splice site, in-frame indels, missense, nonstop, and synonymous. Splice site 
mutations were restricted to substitutions, deletions or insertions overlapping the 2-bp intronic 
sequence defined as the canonical splice acceptor or splice donor. Mutations affecting 3′ UTR, 5′ 
UTR, intergenic sequence and intronic sequence were discarded for the downstream analysis. 
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4.5.2 Determination of the blood-specific mutations  
Read counts for variants were determined using our internally developed tool bam-readcount. 
The variants, which were located on copy number neutral regain, had read coverage greater than 
20× in both blood normal and matched control samples (tumor or adjacent normal), and variant 
supporting reads in blood sample greater than 2, were retained for the downstream statistical test. 
Let the data on the candidate variant as D, consist of T spanning reads, of which V and T–V 
represent variant and reference counts, respectively, and variant allele fraction as p, and the 
conditional probabilities can be calculated based on binomial distribution as equation (1): 
 
Subsequently, we formulate P(Variant_Status|D) directly from Bayes’ rule as the following 
equation (2):  
 
Here, pB and pT indicate variant allele fraction in the blood sample and tumor/adjacent-normal 
sample, respectively, and t and v represent spanning reads and variant supporting reads for 
candidate variant in tumor/adjacent-normal sample.  
Taking the variants in blood samples classified as two mutually exclusive, collectively 
exhaustive statuses, ‘Germline Variants’, S = G, and ‘Blood-specific Somatic Variants’, S = S, 
we can determine the variant status of each candidate by calculating LOD (log odds) score: 
 
 
P(Variant _ Status |D) = (CT ,V pB
V (1− pB )T−V )(Ct,v pTv (1− pT )t−v )P(Variant _ Status)
P(DB,DT )
       (2)
P(D |Variant _ Status) =CT ,V pV (1− p)T−V                                                                       (1)
LOD = ln P(S |D)P(G |D)
        =V ln( pS,BpG,B
)+ (T −V )ln(1− pS,B1− pG,B
)+ v ln( εpG,T
)+ (t − v)ln( 1−ε1− pG,T
)+ ln P(S)P(G)         (3)
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We conservatively set VAF to 0.5 for a germline heterozygous variants in both blood and 
tumor/adjacent-normal samples, while for blood-specific variants in tumor/adjacent-normal 
sample, we assume the VAF in tumor/adjacent-normal is equal to the probability of error of that 
base call (each base has an associated Phred-like quality score q where ε = 10-q/10). Based on the 
pan-cancer analysis, the median frequency of somatic mutation, P(S), in leukemia is 0.037 per 
Mb [10,11], and the frequency of rare germline mutation, P(G), is 50 per Mb. To obtain the high-
confident blood-specific mutation, we use very stringent LOD score, 2.94, as a cutoff, which 
indicates P(S|D) as 95% and P(G|D) as 5%.  
4.5.3 Significantly mutated genes analysis 
We applied the SMG test in the MuSiC suite to identify significant genes. This test assigns 
mutations to seven categories: AT transversion, AT transition, CG transition, CpG transition, 
CpG transversion, CG transversion, and indel, and then uses statistical approaches based on 
convolution, the hypergeometric distribution (Fisher’s exact test), and likelihood to combine the 
category-specific binomials to calculate overall P values. All P-values were combined using the 
methods described previously [9].  
4.5.4 Copy number alteration detection 
Copy number alterations were called by XHMM as described previously [24]. The exome 
information of human gene transcripts was downloaded from Ensembl Release 70_37_v5, 
padded by 2 bp on each side. The mean depth of sequencing coverage on each exon was 
calculated by GATK DepthOfCoverage module (mapping quality greater than 20) across all of 
the 388,584 targets for the exome sequencing data from 5,949 individuals, including blood 
samples, tumor-adjacent normal samples or tumor samples. Samples and targets with outlier 
read-depth values, low complexity, and extreme GC content were filtered out before principal-
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component analysis and read-depth normalization [24]. Taking use of PCA-normalized read-
depth data and removing any targets with high read-depth variance (standard deviation greater 
than 30), sample-level z scores of read depths were calculated by centering relative to all target 
depths in the sample. After that, CNVs were called using default XHMM parameters. In 
addition, all called CNVs were statistically genotyped by forward–backward HMM algorithm 
across all samples. 
4.5.5 Identification of rare blood specific CNV  
To select the rare events, any CNV that overlaps 50% of another CNV that occurs in more than 
1% of all individuals (55 in our study)  was filtered out [24]. To identify the high confident 
blood-specific somatic CNV, we require its quality score (SQ) greater than or equal to 60 in the 
blood sample, and the NQ (Phred-scaled qualities of No CNV event) greater than or equal to 60 
in the matched control sample (tumor-adjacent normal or tumor samples) as well. Genes 
overlapped with the blood specific CNVs were collected for the following analysis.  
4.5.6 Cell culture, transfection, and irradiation  
HEK293T cells were cultured in DMEM (Invitrogen) media supplemented with 10% FBS 
(Gibco). For transfection experiments, HEK293T cells were plated in six-well plates and 
transfected with 2 µg of plasmid using Lipofectamine 3000 (Invitrogen). After 24 h of 
transfection, the cells were exposed to 10 Gy of gamma irradiation (X-rays) and were harvested 
at 2 hours after irradiation.  
4.5.7 Western blotting  
Cells were washed twice with ice-cold 1× PBS and then suspended in RIPA lysis buffer (Santa 
Cruz Biotechnology) supplemented with protease inhibitor (Santa Cruz Biotechnology). After 
sonication and centrifugation, the protein concentrations were measured by bicinchoninic acid 
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(BCA) assay. A total of 30 µg of protein per sample was denatured at 70 °C for 10 min with 
NuPAGE LDS Sample Buffer (Life Technologies) and resolved by electrophoresis. Proteins 
were transferred to a nitrocellulose membrane, and membranes were blocked in Odyssey 
blocking buffer (LI-COR). After blocking, membranes were incubated with primary antibody, 
including mouse antibody to PPM1D (Santa Cruz Biotechnology, sc-376257); rabbit antibody to 
GAPDH (Santa Cruz Biotechnology, sc-25778); rabbit antibody to p53 (Cell Signaling 
Technology, 9282); rabbit antibody to p53 phosphorylated at Ser15 (Cell Signaling Technology, 
9284), overnight at 4 °C. Membranes were washed four times using 1x PBS with 0.1% Tween-
20 and then incubated with infrared fluorescence, IRDye® secondary antibodies for 45 mins, and 
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(Year +/- S.D.) 
BLCA 215 67.87 +/- 11.17 
 
LUAD 363 65.13 +/- 9.721 
BRCA 874 58.12 +/- 12.84 
 
LUSC 220 66.61 +/- 8.947 
CESC 175 48.09 +/- 13.07 
 
OV 358 59.46 +/- 11.47 
COAD 262 65.53 +/- 13.18 
 
PRAD 283 60.51 +/- 6.948 
GBM 340 60.14 +/- 13.34 
 
READ 106 63.92 +/- 12.15 
HNSC 459 60.98 +/- 11.89 
 
SARC 122 61.31 +/- 14.16 
KICH 8 47.12 +/- 11.48 
 
SKCM 343 56.97 +/- 15.75 
KIRC 72 58.23 +/- 11.57 
 
STAD 254 65.63 +/- 10.45 
KIRP 103 57.69 +/- 12.33 
 
THCA 392 46.46 +/- 15.63 
LGG 449 43.0 +/- 13.49 
 
UCEC 463 63.83 +/- 11.16 
LIHC 88 59.94 +/- 14.12 
    








Figure 4.1: Blood-specific mutations identified in 2,363 TCGA cases from 21 cancer types. 
(a) Blood-specific somatic mutations were only present in a small subset of blood cells. Variant 
allele fraction distributions in blood samples are shown here, red indicating germline variants 
and green indicating blood-specific somatic mutations.  (b) Blood specific somatic mutations 
were enriched in the cancer-associated and AML-associated genes. The red bar represents the 
number of mutations in each given gene group. Blue bar indicates the folder change of mutations 
in each given gene group compared to the fraction of each gene group in all human genes. The p-






Figure 4.2: Significantly mutated genes identified in blood samples. The plot illustrates 
mutation frequencies of 26 SMGs and 5 recurrently mutated leukemia/lymphoma-associated 
genes, red representing truncation mutations and blue indicating highly conserved missense 
mutations. Purple dots on the top of each bar indicate significant events, with the size of dots 







Figure 4.3: Overview of rare CNVs identified by XHMM in blood samples. (a) 
Characterization of rare CNVs across all of the participants. The histogram indicates the 
distribution of the number of rare CNVs and blood-specific rare CNVs per individual, and pie 
chart denotes the fraction of CNV deletion and duplication identified in blood samples. (b) 
Positive correlation between blood-specific CNV and carriers’ age. Graph shows median central 








Figure 4.4: Cancer-associated genes affected by rare blood-specific CNVs. (a) Tumor 
suppressor genes and oncogenes were affected by CNV deletion and duplication in blood. (b) 
Copy number variation region plot for ASXL1. This plot shows normalized read depths at given 
targets across all the individuals with blood-specific CNVs. Samples with deletion were colored 
in red, duplications in green, and diploid in brown. Purple indicates the annotated gene region, 













Figure 4.5: Functional validation of PPM1D blood-specific somatic mutations. (a) Blood-
specific mutations were identified in PPM1D. Each dot corresponds to one case, orange, blue 
and dark green denoting nonsense mutations, missense mutations, and frame-shift indels, 
respectively. Variants in different functional domains are indicated with colors as follows: 
orange, PP2Cc, serine/threonine phosphatase, family 2C, catalytic domain; and purple, PP2C, 
protein phosphatase 2C domain. (b) Impact of PPM1D mutations on the phosphorylation of 
TP53 after DNA damage. Western blot shows the expression level of PPM1D, GAPDH, TP53 
and TP53 phosphorylation at Ser15 with or without UV treatment. Indicated in the legend are the 
plasmids transfected to test. ‘Mock’ is empty vector and ‘WT’ represents wild-type PPM1D 





Chapter 5: Discussion and Future Directions  
In cancer genome studies, blood samples represent a critical resource for revealing genetic 
alterations associated with cancer progression. Making use of TCGA whole exome sequencing 
data, we have identified many germline variants associated with cancer predispositions, as well 
as blood-specific somatic precursors for clonal hematopoietic expansion, in “normal” blood 
samples. However, this is just the beginning of a long journey, as many unknown variants, genes 
and molecular mechanisms underlying hematologic malignancy remain to be discovered. Here, 
we discuss other types of genomic alterations potentially present in noncancerous blood samples, 
and consider the collusion between genetic alterations and epigenetic defects that may contribute 
to clonal hematopoietic expansion. 
5.1 Gene fusions in normal blood samples 
A fusion gene is a chimera product formed by two separate genes and caused by chromosomal 
rearrangements, including inter-chromosomal or intra-chromosomal translocation [1, 2]. Gene 
fusions are extremely powerful mutations, which can dramatically change targeted gene 
expression through the juxtaposition of new promoter or enhancer regions, or create a chimeric 
protein with novel function.  
Gene fusions are a very common event in the initial step of tumorigenesis, especially for 
hematologic cancers. The first fusion gene, as known as the Philadelphia chromosome, was 
discovered in the 1970s in chronic myelogenous leukemia (CML) [3]. It is caused by a reciprocal 
translocation between chromosome 9 and chromosome 22, leading to two genes, BCR and ABL1, 
joining together [4].  ABL1 as a tyrosine kinase plays a role in cell differentiation, cell division, 
and stress response [5]. The BCR-ABL1 fusion gene creates a constantly active tyrosine kinase, 
which causes cell proliferation uncontrollably [6].  BCR-ABL1 has been found in more than 95% 
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of CML patients and 25%–40% adults with acute lymphoblastic leukemia (ALL) [7, 8]. It is also 
worth noting that the frequency of the Philadelphia chromosome increases with age in ALL 
patients [9].  
To date, 284 well-curated fusion genes, derived from 326 different reference genes have been 
identified in human neoplasia [10]. Most of the involved genes are transcription factors or 
tyrosine kinases. Interestingly, more than 25% of these fusion genes were found in hematologic 
disorders, and several genes were frequently involved, forming fusion genes with multiple 
partners, such as KMT2A (MLL), ALK, and ETV6, with more than 50, 10, and 5 partners, 
respectively [10]. A few fusion genes show strong cancer-type specificity, commonly present in 
particular leukemia or lymphoma subtypes. For instance, PML-RARA in acute promyelocytic 
leukemia and IGH-CCND1 in mantle cell lymphoma [11, 12]. Moreover, some fusion genes 
could occur at very early stages of development, resulting in severe consequences. For example, 
the expression of an MLL4-AF4 fusion gene at early stages of the embryo’s development can 
cause infants to be born with a very aggressive form of leukemia [13].   
These facts reflect a widely-held opinion that fusion genes play an important role in hematologic 
malignancies, which leads to some important biological questions: Are fusion genes also 
commonly present in noncancerous blood samples? And what are their roles in clonal 
hematopoietic expansion? To answer these questions, we first need to know how to detect fusion 
genes.  
Fluorescence in situ hybridization (FISH) and RT-PCR has been used to identify fusion gene for 
decades [12]. However, these methods require prior knowledge of fusion partner genes, so it is 
hard for them to detect novel fusion genes. Despite this limitation, FISH and PCR are still most 
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valuable and commonly used technologies for fusion gene detection in both research and 
diagnosis of human neoplasia, because of high sensitivity and specificity, low costs, simplicity, 
and speed.  
Recently, sequencing technologies, particularly RNA-Seq, have become more and more 
powerful for identifying and characterizing novel transcripts and fusion genes [14-17]. A number 
of new fusion genes have been detected using RNA-Seq data of tumors and cancer cell lines, 
such as SLC45A3–ELK4 and MSMB-NCOA4 in prostate cancer [14, 15], VAPB-IKZF3 in breast 
cancer [16], and RB1-ITM2B in melanoma [17]. Aside RNA-Seq, whole genome sequencing 
(WGS) is also a very powerful resource for fusion gene detection, and it even provides more 
comprehensive and unbiased characterization of chromosomal translocation and gene fusion. 
Using WGS technology, a variety of fusion genes have been discovered in different cancers. For 
example, Welch et al. applied WGS to AML patients and identified classic bcr3 PML-RARA 
fusion gene and also found two novel fusion genes, LOXL1-PML, and RARA-LOXL1 [18].  
Considering the important roles that fusion genes play in hematologic malignancies and rapidly 
growing number of available RNA-Seq and WGS data, identifying fusion genes from “normal” 
blood samples will become feasible. It could enhance our understanding of the origins and 
progression factors of cancer, and provide potential preventive or therapeutic targets in anti-
cancer treatments.  
5.2 Epigenomic changes in clonal hematopoietic expansion 
Besides genomic alterations, aberrant epigenetic changes are an important characteristic feature 
in a variety of cancers, including hematologic malignancy [19-22]. By incorporation with 
genomic DNA, the epigenome regulates gene expression in different cell types by altering 
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chromatin density and the accessibility of DNA to cellular machinery. Disruption of proper 
epigenetic maintenance can lead to inappropriate activation or inactivation of different genes or 
signal pathways, resulting in severe consequences, including cancer [23]. Although the role of 
epigenetic abnormalities in promoting hematologic malignancies is widely accepted, the detailed 
molecular mechanism remains unclear, so far. 
Recently, genome-wide methylation patterns have been evaluated in blood cancer [22, 24]. A 
large study involving 344 AML patients showed that+AML could be categorized into 16 
subclasses according to methylation signatures. Some of the specific signatures were associated 
with well-known AML genomic alterations, such as PML-RARA, CBFB-MYH11, and RUNX1-
RUNX1T1 (AML1-ETO) [24]. However, PML-RARA had very limited impacts on overall DNA 
methylation by itself. A recent study using a murine model suggested that DNMT3A is required 
for PML-RARA to initiate acute promyelocytic leukemia in vivo [25]. This result suggests the 
methylation pattern in AML could be caused by the interaction of multiple genomic alterations.  
DNA methylation regulators, such as DNMT3A, TET2, and IDH1/2, were recurrently mutated in 
leukemia and lymphoma patients with distinct DNA methylation phenotypes [26, 28]. For 
example, DNMT3A mutations occur in about 20% of AML patients [26]. AML patients with 
DNMT3A R882 mutations showed a pattern of global hypomethylation, especially at CpG 
islands. Some of the hypomethylated genes were previously linked to AML, such as homeobox-
containing transcription factors [27]. On the other hand, TET2 and IDH1/2 mutations can cause 
DNA hypermethylation phenotype in AML patients [28]. Perhaps due to their similar biological 
effects, TET2 and IDH1/2 mutations were mutually exclusive with each other in AML [24].  
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In addition, genes that are involved in histone modification were also frequently mutated in 
AML. For instance, ASXL1 mutations are present in 10-25% myelodysplastic syndrome, 10-15% 
myeloproliferative neoplasia, 5-30% AML and 43%–58% chronic myelomonocytic leukemia 
[29, 30]. ASXL1 mutations can lead to loss of PRC2-mediated histone H3 lysine27 tri-
methylation (H3K27me3), resulting in myeloid transformation [31].  
Genes involved in epigenetic regulation were not only present in patients with hematologic 
malignancies, but also exist in “healthy” elderly individuals, such as DNMT3A, TET2, ASXL1, 
and IDH2 [32]. Although a number of genome-wide studies and functional studies have been 
performed to explore the role of these genes in directing aberrant epigenetic changes and 
leukemogenesis, the detailed mechanisms linking these genes to the dynamic epigenetic change 
in the clonal hematopoietic expansion, and further passing through the bottleneck of the pre-
leukemic state have yet to be fully elucidated.  
Based on current studies, many known cancer-associated genes are regulated through direct or 
indirect epigenetic alterations. Therefore, it will be critical to apply epigenomic platforms to 
comprehensively elucidate how these epigenetic modifier mutations contribute to epigenetic 
alterations and gene expression in the initiation stage of hematologic malignancies. Studies of 
this nature have the potential to benefit the development of novel therapeutic strategies that aim 
to reverse epigenetic alterations in patients with mutations in epigenetic modifiers.  
In summary, we have discussed the genomic alterations and mechanisms that are likely involved 
in the development of hematologic malignancies. As we pursue these goals, it will be critical to 
realize the necessity of functional validation of variants identified by computational and 
statistical approaches. Genome sequencing already represents a significant breakthrough for 
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cancer research, but it alone cannot address all these questions. Ultimately, functional studies are 
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Appendix 1 Supplementary Materials for 
Chapter 2 
Supplementary Note 
We also examined germline sites overlapping recurrent somatic mutations found in the 12 TCGA 
cancer types [1] (Supplementary Table 2.24).  After stringent filtering, we identified 34 missense 
germline hotspot variants that overlapped recurrent somatic mutations in cancer associated 
genes, based on the somatic mutations reported in Kandoth et al [1].  Most of these 34 hotspot 
missense germline variants affected conserved nucleotide/amino acid residues.  This list 
includes six variants in the DNA-binding domain of TP53, all occurring at five previously 
identified hotspots (R110H, R158C, R267Q, R175C, and G245V).  G245V has been reported by 
the IARC as nonfunctional [2], while the four remaining variants were reported to have partial 
functionality (http://p53.iarc.fr/). One ATM (R2691C) variant, involved in CLL [3], is also 
known to interact with TP53 and can result in the transformation of the ATP binding pocket. 
Another prominent cluster of rare germline missense mutations appeared in DNA-repair 
(Fanconi Anemia) pathway. These included two recurrent variants (A625T) in PARP1, 
somatically mutated in bladder and endometrial cancer [1], a variant (E201K) in DDX11, 
proximal to a validated  functional missense variant (R263Q) responsible for  Warsaw Breakage 
[4], and one variant (R1084C) in FANCA.  In addition, a germline variant (K140N) in the 
BRCA1-binding-partner BARD1 was identified and its three adjacent residues were found to be 
recurrently mutated in multiple cancer types (COSMIC). A missense variant (E2020K) in 
BRCA2, recurrently mutated in other samples, is currently classified as a variant of unknown 
significance (BIC) [5].  
Using existing clinical significance data from the NCBI ClinVar database 
(http://www.ncbi.nlm.nih.gov/clinvar/), a total of 101 rare germline missense variants were listed 
as Pathogenic. Of these, 40 were from tumor suppressor genes (TSG) or encoded proteins 
involved in DNA repair, including POLH (DNA repair; 9 variants), BUB1B (TSG; 9), VHL 
(TSG; 5), and APC (TSG; 5), among others. BRCA2 was also on the list but had only 2 variants. 
The low occurrence of BRCA2 variants and lack of BRCA1 variants merit further investigation 
and suggest that this approach may be improved by querying additional clinical databases 
specific to breast cancer and other types of cancer. Other identified variants were involved in 
other diseases (e.g. LRRK2 for Parkinson’s disease) and also included an oncogene (RET proto-
oncogene, 8) and DNA transcription factors (e.g. AR, 4). Additionally, only TYR and BRCA2 are 
common to this list and the list of significant non-oncogenes obtained from truncation variant 
analysis, suggesting that the combination of both methods could be especially useful for 
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Supplementary Figure 2.1: Comparison of Coverage between the Caucasian TCGA cohort 
and WHISP cohort.  We compared the coverage of the 624 cancer genes between 3,125 TCGA 
Caucasian and 1,039 WHI cases. The scatter plot shows the mean percent of coding regions with 
≥30X coverage for each of these 624 genes in the TCGA cohort (X axis) and WHI (Y axis), with 
the Pearson’s correlation coefficient of 0.98. A subset of the 624 dots (denoted in red) represents 
genes with significant enrichment of rare truncation variants determined in the TCGA cohort by 





Supplementary Figure 2.2: Minor allele frequency analysis of BRCA1 and BRCA2 rare 
germline truncations.  The scatter plot shows the relationship between MAFs of BRCA1 and 
BRCA2 germline truncation variants and site-specific P-values from LOH analysis.  For both 
BRCA1 and BRCA2, the variants with low MAFs tend to display significant LOH. Selecting 
0.05% cutoff for rare variants was based on balancing the inclusion of possible false-positives 





Supplementary Figure 2.3: Correlation of truncation frequencies in 32 genes of interest 
between discovery set and validation set.  Using the 3,125 and 1,627 cases in the discovery 
and validation cohorts, respectively, we used gene-specific tallies to calculate frequencies of 
truncations in the 32 genes found to be significant by burden testing. Figure shows the discovery 
and validation frequencies for each gene plotted on the abscissa and ordinate, respectively. These 
data were regressed using the ordinary least-squares (OLS) calculation. A Pearson’s correlation 





Supplementary Figure 2.4: Mutation rate comparison within BRCA basal subtype. Boxplot 
shows the mutation rate distribution in basal cases with BRCA1/2 rare germline truncation 
(n=12) and basal cases without BRCA1/2 rare germline truncation variants (n=101, 2 cases 
missing somatic mutation information). Graph shows median central line, 50% confidence 






Supplementary Figure 2.5: Western blot analysis of expression of BRCA1 mutant 
constructs.  HDR assay results were tested for protein expression of the BRCA1 variant from 
the transfected plasmid. Cells that remained following flow cytometry analysis were extracted 
and soluble proteins analyzed by immunoblots. Since multiple experiments were done, each 
panel should be compared separately from the others. In all samples, the endogenous BRCA1 
protein had been depleted by transfection of the siRNA targeting the 3’-UTR of the BRCA1 
mRNA. All blots were probed for BRCA1, and strips show the proteins that migrated at about 
the 250 kDa marker, and strips were probed for a-tubulin, which migrated near the 50 kDa 
marker, as a loading control. Samples from the various BRCA1 plasmid transfections were as 
follows: vector only (lanes 1, 10, 19, 37, 39, 47, 60, 72, 81, 93, 102, 113); WT (lanes 2, 18, 29, 
38, 48, 61, 73, 82, 94, 103, 112); E23fs (lane 114); S36Y (lane 54); C61G (lane 83); C64G (lane 
84); D67Y (lane 115); E85D (lane 116); E143K (lane 56); E149A (lane 57); Y179C (lane 46); 
S186Y (lane 58); V191I (lane 59); D214G (lane 52); L246V (lane 106); T293S (lane 42); R296G 
(lane 62); S316G (lane 53); A322P (lanes 96, 108); C328R (lane 63); I379M (lane 104); E445Q 
(lane 75); G462R (lane 76); F486L (lane 98); L512V (lanes 95, 109); N550H (lane 101); L574P 
(lane 41); I591T (lane 40); R612G (lane 36); L668F (lanes 20, 117); D695N (lane 35); S708Y 
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(lane 34); E720K (lane 33); R756S (lane 32); V772A (lane 21); A806T (lane 31), T826K (lanes 
97, 118); Y856H (lane 77); R866C (lane 43); E962K (lane 80), I1019V (lane 100); I1044V (lane 
99); P1150S (lane 107); D1152N (lane 44); S1180G (lane 49); E1219D (lane 78); P1238L (lane 
45); V1247I (lane 16); E1250* (lane 119); S1279P (lane 17); Q1281P (lane 79); E1346K (lane 
74); N1354T (lane 22); T1376R (lanes 11, 92); V1378I (lane 30); E1415fs (lane 120); H1421Y 
(lanes 12, 91); G1422E (lanes 13, 90); K1476T (lane 105); V1534M (lane 64); D1546Y (lanes 
14, 110); T1561I (lane 51); L1564P (lane 15); P1579A (lane 9); M1628T (lane 65); P1637L 
(lane 23); A1669S (lanes 3, 85); T1685I (lanes 4, 86); K1690Q (lane 66); R1699W (lanes 24, 
71); A1708V (lanes 5, 87, 121); D1778G (lane 67); Q1779fs (lanes 25, 69); M1783L (lane 50); 
M1783T (lanes 55, 111, 122); L1786P (lane 26); G1788V (lanes 27, 70); G1801D (lane 28); 
I1807M (lanes 7, 89); N1819S (lane 8); R1835Q (lanes 68, 123); L1844I (lane 124); and P1859R 





Supplementary Figure 2.6: Impact of C64G mutation in BRCA1 on splicing.  Integrated 
genomic viewer screen capture of C64G mutation, leading to the activation of an infrequently 
used splice site, is shown. Two ovarian cases with C64G mutation and four ovarian cases 








Supplementary Table 2.1: Coverage and variant calling stats for discovery and control cohorts. 
Coverage Stats 
Mini depth Cancer Type Target space covered (%) Mean depth Stdev depth 
10x 
 
BRCA 92 110.8 57.8 
GBM 90.6 143.4 47.5 
HNSC 94.6 92 22.2 
KIRC 91.8 146.6 70.5 
LAML-WXS 90.3 164.9 61 
LGG 94.4 98.3 28.1 
LUAD 93.5 97.1 31 
LUSC 93.6 105.8 41.7 
OV 82.8 146.1 69 
PRAD 94.6 101.1 30.4 
STAD 94.6 102.3 27.7 
UCEC 93.4 105.9 64.9 
WHISP 92.1 106.2 33.3 
20x 
 
BRCA 85.7 110 58.1 
GBM 86.1 142.7 47.6 
HNSC 89.5 91.2 22.4 
KIRC 86.6 146 70.7 
LAML-WXS 85.3 164.1 61.2 
LGG 89.4 97.5 28.4 
LUAD 88.1 96.2 31.2 
LUSC 88.3 104.9 41.9 
OV 77.3 145.4 69.2 
PRAD 89.6 100.3 30.6 
STAD 89.6 101.5 27.9 
UCEC 87.3 105.2 65.2 
WHISP 86.3 105.4 33.5 
30x 
BRCA 78 108.3 59 
GBM 81.8 141.6 47.8 
HNSC 83.9 89.6 22.8 
KIRC 81.5 144.8 71.1 
LAML-WXS 80.8 162.9 61.6 
LGG 84 96.1 28.8 
LUAD 82.2 94.6 31.7 
LUSC 82.6 103.4 42.4 
OV 72.3 144.2 69.6 
PRAD 84.3 98.9 31 
STAD 84.2 100 28.5 
UCEC 78.6 103.1 66.3 
WHISP 80.3 104 34 
40x 
BRCA 69.6 105.5 60.6 
GBM 77.6 140.1 48.2 
HNSC 77.5 87.2 23.4 
KIRC 76.1 143.1 71.8 
LAML-WXS 76.3 161.2 62.1 
LGG 77.9 93.8 29.5 
LUAD 75.6 92.2 32.4 
LUSC 76.3 101 43.2 
OV 67.6 142.5 70.1 
PRAD 78.3 96.7 31.7 
STAD 78.3 97.8 29.3 
UCEC 68.4 99.7 68.3 




Variant calling stats  


















Nonsense 6241 219 36009 1251 27462 919 3185 136 
Nonstop 353 11 2041 65 1474 50 279 6 
Splice site 3529 123 18693 553 14005 442 1878 30 
Frame shift indels 6055 266 30508 1242 22034 973 3118 88 
In-frame indels 3545 240 20219 965 13687 637 2545 128 
Missense 318072 13630 1655391 70919 1157583 50869 207504 7905 
Silent 175729 9120 947045 47114 606214 30789 156778 7342 
Total Variants 513524 23609 2709906 122109 1842459 84679 375287 15635 





Supplementary Table 2.2: Summary of germline truncation variants identified in 624 cancer 
associated genes. Rare germline truncation variants (<0.05% MAF in discovery case and control 
combined) identified in 624 cancer associated genes across 4,034 cancer cases. 






Supplementary Table 2.3: Rare germline truncation variants (<0.05% MAF in case and control 
combined) identified in 32 genes of interest across 1,627 validation cancer cases. 






Ref Var VAF Ref Var VAF 
7 152357811 A - XRCC2 p.F32fs BRCA 51 24 32 39 24 38.1 
7 6018315 GA - PMS2 p.L729fs BRCA 12 0 0 7 17 70.83 
8 144940189 C - EPPK1 p.L2412fs GBM 19 15 44.12 22 15 40.54 
8 144947107 C - EPPK1 p.L106fs LGG 29 37 56.06 29 20 40.82 
8 144947370 C - EPPK1 p.E18fs LGG 27 23 46 33 19 36.54 
8 144946136 TGAG - EPPK1 p.T428fs LGG 1 10 90.91 4 18 81.82 
8 144941718 C - EPPK1 p.V1902fs LGG 29 16 35.56 27 15 35.71 
8 144946136 TGAG - EPPK1 p.T428fs LUAD 15 5 25 11 10 47.62 
7 6018315 GA - PMS2 p.L729fs LUAD 25 16 39.02 22 12 35.29 
7 6018315 GA - PMS2 p.L729fs LUSC 29 56 65.88 16 21 56.76 
3 142234279 AA - ATR p.F1487fs LUSC 40 63 61.17 67 38 36.19 
7 6026386 TTACC - PMS2 p.S669fs PRAD 45 16 26.23 55 29 34.52 
7 6018315 GA - PMS2 p.L729fs UCEC 44 34 43.59 48 39 44.83 
1 26513692 AA - CNKSR1 p.N190fs UCEC 16 24 60 21 27 56.25 
1 26514778 C - CNKSR1 p.P247fs BRCA 39 42 51.85 32 31 49.21 
2 48026251 AAGAG - MSH6 p.R379fs UCEC 7 6 46.15 20 13 39.39 
2 48026890 C - MSH6 p.P591fs UCEC 10 21 67.74 16 11 40.74 
2 48027686 T - MSH6 p.I856fs UCEC 7 14 66.67 28 19 40.43 
2 48030640 C - MSH6 p.F1088fs UCEC 9 31 77.5 29 14 32.56 
5 131915039 GT - RAD50 p.A134fs HNSC 34 20 37.04 34 21 38.18 
6 33543680 CT - BAK1 p.E32fs HNSC 67 34 33.66 61 37 37.76 
9 35078692 CAGT - FANCG p.T72fs PRAD 31 11 26.19 34 22 39.29 
11 89028498 AG - TYR p.E519fs LUSC 10 12 54.55 20 15 42.86 
12 18446857 A - PIK3C2G p.I315fs UCEC 68 50 42.37 55 40 42.11 
13 32903605 TG - BRCA2 p.V220fs OV 3 13 81.25 17 9 34.62 
13 32903605 TG - BRCA2 p.V220fs BRCA 20 16 44.44 20 10 33.33 
13 32913703 TACT - BRCA2 p.T1738fs OV 22 59 72.84 32 24 42.86 
13 32914061 GAAAC - BRCA2 p.E1857fs OV 18 71 79.78 135 69 33.82 
13 32915134 T - BRCA2 p.Y2215fs BRCA 6 28 82.35 34 26 43.33 
13 32920968 AATA - BRCA2 p.I2315fs BRCA 78 57 42.22 169 122 41.92 
13 32945138 AG - BRCA2 p.E2846fs BRCA 60 45 42.86 23 16 41.03 
16 23647268 A - PALB2 p.L200fs UCEC 8 35 81.4 22 17 43.59 
17 41243480 TTGA - BRCA1 p.N1355fs BRCA 36 24 40 49 18 26.87 
17 41244778 TAAC - BRCA1 p.V923fs PRAD 35 38 52.05 55 37 40.22 
17 41276045 CT - BRCA1 p.E23fs GBM 70 36 33.96 113 49 30.25 
17 48453264 AG - EME1 p.N233fs LGG 82 55 40.15 96 52 35.14 
17 59761199 A - BRIP1 p.S1070fs UCEC 31 24 43.64 25 17 40.48 
17 59821794 TT - BRIP1 p.K752fs LGG 71 42 37.17 55 53 49.07 
13 32912338 TG - BRCA2 p.V1283fs LUSC 8 1 11.11 0 0 0 
9 100444655 AC - XPA p.V244fs PRAD 75 59 44.03 88 51 36.69 
12 18747475 AGTT - PIK3C2G p.V1354fs HNSC 29 11 27.5 19 8 29.63 
13 32914438 T - BRCA2 p.S1982fs OV 55 82 59.85 42 17 28.81 
16 1825947 C - EME2 p.A375fs HNSC 16 0 0 29 0 0 
12 31247556 - T DDX11 p.S469fs UCEC 72 56 43.75 55 38 40.86 
13 32954272 - A BRCA2 p.T3084fs LUSC 43 42 49.41 31 23 42.59 
2 38298106 - A CYP1B1 p.S464fs BRCA 40 18 31.03 31 34 52.31 
13 32907420 - A BRCA2 p.I605fs LUAD 20 15 42.86 15 20 57.14 
17 41209079 - G BRCA1 p.Q247fs OV 223 602 72.97 125 102 44.93 
17 41209079 - G BRCA1 p.Q247fs BRCA 24 38 61.29 69 39 36.11 
[134] 
 
17 41234477 - T BRCA1 p.S1434fs LUSC 111 96 46.38 75 52 40.94 
17 56774172 - C RAD51C p.C176fs LUAD 61 50 45.05 57 55 49.11 
2 48033981 - TTGA MSH6 p.K1357fs BRCA 31 12 27.91 28 21 42.86 
2 48033981 - TTGA MSH6 p.K1357fs LGG 30 12 28.57 44 20 31.25 
12 31256907 C A DDX11 p.C951* BRCA 24 14 36.84 19 17 47.22 
12 31256907 C A DDX11 p.C951* BRCA 25 10 28.57 17 9 34.62 
12 31256907 C A DDX11 p.C951* BRCA 20 10 33.33 14 19 57.58 
3 142279156 A T ATR p.L497* HNSC 54 33 37.93 48 55 53.4 
12 31256907 C A DDX11 p.C951* KIRC 59 68 53.12 66 65 49.62 
8 144945558 C A EPPK1 p.E622* KIRC 6 5 45.45 14 8 36.36 
7 6013096 C T PMS2 p.W841* LUAD 10 9 47.37 9 7 43.75 
12 31256907 C A DDX11 p.C951* PRAD 2 5 71.43 2 10 83.33 
7 6026709 G A PMS2 p.R563* UCEC 42 58 57.43 49 58 54.21 
6 29797323 C T HLA-G p.Q255* UCEC 129 63 32.81 71 56 44.09 
7 6026514 G A PMS2 p.R628* UCEC 38 45 54.22 34 31 47.69 
12 31256907 C A DDX11 p.C951* UCEC 24 21 46.67 17 8 32 
8 144947235 G A EPPK1 p.Q63* UCEC 41 41 49.4 32 16 33.33 
12 31256907 C A DDX11 p.C951* UCEC 15 7 31.82 10 21 67.74 
5 131973889 C T RAD50 p.R1198* LGG 40 36 47.37 50 55 52.38 
5 131973895 C T RAD50 p.R1200* UCEC 14 12 46.15 22 18 45 
9 35074486 G A FANCG p.R548* UCEC 44 60 57.69 41 44 51.76 
9 100451874 C A XPA p.E111* PRAD 15 15 50 16 13 44.83 
13 32913457 C G BRCA2 p.Y1655* HNSC 33 34 50.75 21 37 63.79 
16 1825377 G T EME2 p.E255* BRCA 57 45 44.12 57 40 40.82 
16 23614792 G C PALB2 p.Y1183* BRCA 33 31 48.44 46 38 45.24 
16 23647443 T A PALB2 p.K142* BRCA 43 72 62.61 56 54 49.09 
16 23649415 G A PALB2 p.Q23* LGG 71 55 43.65 63 73 53.68 
17 33428320 C T RAD51D p.W288* LGG 79 64 44.76 106 71 39.44 
17 33433425 G A RAD51D p.R206* OV 14 160 91.95 5 8 61.54 
17 41246494 C A BRCA1 p.E352* BRCA 13 52 80 50 32 39.02 
17 56772543 C T RAD51C p.Q133* UCEC 4 9 69.23 4 7 63.64 
17 56787223 C T RAD51C p.R237* PRAD 94 47 33.33 91 58 38.93 
1 26507075 G A CNKSR1 p.W55* UCEC 22 65 74.71 9 8 47.06 
5 131930642 C G RAD50 p.Y625* GBM 151 127 45.68 88 105 54.4 
6 33541983 T A BAK1 p.R127* BRCA 16 3 15.79 10 14 58.33 
6 33541983 T A BAK1 p.R127* UCEC 10 6 37.5 15 8 34.78 
11 108175528 C T ATM p.R1875* GBM 21 20 48.78 15 21 58.33 
11 108183151 G T ATM p.E1978* BRCA 11 41 78.85 30 28 48.28 
11 108183151 G T ATM p.E1978* BRCA 5 21 80.77 21 22 51.16 
14 45658326 C T FANCM p.Q1701* BRCA 3 1 25 24 19 44.19 
12 31255955 G A DDX11 e23+1 BRCA 48 32 40 44 43 49.43 
7 6043425 T A PMS2 e4-2 LUSC 22 24 52.17 26 17 39.53 
7 6022454 C T PMS2 e12+1 UCEC 0 11 100 21 17 44.74 
16 23641791 C G PALB2 e5-1 OV 0 3 100 2 5 71.43 
16 89813299 C T FANCA e34-1 BRCA 6 6 50 25 20 44.44 
16 89881023 T A FANCA e3-2 LUAD 34 25 42.37 33 37 52.86 
17 48458123 G A EME1 e8-1 BRCA 14 49 77.78 23 30 56.6 





Supplementary Table 2.4: 69 germline truncations validated using whole genome sequencing 
data. 






Supplementary Table 2.5: Cancer associated gene lists used in this study, including 624 cancer 
associated genes, 114 cancer susceptibility genes reported in Rahman et al., 47 genes from 
Fanconi Anemia pathway. 
624 Cancer Associated Genes 
CEP76 DPYD FANCI GSK3B KIT MXRA5 PHOX2B RBM10 SLX4 TLR4 
CERS2 ECSCR FANCL GSTP1 KLF4 MYB PIK3C2G RBMX SMAD2 TMEM127 
CHD4 EGFR FANCM GUCY1A2 KLHL6 MYC PIK3C3 RECQL4 SMAD3 TMPRSS2 
CHD8 EGR3 FAS H3F3A KMT2A MYCL PIK3CA REL SMAD4 TNF 
CHEK1 EIF2S2 FAT1 H3F3C KMT2B MYCN PIK3CG RET SMARCA4 TNFAIP3 
CHEK2 EIF3A FAT3 HAUS3 KMT2C MYD88 PIK3R1 REV3L SMARCB1 TNFRSF14 
CHUK EIF4A2 FBXW7 HDAC4 KMT2D MYLK PIK3R2 RHBDF2 SMARCD1 TOP1 
CIC ELANE FCGR1A HES1 KRAS NAV3 PLCG2 RHEB SMARCE1 TOP3A 
CNBD1 ELF3 FCGR2A HFE LIFR NBN PML RHOA SMC1A TOP3B 
CNKSR1 EME1 FCGR3A HGF LMO1 NBPF1 PMS2 RICTOR SMC3 TP53 
COL7A1 EME2 FGF10 HIF1A LRP1B NCOR1 PMS2CL RIT1 SMO TP53BP1 
COMT EML4 FGF12 HIST1H1C LRP2 NEIL1 PNRC1 RMI1 SNX25 TPMT 
CRBN EP300 FGF14 HIST1H1E LRRK2 NF1 POLD1 RMI2 SOCS1 TPX2 
CREBBP EPHA2 FGF19 HIST1H2BD MALAT1 NF2 POLE RMRP SOD2 TRAF3 
CRIPAK EPHA3 FGF23 HIST1H3B MAN1B1 NFE2L2 POLH RNF43 SOS1 TRAF7 
CRKL EPHA5 FGF3 HIST1H4E MAP2K1 NFKBIA POLI ROS1 SOX10 TRIM37 
CRLF2 EPHB1 FGF4 HLA-A MAP2K2 NKX2-1 POLK RPA1 SOX17 TRRAP 
CSF1R EPHB2 FGF6 HLA-B MAP2K4 NOTCH1 POLQ RPA2 SOX2 TSC1 
CTCF EPHB6 FGF7 HLA-G MAP3K1 NOTCH2 PORCN RPA4 SOX9 TSC2 
CTNNA1 EPPK1 FGFBP1 HMBS MAP3K13 NOTCH3 POU2AF1 RPL22 SPEN TSHR 
CTNNB1 ERBB2 FGFR1 HNF1A MAP3K15 NOTCH4 POU2F2 RPL5 SPOP TSHZ2 
CUL4A ERBB3 FGFR2 HRAS MAP4K1 NPM1 PPM1D RPS14 SPRY4 TSHZ3 
CUL4B ERBB4 FGFR3 HSP90AB1 MAP4K3 NQO1 PPP2R1A RPS15 SRC TYMS 
CUX1 ERCC1 FGFR4 IDH1 MAPK1 NRAS PPP6C RPS2 SRSF2 TYR 
CYLD ERCC2 FH IDH2 MAPK8IP1 NRP2 PRDM1 RPTOR SRY U2AF1 
CYP17A1 ERCC3 FLCN IGF1 MAX NSD1 PRKAR1A RUNX1 STAG2 U2AF2 
CYP1B1 ERCC4 FLT1 IGF1R MBD1 NTN4 PRKDC RUNX1T1 STAT3 UGT1A1 
CYP2C19 ERCC5 FLT3 IGF2 MC1R NTRK1 PRLR RUNX3 STAT4 UMPS 
CYP2C8 ERG FLT4 IKBKE MCL1 NTRK2 PRPF40B RXRA STK11 UROD 
CYP2D6 ESR1 FOXA1 IKZF1 MDM2 NTRK3 PRSS1 SBDS STK19 USP1 
CYP3A4 ESR2 FOXA2 IL7R MDM4 NUP93 PRSS8 SDHA STK38 USP9X 
CYP3A5 ETV1 FOXL2 ING1 MECOM ODAM PTCH1 SDHAF2 STX2 VANGL2 
DAXX ETV4 FOXQ1 INHA MED12 OTUD7A PTEN SDHB SUFU VEZF1 
DCAF6 ETV5 FUBP1 INHBA MED23 PAK3 PTPN11 SDHC SULT1A1 VHL 
DDB2 ETV6 FZD1 INPPL1 MEF2A PAK7 PTPRC SDHD SUZ12 WAC 
DDR1 EWSR1 GAB2 IPO7 MEF2B PALB2 PTPRD SERPINA1 SYK WAS 
DDR2 EXO1 GATA1 IRF4 MEN1 PAPD5 QKI SERPINB13 SZRD1 WASF3 
DDX11 EXT1 GATA2 IRS2 MET PARP1 RAB40A SETBP1 TAF1 WDR48 
DDX3X EXT2 GATA3 ITGAV MGA PARP2 RAC1 SETD2 TBC1D12 WISP3 
[137] 
 
DDX5 EZH1 GBA ITK MIR142 PARP3 RAD21 SETDB1 TBL1XR1 WNK1 
DIAPH1 EZH2 GID4 ITPA MITF PARP4 RAD50 SF1 TBX3 WRN 
DICER1 EZR GJB2 JAK1 MLH1 PAX5 RAD51 SF3B1 TCEB1 WT1 
DIDO1 FAH GNA11 JAK2 MNDA PBRM1 RAD51B SGK1 TCF7L2 XPA 
DIS3 FAM129B GNA13 JAK3 MORC4 PCBP1 RAD51C SH2B3 TELO2 XPC 
DIS3L2 FAM46C GNAQ JUN MPL PCDH10 RAD51D SH2D1A TERT XPO1 
DKC1 FANCA GNAS KAT6A MRE11A PDAP1 RAD52 SIN3A TET2 XRCC2 
DLC1 FANCB GNB1 KDM5A MSH2 PDCD2L RAD54L SIRPA TFG XRCC3 
DNER FANCC GPC3 KDM5C MSH6 PDGFRA RAF1 SIRT4 TGFBR1 ZFHX3 
DNMT1 FANCD2 GPR124 KDM6A MTAP PDGFRB RALY SLC19A1 TGFBR2 ZNF217 
DNMT3A FANCE GPS2 KDR MTHFR PDK1 RARA SLC22A2 TIMM17A ZNF703 
DOCK8 FANCF GRIN2A KEAP1 MTOR PDSS2 RASA1 SLC25A13 TIPARP ZRANB3 
DOT1L FANCG GRM3 KIF5B MUTYH PHF6 RB1 SLCO1B3 TLK2 ZRSR2 
 
47 genes in Fanconi Anemia Pathway 
APITD1 BRCA1 ERCC1 FANCB FANCG MLH1 RAD51 RPA1 SMC3 WDR48 
ATM BRCA2 ERCC4 FANCC FANCI PALB2 RAD51C RPA2 TELO2 XPC 
ATR BRIP1 ERCC5 FANCD2 FANCL PMS2CL REV3L RPA4 TOP3A  
ATRIP CHEK2 EXO1 FANCE FANCM POLI RMI1 SLX4 TOP3B  
BLM EME1 FANCA FANCF HES1 POLK RMI2 SMC1A USP1  
 
114 Rahman Genes 
ABCB11 CBL DIS3L2 FANCA ITK NF2 PTPN11 SDHB STAT3 VHL 
ALK CDC73 DKC1 FANCC KIT PALB2 RAD51C SDHC STK11 WAS 
APC CDH1 DOCK8 FANCG MAX PDGFRA RAD51D SDHD SUFU WRN 
ATM CDK4 EGFR FH MEN1 PHOX2B RB1 SERPINA1 TERT WT1 
AXIN2 CDKN1B ELANE FLCN MET PMS2 RECQL4 SH2D1A TGFBR1 XPA 
BAP1 CDKN2A ERCC2 GATA2 MLH1 POLD1 RET SLC25A13 TMEM127 XPC 
BLM CEBPA ERCC3 GBA MSH2 POLE RHBDF2 SMAD4 TNFRSF6 (FAS) 
BMPR1A CHEK2 ERCC4 GJB2 MSH6 POLH RMRP SMARCA4 TP53 
 BRCA1 COL7A1 ERCC5 GPC3 MTAP PRKAR1A RUNX1 SMARCB1 TRIM37 
 BRCA2 CYLD EXT1 HFE MUTYH PRSS1 SBDS SMARCE1 TSC1 
 BRIP1 DDB2 EXT2 HMBS NBN PTCH1 SDHA SOS1 TSC2 





Supplementary Table 2.6: Frequencies of rare truncation variants in 3 gene lists across 12 
cancer types. 
Fanconi Anemia Pathway (47 Genes) Rare truncation variants Sample Size (n) Truncation variant/sample 
OV 73 429 0.1702 
BRCA 65 770 0.0844 
PRAD 14 178 0.0787 
STAD 25 321 0.0779 
LUSC 11 193 0.057 
HNSC 16 291 0.055 
GBM 13 267 0.0487 
LAML 8 200 0.04 
LUAD 16 462 0.0346 
UCEC 8 248 0.0323 
KIRC 13 452 0.0288 
LGG 5 223 0.0224 
    Rahman et al. 2014 (114 Genes) Rare truncation variants Sample Size (n) Truncation variant/sample 
OV 81 429 0.1888 
STAD 34 321 0.1059 
BRCA 69 770 0.0896 
PRAD 15 178 0.0843 
LUSC 16 193 0.0829 
LGG 17 223 0.0762 
HNSC 22 291 0.0756 
UCEC 18 248 0.0726 
LUAD 32 462 0.0693 
KIRC 21 452 0.0465 
GBM 12 267 0.0449 
LAML 8 200 0.04 
    Cancer Associated Genes (624 genes) Rare truncation variants Sample Size (n) Truncation variant/sample 
OV 114 429 0.2657 
BRCA 163 770 0.2117 
STAD 67 321 0.2087 
LUSC 35 193 0.1813 
LAML 36 200 0.18 
LGG 38 223 0.1704 
PRAD 30 178 0.1685 
UCEC 39 248 0.1573 
HNSC 44 291 0.1512 
LUAD 68 462 0.1472 
GBM 39 267 0.1461 





Supplementary Table 2.7: Burden analysis results for Pan-Cancer discovery cohort using rare 
truncation variants from 624 cancer associated genes in 3,125 Caucasian samples. The control 
cohort is 1,039 WHI Caucasian cases. 
PAN12         













1 BRCA1 0.0000 0.0000 0.0000 0 53 2078 6250 
2 BRCA2 0.0000 0.0000 0.0000 3 50 2078 6250 
3 ATM 0.0008 0.0003 0.0126 2 23 2078 6250 
4 BRIP1 0.0016 0.0015 0.0526 1 16 2078 6250 
5 PALB2 0.0003 0.0016 0.0526 0 12 2078 6250 
6 MSH6 0.0005 0.0028 0.0666 0 11 2078 6250 
7 XRCC2 0.0041 0.0237 0.4844 0 7 2078 6250 
8 PIK3C2G 0.1437 0.0295 0.5278 5 19 2078 6250 
9 NBN 0.0404 0.0385 0.6113 1 9 2078 6250 
10 RAD51C 0.0071 0.0405 0.6113 0 6 2078 6250 
11 CYP1B1 0.0071 0.0405 0.6113 0 6 2078 6250 
12 DIS3 0.0896 0.0471 0.6113 2 11 2078 6250 
13 TYR 0.0126 0.0691 0.7597 0 5 2078 6250 
14 CNKSR1 0.1237 0.0695 0.7597 2 10 2078 6250 
15 ERCC2 0.1237 0.0695 0.7597 2 10 2078 6250 
16 EPPK1 0.1236 0.0695 0.7597 2 10 2078 6250 
17 FANCM 0.2711 0.1034 0.8699 4 13 2078 6250 
18 RAD51D 0.0227 0.1179 0.9364 0 4 2078 6250 
19 MRE11A 0.0227 0.1179 0.9364 0 4 2078 6250 
20 ODAM 0.0227 0.1179 0.9364 0 4 2078 6250 
21 SLX4 0.0227 0.1179 0.9364 0 4 2078 6250 
22 RAD51B 0.0227 0.1179 0.9364 0 4 2078 6250 
23 BAK1 0.0227 0.1179 0.9364 0 4 2078 6250 
24 DDX11 0.3275 0.1397 0.9364 4 12 2078 6250 
25 FANCI 0.1409 0.1410 0.9364 1 6 2078 6250 
26 ABCC4 0.1409 0.1410 0.9364 1 6 2078 6250 
27 FANCG 0.1409 0.1410 0.9364 1 6 2078 6250 
28 RAD50 0.2243 0.1457 0.9364 2 8 2078 6250 
29 SLC19A1 0.0416 0.2012 0.9919 0 3 2078 6250 
30 SGK1 0.0416 0.2012 0.9919 0 3 2078 6250 
31 POLI 0.0416 0.2012 0.9919 0 3 2078 6250 
32 HLA-G 0.0416 0.2012 0.9919 0 3 2078 6250 
33 BCR 0.0416 0.2012 0.9919 0 3 2078 6250 
34 TRAF7 0.0416 0.2012 0.9919 0 3 2078 6250 
35 TP53BP1 0.0416 0.2012 0.9919 0 3 2078 6250 
36 RAD52 0.0416 0.2012 0.9919 0 3 2078 6250 
37 POLH 0.0416 0.2012 0.9919 0 3 2078 6250 
38 KRAS 0.0416 0.2012 0.9919 0 3 2078 6250 
39 IRF4 0.0416 0.2012 0.9919 0 3 2078 6250 
40 IL7R 0.0416 0.2012 0.9919 0 3 2078 6250 
41 IDH1 0.0416 0.2012 0.9919 0 3 2078 6250 
42 GPS2 0.0416 0.2012 0.9919 0 3 2078 6250 
43 FAH 0.0416 0.2012 0.9919 0 3 2078 6250 
44 EXT2 0.0416 0.2012 0.9919 0 3 2078 6250 
45 ERCC1 0.0416 0.2012 0.9919 0 3 2078 6250 
46 EME2 0.0416 0.2012 0.9919 0 3 2078 6250 
47 EME1 0.0416 0.2012 0.9919 0 3 2078 6250 
48 DIS3L2 0.0416 0.2012 0.9919 0 3 2078 6250 
49 FANCC 0.2937 0.2063 0.9919 2 7 2078 6250 
50 SLC25A13 0.2067 0.2120 0.9919 1 5 2078 6250 
51 ESR2 0.2067 0.2120 0.9919 1 5 2078 6250 
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52 ATR 0.2067 0.2120 0.9919 1 5 2078 6250 
53 ABL2 0.2067 0.2120 0.9919 1 5 2078 6250 
54 XPA 0.2067 0.2120 0.9919 1 5 2078 6250 
55 NRP2 0.2067 0.2120 0.9919 1 5 2078 6250 
56 FLT3 0.2067 0.2120 0.9919 1 5 2078 6250 
57 FANCA 0.4235 0.2640 0.9919 3 8 2078 6250 
58 GJB2 0.4235 0.2640 0.9919 3 8 2078 6250 
59 PARP2 0.2961 0.3131 0.9919 1 4 2078 6250 
60 TET2 0.2961 0.3131 0.9919 1 4 2078 6250 
61 BUB1B 0.2961 0.3131 0.9919 1 4 2078 6250 
62 WDR48 0.0786 0.3433 0.9919 0 2 2078 6250 
63 USP9X 0.0786 0.3433 0.9919 0 2 2078 6250 
64 UROD 0.0786 0.3433 0.9919 0 2 2078 6250 
65 TPX2 0.0786 0.3433 0.9919 0 2 2078 6250 
66 SUZ12 0.0786 0.3433 0.9919 0 2 2078 6250 
67 RUNX1 0.0786 0.3433 0.9919 0 2 2078 6250 
68 PDCD2L 0.0786 0.3433 0.9919 0 2 2078 6250 
69 NQO1 0.0786 0.3433 0.9919 0 2 2078 6250 
70 MYB 0.0786 0.3433 0.9919 0 2 2078 6250 
71 MET 0.0786 0.3433 0.9919 0 2 2078 6250 
72 KAT6A 0.0786 0.3433 0.9919 0 2 2078 6250 
73 HIST1H2BD 0.0786 0.3433 0.9919 0 2 2078 6250 
74 HIST1H1E 0.0786 0.3433 0.9919 0 2 2078 6250 
75 HGF 0.0786 0.3433 0.9919 0 2 2078 6250 
76 HFE 0.0786 0.3433 0.9919 0 2 2078 6250 
77 FLT1 0.0786 0.3433 0.9919 0 2 2078 6250 
78 FLCN 0.0786 0.3433 0.9919 0 2 2078 6250 
79 FANCF 0.0786 0.3433 0.9919 0 2 2078 6250 
80 ETV4 0.0786 0.3433 0.9919 0 2 2078 6250 
81 EPHB2 0.0786 0.3433 0.9919 0 2 2078 6250 
82 EPHA5 0.0786 0.3433 0.9919 0 2 2078 6250 
83 DAXX 0.0786 0.3433 0.9919 0 2 2078 6250 
84 CYP2C19 0.0786 0.3433 0.9919 0 2 2078 6250 
85 CDKN2A 0.0786 0.3433 0.9919 0 2 2078 6250 
86 BARD1 0.0786 0.3433 0.9919 0 2 2078 6250 
87 BAP1 0.0786 0.3433 0.9919 0 2 2078 6250 
88 AZGP1 0.0786 0.3433 0.9919 0 2 2078 6250 
89 APOL2 0.0786 0.3433 0.9919 0 2 2078 6250 
90 APITD1 0.0786 0.3433 0.9919 0 2 2078 6250 
91 AKT3 0.0786 0.3433 0.9919 0 2 2078 6250 
92 ACO1 0.0786 0.3433 0.9919 0 2 2078 6250 
93 PARP3 0.5037 0.3477 0.9919 3 7 2078 6250 
94 RAD54L 0.4698 0.3897 0.9919 2 5 2078 6250 
95 PMS2 0.4698 0.3897 0.9919 2 5 2078 6250 
96 MAP3K15 0.6003 0.3988 0.9919 4 8 2078 6250 
97 BLM 0.7338 0.4376 0.9919 7 12 2078 6250 
98 TELO2 0.4116 0.4510 0.9919 1 3 2078 6250 
99 MNDA 0.4116 0.4510 0.9919 1 3 2078 6250 
100 MED23 0.4116 0.4510 0.9919 1 3 2078 6250 
101 HIST1H4E 0.4116 0.4510 0.9919 1 3 2078 6250 
102 GPR124 0.4116 0.4510 0.9919 1 3 2078 6250 
103 ERBB3 0.4116 0.4510 0.9919 1 3 2078 6250 
104 DNMT3A 0.4116 0.4510 0.9919 1 3 2078 6250 
105 CRLF2 0.4116 0.4510 0.9919 1 3 2078 6250 
106 COMT 0.4116 0.4510 0.9919 1 3 2078 6250 
107 ALK 0.4116 0.4510 0.9919 1 3 2078 6250 
108 COL7A1 0.6715 0.4940 0.9919 4 7 2078 6250 
109 ABCC2 0.6716 0.4940 0.9919 4 7 2078 6250 
110 HNF1A 0.5713 0.5152 0.9919 2 4 2078 6250 
[141] 
 
111 MUTYH 0.5713 0.5152 0.9919 2 4 2078 6250 
112 POLE 0.5713 0.5152 0.9919 2 4 2078 6250 
113 XPC 0.5713 0.5152 0.9919 2 4 2078 6250 
114 WRN 0.6703 0.5613 0.9919 3 5 2078 6250 
115 CHEK2 0.7393 0.5974 0.9919 4 6 2078 6250 
116 APC 0.5506 0.6276 0.9919 1 2 2078 6250 
117 ATRIP 0.5506 0.6276 0.9919 1 2 2078 6250 
118 DOCK8 0.5506 0.6276 0.9919 1 2 2078 6250 
119 ERCC4 0.5506 0.6276 0.9919 1 2 2078 6250 
120 ITGAV 0.5506 0.6276 0.9919 1 2 2078 6250 
121 NEIL1 0.5506 0.6276 0.9919 1 2 2078 6250 
122 PRKDC 0.5506 0.6276 0.9919 1 2 2078 6250 
123 RECQL4 0.5506 0.6276 0.9919 1 2 2078 6250 
124 SBDS 0.5506 0.6276 0.9919 1 2 2078 6250 
125 SDHA 0.6747 0.6580 0.9919 2 3 2078 6250 
126 CASP8 0.6748 0.6580 0.9919 2 3 2078 6250 
127 TOP3A 0.6748 0.6580 0.9919 2 3 2078 6250 
128 PARP4 0.7493 0.6825 0.9919 3 4 2078 6250 
129 ERCC3 0.8920 0.7524 0.9919 7 8 2078 6250 
130 EXO1 0.8199 0.8008 0.9919 3 3 2078 6250 
131 AURKB 0.8200 0.8008 0.9919 3 3 2078 6250 
132 FGFR4 0.8200 0.8008 0.9919 3 3 2078 6250 
133 FAT1 0.8200 0.8008 0.9919 3 3 2078 6250 
134 ROS1 0.8200 0.8008 0.9919 3 3 2078 6250 
135 CBLC 0.7726 0.8042 0.9919 2 2 2078 6250 
136 HAUS3 0.7726 0.8042 0.9919 2 2 2078 6250 
137 SERPINA1 0.7726 0.8042 0.9919 2 2 2078 6250 
138 FANCD2 0.8814 0.8093 0.9919 5 5 2078 6250 
139 POLQ 0.9839 0.8555 0.9919 18 19 2078 6250 
140 POLK 0.8993 0.8895 0.9919 4 3 2078 6250 
141 FANCL 0.8994 0.8895 0.9919 4 3 2078 6250 
142 ZRANB3 0.9677 0.9693 0.9919 6 3 2078 6250 
143 MC1R 0.9874 0.9747 0.9919 10 6 2078 6250 
BRCA 
        













1 BRCA2 0.0000 0.0000 0.0000 3 19 2078 1156 
2 BRCA1 0.0003 0.0000 0.0000 0 12 2078 1156 
3 FANCM 0.0231 0.0158 0.2048 4 8 2078 1156 
4 MSH6 0.0414 0.0341 0.3327 0 3 2078 1156 
5 BAK1 0.0414 0.0341 0.3327 0 3 2078 1156 
6 ATR 0.0449 0.0410 0.3327 1 4 2078 1156 
7 ATM 0.0792 0.0915 0.5098 2 4 2078 1156 
8 ESR2 0.0832 0.1033 0.5098 1 3 2078 1156 
9 CRLF2 0.0832 0.1033 0.5098 1 3 2078 1156 
10 TET2 0.0831 0.1033 0.5098 1 3 2078 1156 
11 BRIP1 0.0831 0.1033 0.5098 1 3 2078 1156 
12 XRCC2 0.0785 0.1052 0.5098 0 2 2078 1156 
13 TYR 0.0785 0.1052 0.5098 0 2 2078 1156 
14 RAD52 0.0785 0.1052 0.5098 0 2 2078 1156 
15 RAD51B 0.0785 0.1052 0.5098 0 2 2078 1156 
16 IRF4 0.0785 0.1052 0.5098 0 2 2078 1156 
17 FLT1 0.0785 0.1052 0.5098 0 2 2078 1156 
18 AKT3 0.0785 0.1052 0.5098 0 2 2078 1156 
19 PIK3C2G 0.0985 0.1090 0.5098 5 6 2078 1156 
20 EPPK1 0.1437 0.1968 0.5098 2 3 2078 1156 
21 CHEK2 0.1881 0.2405 0.5098 4 4 2078 1156 
22 ABCC2 0.1879 0.2405 0.5098 4 4 2078 1156 
23 SBDS 0.1595 0.2474 0.5098 1 2 2078 1156 
[142] 
 
24 MNDA 0.1595 0.2474 0.5098 1 2 2078 1156 
25 DNMT3A 0.1595 0.2474 0.5098 1 2 2078 1156 
26 RAD54L 0.2658 0.3914 0.5872 2 2 2078 1156 
27 ERCC2 0.2658 0.3914 0.5872 2 2 2078 1156 
28 CNKSR1 0.2658 0.3914 0.5872 2 2 2078 1156 
29 DIS3 0.2658 0.3914 0.5872 2 2 2078 1156 
30 CASP8 0.2658 0.3914 0.5872 2 2 2078 1156 
31 AURKB 0.3851 0.5212 0.6558 3 2 2078 1156 
32 MAP3K15 0.5044 0.6309 0.7689 4 2 2078 1156 
33 DDX11 0.5044 0.6309 0.7689 4 2 2078 1156 
34 FANCD2 0.6140 0.7197 0.8256 5 2 2078 1156 
35 ZRANB3 0.7082 0.7898 0.8801 6 2 2078 1156 
36 BLM 0.7850 0.8439 0.9142 7 2 2078 1156 
37 ERCC3 0.7850 0.8439 0.9142 7 2 2078 1156 
38 MC1R 0.9237 0.9388 0.9635 10 2 2078 1156 
39 POLQ 0.9865 0.9842 0.9842 18 3 2078 1156 
GBM 
        













1 RAD50 0.0584 0.0118 0.0588 2 3 2078 474 
2 MSH6 0.0782 0.0125 0.0588 0 2 2078 474 
3 CYP1B1 0.0782 0.0125 0.0588 0 2 2078 474 
4 APITD1 0.0782 0.0125 0.0588 0 2 2078 474 
5 BLM 0.2380 0.2665 0.2665 7 2 2078 474 
HNSC 
        













1 PALB2 0.0782 0.0159 0.1116 0 2 2078 446 
2 FANCA 0.0732 0.0299 0.1116 3 3 2078 446 
3 FANCM 0.0870 0.0475 0.1116 4 3 2078 446 
4 PMS2 0.1180 0.0803 0.1405 2 2 2078 446 
5 FANCC 0.1180 0.0803 0.1405 2 2 2078 446 
6 CNKSR1 0.1178 0.0803 0.1405 2 2 2078 446 
7 POLQ 0.1668 0.1562 0.1562 18 5 2078 446 
KIRC 
        













1 EME1 0.0784 0.0174 0.1395 0 2 2078 838 
2 BCR 0.0784 0.0174 0.1395 0 2 2078 838 
3 BAP1 0.0784 0.0174 0.1395 0 2 2078 838 
4 XPC 0.0663 0.0187 0.1395 2 3 2078 838 
5 PARP3 0.0823 0.0338 0.1395 3 3 2078 838 
6 ERCC2 0.1284 0.0871 0.1395 2 2 2078 838 
7 FANCM 0.1943 0.1822 0.2082 4 2 2078 838 
8 COL7A1 0.1943 0.1822 0.2082 4 2 2078 838 
LAML 
        













1 RAD51C 0.0781 0.0118 0.0474 0 2 2078 362 
2 DDX11 0.0773 0.0322 0.0644 4 3 2078 362 
3 FANCC 0.1099 0.0612 0.0816 2 2 2078 362 
4 DIS3 0.1099 0.0612 0.0816 2 2 2078 362 
LGG 
        













1 EPPK1 0.0581 0.0117 0.0703 2 3 2078 418 
2 HLA-G 0.0782 0.0125 0.0703 0 2 2078 418 
3 ABL2 0.0943 0.0347 0.0703 1 2 2078 418 
4 PMS2 0.1119 0.0642 0.0963 2 2 2078 418 
[143] 
 
5 MUTYH 0.1119 0.0642 0.0963 2 2 2078 418 
6 POLQ 0.6076 0.6711 0.6711 18 2 2078 418 
LUAD 
        













1 ATM 0.0236 0.0048 0.0673 2 5 2078 594 
2 TRAF7 0.0783 0.0405 0.2835 0 2 2078 594 
3 ERCC2 0.0801 0.0589 0.2835 2 3 2078 594 
4 DIS3 0.0801 0.0589 0.2835 2 3 2078 594 
5 GJB2 0.1064 0.1004 0.2835 3 3 2078 594 
6 FANCG 0.1127 0.1052 0.2835 1 2 2078 594 
7 XPA 0.1125 0.1052 0.2835 1 2 2078 594 
8 NRP2 0.1125 0.1052 0.2835 1 2 2078 594 
9 NBN 0.1125 0.1052 0.2835 1 2 2078 594 
10 FLT3 0.1125 0.1052 0.2835 1 2 2078 594 
11 WRN 0.2046 0.2653 0.3376 3 2 2078 594 
12 FAT1 0.2044 0.2653 0.3376 3 2 2078 594 
13 ABCC2 0.2605 0.3477 0.3745 4 2 2078 594 
14 PIK3C2G 0.3219 0.4267 0.4267 5 2 2078 594 
LUSC 
        













1 FANCA 0.0642 0.0203 0.1017 3 3 2078 226 
2 BRIP1 0.0924 0.0333 0.1017 1 2 2078 226 
3 BRCA2 0.1253 0.0957 0.1596 3 2 2078 226 
4 MC1R 0.2951 0.3844 0.4805 10 2 2078 226 
5 POLQ 0.3250 0.4083 0.4805 18 3 2078 226 
OV 
        













1 BRCA1 0.0000 0.0000 0.0000 0 34 2078 740 
2 BRCA2 0.0000 0.0000 0.0000 3 25 2078 740 
3 RAD51D 0.0415 0.0062 0.0248 0 3 2078 740 
4 PALB2 0.0413 0.0062 0.0248 0 3 2078 740 
5 CNKSR1 0.0421 0.0125 0.0299 2 4 2078 740 
6 BRIP1 0.0576 0.0214 0.0428 1 3 2078 740 
7 PIK3C2G 0.0514 0.0232 0.0428 5 5 2078 740 
8 RAD51C 0.0784 0.0338 0.0507 0 2 2078 740 
9 SDHA 0.1513 0.1564 0.2085 2 2 2078 740 
10 FANCD2 0.3097 0.3782 0.4538 5 2 2078 740 
11 BLM 0.4349 0.5133 0.5600 7 2 2078 740 
12 POLQ 0.9206 0.9052 0.9052 18 2 2078 740 
PRAD 
        













1 ATM 0.0085 0.0000 0.0000 2 6 2078 260 
2 POLK 0.1339 0.1021 0.1021 4 2 2078 260 
STAD 
        













1 PALB2 0.0221 0.0019 0.0224 0 4 2078 350 
2 XRCC2 0.0410 0.0090 0.0538 0 3 2078 350 
3 EME2 0.0410 0.0090 0.0538 0 3 2078 350 
4 ATM 0.0413 0.0195 0.0584 2 4 2078 350 
5 MSH6 0.0781 0.0432 0.1036 0 2 2078 350 
6 HIST1H1E 0.0781 0.0432 0.1036 0 2 2078 350 
7 NBN 0.1097 0.1116 0.1913 1 2 2078 350 
8 BRIP1 0.1097 0.1116 0.1913 1 2 2078 350 
9 POLE 0.1484 0.1929 0.2572 2 2 2078 350 
[144] 
 
10 EPPK1 0.1484 0.1929 0.2572 2 2 2078 350 
11 BRCA2 0.1938 0.2788 0.3041 3 2 2078 350 
12 PIK3C2G 0.3015 0.4447 0.4447 5 2 2078 350 
UCEC 
        













1 MSH6 0.0410 0.0013 0.0088 0 3 2078 386 
2 BRCA1 0.0410 0.0013 0.0088 0 3 2078 386 
3 MRE11A 0.0781 0.0116 0.0271 0 2 2078 386 
4 FANCG 0.0931 0.0323 0.0566 1 2 2078 386 
5 CNKSR1 0.1103 0.0601 0.0841 2 2 2078 386 
6 MAP3K15 0.1498 0.1299 0.1515 4 2 2078 386 





Supplementary Table 2.8: Burden analysis results for Pan-Cancer discovery cohort using rare 
truncation variants from 624 cancer associated genes in 4,034 cases. The control cohort is ESP 
6503 sample set. 
PAN12 
        















1 BRCA1 0.0000 0.0000 0.0000 10 53 13006 8068 
2 BRCA2 0.0000 0.0000 0.0000 44 50 13006 8068 
3 ATM 0.0001 0.0000 0.0000 13 23 13006 8068 
4 BRIP1 0.0006 0.0000 0.0001 7 16 13006 8068 
5 MSH6 0.0040 0.0002 0.0043 5 11 13006 8068 
6 NBN 0.0079 0.0006 0.0138 4 9 13006 8068 
7 PIK3C2G 0.0097 0.0008 0.0153 21 19 13006 8068 
8 XRCC2 0.0104 0.0009 0.0153 2 7 13006 8068 
9 RAD51C 0.0117 0.0010 0.0153 1 6 13006 8068 
10 ERCC2 0.0097 0.0010 0.0153 6 10 13006 8068 
11 PALB2 0.0172 0.0028 0.0333 11 12 13006 8068 
12 DIS3 0.0362 0.0095 0.1050 12 11 13006 8068 
13 DDX11 0.0379 0.0096 0.1050 14 12 13006 8068 
14 BLM 0.0379 0.0096 0.1050 14 12 13006 8068 
15 FLT3 0.0327 0.0099 0.1050 2 5 13006 8068 
16 RAD51B 0.0378 0.0125 0.1050 1 4 13006 8068 
17 SLC19A1 0.0416 0.0131 0.1050 0 3 13006 8068 
18 IRF4 0.0416 0.0131 0.1050 0 3 13006 8068 
19 ERCC1 0.0416 0.0131 0.1050 0 3 13006 8068 
20 FANCM 0.0606 0.0181 0.1202 18 13 13006 8068 
21 SLC25A13 0.0492 0.0213 0.1347 3 5 13006 8068 
22 MRE11A 0.0591 0.0306 0.1849 2 4 13006 8068 
23 PARP2 0.0591 0.0306 0.1849 2 4 13006 8068 
24 ATR 0.0708 0.0387 0.2143 4 5 13006 8068 
25 TYR 0.0708 0.0387 0.2143 4 5 13006 8068 
26 NRP2 0.0708 0.0387 0.2143 4 5 13006 8068 
27 GJB2 0.0870 0.0416 0.2143 10 8 13006 8068 
28 MC1R 0.0786 0.0418 0.2143 6 6 13006 8068 
29 SGK1 0.0699 0.0432 0.2143 1 3 13006 8068 
30 KRAS 0.0699 0.0432 0.2143 1 3 13006 8068 
31 POLH 0.0699 0.0432 0.2143 1 3 13006 8068 
32 GPS2 0.0699 0.0432 0.2143 1 3 13006 8068 
33 DIS3L2 0.0699 0.0432 0.2143 1 3 13006 8068 
34 RAD51D 0.0877 0.0582 0.2275 3 4 13006 8068 
35 HNF1A 0.0877 0.0582 0.2275 3 4 13006 8068 
36 BUB1B 0.0877 0.0582 0.2275 3 4 13006 8068 
37 CRLF2 0.1089 0.0891 0.3202 2 3 13006 8068 
38 TP53BP1 0.1089 0.0891 0.3202 2 3 13006 8068 
39 RAD52 0.1089 0.0891 0.3202 2 3 13006 8068 
40 CNKSR1 0.1896 0.1017 0.3383 18 10 13006 8068 
41 CYP1B1 0.1717 0.1188 0.3855 9 6 13006 8068 
42 ABCC4 0.1717 0.1188 0.3855 9 6 13006 8068 
43 FANCA 0.2013 0.1246 0.3855 14 8 13006 8068 
44 FLT1 0.1347 0.1405 0.4248 1 2 13006 8068 
45 CDKN2A 0.1347 0.1405 0.4248 1 2 13006 8068 
46 SBDS 0.1347 0.1405 0.4248 1 2 13006 8068 
47 RUNX1 0.1347 0.1405 0.4248 1 2 13006 8068 
48 HIST1H1E 0.1347 0.1405 0.4248 1 2 13006 8068 
49 ETV4 0.1347 0.1405 0.4248 1 2 13006 8068 
50 AKT3 0.1347 0.1405 0.4248 1 2 13006 8068 
51 SDHA 0.1587 0.1476 0.4248 3 3 13006 8068 
[146] 
 
52 BCR 0.1587 0.1476 0.4248 3 3 13006 8068 
53 GPR124 0.1586 0.1476 0.4248 3 3 13006 8068 
54 FANCL 0.1586 0.1476 0.4248 3 3 13006 8068 
55 ERBB3 0.1586 0.1476 0.4248 3 3 13006 8068 
56 CHEK2 0.2124 0.1539 0.4248 10 6 13006 8068 
57 RAD50 0.2785 0.1851 0.4320 16 8 13006 8068 
58 XPC 0.2196 0.1919 0.4400 6 4 13006 8068 
59 FANCI 0.2572 0.1929 0.4400 11 6 13006 8068 
60 POLQ 0.4185 0.1950 0.4400 47 19 13006 8068 
61 HIST1H4E 0.2184 0.2146 0.4680 4 3 13006 8068 
62 MNDA 0.2184 0.2146 0.4680 4 3 13006 8068 
63 FAT1 0.2184 0.2146 0.4680 4 3 13006 8068 
64 ALK 0.2184 0.2146 0.4680 4 3 13006 8068 
65 ABL2 0.2671 0.2180 0.4680 9 5 13006 8068 
66 PMS2 0.2671 0.2180 0.4680 9 5 13006 8068 
67 HGF 0.2071 0.2379 0.4723 2 2 13006 8068 
68 CYP2C19 0.2071 0.2379 0.4723 2 2 13006 8068 
69 UROD 0.2071 0.2379 0.4723 2 2 13006 8068 
70 PRKDC 0.2071 0.2379 0.4723 2 2 13006 8068 
71 ITGAV 0.2071 0.2379 0.4723 2 2 13006 8068 
72 HIST1H2BD 0.2071 0.2379 0.4723 2 2 13006 8068 
73 HFE 0.2071 0.2379 0.4723 2 2 13006 8068 
74 BAP1 0.2071 0.2379 0.4723 2 2 13006 8068 
75 APITD1 0.2071 0.2379 0.4723 2 2 13006 8068 
76 PARP3 0.3376 0.2470 0.4723 15 7 13006 8068 
77 RAD54L 0.3212 0.2675 0.4723 10 5 13006 8068 
78 ESR2 0.3212 0.2675 0.4723 10 5 13006 8068 
79 TOP3A 0.2862 0.2864 0.4821 5 3 13006 8068 
80 MED23 0.2862 0.2864 0.4821 5 3 13006 8068 
81 MUTYH 0.3390 0.3076 0.5051 8 4 13006 8068 
82 BAK1 0.3390 0.3076 0.5051 8 4 13006 8068 
83 ABCC2 0.4348 0.3302 0.5291 17 7 13006 8068 
84 NQO1 0.2922 0.3372 0.5339 3 2 13006 8068 
85 EPHB2 0.2922 0.3372 0.5339 3 2 13006 8068 
86 APC 0.2922 0.3372 0.5339 3 2 13006 8068 
87 ERCC4 0.2922 0.3372 0.5339 3 2 13006 8068 
88 EPHA5 0.2922 0.3372 0.5339 3 2 13006 8068 
89 CBLC 0.2922 0.3372 0.5339 3 2 13006 8068 
90 AZGP1 0.2922 0.3372 0.5339 3 2 13006 8068 
91 HLA-G 0.3596 0.3595 0.5339 6 3 13006 8068 
92 TELO2 0.3596 0.3595 0.5339 6 3 13006 8068 
93 FGFR4 0.3596 0.3595 0.5339 6 3 13006 8068 
94 ODAM 0.4037 0.3681 0.5339 9 4 13006 8068 
95 WRN 0.4364 0.3718 0.5339 12 5 13006 8068 
96 XPA 0.4364 0.3718 0.5339 12 5 13006 8068 
97 COL7A1 0.5329 0.4166 0.5712 19 7 13006 8068 
98 POLK 0.4354 0.4313 0.5854 7 3 13006 8068 
99 POLI 0.4354 0.4313 0.5854 7 3 13006 8068 
100 EXT2 0.4354 0.4313 0.5854 7 3 13006 8068 
101 CASP8 0.4354 0.4313 0.5854 7 3 13006 8068 
102 SUZ12 0.3845 0.4320 0.5854 4 2 13006 8068 
103 RECQL4 0.3845 0.4320 0.5854 4 2 13006 8068 
104 ATRIP 0.3845 0.4320 0.5854 4 2 13006 8068 
105 APOL2 0.3845 0.4320 0.5854 4 2 13006 8068 
106 FANCC 0.5806 0.4597 0.5854 20 7 13006 8068 
107 FANCD2 0.5522 0.4760 0.5917 14 5 13006 8068 
108 ZRANB3 0.5110 0.4999 0.6157 8 3 13006 8068 
109 IL7R 0.5110 0.4999 0.6157 8 3 13006 8068 
[147] 
 
110 EME1 0.5110 0.4999 0.6157 8 3 13006 8068 
111 MYB 0.4783 0.5189 0.6218 5 2 13006 8068 
112 MAP3K15 0.6752 0.5311 0.6307 25 8 13006 8068 
113 ERCC3 0.6752 0.5311 0.6307 25 8 13006 8068 
114 DNMT3A 0.5836 0.5640 0.6580 9 3 13006 8068 
115 PARP4 0.6547 0.5948 0.6880 13 4 13006 8068 
116 SLX4 0.6547 0.5948 0.6880 13 4 13006 8068 
117 FAH 0.6512 0.6228 0.7080 10 3 13006 8068 
118 IDH1 0.6512 0.6228 0.7080 10 3 13006 8068 
119 TRAF7 0.6512 0.6228 0.7080 10 3 13006 8068 
120 POLE 0.7084 0.6436 0.7133 14 4 13006 8068 
121 FLCN 0.6509 0.6642 0.7300 7 2 13006 8068 
122 USP9X 0.7236 0.7224 0.7875 8 2 13006 8068 
123 FANCG 0.8480 0.7434 0.8039 24 6 13006 8068 
124 COMT 0.8129 0.7650 0.8205 13 3 13006 8068 
125 TET2 0.8681 0.7977 0.8488 18 4 13006 8068 
126 EME2 0.8522 0.8014 0.8488 14 3 13006 8068 
127 DOCK8 0.8362 0.8134 0.8518 10 2 13006 8068 
128 FANCF 0.8362 0.8134 0.8518 10 2 13006 8068 
129 EPPK1 0.9536 0.8507 0.8771 44 10 13006 8068 
130 AURKB 0.9111 0.8602 0.8800 16 3 13006 8068 
131 ACO1 0.9090 0.8767 0.8901 12 2 13006 8068 
132 EXO1 0.9718 0.9337 0.9407 20 3 13006 8068 
133 ROS1 0.9945 0.9755 0.9755 25 3 13006 8068 
BRCA 
        













1 BRCA1 0.0006 0.0000 0.0000 10 12 13006 1540 
2 BRCA2 0.0002 0.0000 0.0000 44 19 13006 1540 
3 FANCM 0.0110 0.0004 0.0050 18 8 13006 1540 
4 ATR 0.0335 0.0016 0.0152 4 4 13006 1540 
5 CRLF2 0.0511 0.0035 0.0269 2 3 13006 1540 
6 PIK3C2G 0.0421 0.0121 0.0766 21 6 13006 1540 
7 FLT1 0.0878 0.0154 0.0835 1 2 13006 1540 
8 SBDS 0.0877 0.0154 0.0835 1 2 13006 1540 
9 RAD51B 0.0877 0.0154 0.0835 1 2 13006 1540 
10 AKT3 0.0877 0.0154 0.0835 1 2 13006 1540 
11 CHEK2 0.0574 0.0160 0.0835 10 4 13006 1540 
12 MSH6 0.0684 0.0167 0.0835 5 3 13006 1540 
13 XRCC2 0.0977 0.0293 0.0856 2 2 13006 1540 
14 RAD52 0.0977 0.0293 0.0856 2 2 13006 1540 
15 ATM 0.0732 0.0319 0.0856 13 4 13006 1540 
16 BRIP1 0.0822 0.0321 0.0856 7 3 13006 1540 
17 BAK1 0.0898 0.0418 0.0934 8 3 13006 1540 
18 ABCC2 0.0993 0.0636 0.1344 17 4 13006 1540 
19 ESR2 0.1066 0.0649 0.1344 10 3 13006 1540 
20 TYR 0.1200 0.0663 0.1344 4 2 13006 1540 
21 MNDA 0.1200 0.0663 0.1344 4 2 13006 1540 
22 MC1R 0.1456 0.1123 0.1939 6 2 13006 1540 
23 ERCC2 0.1456 0.1123 0.1939 6 2 13006 1540 
24 CASP8 0.1595 0.1376 0.2178 7 2 13006 1540 
25 ZRANB3 0.1742 0.1639 0.2492 8 2 13006 1540 
26 DNMT3A 0.1897 0.1911 0.2792 9 2 13006 1540 
27 TET2 0.1943 0.1971 0.2792 18 3 13006 1540 
28 RAD54L 0.2061 0.2187 0.2968 10 2 13006 1540 
29 DIS3 0.2409 0.2748 0.3600 12 2 13006 1540 
30 DDX11 0.2783 0.3306 0.4187 14 2 13006 1540 
31 BLM 0.2783 0.3306 0.4187 14 2 13006 1540 
[148] 
 
32 FANCD2 0.2783 0.3306 0.4187 14 2 13006 1540 
33 AURKB 0.3182 0.3851 0.4435 16 2 13006 1540 
34 CNKSR1 0.3600 0.4376 0.4891 18 2 13006 1540 
35 ERCC3 0.5144 0.5995 0.6509 25 2 13006 1540 
36 MAP3K15 0.5144 0.5995 0.6509 25 2 13006 1540 
37 EPPK1 0.6323 0.6804 0.6988 44 3 13006 1540 
38 POLQ 0.6816 0.7206 0.7206 47 3 13006 1540 
GBM 
        













1 APITD1 0.0830 0.0027 0.0134 2 2 13006 534 
2 RAD50 0.0635 0.0074 0.0185 16 3 13006 534 
3 MSH6 0.0906 0.0090 0.0185 5 2 13006 534 
4 CYP1B1 0.1017 0.0223 0.0279 9 2 13006 534 
5 BLM 0.1164 0.0453 0.0453 14 2 13006 534 
HNSC 
        













1 FANCA 0.0630 0.0072 0.0504 14 3 13006 582 
2 POLQ 0.0435 0.0080 0.0504 47 5 13006 582 
3 FANCM 0.0706 0.0131 0.0504 18 3 13006 582 
4 PMS2 0.1048 0.0272 0.0504 9 2 13006 582 
5 PALB2 0.1114 0.0373 0.0523 11 2 13006 582 
6 CNKSR1 0.1369 0.0816 0.0952 18 2 13006 582 
7 FANCC 0.1448 0.0962 0.0962 20 2 13006 582 
KIRC 
        













1 XPC 0.0517 0.0017 0.0132 6 3 13006 904 
2 BAP1 0.0850 0.0046 0.0184 2 2 13006 904 
3 BCR 0.0884 0.0075 0.0200 3 2 13006 904 
4 PARP3 0.0708 0.0133 0.0266 15 3 13006 904 
5 ERCC2 0.0992 0.0199 0.0318 6 2 13006 904 
6 EME1 0.1070 0.0308 0.0410 8 2 13006 904 
7 FANCM 0.1521 0.1081 0.1235 18 2 13006 904 
8 COL7A1 0.1572 0.1173 0.1235 19 2 13006 904 
LAML 
        













1 RAD51C 0.0803 0.0012 0.0048 1 2 13006 400 
2 DDX11 0.0589 0.0045 0.0090 14 3 13006 400 
3 DIS3 0.1079 0.0315 0.0420 12 2 13006 400 
4 FANCC 0.1312 0.0720 0.0720 20 2 13006 400 
LGG 
        













1 HLA-G 0.0931 0.0115 0.0688 6 2 13006 446 
2 MUTYH 0.0981 0.0179 0.0688 8 2 13006 446 
3 ABL2 0.1011 0.0216 0.0688 9 2 13006 446 
4 PMS2 0.1008 0.0216 0.0688 9 2 13006 446 
5 EPPK1 0.1199 0.0769 0.0922 44 3 13006 446 
6 POLQ 0.2462 0.2769 0.2769 47 2 13006 446 
LUAD 
        












(CONTROLS) N (CASES) 
[149] 
 
1 ATM 0.0233 0.0005 0.0073 13 5 13006 924 
2 ERCC2 0.0566 0.0043 0.0299 6 3 13006 924 
3 FLT3 0.0877 0.0088 0.0410 2 2 13006 924 
4 GJB2 0.0685 0.0129 0.0452 10 3 13006 924 
5 DIS3 0.0755 0.0194 0.0543 12 3 13006 924 
6 NRP2 0.0978 0.0209 0.0543 4 2 13006 924 
7 NBN 0.0978 0.0209 0.0543 4 2 13006 924 
8 FAT1 0.0978 0.0209 0.0543 4 2 13006 924 
9 TRAF7 0.1329 0.0785 0.1221 10 2 13006 924 
10 WRN 0.1464 0.1029 0.1440 12 2 13006 924 
11 XPA 0.1463 0.1029 0.1440 12 2 13006 924 
12 ABCC2 0.1834 0.1704 0.1988 17 2 13006 924 
13 PIK3C2G 0.2170 0.2282 0.2458 21 2 13006 924 
14 FANCG 0.2442 0.2724 0.2724 24 2 13006 924 
LUSC 
        













1 FANCA 0.0574 0.0039 0.0196 14 3 13006 386 
2 MC1R 0.0913 0.0095 0.0238 6 2 13006 386 
3 BRIP1 0.0939 0.0121 0.0238 7 2 13006 386 
4 POLQ 0.1160 0.0711 0.0889 47 3 13006 386 
5 BRCA2 0.2123 0.2206 0.2206 44 2 13006 386 
OV 
        













1 BRCA1 0.0000 0.0000 0.0000 10 34 13006 858 
2 BRCA2 0.0000 0.0000 0.0000 44 25 13006 858 
3 RAD51D 0.0482 0.0010 0.0040 3 3 13006 858 
4 PIK3C2G 0.0321 0.0027 0.0080 21 5 13006 858 
5 RAD51C 0.0828 0.0042 0.0102 1 2 13006 858 
6 BRIP1 0.0584 0.0054 0.0108 7 3 13006 858 
7 CNKSR1 0.0514 0.0088 0.0151 18 4 13006 858 
8 SDHA 0.0922 0.0134 0.0201 3 2 13006 858 
9 PALB2 0.0706 0.0146 0.0201 11 3 13006 858 
10 BLM 0.1568 0.1221 0.1465 14 2 13006 858 
11 FANCD2 0.1567 0.1221 0.1465 14 2 13006 858 
12 POLQ 0.4738 0.5606 0.5606 47 2 13006 858 
         
PRAD 
        













1 ATM 0.0087 0.0000 0.0000 13 6 13006 356 
2 POLK 0.0914 0.0093 0.0093 7 2 13006 356 
STAD 
        













1 XRCC2 0.0456 0.0005 0.0060 2 3 13006 642 
2 PALB2 0.0372 0.0020 0.0118 11 4 13006 642 
3 ATM 0.0409 0.0032 0.0129 13 4 13006 642 
4 HIST1H1E 0.0826 0.0041 0.0129 1 2 13006 642 
5 NBN 0.0964 0.0192 0.0461 4 2 13006 642 
6 EME2 0.0795 0.0244 0.0488 14 3 13006 642 
7 MSH6 0.1013 0.0262 0.0488 5 2 13006 642 
8 BRIP1 0.1118 0.0428 0.0642 7 2 13006 642 
9 POLE 0.1541 0.1200 0.1601 14 2 13006 642 
10 PIK3C2G 0.2057 0.2140 0.2568 21 2 13006 642 
11 EPPK1 0.4277 0.5208 0.5681 44 2 13006 642 
[150] 
 
12 BRCA2 0.4277 0.5208 0.5681 44 2 13006 642 
UCEC 
        













1 MSH6 0.0468 0.0004 0.0029 5 3 13006 496 
2 BRCA1 0.0531 0.0020 0.0069 10 3 13006 496 
3 MRE11A 0.0827 0.0023 0.0069 2 2 13006 496 
4 DDX11 0.1133 0.0400 0.0699 14 2 13006 496 
5 CNKSR1 0.1254 0.0600 0.0841 18 2 13006 496 
6 FANCG 0.1444 0.0950 0.1108 24 2 13006 496 





Supplementary Table 2.9: Gene-based LOH analysis using rare truncation variants in 
significant genes from burden analysis. 
Gene P-value FDR 
BRCA1    5.55E-17 8.88E-16 
BRCA2    3.50E-14 2.80E-13 
RAD51D   1.21E-05 6.46E-05 
PALB2    0.0035285 0.014114 
BAP1     0.0050624 0.0161997 
RAD51C   0.0098984 0.0263957 
ATM      0.021792 0.0498103 
BRIP1    0.0329 0.0658 
FANCM    0.0824 0.146489 
POLK     0.10393 0.166288 
APITD1   0.29351 0.426924 
HIST1H1E 0.31589 0.421187 
FANCA    0.35538 0.437391 
MRE11A   0.36367 0.415623 
HLA-G    0.40043 0.427125 





Supplementary Table 2.10: Site-based LOH analysis for rare truncation variants in 624 cancer 
associated genes. 
Gene Chr Position Ref Var Normal Tumor Cancer Type 
Pool 
MAF FDR Ref Var VAF Ref Var VAF 
BRCA1 17 41209079 - G 940 735 43.88 777 3639 82.4 OV 0.047 0 
BRCA1 17 41209079 - G 447 300 40.16 121 468 79.46 OV 0.047 6.1E-46 
BRCA1 17 41246433 C T 307 302 49.51 37 377 90.84 OV 0.005 1.0E-45 
BRCA1 17 41245159 C A 531 481 47.53 153 603 79.45 OV 0.005 4.7E-42 
BRCA1 17 41245073 G - 479 383 44.43 150 518 77.54 OV 0.009 1.7E-37 
PALB2 16 23647108 - A 186 133 41.69 50 320 86.49 OV 0.014 4.2E-34 
BRCA1 17 41245410 G C 164 144 46.75 27 255 90.43 OV 0.005 4.1E-30 
BRCA1 17 41209079 - G 313 196 38.51 221 529 70.53 OV 0.047 4.0E-27 
BRCA1 17 41244145 G A 253 224 46.96 96 357 78.81 OV 0.005 5.2E-22 
BRCA1 17 41251825 G - 115 80 41.03 40 227 85.02 OV 0.005 1.8E-21 
BRCA1 17 41209079 - G 410 295 41.84 38 147 79.46 OV 0.047 1.2E-18 
POLK 5 74892232 C T 96 74 43.27 12 126 91.3 OV 0.014 1.3E-18 
BRIP1 17 59857686 G T 112 85 42.71 22 148 87.06 OV 0.005 1.1E-17 
BRCA1 17 41276045 CT - 175 137 43.91 27 144 84.21 OV 0.043 3.2E-17 
RAD51C 17 56801399 AG - 282 121 30.02 58 128 68.82 OV 0.005 1.2E-16 
BRCA1 17 41243513 T - 150 102 40.48 36 142 79.78 BRCA 0.019 8.1E-15 
BRCA1 17 41246038 G - 355 275 43.65 47 153 76.5 OV 0.005 1.0E-14 
BRCA1 17 41276045 CT - 190 105 35.59 43 127 74.71 OV 0.043 1.4E-14 
MSH6 2 48032149 C G 56 27 32.53 9 81 90 GBM 0.005 1.5E-14 
BRCA2 13 32906495 G T 88 90 50.56 3 75 96.15 OV 0.005 3.3E-14 
ATM 11 108183151 G T 155 99 38.98 31 117 79.05 PRAD 0.014 9.6E-14 
RAD51C 17 56780562 C T 77 57 42.54 68 279 80.4 BRCA 0.009 1.1E-13 
BRIP1 17 59934505 TTGT - 307 204 39.92 93 203 68.58 OV 0.005 2.0E-13 
BRCA1 17 41276045 CT - 118 68 36.56 42 136 76.4 OV 0.043 4.3E-13 
BRCA2 13 32913778 T G 47 23 32.86 5 61 92.42 OV 0.005 6.2E-13 
BRCA1 17 41245332 - AG 118 108 47.79 38 170 81.73 OV 0.005 1.9E-12 
BRCA1 17 41245091 G - 226 192 45.93 53 170 76.23 OV 0.005 2.3E-12 
RAD51D 17 33434045 G A 211 218 50.46 61 218 78.14 OV 0.005 3.1E-12 
BRIP1 17 59821942 T GGA 161 135 45.61 56 181 76.37 OV 0.005 1.1E-11 
BRCA1 17 41209079 - G 315 254 44.64 99 225 69.44 BRCA 0.047 2.5E-11 
PALB2 16 23647357 TC - 74 55 42.64 39 160 80.4 BRCA 0.009 5.3E-11 
BRCA1 17 41209079 - G 375 298 44.28 239 413 63.34 OV 0.047 1.5E-10 
BRCA2 13 32929170 A T 207 168 44.56 42 129 75.44 OV 0.005 3.2E-10 
BRCA1 17 41242962 - GA 56 23 29.11 15 64 81.01 OV 0.005 5.0E-10 
BRCA1 17 41276045 CT - 128 103 44.59 41 137 76.97 BRCA 0.043 5.3E-10 
BRCA1 17 41243513 T - 118 126 51.64 99 325 76.65 OV 0.019 9.3E-10 
BRCA2 13 32907420 - A 99 68 40.72 52 151 74.38 OV 0.009 1.2E-09 
BRCA1 17 41246652 AC - 109 78 41.71 12 63 84 OV 0.005 1.7E-09 
BRCA1 17 41199682 C T 38 52 57.78 15 155 91.18 OV 0.005 2.0E-09 
BRCA1 17 41209079 - G 134 83 38.25 62 139 69.15 STAD 0.047 5.7E-09 
BRCA1 17 41276045 CT - 130 62 32.29 83 143 63.27 OV 0.043 8.2E-09 
FANCM 14 45658326 C T 94 65 40.88 20 76 79.17 HNSC 0.038 1.8E-08 
BRCA1 17 41243800 C A 94 111 54.15 22 112 83.58 UCEC 0.005 7.9E-08 
PALB2 16 23640545 G A 77 60 43.8 14 66 82.5 STAD 0.005 1.0E-07 
BRCA2 13 32931944 GT - 100 54 35.06 31 77 71.3 BRCA 0.005 1.3E-07 
BRCA1 17 41209079 - G 93 79 45.93 20 81 80.2 BRCA 0.047 1.5E-07 
BRCA2 13 32914438 T - 138 90 39.47 62 130 67.71 OV 0.047 1.5E-07 
BRCA2 13 32913044 G T 131 111 45.87 47 131 73.6 BRCA 0.005 1.5E-07 
BRCA1 17 41243581 G A 105 99 48.53 46 145 75.92 BRCA 0.005 2.2E-07 
ATM 11 108173702 G - 110 86 43.88 70 167 70.46 BRCA 0.005 3.7E-07 
BRCA2 13 32903605 TG - 131 78 37.32 17 52 75.36 BRCA 0.009 4.3E-07 
BRCA2 13 32913381 C G 88 92 51.11 51 163 76.17 OV 0.005 2.1E-06 
BRCA2 13 32914529 A T 28 39 58.21 6 69 92 OV 0.005 2.7E-06 
[153] 
 
BRCA1 17 41209079 - G 138 114 45.24 25 75 75 OV 0.047 3.2E-06 
BRCA2 13 32914438 T - 120 84 41.18 35 84 70.59 OV 0.047 3.8E-06 
BRCA1 17 41276045 CT - 64 50 43.86 17 64 79.01 OV 0.043 5.0E-06 
ABL2 1 179079416 C T 282 157 35.76 199 224 52.83 LGG 0.047 8.6E-06 
BRCA1 17 41245073 G - 137 121 46.9 62 140 69.31 OV 0.009 1.5E-05 
BRCA2 13 32914438 T - 91 87 48.88 30 93 75.61 OV 0.047 2.1E-05 
ATM 11 108172487 C - 38 19 33.33 22 59 72.84 LUAD 0.005 4.3E-05 
BRCA2 13 32968951 C T 40 24 37.5 17 54 76.06 LUSC 0.005 4.6E-05 
BRCA1 17 41276045 CT - 52 34 39.53 9 36 80 OV 0.043 4.6E-05 
RAD51D 17 33433425 G A 32 35 52.24 6 45 88.24 OV 0.009 4.6E-05 
RAD51D 17 33433425 G A 60 45 42.86 7 33 82.5 OV 0.009 5.5E-05 
BRCA1 17 41201209 G - 51 40 43.96 23 72 75.79 OV 0.005 6.2E-05 
FANCM 14 45654441 G - 40 22 35.48 50 111 68.94 BRCA 0.005 6.9E-05 
BRCA1 17 41244016 - A 66 38 36.54 44 86 66.15 BRCA 0.005 7.4E-05 
BRIP1 17 59871048 A C 56 95 62.91 45 205 82 BRCA 0.005 8.5E-05 
BRCA1 17 41234535 C - 110 105 48.84 88 190 68.35 UCEC 0.005 0.00010 
BRCA1 17 41243513 T - 43 31 41.89 30 82 73.21 BRCA 0.019 0.00015 
BRCA1 17 41245587 T - 37 15 28.85 29 58 66.67 OV 0.005 0.00017 
BRCA1 17 41276045 CT - 85 66 43.71 40 87 68.5 UCEC 0.043 0.00027 
BAP1 3 52436624 G A 122 117 48.75 58 127 68.28 KIRC 0.005 0.00032 
BRCA2 13 32914438 T - 81 71 46.71 25 66 72.53 OV 0.047 0.00046 
BRCA2 13 32937541 - C 226 187 45.28 150 222 59.68 BRCA 0.005 0.00052 
BRCA2 13 32913837 AA - 30 39 56.52 19 89 82.41 BRCA 0.009 0.00057 
ATM 11 108121753 AG - 121 69 36.32 72 96 57.14 LUAD 0.024 0.00088 
BRCA2 13 32913604 AATA - 75 56 42.75 19 47 71.21 OV 0.005 0.00090 
BRCA1 17 41246625 C - 79 55 41.04 33 65 66.33 BRCA 0.005 0.00103 
RAD51C 17 56780562 C T 44 35 44.3 16 47 74.6 OV 0.009 0.00126 
ATM 11 108216491 G - 46 25 35.21 24 48 66.67 BRCA 0.005 0.00129 
MRE11A 11 94180442 G A 140 119 45.95 191 291 60.37 UCEC 0.009 0.00133 
PALB2 16 23646388 G - 138 87 38.67 111 141 55.95 OV 0.005 0.00152 
BRCA2 13 32930687 C T 91 85 48.3 33 77 70 STAD 0.014 0.00152 
ATM 11 108165719 - CT 78 40 33.9 36 53 59.55 LUAD 0.005 0.00219 
FANCM 14 45628392 - A 31 20 39.22 13 36 73.47 BRCA 0.005 0.00261 
BAP1 3 52441973 C T 29 24 45.28 13 43 76.79 KIRC 0.005 0.00260 
BRCA2 13 32968863 C G 25 27 51.92 8 38 82.61 BRCA 0.005 0.00260 
ATM 11 108121753 AG - 130 79 37.8 36 53 59.55 STAD 0.024 0.00425 
BRCA1 17 41209079 - G 54 33 37.93 74 110 59.78 BRCA 0.047 0.00554 
PALB2 16 23649207 ACAA - 62 33 34.74 39 56 58.95 STAD 0.009 0.00619 
BRCA2 13 32906640 A - 69 73 51.41 34 79 69.91 OV 0.005 0.01000 
BRCA1 17 41243513 T - 43 37 46.25 22 52 70.27 OV 0.019 0.00997 
BRCA1 17 41215906 C - 96 64 40 53 74 58.27 BRCA 0.005 0.01288 
BRCA2 13 32914438 T - 121 116 48.95 62 108 63.53 OV 0.047 0.01533 
BRCA1 17 41256250 - T 409 278 40.47 271 262 49.16 BRCA 0.005 0.01629 
ATM 11 108115640 T - 36 15 29.41 48 59 55.14 PRAD 0.005 0.01725 
DDX11 12 31256740 G A 121 64 34.59 159 147 48.04 LAML 0.009 0.02419 
BRCA2 13 32914438 T - 98 74 43.02 31 49 61.25 OV 0.047 0.03180 
PALB2 16 23649207 ACAA - 38 23 37.7 19 30 61.22 LUAD 0.009 0.06352 
PALB2 16 23647357 TC - 136 104 43.33 63 80 55.94 STAD 0.009 0.07285 
MSH6 2 48033981 - 
TTG
A 72 50 40.98 53 68 56.2 BRCA 0.028 0.07762 
HLA-G 6 29796574 A T 66 59 46.83 46 73 60.83 LGG 0.005 0.08982 
BRCA1 17 41276045 CT - 80 69 46.31 27 44 61.97 OV 0.043 0.09724 
PIK3C2G 12 18691246 G - 42 32 43.24 53 77 59.23 LUAD 0.014 0.10222 
MAP3K1
5 X 19392724 G A 83 59 41.55 90 105 53.3 LAML 0.009 0.10491 
EPPK1 8 144941508 C A 42 33 42.86 19 31 59.62 STAD 0.009 0.14932 
MSH6 2 48033745 AAGC - 39 19 32.76 35 37 51.39 UCEC 0.005 0.15187 
FANCM 14 45636336 C T 31 38 55.07 14 33 70.21 BRCA 0.019 0.18008 
FANCG 9 35075554 G C 62 65 51.18 49 80 62.02 UCEC 0.005 0.19452 
[154] 
 
Supplementary Table 2.11: Gene-based LOH analysis for rare missense variants in 624 cancer 
associated genes. 
Gene P-Value FDR 
BRCA1 0.000723162 0.004338975 
ATM 0.001159173 0.004338975 
BRCA2 0.065008945 0.13001789 
RAD51C 0.100971489 0.151457234 
BRIP1 0.258099528 0.309719433 





Supplementary Table 2.12: Site-based LOH analysis for rare missense variants in 624 cancer 
associated genes. 
Gene Chr Position Ref Var Normal Tumor Cancer Type 
Pool 
MAF FDR Ref Var VAF Ref Var VAF 
BRIP1 17 59937223 G C 248 221 47.12 10 426 97.71 OV 0.028 1.06E-71 
BRCA1 17 41245027 G A 644 613 48.69 146 732 83.28 OV 0.247 2.68E-59 
PARP3 3 51978526 T C 13 65 83.33 179 0 0 LAML 0.005 1.76E-43 
XRCC2 7 152346287 T C 113 139 55.16 14 460 96.64 OV 0.043 1.35E-42 
BRCA1 17 41245233 A G 231 230 49.78 25 267 91.44 OV 0.033 1.09E-32 
BRCA1 17 41243509 T C 262 286 52.19 86 483 84.89 OV 0.489 5.04E-30 
POLK 5 74869615 G T 149 121 44.65 152 0 0 LUAD 0.005 1.22E-25 
EME1 17 48453202 C A 168 162 49.09 38 270 87.66 OV 0.009 5.20E-24 
FANCM 14 45658366 C T 101 104 50.24 51 360 87.59 GBM 0.043 5.75E-20 
FANCC 9 98011545 C T 87 90 50.85 14 182 92.86 BRCA 0.033 8.02E-19 
MSH6 2 48032068 T C 188 180 48.91 107 407 78.88 OV 0.005 3.92E-18 
EPPK1 8 144941013 G T 139 111 44.22 39 205 84.02 KIRC 0.005 3.72E-18 
ATM 11 108201008 C G 128 85 39.91 9 96 91.43 OV 0.009 3.57E-18 
BRCA2 13 32968940 A T 217 246 52.12 41 239 83.57 BRCA 0.005 5.46E-18 
PIK3C2G 12 18435620 A T 477 437 47.81 225 528 69.84 OV 0.024 1.81E-17 
BRCA1 17 41201181 C A 35 46 56.79 4 213 98.16 OV 0.005 1.89E-17 
BRCA1 17 41201187 A G 142 121 45.66 37 197 84.19 BRCA 0.005 3.89E-17 
FANCM 14 45644409 A G 217 204 48.34 69 274 79.88 KIRC 0.014 3.82E-17 
BRCA1 17 41258495 A C 56 54 49.09 5 130 96.3 OV 0.009 3.69E-17 
PALB2 16 23641340 G A 97 63 39.38 137 478 77.6 BRCA 0.047 5.06E-17 
MAP3K15 X 19410570 C T 183 187 50.54 22 159 87.85 OV 0.005 5.53E-17 
BRCA1 17 41223196 G C 273 239 46.5 78 264 77.19 OV 0.009 5.66E-17 
ATM 11 108142070 A G 332 324 49.39 179 494 73.29 OV 0.024 6.09E-17 
BRCA2 13 32914755 C T 92 80 46.51 3 86 96.63 OV 0.005 6.10E-17 
BRIP1 17 59821942 T A 131 137 47.4 24 181 83.41 OV 0.005 9.46E-17 
RAD50 5 131977907 C T 106 106 50 31 216 87.45 OV 0.005 9.28E-17 
RAD50 5 131924529 G C 84 84 49.7 3 95 96.94 OV 0.005 1.24E-16 
ATM 11 108150267 C G 172 189 52.35 10 120 92.31 OV 0.005 1.32E-16 
ATM 11 108143552 G A 102 112 52.34 19 176 90.26 HNSC 0.005 2.83E-16 
BAP1 3 52437281 G C 14 38 73.08 65 0 0 LAML 0.005 5.00E-16 
ATM 11 108165748 A G 41 44 51.76 2 116 98.31 UCEC 0.019 1.01E-15 
EME2 16 1825096 C T 108 88 44.9 21 132 86.27 STAD 0.005 2.51E-14 
BRIP1 17 59878645 T C 417 456 52.23 88 288 76.6 OV 0.005 3.77E-14 
EME1 17 48453305 G A 107 72 40 97 0 0 BRCA 0.005 8.05E-14 
BRCA1 17 41246812 A C 47 57 54.81 5 125 95.42 OV 0.024 1.02E-13 
BRIP1 17 59885868 T C 71 67 48.55 30 201 87.01 UCEC 0.005 1.51E-13 
EPPK1 8 144940828 C G 147 172 53.92 93 378 80.08 HNSC 0.009 4.81E-13 
ERCC2 19 45858047 C T 87 67 43.51 9 85 90.43 LGG 0.014 4.73E-13 
FANCM 14 45646041 G A 63 84 57.14 4 102 96.23 GBM 0.014 9.19E-13 
MSH6 2 48025871 T C 114 87 43.07 14 92 86.79 PRAD 0.009 1.30E-12 
MAP3K15 X 19389563 C T 114 96 45.71 10 85 89.47 BRCA 0.005 1.38E-12 
BRIP1 17 59793364 G A 55 64 53.78 15 164 91.62 OV 0.014 1.50E-12 
FANCA 16 89815165 G A 40 29 40.85 4 75 94.94 BRCA 0.005 5.67E-12 
MSH6 2 48026778 T A 211 234 52.47 274 730 72.64 OV 0.005 2.07E-11 
BRCA1 17 41245381 T C 132 105 44.3 27 118 80.82 UCEC 0.161 2.36E-11 
MRE11A 11 94180441 C T 163 132 44.59 102 273 72.8 UCEC 0.038 2.32E-11 
BRCA1 17 41244982 A G 199 198 49.75 72 236 76.62 STAD 0.033 2.54E-11 
ATM 11 108158333 C G 39 23 37.1 5 67 93.06 STAD 0.005 3.04E-11 
FANCA 16 89838139 A T 131 132 50.19 40 173 81.22 UCEC 0.005 7.15E-11 
MUTYH 1 45800164 C T 79 101 56.11 6 87 93.55 LGG 0.005 1.66E-10 
ATM 11 108202716 A C 97 85 46.7 37 156 80.83 OV 0.005 2.61E-10 
FANCG 9 35078332 T C 26 26 50 1 67 98.53 STAD 0.005 2.57E-10 
BRCA2 13 32914229 T C 91 67 42.41 16 85 84.16 BRCA 0.005 4.06E-10 
[156] 
 
FANCM 14 45644401 C T 75 50 40 18 88 83.02 OV 0.009 7.25E-10 
MAP3K15 X 19392655 C T 173 145 45.6 40 133 76.88 OV 0.005 8.99E-10 
BRCA1 17 41258504 A C 64 42 39.62 12 73 85.88 BRCA 0.019 1.13E-09 
POLK 5 74892218 T G 49 47 48.96 10 94 90.38 GBM 0.009 1.27E-09 
ATM 11 108121543 C T 91 91 50 34 158 82.29 BRCA 0.005 1.27E-09 
MRE11A 11 94180450 C T 189 212 52.48 65 224 76.98 BRCA 0.005 1.33E-09 
MRE11A 11 94212892 T C 38 32 45.71 5 70 93.33 LUAD 0.005 1.35E-09 
RAD50 5 131976461 G A 42 48 53.33 3 69 95.83 BRCA 0.005 1.39E-09 
ERCC2 19 45854910 C G 94 92 48.94 15 92 85.98 LGG 0.033 3.68E-09 
ATM 11 108224538 T C 215 179 45.43 85 203 70.49 BRCA 0.005 5.35E-09 
BRCA2 13 32915144 G A 44 24 35.29 105 0 0 LAML 0.005 6.49E-09 
BRCA2 13 32907098 G C 45 48 51.61 5 68 93.15 BRCA 0.005 1.46E-08 
FANCA 16 89851273 G A 45 40 47.06 8 73 89.02 BRCA 0.009 1.83E-08 
BRCA2 13 32914550 G A 50 53 51.46 3 54 94.74 GBM 0.005 1.87E-08 
RAD51C 17 56787260 G A 103 99 49.01 13 78 85.71 BRCA 0.005 1.87E-08 
FANCA 16 89825017 A C 83 78 48.45 11 72 86.75 OV 0.019 3.57E-08 
BRCA2 13 32954181 G A 58 72 55.38 8 82 91.11 PRAD 0.005 3.80E-08 
PALB2 16 23614833 G A 114 117 50.65 50 175 77.78 OV 0.014 6.12E-08 
FANCA 16 89874705 T G 107 98 47.8 45 151 77.04 OV 0.005 6.52E-08 
XPC 3 14214383 C T 42 30 41.67 6 53 89.83 UCEC 0.005 6.97E-08 
BRCA1 17 41258504 A C 103 60 36.81 71 152 68.16 BRCA 0.019 8.19E-08 
BRCA1 17 41258504 A C 67 38 36.19 8 45 84.91 BRCA 0.019 8.20E-08 
MAP3K15 X 19398357 C T 51 50 49.02 5 56 91.8 OV 0.009 8.82E-08 
BRCA1 17 41219645 G A 44 28 38.89 11 64 85.33 OV 0.005 9.74E-08 
FANCG 9 35076812 G A 119 107 47.35 36 122 77.22 KIRC 0.005 1.25E-07 
ATM 11 108203612 T G 48 30 38.46 10 56 84.85 BRCA 0.009 2.14E-07 
BRCA2 13 32937554 G A 114 107 48.42 9 57 86.36 UCEC 0.009 2.32E-07 
BRCA1 17 41256153 C T 99 80 44.44 42 128 74.85 STAD 0.005 2.33E-07 
FANCA 16 89813078 G C 28 27 49.09 1 38 97.44 OV 0.047 2.70E-07 
BRCA2 13 32907128 A G 88 88 50 15 80 84.21 HNSC 0.005 2.76E-07 
BRCA1 17 41247892 T C 63 44 41.12 7 45 86.54 OV 0.014 4.41E-07 
PARP3 3 51979205 C T 55 54 49.54 15 87 85.29 LUSC 0.005 4.52E-07 
MUTYH 1 45798309 C T 138 108 43.72 176 342 65.9 OV 0.005 5.53E-07 
PARP3 3 51978552 C G 155 97 38.34 98 170 63.2 LUAD 0.014 9.77E-07 
PARP3 3 51982404 G A 39 38 49.35 13 86 86.87 OV 0.024 9.87E-07 
BRCA1 17 41245233 A G 130 106 44.92 72 169 70.12 LUAD 0.033 1.28E-06 
MAP3K15 X 19380945 T C 93 99 51.56 19 88 82.24 OV 0.005 1.70E-06 
EPPK1 8 144942354 T C 57 34 37.36 23 75 76.53 HNSC 0.014 1.78E-06 
EME1 17 48456028 G A 31 32 50.79 11 85 88.54 BRCA 0.033 2.13E-06 
FANCM 14 45667962 G T 187 189 50.27 9 51 83.61 OV 0.014 2.82E-06 
BRCA2 13 32929291 A C 100 123 55.16 22 103 82.4 OV 0.005 3.35E-06 
DIS3 13 73351586 T A 33 32 49.23 6 55 90.16 LUAD 0.005 3.57E-06 
FANCA 16 89851334 G C 73 60 45.11 4 34 89.47 BRCA 0.009 4.00E-06 
BRCA1 17 41245176 A G 376 353 48.36 213 366 63.21 LAML 0.005 5.07E-06 
BRCA1 17 41251803 T C 82 56 40.58 30 83 73.45 HNSC 0.038 6.27E-06 
PALB2 16 23641001 C G 36 27 42.86 11 60 84.51 STAD 0.005 6.90E-06 
BRCA1 17 41243509 T C 83 92 52.57 15 75 83.33 OV 0.489 7.70E-06 
FANCA 16 89828357 C T 44 40 47.62 5 42 89.36 BRCA 0.009 7.98E-06 
BRCA1 17 41243509 T C 80 71 47.02 28 94 77.05 HNSC 0.489 1.02E-05 
PMS2 7 6045549 C A 209 159 43.21 192 302 60.89 LGG 0.024 1.08E-05 
BRCA2 13 32912763 C G 59 44 42.72 40 116 73.42 LUSC 0.005 1.15E-05 
POLK 5 74865291 A G 35 26 42.62 7 45 86.54 LUAD 0.014 1.23E-05 
EPPK1 8 144942462 C T 34 28 45.16 10 59 85.51 BRCA 0.014 1.27E-05 
FANCA 16 89877200 G C 49 44 47.31 10 55 84.62 BRCA 0.038 1.61E-05 
EME2 16 1826153 C T 61 45 42.45 18 64 78.05 LUAD 0.005 1.86E-05 
ATM 11 108117798 C T 32 23 41.82 9 50 84.75 BRCA 0.014 2.26E-05 
FANCG 9 35076015 C T 72 65 47.45 48 139 74.33 STAD 0.005 2.39E-05 
ATM 11 108115564 A G 197 175 47.04 161 291 64.38 OV 0.005 2.65E-05 
BRCA2 13 32953604 G A 63 55 46.22 12 54 81.82 LGG 0.038 3.35E-05 
[157] 
 
MRE11A 11 94197302 T C 66 85 55.92 9 60 86.96 LUSC 0.014 3.48E-05 
BRCA1 17 41215948 G A 42 30 41.67 17 64 79.01 OV 0.014 4.47E-05 
EPPK1 8 144945071 C T 145 155 51.67 50 137 72.87 UCEC 0.009 4.82E-05 
ATM 11 108158399 A G 28 27 49.09 2 29 93.55 HNSC 0.024 5.03E-05 
PIK3C2G 12 18435145 G A 91 95 51.08 5 36 87.8 OV 0.019 5.32E-05 
DIS3 13 73333982 T C 60 69 53.49 23 98 80.99 OV 0.005 5.29E-05 
XRCC2 7 152346287 T C 58 75 56.39 61 228 78.89 OV 0.043 5.26E-05 
DIS3 13 73355036 C T 157 160 50.47 90 204 69.39 BRCA 0.005 5.67E-05 
DIS3 13 73340135 T C 47 31 39.74 11 44 80 BRCA 0.019 5.80E-05 
FANCA 16 89813078 G C 40 27 40.3 14 54 79.41 GBM 0.047 6.14E-05 
PARP3 3 51978529 C T 210 176 45.48 75 143 65.3 STAD 0.014 7.61E-05 
BRCA1 17 41246092 A G 64 40 38.46 27 68 71.58 HNSC 0.038 8.01E-05 
BRCA1 17 41245027 G A 80 74 48.05 52 138 72.25 UCEC 0.247 8.40E-05 
BRCA2 13 32900252 A G 56 62 52.54 18 79 81.44 OV 0.009 9.92E-05 
PARP3 3 51978503 G T 149 117 43.98 95 170 64.15 LUAD 0.005 0.00011 
FANCA 16 89813078 G C 27 20 42.55 14 63 80.77 STAD 0.047 0.00013 
BAP1 3 52438541 T C 135 107 44.21 36 82 69.49 KIRC 0.005 0.00017 
EPPK1 8 144942519 C T 74 53 41.73 26 67 72.04 KIRC 0.005 0.00019 
MUTYH 1 45798837 C T 113 79 41.15 73 129 63.86 LUAD 0.005 0.00023 
RAD51D 17 33434093 C T 101 71 41.28 44 89 66.92 OV 0.014 0.00026 
FANCM 14 45644409 A G 45 46 50.55 18 74 80.43 BRCA 0.014 0.00026 
RAD51D 17 33428027 A T 78 67 46.21 22 66 74.16 LUSC 0.028 0.00028 
RAD51C 17 56772310 C T 35 45 56.25 23 111 82.84 OV 0.005 0.00032 
XRCC2 7 152346287 T C 173 141 44.9 146 235 61.52 KIRC 0.043 0.00035 
ATM 11 108203541 C T 65 47 41.96 20 56 72.73 BRCA 0.005 0.00034 
FANCM 14 45642287 A T 70 56 44.09 21 61 73.49 OV 0.005 0.00036 
RAD51D 17 33428027 A T 59 68 53.54 10 51 82.26 BRCA 0.028 0.00037 
ATM 11 108205832 T C 59 70 54.26 22 87 79.82 LUAD 0.009 0.00037 
EPPK1 8 144942329 C T 41 43 50.59 17 72 80 HNSC 0.009 0.00040 
BRCA2 13 32912007 C T 65 39 37.5 31 65 67.71 KIRC 0.047 0.00054 
ATM 11 108137953 A C 65 45 40.91 30 70 70 BRCA 0.005 0.00055 
BRCA1 17 41243509 T C 225 228 50.22 103 199 65.89 BRCA 0.489 0.00055 
BRCA1 17 41226488 C A 24 36 60 22 131 85.62 BRCA 0.285 0.00062 
PMS2 7 6027143 G A 50 39 43.33 27 74 73.27 LUAD 0.005 0.00072 
FANCM 14 45645949 C T 96 78 44.83 44 95 68.35 KIRC 0.038 0.00072 
FANCG 9 35078184 C T 111 68 37.57 25 50 66.67 STAD 0.009 0.00082 
MAP3K15 X 19380887 C G 133 75 36.06 62 88 58.67 HNSC 0.014 0.00084 
RAD51C 17 56774155 T C 60 68 53.12 11 50 81.97 UCEC 0.019 0.00084 
FANCM 14 45642337 A G 61 54 46.55 12 44 77.19 STAD 0.009 0.00087 
FANCM 14 45665709 A C 65 48 42.48 40 88 68.75 LUAD 0.005 0.00093 
PALB2 16 23632740 A G 45 32 41.56 49 111 68.94 OV 0.014 0.00108 
ATM 11 108203580 A G 50 36 41.86 14 43 75.44 LUSC 0.005 0.00110 
FANCC 9 97879600 G C 25 36 59.02 4 37 90.24 OV 0.005 0.00148 
BRCA2 13 32912190 C T 33 28 45.9 11 44 80 LUSC 0.005 0.00159 
BRCA1 17 41226488 C A 30 29 49.15 8 40 83.33 HNSC 0.285 0.00164 
BRCA2 13 32937333 A G 73 65 47.1 24 65 73.03 GBM 0.047 0.00166 
ATM 11 108153488 A G 81 35 30.17 44 59 57.28 LUAD 0.009 0.00191 
BRCA2 13 32913562 A C 54 56 50.91 14 52 78.79 BRCA 0.033 0.00205 
BRCA2 13 32930613 T C 321 208 39.32 84 107 55.73 LAML 0.005 0.00225 
BRCA1 17 41226488 C A 82 73 47.1 20 55 73.33 BRCA 0.285 0.00226 
BRCA2 13 32893369 G C 64 48 42.86 15 41 71.93 LUSC 0.028 0.00285 
DDX11 12 31255911 C T 48 31 39.24 25 56 69.14 BRCA 0.019 0.00289 
BRCA1 17 41245714 T C 65 74 53.24 31 93 75 OV 0.005 0.00292 
ATM 11 108236150 G A 164 163 49.85 63 126 66.67 OV 0.028 0.00353 
ATM 11 108168053 A G 116 58 33.33 74 87 54.04 BRCA 0.019 0.00439 
MSH6 2 48027683 A T 57 51 47.22 32 78 70.91 LUSC 0.038 0.00558 
ATM 11 108141988 T C 136 96 41.38 136 182 57.23 BRCA 0.043 0.00609 
DDX11 12 31249614 G A 33 43 56.58 50 171 77.38 BRCA 0.028 0.00638 
RAD50 5 131939181 G C 33 21 38.89 18 45 71.43 STAD 0.028 0.00656 
[158] 
 
ATM 11 108203612 T G 83 59 41.55 43 76 63.87 BRCA 0.009 0.00662 
ATM 11 108121787 G A 89 57 39.04 51 79 60.31 HNSC 0.009 0.00724 
ATM 11 108115522 A G 150 173 53.4 37 91 71.09 BRCA 0.019 0.00725 
BRCA1 17 41223021 G A 37 43 53.75 10 43 81.13 OV 0.005 0.00744 
BRCA1 17 41223048 A G 32 40 55.56 18 71 79.78 BRCA 0.057 0.00764 
ATM 11 108128246 T A 46 53 53.54 13 49 79.03 HNSC 0.043 0.00761 
BRCA1 17 41246164 C T 88 82 48.24 199 346 63.25 LUSC 0.009 0.00779 
FANCC 9 97873856 C G 133 111 45.49 55 96 63.16 BRCA 0.005 0.00832 
BRCA1 17 41223048 A G 46 38 45.24 81 163 66.8 BRCA 0.057 0.00879 
CNKSR1 1 26515965 C T 41 68 61.82 14 68 82.93 LGG 0.024 0.00880 
BRCA2 13 32913947 C T 27 26 49.06 8 34 80.95 BRCA 0.014 0.00904 
FANCM 14 45605730 G A 41 31 43.06 30 68 68.69 BRCA 0.009 0.00901 
ERCC2 19 45854910 C G 172 159 47.32 201 304 59.96 STAD 0.033 0.01000 
PALB2 16 23647569 G A 64 60 48.39 16 45 73.77 BRCA 0.028 0.01025 
ATM 11 108121632 A C 32 27 45.76 14 43 75.44 OV 0.009 0.01107 
FANCM 14 45623169 G A 114 90 44.12 16 37 69.81 GBM 0.005 0.01118 
ATM 11 108183194 A C 120 74 38.14 201 228 53.15 BRCA 0.028 0.01237 
BRCA2 13 32911818 C T 60 39 39 29 53 64.63 KIRC 0.005 0.01262 
XPC 3 14220032 C G 50 27 35.06 31 51 62.2 LUAD 0.043 0.01266 
DDX11 12 31231421 C T 42 29 40.85 13 33 71.74 OV 0.028 0.01316 
FANCA 16 89836623 C G 32 37 53.62 9 38 80.85 BRCA 0.014 0.01421 
FANCM 14 45645955 A C 100 91 47.64 70 126 63.96 OV 0.019 0.01446 
FANCA 16 89838136 T C 164 148 47.44 99 157 61.33 BRCA 0.014 0.01520 
EME1 17 48453514 C T 48 47 49.47 53 120 69.36 OV 0.005 0.01670 
CNKSR1 1 26515361 C T 69 62 46.27 53 104 66.24 OV 0.005 0.01681 
RAD50 5 131924538 A G 200 144 41.86 74 99 57.23 GBM 0.019 0.01837 
FANCM 14 45665637 A G 136 126 48.09 68 118 63.44 OV 0.005 0.01838 
FANCM 14 45644691 A G 122 97 44.29 71 109 60.56 LUSC 0.009 0.01982 
DDX11 12 31236777 C T 150 116 43.61 76 110 59.14 LUAD 0.005 0.01974 
XPC 3 14212018 T A 78 61 43.88 16 36 69.23 BRCA 0.005 0.02122 
XPC 3 14199801 T C 39 36 48 32 77 70.64 KIRC 0.005 0.02182 
MSH6 2 48027541 G A 194 201 50.89 148 241 61.79 GBM 0.005 0.02372 
MRE11A 11 94169056 C T 82 58 41.43 53 81 60.45 LGG 0.005 0.02680 
EME1 17 48453272 G A 73 44 37.61 52 72 58.06 LUAD 0.005 0.02729 
FANCA 16 89839732 G T 28 32 53.33 10 38 79.17 BRCA 0.005 0.02940 
PIK3C2G 12 18435620 A T 144 167 53.7 80 157 66.24 LAML 0.024 0.03184 
XPC 3 14199969 C T 68 70 50.36 72 144 66.36 UCEC 0.009 0.03171 
DDX11 12 31249614 G A 35 20 36.36 29 50 63.29 STAD 0.028 0.03361 
EPPK1 8 144946503 C T 93 78 45.61 41 72 63.72 STAD 0.005 0.03524 
BRCA1 17 41243509 T C 69 58 45.67 70 118 62.77 STAD 0.489 0.03633 
EPPK1 8 144947076 C T 36 17 32.08 27 41 60.29 STAD 0.005 0.03625 
DIS3 13 73333944 G A 61 69 53.08 11 35 74.47 UCEC 0.019 0.03755 
ATM 11 108192118 G T 138 142 50.71 125 208 62.28 UCEC 0.033 0.04014 
ATM 11 108183194 A C 92 109 54.23 58 125 68.31 KIRC 0.028 0.04226 
BRCA1 17 41246411 A C 126 119 48.57 60 102 62.96 PRAD 0.147 0.04925 
EPPK1 8 144941205 G A 46 47 50.54 50 106 67.95 LUAD 0.028 0.06117 
MRE11A 11 94180388 T C 114 137 54.58 54 112 67.47 BRCA 0.005 0.07082 
MAP3K15 X 19392700 C T 84 68 44.74 27 48 64 GBM 0.014 0.07055 
ERCC2 19 45855574 G A 70 72 50.7 42 84 66.67 GBM 0.014 0.07494 
BRIP1 17 59934481 C T 157 158 50.16 129 199 60.67 BRCA 0.033 0.07950 
BRCA1 17 41251803 T C 130 84 39.07 125 136 52.11 BRCA 0.038 0.08176 
FANCG 9 35075302 C T 63 65 50.78 21 48 69.57 BRCA 0.009 0.08444 
MSH6 2 48033735 G C 112 113 50.22 111 180 61.64 BRCA 0.005 0.08434 
RAD50 5 131940620 C T 52 27 34.18 39 49 55.68 GBM 0.043 0.08546 
MSH6 2 48027037 G A 136 110 44.72 117 153 56.67 LGG 0.009 0.08513 
EPPK1 8 144942246 T C 57 46 44.66 38 65 63.11 BRCA 0.009 0.08610 
BRCA2 13 32944563 G A 0 362 100 1 444 99.33 BRCA 0.005 0.09000 
FANCM 14 45658156 G A 1 187 99.47 0 117 100 BRCA 0.038 0.09830 
FANCM 14 45644706 A G 110 101 47.87 51 83 61.94 OV 0.047 0.10640 
[159] 
 
ATM 11 108119760 T C 182 163 47.25 110 151 57.85 UCEC 0.005 0.10708 
RAD50 5 131939072 G A 92 72 43.9 88 119 57.49 GBM 0.019 0.11089 
MAP3K15 X 19413274 G A 108 60 35.5 152 144 48.65 LUAD 0.005 0.11062 
ATM 11 108163377 A G 281 188 40 264 249 48.44 KIRC 0.005 0.11341 
FANCA 16 89836366 T C 41 36 46.75 15 33 68.75 STAD 0.014 0.12526 
FANCG 9 35078282 C G 51 48 48.48 23 47 67.14 KIRC 0.009 0.12747 
BRCA2 13 32972575 G A 31 42 57.53 20 59 74.68 LUAD 0.024 0.12730 
PALB2 16 23646867 A C 101 123 54.91 26 59 69.41 BRCA 0.009 0.12835 
PMS2 7 6026906 C T 81 80 49.38 37 68 64.76 STAD 0.019 0.12801 
EPPK1 8 144946799 C T 24 22 47.83 17 41 70.69 STAD 0.028 0.12778 
RAD50 5 131973868 G A 75 46 38.02 30 40 57.14 LUAD 0.005 0.13377 
PMS2 7 6026840 T C 0 32 100 0 35 100 BRCA 0.005 0.14086 
ATM 11 108138061 G C 0 65 100 0 97 100 LUAD 0.005 0.14028 
FANCC 9 97879669 G A 0 32 100 0 37 97.37 PRAD 0.009 0.13970 
ATM 11 108202273 G A 49 41 45.56 33 57 63.33 STAD 0.005 0.14933 
ERCC2 19 45854910 C G 128 120 47.62 93 136 58.62 KIRC 0.033 0.14891 
BRCA1 17 41245546 G A 45 35 43.75 17 32 65.31 OV 0.005 0.14940 
XRCC2 7 152346389 G T 70 74 51.39 67 120 63.83 STAD 0.014 0.14899 
RAD51C 17 56770018 C T 48 24 33.33 44 50 52.63 KIRC 0.014 0.14928 
BRCA2 13 32913898 A C 62 69 52.67 86 159 64.9 BRCA 0.014 0.15380 
BRIP1 17 59924502 T C 166 158 48.77 198 267 57.42 BRCA 0.014 0.15401 
BRCA2 13 32937554 G A 152 157 50.81 124 187 60.13 UCEC 0.009 0.16263 
DDX11 12 31242979 C A 47 39 45.35 37 62 61.39 BRCA 0.033 0.16256 
BRCA2 13 32954037 A C 50 31 38.27 20 30 60 BRCA 0.009 0.16614 
FANCM 14 45645426 G A 36 21 36.84 19 29 60.42 BRCA 0.009 0.17201 
MUTYH 1 45798269 T C 64 67 51.15 53 95 63.76 OV 0.024 0.19622 
XRCC2 7 152346287 T C 73 82 52.9 75 135 64.29 STAD 0.043 0.19586 
BRCA2 13 32929222 A C 92 68 42.24 63 80 55.94 OV 0.005 0.19756 
EME1 17 48453487 G A 35 25 41.67 28 45 61.64 HNSC 0.009 0.19740 




Supplementary Table 2.13: LOH analysis of rare missense variants for discovering hotspot 
clusters. 
Rank Region P-Value FDR 
RANK 1: (EPPK1: 1635 to 1726) 0.000103934 0.003118018 
RANK 2: (PARP3: 144 to 283) 0.000307675 0.00461512 
RANK 3: (ATM: 2459 to 2717) 0.000341543 0.003415432 
RANK 4: (BRCA1: 61 to 246) 0.000521565 0.003911739 
RANK 5: (ERCC2: 695 to 754) 0.000642717 0.003856304 
RANK 6: (FANCM: 730 to 918) 0.000980384 0.004901922 
RANK 7: (XRCC2: 61 to 124) 0.001459117 0.00625336 
RANK 8: (FANCA: 951 to 1172) 0.002081455 0.007805457 
RANK 9: (MRE11A: 404 to 649) 0.002114544 0.00704848 
RANK 10: (FANCM: 1331 to 1362) 0.002505345 0.007516036 
RANK 11: (EME1: 211 to 326) 0.002879257 0.007852518 
RANK 12: (BRCA1: 612 to 857) 0.006289302 0.015723254 
RANK 13: (FANCA: 654 to 795) 0.008787266 0.020278307 
RANK 14: (RAD50: 1191 to 1264) 0.010473836 0.022443933 
RANK 15: (PMS2: 418 to 519) 0.011760717 0.023521434 
RANK 16: (MAP3K15: 539 to 738) 0.01202091 0.022539206 
RANK 17: (FANCG: 106 to 279) 0.012120043 0.021388311 
RANK 18: (FANCC: 334 to 407) 0.015479323 0.025798871 
RANK 19: (XPC: 13 to 112) 0.015946328 0.025178413 
RANK 20: (EPPK1: 2073 to 2198) 0.025175917 0.037763876 
RANK 21: (FANCM: 1868 to 1945) 0.027610014 0.039442877 
RANK 22: (RAD50: 763 to 884) 0.038359536 0.052308458 
RANK 23: (BRCA1: 1579 to 1788) 0.040442038 0.052750484 
RANK 24: (BRCA2: 2665 to 2786) 0.049978996 0.062473745 
RANK 25: (BRCA2: 1109 to 1234) 0.054021647 0.064825977 
RANK 26: (ATM: 337 to 532) 0.05986289 0.069072566 
RANK 27: (ATM: 978 to 1113) 0.060714125 0.067460139 
RANK 28: (EPPK1: 116 to 307) 0.070785715 0.075841838 
RANK 29: (MAP3K15: 897 to 1048) 0.088932652 0.091999295 





Supplementary Table 2.14: Somatic mutations discovered in 3,368 out of 4,034 cancer cases. 





Supplementary Table 2.15: Somatic and Germline Mutation Relationship (mutual exclusive/co-
occuring) across 12 cancer types.  The genes used are 34 burden test significant genes and 
recurrent mutated genes (>= 5 somatic mutations across all cancer types). 























TP53 BRCA1 708 53 29 703 13.3563 734.2874 0 1 
RPL22 MSH6 27 11 2 34 0.1102 37.7796 0.004 1 
DDX11 PMS2 5 5 1 8 0.0089 9.9822 0.0089 1 
CHD4 MRE11A 6 4 1 8 0.0091 9.9818 0.0091 1 
ALPK2 PMS2 5 5 1 8 0.0097 9.9806 0.0096 0.9999 
FAT3 FANCG 5 6 1 9 0.0106 10.9788 0.0106 1 
VHL EME1 11 3 1 12 0.0125 13.975 0.0124 0.9999 
DDX11 FANCA 5 8 1 11 0.0141 12.9718 0.014 0.9999 
IDH1 HLAG 198 3 2 197 0.2217 200.5566 0.015 0.9994 
ERBB3 XRCC2 6 7 1 11 0.0162 12.9676 0.0162 1 
CHD4 XRCC2 6 7 1 11 0.0168 12.9664 0.0166 0.9998 
ERBB3 FANCA 6 8 1 12 0.0175 13.965 0.0173 0.9998 
CHEK2 HLAG 18 3 1 19 0.0225 20.955 0.0224 0.9999 
VEZF1 DDX11 6 12 1 16 0.0266 17.9468 0.0264 0.9998 
NFE2L2 RAD50 10 8 1 16 0.0299 17.9402 0.0299 1 
CHEK2 FANCG 18 6 1 22 0.0381 23.9238 0.0376 0.9995 
PPP2R1A DDX11 8 12 1 18 0.038 19.924 0.0376 0.9996 
PIK3R1 RAD50 13 8 1 19 0.0383 20.9234 0.0377 0.9994 
DNMT3A MRE11A 28 4 1 30 0.042 31.916 0.0418 0.9998 
IDH1 PMS2 198 5 2 199 0.3703 202.2594 0.0449 0.9962 
VHL DDX11 11 12 1 21 0.0486 22.9028 0.0476 0.999 
CTNNB1 PIK3C2G 49 19 2 64 0.3582 67.2836 0.0478 0.995 
RPL22 PMS2 27 5 1 30 0.0498 31.9004 0.0489 0.9991 
























PIK3CA BRCA1 444 53 1 495 8.4768 480.0464 1 2.00E-04 
IDH1 BRCA1 198 53 0 251 3.85 243.3 1 0.0152 
IDH1 BRCA2 198 50 0 248 3.6275 240.745 1 0.0213 
PIK3CA BRCA2 444 50 3 488 7.9735 478.053 0.9902 0.0294 
PIK3CA PIK3C2G 444 19 0 463 3.0323 456.9354 1 0.0367 
 
*Gene1 indicates gene with recurrent somatic mutations 




Supplementary Table 2.16:  Somatic and Germline Mutation Relationship (mutual 
exclusive/co-occuring) for individual cancer types.  The genes used are 34 burden test significant 




























FANCB DIS3 1 2 1 1 0.0024 2.9952 0.0024 1 BRCA 
CARD11 PIK3C2G 1 6 1 5 0.0076 6.9848 0.0076 1 BRCA 
WNK1 XRCC2 3 2 1 3 0.0079 4.9842 0.0079 1 BRCA 
TP53 BRCA1 185 12 7 183 2.9616 191.0768 0.0118 0.9977 BRCA 
VEZF1 DDX11 5 2 1 5 0.0135 6.973 0.0135 1 BRCA 
KRAS MAP3K15 5 2 1 5 0.0143 6.9714 0.0142 0.9999 BRCA 
KRAS EPPK1 5 3 1 6 0.0225 7.955 0.0222 0.9997 BRCA 
POLD1 BRCA2 1 19 1 18 0.0227 19.9546 0.0227 1 BRCA 
CYP2D6 FANCM 2 8 1 8 0.0228 9.9544 0.0228 1 BRCA 
WNK1 PIK3C2G 3 6 1 7 0.0241 8.9518 0.024 0.9999 BRCA 
FGFR3 BRCA1 2 12 1 12 0.0321 13.9358 0.0319 0.9998 BRCA 
KDM6A BRCA1 3 12 1 13 0.0485 14.903 0.0476 0.9991 BRCA 
KDR ERCC2 1 1 1 0 0.0049 1.9902 0.0049 1 GBM 
FAM46C MAP3K15 1 1 1 0 0.0049 1.9902 0.0049 1 GBM 
FLT1 CYP1B1 1 2 1 1 0.0093 2.9814 0.0093 1 GBM 
NF1 MSH6 4 2 1 4 0.0366 5.9268 0.0366 1 GBM 
APC ATM 1 1 1 0 0.0029 1.9942 0.0029 1 HNSC 
FAT3 FANCG 2 1 1 1 0.0079 2.9842 0.0079 1 HNSC 
INPPL1 MSH6 2 1 1 1 0.0084 2.9832 0.0084 1 HNSC 
ARID5B PALB2 1 2 1 1 0.009 2.982 0.009 1 HNSC 
CRKL CNKSR1 1 2 1 1 0.0092 2.9816 0.0092 1 HNSC 
SETDB1 FANCM 1 3 1 2 0.0116 3.9768 0.0116 1 HNSC 
INHBA FANCM 1 3 1 2 0.013 3.974 0.013 1 HNSC 
MAPK1 DDX11 3 1 1 2 0.0159 3.9682 0.0159 1 HNSC 
DDX11 PMS2 2 2 1 2 0.018 3.964 0.018 1 HNSC 
DDX11 FANCA 2 3 1 3 0.0246 4.9508 0.0246 1 HNSC 
NCOR1 CNKSR1 4 2 1 4 0.0347 5.9306 0.0344 0.9997 HNSC 
NFE2L2 RAD50 10 1 1 9 0.0427 10.9146 0.0427 1 HNSC 
ACO1 ERCC2 1 2 1 1 0.005 2.99 0.005 1 KIRC 
CRIPAK PARP3 1 3 1 2 0.0078 3.9844 0.0078 1 KIRC 
TP53 BAP1 5 2 1 5 0.0242 6.9516 0.0242 1 KIRC 
TP53 FANCM 5 2 1 5 0.0256 6.9488 0.0254 0.9998 KIRC 
PBRM1 DDX11 16 1 1 15 0.0347 16.9306 0.0347 1 KIRC 
CHD4 MRE11A 1 1 1 0 0.0051 1.9898 0.0051 1 LAML 
SOS1 FANCC 1 2 1 1 0.0118 2.9764 0.0118 1 LAML 
CHD4 MUTYH 1 2 1 1 0.0075 2.985 0.0075 1 LGG 
SMARCA4 HLAG 3 2 1 3 0.0266 4.9468 0.0264 0.9998 LGG 
PTEN BRIP1 7 1 1 6 0.0275 7.945 0.0275 1 LGG 
CCND2 DIS3 1 3 1 2 0.0198 3.9604 0.0198 1 LUAD 
BRWD3 DIS3 2 3 1 3 0.04 4.92 0.0394 0.9994 LUAD 
EML4 DIS3 1 1 1 0 0.0096 1.9808 0.0096 1 LUSC 
FAT3 BRCA2 1 2 1 1 0.0225 2.955 0.0225 1 LUSC 
IGF1 BRCA2 1 2 1 1 0.0247 2.9506 0.0247 1 LUSC 
SMAD4 FANCA 1 3 1 2 0.0345 3.931 0.0345 1 LUSC 
MAPK8IP1 BRIP1 1 3 1 2 0.0064 3.9872 0.0064 1 OV 
NRAS BRIP1 2 3 1 3 0.0146 4.9708 0.0146 1 OV 
TP53 BRCA2 315 25 24 292 19.8331 300.3338 0.0147 0.9984 OV 
B2M RAD51D 2 3 1 3 0.0155 4.969 0.0155 1 OV 
RB1 PALB2 3 3 1 4 0.0238 5.9524 0.0237 0.9999 OV 
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NRAS PIK3C2G 2 5 1 5 0.0243 6.9514 0.0242 0.9999 OV 
INHBA EPPK1 1 1 1 0 0.0071 1.9858 0.0071 1 PRAD 
GUCY1A2 EPPK1 1 1 1 0 0.0096 1.9808 0.0096 1 PRAD 
CHEK2 FANCG 3 1 1 2 0.0206 3.9588 0.0206 1 PRAD 
CRIPAK ATM 1 5 1 4 0.0377 5.9246 0.0377 1 PRAD 
PIK3CA BRCA1 5 1 1 4 0.0379 5.9242 0.0379 1 PRAD 
ERCC3 MUTYH 1 1 1 0 0.0136 1.9728 0.0136 1 STAD 
EIF3A FANCC 1 1 1 0 0.0148 1.9704 0.0148 1 STAD 
AURKB MUTYH 1 1 1 0 0.0152 1.9696 0.0152 1 STAD 
BUB1B FANCC 1 1 1 0 0.0156 1.9688 0.0156 1 STAD 
AKT3 DIS3 1 1 1 0 0.0164 1.9672 0.0164 1 STAD 
TMPRSS2 MUTYH 1 1 1 0 0.0184 1.9632 0.0184 1 STAD 
GPR124 FANCC 2 1 1 1 0.0266 2.9468 0.0266 1 STAD 
BCOR HLAG 2 1 1 1 0.027 2.946 0.027 1 STAD 
BCL6 MUTYH 2 1 1 1 0.028 2.944 0.028 1 STAD 
HSP90AB1 MUTYH 2 1 1 1 0.028 2.944 0.028 1 STAD 
DDR2 EPPK1 1 2 1 1 0.0292 2.9416 0.0292 1 STAD 
MAP4K1 DIS3 2 1 1 1 0.0292 2.9416 0.0292 1 STAD 
B2M DIS3 2 1 1 1 0.0302 2.9396 0.0302 1 STAD 
TSC2 MUTYH 2 1 1 1 0.0312 2.9376 0.0312 1 STAD 
ATR MUTYH 2 1 1 1 0.0328 2.9344 0.0328 1 STAD 
SMARCB1 MUTYH 3 1 1 2 0.0412 3.9176 0.0412 1 STAD 
SOS1 XRCC2 1 3 1 2 0.0416 3.9168 0.0416 1 STAD 
ARID5B DIS3 3 1 1 2 0.0426 3.9148 0.0426 1 STAD 
HGF FANCA 3 1 1 2 0.0448 3.9104 0.0448 1 STAD 
EWSR1 DIS3 3 1 1 2 0.0452 3.9096 0.0452 1 STAD 
NOTCH3 MUTYH 3 1 1 2 0.0468 3.9064 0.0468 1 STAD 
GRM3 FANCA 3 1 1 2 0.0476 3.9048 0.0476 1 STAD 
EPHB1 FANCA 3 1 1 2 0.0492 3.9016 0.0492 1 STAD 
BRE RAD50 2 1 1 1 0.0462 2.9076 0.0462 1 UCEC 
            























exclusivity Cancer Type 
PIK3CA BRCA1 235 12 0 247 3.7578 239.4844 1 0.0101 BRCA 
PIK3CA BRCA2 235 19 2 250 5.9606 242.0788 0.9944 0.0297 BRCA 
TP53 ATM 96 5 0 101 2.2913 96.4174 1 0.0412 LUAD 
TP53 PALB2 88 4 0 92 2.4414 87.1172 1 0.0224 STAD 
PIK3CA BRCA1 116 3 0 119 2.2264 114.5472 1 0.0126 UCEC 
PTEN BRCA1 119 3 0 122 2.2404 117.5192 1 0.0138 UCEC 
 
*Gene1 indicates gene with recurrent somatic mutations 




Supplementary Table 2.17: Distribution of BRCA1, BRCA2, and ATM germline truncation 
variants and somatic mutations across 12 cancer types. 
 Type  Gene BRCA GBM HNSC KIRC LAML LGG LUAD LUSC OV PRAD STAD UCEC 
  ATM 1.82% 0.75% 1.72% 2.43% 0.00% 0.00% 4.11% 1.55% 1.63% 5.62% 7.48% 11.69% 
Somatic BRCA1 1.17% 1.12% 2.41% 0.88% 0.00% 0.00% 1.95% 2.07% 4.90% 0.56% 4.05% 4.84% 





ATM 0.52% 0.00% 0.34% 0.00% 0.50% 0.45% 1.08% 0.00% 0.23% 2.81% 1.25% 0.00% 
BRCA1 1.56% 0.00% 0.00% 0.22% 0.00% 0.00% 0.22% 0.00% 7.93% 0.56% 0.31% 1.21% 





Supplementary Table 2.18: Genes with rare germline truncation variants associated with 
somatic mutation frequencies. 
Cancer 
Type Gene Clinic Feature Method 
Num of 
Cases in each 
cancer type 
Statistic P-value 
BRCA BRCA1 Somatic Mutation Frequency wilcox 758 1.3150E+03 2.6613E-05 
OV BRCA2 Somatic Mutation Frequency wilcox 426 2.6150E+03 5.9785E-05 
BRCA BRCA2 Somatic Mutation Frequency wilcox 758 3.9915E+03 1.3088E-03 
OV BRCA1 Somatic Mutation Frequency wilcox 426 4.8970E+03 1.0307E-02 
OV RAD51D Somatic Mutation Frequency wilcox 426 1.6050E+02 2.5850E-02 
OV RAD51C Somatic Mutation Frequency wilcox 426 6.1000E+01 3.6887E-02 
OV ERCC2 Somatic Mutation Frequency wilcox 426 0.0000E+00 8.4695E-02 
OV CYP1B1 Somatic Mutation Frequency wilcox 426 1.5500E+01 1.1004E-01 
OV BRIP1 Somatic Mutation Frequency wilcox 426 9.8650E+02 9.8071E-02 
UCEC MSH6 Somatic Mutation Frequency wilcox 248 6.5000E+01 1.4462E-02 
BRCA PIK3C2G Somatic Mutation Frequency wilcox 758 2.9180E+03 3.3905E-02 
OV PIK3C2G Somatic Mutation Frequency wilcox 426 5.5600E+02 6.9914E-02 
OV PALB2 Somatic Mutation Frequency wilcox 426 2.6750E+02 8.4550E-02 
UCEC BRIP1 Somatic Mutation Frequency wilcox 248 2.4050E+02 1.0365E-01 
KIRC EME1 Somatic Mutation Frequency wilcox 387 3.5000E+01 2.6730E-02 
OV DIS3 Somatic Mutation Frequency wilcox 426 6.0500E+01 2.1793E-01 
OV CNKSR1 Somatic Mutation Frequency wilcox 426 5.5600E+02 2.4072E-01 
UCEC RAD50 Somatic Mutation Frequency wilcox 248 2.0000E+01 1.5020E-01 
UCEC DDX11 Somatic Mutation Frequency wilcox 248 4.1150E+02 1.0244E-01 
OV MAP3K15 Somatic Mutation Frequency wilcox 426 8.3500E+01 2.9602E-01 
STAD EME2 Somatic Mutation Frequency wilcox 220 3.4550E+02 1.5640E-01 
LGG MUTYH Somatic Mutation Frequency wilcox 217 1.0850E+02 2.3030E-01 
LGG DDX11 Somatic Mutation Frequency wilcox 217 5.1500E+01 3.7123E-01 
LGG HLA_G Somatic Mutation Frequency wilcox 217 1.0000E+02 1.9506E-01 
UCEC CNKSR1 Somatic Mutation Frequency wilcox 248 7.7000E+01 9.5363E-02 
LGG BRIP1 Somatic Mutation Frequency wilcox 217 4.8500E+01 3.4616E-01 
STAD EPPK1 Somatic Mutation Frequency wilcox 220 8.8000E+01 1.4840E-01 
LGG PMS2 Somatic Mutation Frequency wilcox 217 3.0600E+02 3.0576E-01 
LGG CYP1B1 Somatic Mutation Frequency wilcox 217 1.8500E+01 1.5529E-01 
KIRC BRCA2 Somatic Mutation Frequency wilcox 387 5.4500E+01 2.1664E-01 
UCEC MRE11A Somatic Mutation Frequency wilcox 248 4.3150E+02 6.7090E-02 
LUAD DIS3 Somatic Mutation Frequency wilcox 228 3.0000E+00 9.4662E-02 
STAD ATM Somatic Mutation Frequency wilcox 220 7.1250E+02 2.6437E-02 
UCEC PMS2 Somatic Mutation Frequency wilcox 248 3.9000E+01 2.4063E-01 
UCEC PIK3C2G Somatic Mutation Frequency wilcox 248 1.9150E+02 3.4573E-01 
KIRC EPPK1 Somatic Mutation Frequency wilcox 387 3.0900E+02 3.0111E-01 
OV ATM Somatic Mutation Frequency wilcox 426 1.0800E+02 3.9768E-01 
KIRC ERCC2 Somatic Mutation Frequency wilcox 387 2.1050E+02 2.7004E-01 
OV PARP3 Somatic Mutation Frequency wilcox 426 3.0800E+02 4.3977E-01 
BRCA FANCC Somatic Mutation Frequency wilcox 758 3.0000E+01 1.1171E-01 
LAML DIS3 Somatic Mutation Frequency wilcox 196 7.1500E+01 1.2580E-01 
KIRC XPC Somatic Mutation Frequency wilcox 387 8.8500E+01 3.5180E-01 
UCEC ERCC2 Somatic Mutation Frequency wilcox 248 5.3500E+01 3.3162E-01 
LGG PARP3 Somatic Mutation Frequency wilcox 217 2.0700E+02 1.1577E-01 
BRCA RAD51C Somatic Mutation Frequency wilcox 758 6.1000E+01 1.4737E-01 
STAD DIS3 Somatic Mutation Frequency wilcox 220 1.7000E+01 1.4743E-01 
KIRC BAP1 Somatic Mutation Frequency wilcox 387 2.5750E+02 4.2080E-01 
KIRC FANCM Somatic Mutation Frequency wilcox 387 1.8850E+02 2.1408E-01 
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STAD PALB2 Somatic Mutation Frequency wilcox 220 1.5700E+02 1.2495E-01 
UCEC MUTYH Somatic Mutation Frequency wilcox 248 1.9450E+02 3.2471E-01 
HNSC FANCA Somatic Mutation Frequency wilcox 238 5.5950E+02 8.1384E-02 
KIRC CYP1B1 Somatic Mutation Frequency wilcox 387 1.2250E+02 5.3085E-01 
LGG EPPK1 Somatic Mutation Frequency wilcox 217 3.8100E+02 5.8159E-01 
KIRC BRCA1 Somatic Mutation Frequency wilcox 387 3.0000E+00 8.9776E-02 
KIRC RAD50 Somatic Mutation Frequency wilcox 387 2.6950E+02 4.9624E-01 
HNSC FANCM Somatic Mutation Frequency wilcox 238 4.2000E+01 4.5960E-02 
LAML PIK3C2G Somatic Mutation Frequency wilcox 196 1.4500E+02 4.0546E-01 
STAD FANCA Somatic Mutation Frequency wilcox 220 7.0000E+00 1.0825E-01 
LUSC MAP3K15 Somatic Mutation Frequency wilcox 82 7.9000E+01 1.0839E-01 
LAML MAP3K15 Somatic Mutation Frequency wilcox 196 6.5500E+01 5.7715E-01 
STAD HIST1H1E Somatic Mutation Frequency wilcox 220 2.8700E+02 4.4460E-01 
LAML FANCC Somatic Mutation Frequency wilcox 196 2.4750E+02 5.0602E-01 
BRCA BRIP1 Somatic Mutation Frequency wilcox 758 1.2860E+03 6.8601E-01 
KIRC DDX11 Somatic Mutation Frequency wilcox 387 3.3300E+02 2.1169E-01 
LUSC DIS3 Somatic Mutation Frequency wilcox 82 5.8500E+01 4.5969E-01 
BRCA MAP3K15 Somatic Mutation Frequency wilcox 758 4.8600E+02 3.8344E-01 
BRCA PALB2 Somatic Mutation Frequency wilcox 758 1.1550E+02 2.3022E-01 
GBM PIK3C2G Somatic Mutation Frequency wilcox 197 1.6500E+01 1.5428E-01 
OV POLK Somatic Mutation Frequency wilcox 426 1.5700E+02 6.5467E-01 
STAD XRCC2 Somatic Mutation Frequency wilcox 220 2.3800E+02 4.2687E-01 
BRCA XRCC2 Somatic Mutation Frequency wilcox 758 8.9100E+02 6.6358E-01 
LAML MRE11A Somatic Mutation Frequency wilcox 196 4.4500E+01 3.5276E-01 
KIRC PIK3C2G Somatic Mutation Frequency wilcox 387 3.7500E+01 1.6523E-01 
BRCA FANCM Somatic Mutation Frequency wilcox 758 3.5610E+03 3.6284E-01 
OV EME1 Somatic Mutation Frequency wilcox 426 1.7050E+02 7.3574E-01 
STAD BRCA2 Somatic Mutation Frequency wilcox 220 1.3700E+02 3.6899E-01 
BRCA DDX11 Somatic Mutation Frequency wilcox 758 2.8150E+02 6.5917E-01 
LUAD XRCC2 Somatic Mutation Frequency wilcox 228 1.3550E+02 7.4392E-01 
PRAD POLK Somatic Mutation Frequency wilcox 171 7.6500E+01 1.8614E-01 
STAD CYP1B1 Somatic Mutation Frequency wilcox 220 1.6150E+02 4.1740E-01 
STAD FANCC Somatic Mutation Frequency wilcox 220 4.8000E+01 3.3679E-01 
BRCA CNKSR1 Somatic Mutation Frequency wilcox 758 9.8100E+02 4.6781E-01 
LAML RAD51C Somatic Mutation Frequency wilcox 196 3.2700E+02 9.6388E-02 
PRAD ATM Somatic Mutation Frequency wilcox 171 2.3000E+02 2.9006E-01 
BRCA EPPK1 Somatic Mutation Frequency wilcox 758 9.6450E+02 6.5806E-01 
STAD BRCA1 Somatic Mutation Frequency wilcox 220 1.4600E+02 5.7080E-01 
BRCA DIS3 Somatic Mutation Frequency wilcox 758 1.0425E+03 3.5500E-01 
LGG ATM Somatic Mutation Frequency wilcox 217 2.1500E+02 8.9035E-02 
BRCA RAD50 Somatic Mutation Frequency wilcox 758 5.1300E+02 5.4023E-01 
HNSC CNKSR1 Somatic Mutation Frequency wilcox 238 1.2000E+02 2.3355E-01 
LUSC BRCA2 Somatic Mutation Frequency wilcox 82 4.6000E+01 8.3269E-01 
BRCA ERCC2 Somatic Mutation Frequency wilcox 758 6.1500E+02 6.4955E-01 
LUSC PARP3 Somatic Mutation Frequency wilcox 82 6.0000E+01 4.2213E-01 
LUSC FANCA Somatic Mutation Frequency wilcox 82 5.0000E+01 7.0376E-01 
BRCA MSH6 Somatic Mutation Frequency wilcox 758 7.6600E+02 3.3350E-01 
LUAD ATM Somatic Mutation Frequency wilcox 228 1.8800E+02 6.8638E-01 
GBM CYP1B1 Somatic Mutation Frequency wilcox 197 1.7100E+02 7.6952E-01 
LUAD ERCC2 Somatic Mutation Frequency wilcox 228 1.6600E+02 5.2175E-01 
PRAD EPPK1 Somatic Mutation Frequency wilcox 171 1.2400E+02 4.3532E-01 
BRCA ATM Somatic Mutation Frequency wilcox 758 1.7170E+03 6.3305E-01 
STAD MSH6 Somatic Mutation Frequency wilcox 220 1.8100E+02 6.8376E-01 
LUAD PIK3C2G Somatic Mutation Frequency wilcox 228 3.1250E+02 3.5445E-01 
GBM RAD50 Somatic Mutation Frequency wilcox 197 2.2700E+02 6.9451E-01 
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STAD RAD50 Somatic Mutation Frequency wilcox 220 1.2550E+02 8.0718E-01 
GBM BRIP1 Somatic Mutation Frequency wilcox 197 9.1000E+01 9.0899E-01 
LAML DDX11 Somatic Mutation Frequency wilcox 196 1.9650E+02 3.4203E-01 
STAD HLA_G Somatic Mutation Frequency wilcox 220 9.0500E+01 7.7082E-01 
STAD MUTYH Somatic Mutation Frequency wilcox 220 6.0000E+00 1.0483E-01 
UCEC MAP3K15 Somatic Mutation Frequency wilcox 248 2.1500E+02 7.6274E-01 
STAD PIK3C2G Somatic Mutation Frequency wilcox 220 2.1450E+02 9.7329E-01 
KIRC PARP3 Somatic Mutation Frequency wilcox 387 3.9000E+02 9.7724E-01 
LAML ATM Somatic Mutation Frequency wilcox 196 9.9500E+01 9.7882E-01 
PRAD FANCG Somatic Mutation Frequency wilcox 171 8.3500E+01 9.8383E-01 
PRAD BRCA1 Somatic Mutation Frequency wilcox 171 8.3500E+01 9.8383E-01 
UCEC FANCG Somatic Mutation Frequency wilcox 248 2.4350E+02 9.8421E-01 
UCEC XRCC2 Somatic Mutation Frequency wilcox 248 1.1550E+02 9.1656E-01 
STAD BRIP1 Somatic Mutation Frequency wilcox 220 1.0400E+02 9.3725E-01 
GBM MAP3K15 Somatic Mutation Frequency wilcox 197 6.8500E+01 6.1002E-01 
GBM ERCC2 Somatic Mutation Frequency wilcox 197 1.2700E+02 6.1620E-01 
GBM XPC Somatic Mutation Frequency wilcox 197 4.8500E+01 3.8880E-01 
GBM MSH6 Somatic Mutation Frequency wilcox 197 7.5000E+01 6.9231E-01 
GBM PARP3 Somatic Mutation Frequency wilcox 197 8.5000E+00 1.1752E-01 
HNSC BRCA2 Somatic Mutation Frequency wilcox 238 1.0450E+02 8.4422E-01 
HNSC FANCC Somatic Mutation Frequency wilcox 238 1.5050E+02 6.4660E-01 
HNSC DIS3 Somatic Mutation Frequency wilcox 238 1.6150E+02 5.3618E-01 
HNSC RAD50 Somatic Mutation Frequency wilcox 238 1.2450E+02 9.3619E-01 
HNSC DDX11 Somatic Mutation Frequency wilcox 238 3.3000E+01 2.1601E-01 
HNSC MSH6 Somatic Mutation Frequency wilcox 238 1.0100E+02 8.0457E-01 
HNSC ATM Somatic Mutation Frequency wilcox 238 8.4000E+01 6.2068E-01 
HNSC RAD51D Somatic Mutation Frequency wilcox 238 1.7100E+02 4.4912E-01 
HNSC FANCG Somatic Mutation Frequency wilcox 238 1.2050E+02 9.8258E-01 
HNSC PALB2 Somatic Mutation Frequency wilcox 238 1.1800E+02 1.0000E+00 
HNSC PMS2 Somatic Mutation Frequency wilcox 238 2.9800E+02 5.2588E-01 
LUSC BRIP1 Somatic Mutation Frequency wilcox 82 1.9000E+01 3.7495E-01 
PRAD FANCA Somatic Mutation Frequency wilcox 171 1.0000E+02 7.6890E-01 
PRAD RAD51C Somatic Mutation Frequency wilcox 171 1.9000E+01 1.8443E-01 
PRAD PALB2 Somatic Mutation Frequency wilcox 171 9.0500E+01 9.1930E-01 





Supplementary Table 2.19: Genes with rare germline truncation variants associated with 
younger age of initial diagnosis with cancer type as a covariate. 
Gene Clinic Feature p-value Covariants 
BRCA1 Age at Diagnosis 5.20E-07 Cancer Type 
BRCA2 Age at Diagnosis 2.04E-04 Cancer Type 
ERCC2 Age at Diagnosis 3.18E-02 Cancer Type 
DIS3 Age at Diagnosis 4.66E-02 Cancer Type 
PMS2 Age at Diagnosis 4.87E-02 Cancer Type 
ATM Age at Diagnosis 5.39E-02 Cancer Type 
FANCM Age at Diagnosis 6.69E-02 Cancer Type 
PIK3C2G Age at Diagnosis 1.08E-01 Cancer Type 
BRIP1 Age at Diagnosis 1.40E-01 Cancer Type 
EPPK1 Age at Diagnosis 1.84E-01 Cancer Type 
POLK Age at Diagnosis 2.48E-01 Cancer Type 
RAD50 Age at Diagnosis 3.16E-01 Cancer Type 
PALB2 Age at Diagnosis 3.28E-01 Cancer Type 
RAD51C Age at Diagnosis 3.37E-01 Cancer Type 
MAP3K15 Age at Diagnosis 3.45E-01 Cancer Type 
PARP3 Age at Diagnosis 3.56E-01 Cancer Type 
XPC Age at Diagnosis 3.94E-01 Cancer Type 
CNKSR1 Age at Diagnosis 4.15E-01 Cancer Type 
BAP1 Age at Diagnosis 4.42E-01 Cancer Type 
FANCA Age at Diagnosis 4.71E-01 Cancer Type 
EME1 Age at Diagnosis 5.12E-01 Cancer Type 
RAD51D Age at Diagnosis 5.27E-01 Cancer Type 
FANCG Age at Diagnosis 5.33E-01 Cancer Type 
MUTYH Age at Diagnosis 5.54E-01 Cancer Type 
XRCC2 Age at Diagnosis 6.30E-01 Cancer Type 
DDX11 Age at Diagnosis 7.03E-01 Cancer Type 
HLA_G Age at Diagnosis 7.12E-01 Cancer Type 
MSH6 Age at Diagnosis 7.44E-01 Cancer Type 
FANCC Age at Diagnosis 7.69E-01 Cancer Type 
CYP1B1 Age at Diagnosis 7.75E-01 Cancer Type 
APITD1 Age at Diagnosis 8.69E-01 Cancer Type 
MRE11A Age at Diagnosis 8.91E-01 Cancer Type 
HIST1H1E Age at Diagnosis 9.15E-01 Cancer Type 





Supplementary Table 2.20: Genes with rare germline truncation variants associated with 
younger age of initial diagnosis for each cancer type. 
Cancer 
Type Gene Clinic Feature Method 
Number of total cases in 
cancer cohort P-value 
BRCA BRCA2 Age at Diagnosis wilcox 770 8.71E-03 
BRCA BRCA1 Age at Diagnosis wilcox 770 5.04E-03 
BRCA PIK3C2G Age at Diagnosis wilcox 770 2.14E-01 
BRCA RAD50 Age at Diagnosis wilcox 770 2.89E-01 
BRCA ATM Age at Diagnosis wilcox 770 4.85E-01 
BRCA ERCC2 Age at Diagnosis wilcox 770 2.03E-01 
BRCA MSH6 Age at Diagnosis wilcox 770 4.63E-01 
BRCA CNKSR1 Age at Diagnosis wilcox 770 4.20E-01 
BRCA RAD51C Age at Diagnosis wilcox 770 6.89E-01 
BRCA DIS3 Age at Diagnosis wilcox 770 3.74E-01 
BRCA FANCC Age at Diagnosis wilcox 770 5.89E-01 
BRCA PALB2 Age at Diagnosis wilcox 770 6.46E-01 
BRCA DDX11 Age at Diagnosis wilcox 770 9.99E-01 
BRCA BRIP1 Age at Diagnosis wilcox 770 8.64E-01 
BRCA EPPK1 Age at Diagnosis wilcox 770 8.46E-01 
BRCA MAP3K15 Age at Diagnosis wilcox 770 9.31E-01 
BRCA FANCM Age at Diagnosis wilcox 770 1.75E-01 
BRCA XRCC2 Age at Diagnosis wilcox 770 9.95E-01 
GBM MSH6 Age at Diagnosis wilcox 267 1.66E-01 
GBM PIK3C2G Age at Diagnosis wilcox 267 1.63E-01 
GBM APITD1 Age at Diagnosis wilcox 267 9.38E-01 
GBM CYP1B1 Age at Diagnosis wilcox 267 8.15E-01 
GBM BRIP1 Age at Diagnosis wilcox 267 5.21E-01 
GBM MAP3K15 Age at Diagnosis wilcox 267 6.59E-01 
GBM RAD50 Age at Diagnosis wilcox 267 9.19E-01 
GBM XPC Age at Diagnosis wilcox 267 1.01E-01 
GBM ERCC2 Age at Diagnosis wilcox 267 7.90E-01 
GBM DDX11 Age at Diagnosis wilcox 267 8.00E-01 
GBM PARP3 Age at Diagnosis wilcox 267 5.86E-01 
HNSC FANCA Age at Diagnosis wilcox 290 2.95E-02 
HNSC MSH6 Age at Diagnosis wilcox 290 9.32E-02 
HNSC RAD50 Age at Diagnosis wilcox 290 1.25E-01 
HNSC RAD51D Age at Diagnosis wilcox 290 2.39E-01 
HNSC BRCA2 Age at Diagnosis wilcox 290 2.74E-01 
HNSC FANCM Age at Diagnosis wilcox 290 2.20E-01 
HNSC PMS2 Age at Diagnosis wilcox 290 7.69E-02 
HNSC DDX11 Age at Diagnosis wilcox 290 2.12E-01 
HNSC FANCC Age at Diagnosis wilcox 290 8.59E-01 
HNSC CNKSR1 Age at Diagnosis wilcox 290 8.36E-01 
HNSC BRIP1 Age at Diagnosis wilcox 290 8.30E-01 
HNSC FANCG Age at Diagnosis wilcox 290 8.30E-01 
HNSC DIS3 Age at Diagnosis wilcox 290 5.87E-01 
HNSC ATM Age at Diagnosis wilcox 290 6.63E-01 
HNSC PALB2 Age at Diagnosis wilcox 290 7.86E-01 
KIRC BRCA1 Age at Diagnosis wilcox 452 1.38E-01 
KIRC EPPK1 Age at Diagnosis wilcox 452 1.36E-01 
KIRC BRCA2 Age at Diagnosis wilcox 452 4.81E-01 
KIRC BRIP1 Age at Diagnosis wilcox 452 4.48E-01 
KIRC PIK3C2G Age at Diagnosis wilcox 452 2.52E-01 
KIRC BAP1 Age at Diagnosis wilcox 452 3.10E-01 
KIRC FANCM Age at Diagnosis wilcox 452 1.05E-01 
KIRC ERCC2 Age at Diagnosis wilcox 452 4.44E-01 
KIRC XPC Age at Diagnosis wilcox 452 8.07E-01 
[171] 
 
KIRC PARP3 Age at Diagnosis wilcox 452 7.14E-01 
KIRC CYP1B1 Age at Diagnosis wilcox 452 6.65E-01 
KIRC DDX11 Age at Diagnosis wilcox 452 7.88E-01 
KIRC RAD50 Age at Diagnosis wilcox 452 4.30E-01 
KIRC EME1 Age at Diagnosis wilcox 452 6.62E-02 
LAML DDX11 Age at Diagnosis wilcox 200 3.93E-01 
LAML FANCC Age at Diagnosis wilcox 200 4.95E-01 
LAML DIS3 Age at Diagnosis wilcox 200 6.19E-01 
LAML MAP3K15 Age at Diagnosis wilcox 200 7.49E-01 
LAML PIK3C2G Age at Diagnosis wilcox 200 2.35E-01 
LAML ATM Age at Diagnosis wilcox 200 3.63E-01 
LAML MRE11A Age at Diagnosis wilcox 200 9.79E-01 
LAML RAD51C Age at Diagnosis wilcox 200 1.87E-01 
LGG MUTYH Age at Diagnosis wilcox 223 6.96E-01 
LGG PMS2 Age at Diagnosis wilcox 223 6.64E-01 
LGG BRIP1 Age at Diagnosis wilcox 223 3.01E-01 
LGG DDX11 Age at Diagnosis wilcox 223 9.44E-01 
LGG EPPK1 Age at Diagnosis wilcox 223 6.43E-01 
LGG HLA_G Age at Diagnosis wilcox 223 2.15E-01 
LGG ATM Age at Diagnosis wilcox 223 5.39E-01 
LGG PARP3 Age at Diagnosis wilcox 223 1.09E-01 
LGG CYP1B1 Age at Diagnosis wilcox 223 5.09E-01 
LUAD MRE11A Age at Diagnosis wilcox 381 3.58E-01 
LUAD BRIP1 Age at Diagnosis wilcox 381 3.21E-01 
LUAD ERCC2 Age at Diagnosis wilcox 381 1.38E-01 
LUAD PALB2 Age at Diagnosis wilcox 381 4.95E-01 
LUAD ATM Age at Diagnosis wilcox 381 2.36E-01 
LUAD FANCG Age at Diagnosis wilcox 381 3.20E-01 
LUAD BRCA1 Age at Diagnosis wilcox 381 9.53E-01 
LUAD DIS3 Age at Diagnosis wilcox 381 9.00E-01 
LUAD PIK3C2G Age at Diagnosis wilcox 381 8.59E-01 
LUAD XRCC2 Age at Diagnosis wilcox 381 1.04E-01 
LUSC BRIP1 Age at Diagnosis wilcox 185 1.65E-02 
LUSC BRCA2 Age at Diagnosis wilcox 185 1.44E-01 
LUSC DIS3 Age at Diagnosis wilcox 185 1.07E-01 
LUSC FANCA Age at Diagnosis wilcox 185 3.75E-01 
LUSC MAP3K15 Age at Diagnosis wilcox 185 4.82E-01 
LUSC PARP3 Age at Diagnosis wilcox 185 7.64E-01 
LUSC FANCC Age at Diagnosis wilcox 185 7.15E-01 
OV BRCA1 Age at Diagnosis wilcox 428 1.69E-05 
OV EME1 Age at Diagnosis wilcox 428 1.30E-01 
OV MAP3K15 Age at Diagnosis wilcox 428 1.13E-01 
OV BRCA2 Age at Diagnosis wilcox 428 9.74E-02 
OV PALB2 Age at Diagnosis wilcox 428 7.38E-01 
OV RAD51C Age at Diagnosis wilcox 428 8.25E-01 
OV RAD51D Age at Diagnosis wilcox 428 9.72E-01 
OV ATM Age at Diagnosis wilcox 428 7.34E-01 
OV BRIP1 Age at Diagnosis wilcox 428 9.20E-01 
OV CNKSR1 Age at Diagnosis wilcox 428 5.28E-01 
OV POLK Age at Diagnosis wilcox 428 4.76E-01 
OV PARP3 Age at Diagnosis wilcox 428 6.98E-01 
OV PIK3C2G Age at Diagnosis wilcox 428 6.47E-01 
OV CYP1B1 Age at Diagnosis wilcox 428 6.07E-01 
OV ERCC2 Age at Diagnosis wilcox 428 4.42E-01 
OV DIS3 Age at Diagnosis wilcox 428 6.07E-01 
PRAD FANCG Age at Diagnosis wilcox 177 1.58E-01 
PRAD RAD51C Age at Diagnosis wilcox 177 3.88E-01 
PRAD BRCA1 Age at Diagnosis wilcox 177 3.88E-01 
PRAD FANCA Age at Diagnosis wilcox 177 1.12E-01 
[172] 
 
PRAD EPPK1 Age at Diagnosis wilcox 177 3.08E-01 
PRAD PALB2 Age at Diagnosis wilcox 177 2.56E-01 
PRAD POLK Age at Diagnosis wilcox 177 8.35E-02 
PRAD ATM Age at Diagnosis wilcox 177 9.61E-01 
STAD ATM Age at Diagnosis wilcox 315 1.56E-02 
STAD HLA_G Age at Diagnosis wilcox 315 1.49E-01 
STAD BRCA1 Age at Diagnosis wilcox 315 1.49E-01 
STAD HIST1H1E Age at Diagnosis wilcox 315 3.74E-01 
STAD CYP1B1 Age at Diagnosis wilcox 315 2.69E-01 
STAD XRCC2 Age at Diagnosis wilcox 315 2.96E-01 
STAD EPPK1 Age at Diagnosis wilcox 315 2.50E-01 
STAD PIK3C2G Age at Diagnosis wilcox 315 3.42E-01 
STAD RAD50 Age at Diagnosis wilcox 315 2.28E-01 
STAD FANCA Age at Diagnosis wilcox 315 3.73E-01 
STAD PALB2 Age at Diagnosis wilcox 315 1.22E-01 
STAD EME2 Age at Diagnosis wilcox 315 2.16E-01 
STAD MSH6 Age at Diagnosis wilcox 315 4.73E-01 
STAD DDX11 Age at Diagnosis wilcox 315 5.13E-01 
STAD BRIP1 Age at Diagnosis wilcox 315 1.03E-01 
STAD MUTYH Age at Diagnosis wilcox 315 6.21E-01 
STAD BRCA2 Age at Diagnosis wilcox 315 7.52E-01 
STAD DIS3 Age at Diagnosis wilcox 315 8.81E-02 
STAD FANCC Age at Diagnosis wilcox 315 8.99E-01 
UCEC BRCA1 Age at Diagnosis wilcox 248 1.11E-01 
UCEC FANCG Age at Diagnosis wilcox 248 5.79E-02 
UCEC DDX11 Age at Diagnosis wilcox 248 7.97E-01 
UCEC CNKSR1 Age at Diagnosis wilcox 248 5.36E-01 
UCEC MAP3K15 Age at Diagnosis wilcox 248 7.40E-01 
UCEC BRIP1 Age at Diagnosis wilcox 248 6.20E-01 
UCEC MUTYH Age at Diagnosis wilcox 248 9.00E-01 
UCEC MSH6 Age at Diagnosis wilcox 248 3.88E-01 
UCEC XRCC2 Age at Diagnosis wilcox 248 1.00E+00 
UCEC PMS2 Age at Diagnosis wilcox 248 3.60E-01 
UCEC PIK3C2G Age at Diagnosis wilcox 248 5.25E-01 
UCEC RAD50 Age at Diagnosis wilcox 248 4.50E-01 
UCEC MRE11A Age at Diagnosis wilcox 248 2.31E-01 





Supplementary Table 2.21: Primers used for creating 72 BRCA1 expression constructs with 68 
rare missense variants introduced and 4 control truncation constructs. 
BRCA1 Variant 
Annotation Forward Primer Sequence Reverse Primer Sequence 
Missense 
(68) 
S36Y GAACCTGTCTaCACAAAGTGTG CTTGATCAACTCCAGACAG 
C61G GCCTTCACAGgGTCCTTTATG CCTTTCTTCTGGTTGAGAAG 
C64G GTGTCCTTTAgGTAAGAATGATATAAC TGTGAAGGCCCTTTCTTC 
E143K GAGTGAACCCaAAAATCCTTCC TGTAGAAGTCTTTTGGCAC 
E149A TCCTTGCAGGcAACCAGTCTC AGGATTTTCGGGTTCACTC 
Y179C ACGTCTGTCTgCATTGAATTG CTTTTGAGGTTGTATCCG 
S186Y GGATCTGATTaTTCTGAAGATACC CAATTCAATGTAGACAGACG 
V191I TGAAGATACCaTTAATAAGGCAAC GAAGAATCAGATCCCAATTC 
D214G GGAACCAGGGgTGAAATCAGTTTG TTGAGGGGTGATTTGTAACAATTC 
T293S TTATTACTCAgTAAAGACAGAATGAATG ACTGCTGTTCTCATGCTG 
R296G CACTAAAGACgGAATGAATGTAG AGTAATAAACTGCTGTTCTC 
S316G CTTAGCAAGGgGCCAACATAAC CCAGGCTGTTTGCTTTTATTAC 
A322P TAACAGATGGcCTGGAAGTAAGG TGTTGGCTCCTTGCTAAG 
C328R TAAGGAAACAcGTAATGATAGGCG CTTCCAGCCCATCTGTTATG 
I379M ATAGCAGCATgCAGAAAGTTAATG TTAGTGTTATCCAAGGAACATC 
E445Q ATGTAAAAGTcAAAGAGTTCACTCC ATTAAAGCCTCATGAGGATC 
G462R CAAAATATTTaGGAAAACCTATCGGAAG TCTTCAATATTACTCTCTACTGATTTG 
F486L TATAGGAGCAcTTGTTACTGAG ATTAGATTTTCAGTTACATGGC 
L512V TACATCAGGCgTTCATCCTGAG GGTCTCCTTTTACGCTTTAATTTATTTG 
N550H GAATATTACTcATAGTGGTCATGAGAATAAAAC ATCACTTGACCATTCTGC 
I591T AGCAGCAGTAcAAGCAATATG TATAGGTTCAGCTTTCGTTTTG 
R612G GAATAGGCTGgGGAGGAAGTC TTTTTAGGTGCTTTTGAATTGTG 
L668F AAACCTACAAtTCATGGAAGGTAAAGAACC CTGCTGTGCCTGACTGGC 
D695N ACATGACAGTaATACTTTCCCAG CTTTTACTTGTCTGTTCATTTG 
S708Y GCACCTGGTTaTTTTACTAAG ATTTGTTAACTTCAGCTCTG 
E720K TGAACTTAAAaAATTTGTCAATCCTAG CTGGTATTTGAACACTTAGTAAAAG 
V772A ATTTCATTGGcACCTGGTACTG ACTGCTACTCTCTACAGATC 
A806T GAGTCAGTGTaCAGCATTTGAAAAC ACACATTTATTTGGTTCTGTTTTTG 
T826K AGAAATGACAaAGAAGGCTTTAAG ATTATCTTTGGAACAACCATG 
Y856H TGATGCTCAGcATTTGCAGAATAC AGTTCACTTTCTTCCATTTCTATG 
R866C GGTTTCAAAGtGCCAGTCATTTG TTGAATGTATTCTGCAAATACTG 
E962K CAGAGGCAACaAAACTGGACTC AACTGAGATGATAGACAAAAC 
I1019V AAATGAGAACgTTCCAAGTACAG CCCATTTCTCTTTCAGGTG 
I1044V CTCAAGCAATgTTAATGAAGTAGG CTGGCTCCTTTAAAAACATTTTC 
P1150S TTCTGAGACAtCTGATGACCTG CAAACCTGAGATGCATGAC 
D1152N GACACCTGATaACCTGTTAGATG TCAGAACAAACCTGAGATG 
E1219D TATCTAGTGAcGATGAAGAGCTTCC AGTTCTCTTCTGAGGACTC 
P1238L AACAATATACtTTCTCAGTCTACTAG TACTTTACCAAATAACAAGTGTTG 
V1247I GCATAGCACCaTTGCTACCGA CTAGTAGACTGAGAAGGTATATTG 
Q1281P AAGGCATCTCcGGAACATCAC TGCCAATATTACCTGGTTAC 
E1346K AGATGATGAAaAAAGAGGAACG GAAACCAATTCCTTGTCAC 
N1354T TTGGAAGAAAcTAATCAAGAAGAGC GCCCGTTCCTCTTTCTTC 
[174] 
 
T1376R GAGAGTGAAAgAAGCGTCTCTG ACACCCAGATGCTGCTTC 
V1378I TGAAACAAGCaTCTCTGAAGACTG CTCTCACACCCAGATGCTG 
H1421Y GTTAGAACAGtATGGGAGCCAG ACAGCTTCTAGTTCAGCC 
G1422E GAACAGCATGaGAGCCAGCCT TAACACAGCTTCTAGTTCAGC 
K1476T TCTGCTGACAcGTTTGAGGTG AAGGCCTTCTGGATTCTG 
V1534M GGTTGTTGATaTGGAGGAGCAAC TTAATGAGCTCCTCTTGAGATG 
D1546Y TGGGCCACACtATTTGACGGA GACTCTTCCAGCTGTTGC 
T1561I CTAGAGGGAAtCCCTTACCTG ATCTTGCCTTGGCAAGTAAG 
L1564P ACCCCTTACCcGGAATCTGGAATC TCCCTCTAGATCTTGCCTTG 
P1579A TGAATCTGATgCTTCTGAAGAC GGGTCATCAGAGAAGAGG 
M1628T TATAATGCAAcGGAAGAAAGTGTG CCCAGCAGTATCAGTAGTATG 
P1637L AGGGAGAAGCtAGAATTGACAG GCTCACACTTTCTTCCATTG 
A1669S GTACAAGTTTtCCAGAAAACACC ACGAGCATAAATTCTTCTGG 
T1685I GAAGAGACTAtTCATGTTGTTATGAAAAC AGTAATTAGATTAGTTAAAGTGATG 
K1690Q TGTTGTTATGcAAACAGATGCTG TGAGTAGTCTCTTCAGTAATTAG 
R1699W TGTGTGTGAAtGGACACTGAAATATTTTC AACTCAGCATCTGTTTTCATAAC 
A1708V CTAGGAATTGtGGGAGGAAAATG AAAATATTTCAGTGTCCGTTC 
D1778G ATGCCCACAGgTCAACTGGAA GTTGGTGAAGGGCCCATA 
M1783L ACTGGAATGGcTGGTACAGCTG TGATCTGTGGGCATGTTG 
M1783T CTGGAATGGAcGGTACAGCTG TTGATCTGTGGGCATGTTG 
L1786P ATGGTACAGCcGTGTGGTGCTTC CCATTCCAGTTGATCTGTGG 
G1788V CAGCTGTGTGtTGCTTCTGTG TACCATCCATTCCAGTTG 
G1801D TTCACCCTTGaCACAGGTGTC TGATGAAAGCTCCTTCAC 
N1819S ACAGAGGACAgTGGCTTCCATG CCAGGCATCTGGCTGCAC 
R1835Q GTGGTGACCCaAGAGTGGGTG AGGTGCCTCACACATCTG 
P1859R CCCCAGATCCgCCACAGCCAC TATCAGGTAGGTGTCCAGCTC 
Positive 
Control     
(4) 
E23fs TGTCCCATCTGTCTGGAG CTAAGATTTTCTGCATAGCATTAATG 
E1250* CGTTGCTACCTAGTGTCTGTC GTGCTATGCCTAGTAGAC 
E1415fs AAGCTGTGTTAGAACAGC TAGTTCAGCCATTTCCTG 





Supplementary Table 2.22: Homologous directed recombination assay results for 68 missense 
constructs, and 4 truncations as positive controls. 
Variants Rep1 Rep2 Rep3 Rep4 Rep5 Rep6 Mean Stdev BIC database annotation 




pcDNA3 0.0820 0.0867 0.0804 0.2487 0.3140 0.3679 0.1966 0.1301   
Missense 
(68) 
S36Y 1.4331 1.3359 1.4377    1.4022 0.0575 Not Reported 
C61G 0.2232 0.2054 0.2798    0.2361 0.0388 Pathogenic/likely pathogenic 
C64G 0.2113 0.2917 0.2321    0.2450 0.0417 Unknown clinical importance 
E143K 1.2487 1.2738 1.2377    1.2534 0.0185 Unknown clinical importance 
E149A 1.1607 1.2126 1.2393    1.2042 0.0399 Not Reported 
Y179C 1.6730 1.5735 1.4668    1.5711 0.1031 Unknown clinical importance 
S186Y 1.1529 1.0398 1.2707    1.1545 0.1155 Unknown clinical importance 
V191I 1.1277 1.0618 1.2817    1.1571 0.1128 Unknown clinical importance 
D214G 1.4574 1.3024 1.3708    1.3769 0.0777 Unknown clinical importance 
T293S 1.6777 1.3412 1.6209    1.5466 0.1801 Not Reported 
R296G 1.2361 1.0979 1.1450    1.1597 0.0703 Not Reported 
S316G 1.1626 1.2492 1.2903    1.2340 0.0652 Unknown clinical importance 
A322P 0.8928 0.8769 0.8848 0.7508 0.7938 0.7554 0.8258 0.0666 Unknown clinical importance 
C328R 1.1262 1.1073 1.0539    1.0958 0.0375 Not Reported 
I379M 0.9384 0.9897 0.9954    0.9745 0.0314 No clinical importance 
E445Q 0.9875 1.0228 0.9977    1.0027 0.0182 Unknown clinical importance 
G462R 0.9327 0.8141 0.8084    0.8518 0.0702 Unknown clinical importance 
F486L 1.6108 1.5692 1.6200    1.6000 0.0270 Unknown clinical importance 
L512V 0.8803 0.8130 0.9293 0.6754 0.6523 0.6385 0.7648 0.1260 Not Reported 
N550H 0.9092 0.8892 0.9262    0.9082 0.0185 Unknown clinical importance 
I591T 1.5450 1.2441 1.2109    1.3333 0.1841 Unknown clinical importance 
R612G 1.0725 1.0613 1.0936    1.0758 0.0164 Unknown clinical importance 
L668F 1.1397 0.5592 0.8360 1.0713 1.1452 1.0536 0.9675 0.2295 Unknown clinical importance 
D695N 1.2263 1.3010 1.1839    1.2371 0.0593 Unknown clinical importance 
S708Y 1.2553 1.2185 1.2397    1.2378 0.0185 Unknown clinical importance 
E720K 1.3255 1.3144 1.2631    1.3010 0.0333 Unknown clinical importance 
V772A 1.0836 1.0820 1.1453    1.1037 0.0361 Unknown clinical importance 
A806T 1.2363 1.2107 1.1750    1.2074 0.0308 Unknown clinical importance 
T826K 0.8554 1.0134 1.0736 0.8809 0.9060 0.8006 0.9216 0.1024 Unknown clinical importance 
Y856H 0.9966 1.0718 1.0068    1.0251 0.0408 Unknown clinical importance 
R866C 1.6611 1.7275 1.8768    1.7551 0.1104 No clinical importance 
E962K 0.9361 0.8506 0.9464    0.9111 0.0526 Not Reported 
I1019V 1.0523 1.4908 1.0385    1.1938 0.2572 Unknown clinical importance 
I1044V 1.1446 1.1138 1.0569    1.1051 0.0445 Unknown clinical importance 
P1150S 0.9396 0.9179 0.8107    0.8894 0.0690 Unknown clinical importance 
D1152N 1.6659 1.8555 1.6706    1.7306 0.1081 Unknown clinical importance 
E1219D 1.0319 1.0148 1.0171    1.0213 0.0093 Unknown clinical importance 
P1238L 1.4431 1.3626 1.3460    1.3839 0.0520 Unknown clinical importance 
V1247I 1.1118 1.0806 1.1391    1.1105 0.0293 Not Reported 
Q1281P 1.0445 1.1049 1.0046    1.0513 0.0505 Unknown clinical importance 
E1346K 0.9920 1.0046 0.9578    0.9848 0.0242 Unknown clinical importance 
N1354T 1.1270 1.1115 0.9612    1.0666 0.0915 Not Reported 
[176] 
 
T1376R 1.4040 1.6880 1.5200    1.5373 0.1428 Unknown clinical importance 
V1378I 1.1014 1.2977 1.1483    1.1825 0.1025 Unknown clinical importance 
H1421Y 1.9300 1.7460 1.8440    1.8400 0.0921 Unknown clinical importance 
G1422E 1.6780 1.6580 1.9140    1.7500 0.1424 Not Reported 
K1476T 1.0547 1.0331 1.0342    1.0407 0.0122 Not Reported 
V1534M 1.0806 1.0916 1.0492    1.0738 0.0220 Unknown clinical importance 
D1546Y 0.7393 0.8231 0.8105 0.7512 0.8365 0.8236 0.7974 0.0414 Unknown clinical importance 
T1561I 1.2994 1.4240 1.2736    1.3323 0.0805 Unknown clinical importance 
L1564P 1.1255 1.0855 1.1655    1.1255 0.0400 No clinical importance 
P1579A 1.2503 1.1274 1.0982    1.1586 0.0807 Not Reported 
M1628T 1.0005 1.1717 1.0461    1.0728 0.0887 Unknown clinical importance 
P1637L 0.9277 0.9443 1.0930    0.9883 0.0911 Unknown clinical importance 
A1669S 1.2530 1.2976 1.5446    1.3651 0.1571 Unknown clinical importance 
T1685I 0.1935 0.2381 0.1726    0.2014 0.0335 Unknown clinical importance 
K1690Q 1.0759 0.9613 1.0963    1.0445 0.0728 Not Reported 
R1699W 0.1254 0.1269 0.0659 0.1492 0.1618 0.1555 0.1308 0.0351 Pathogenic/likely pathogenic 
A1708V 0.5938 0.6604 0.5362 0.5030 0.1951 0.3360 0.4707 0.1735 Unknown clinical importance 
D1778G 1.0037 1.0005 1.1042    1.0361 0.0590 Not Reported 
M1783L 1.2264 1.2371 1.3739    1.2791 0.0822 Unknown clinical importance 
M1783T 0.5188 0.5450 0.5268 0.8146 0.8222 0.8708 0.6616 0.1377 Unknown clinical importance 
L1786P 0.0514 0.0774 0.0465    0.0585 0.0166 Unknown clinical importance 
G1788V 0.0740 0.0913 0.0484 0.1712 0.1791 0.1602 0.1207 0.0562 Pathogenic/likely pathogenic 
G1801D 0.9132 0.9241 0.7461    0.8612 0.0998 Not Reported 
N1819S 1.1245 1.1460 1.1479    1.1395 0.0130 Unknown clinical importance 
R1835Q 0.5827 0.5796 0.6016 0.2930 0.3187 0.3358 0.4519 0.1499 Unknown clinical importance 




E23fs 0.0957 0.0888 0.0997    0.0947 0.0055   
E1250* 0.0908 0.0826 0.0715    0.0816 0.0097  
E1415fs 0.0566 0.0648 0.0640    0.0618 0.0045  





Supplementary Table 2.23: Summary of BRCA1 validation status for A.I./non A.I. events and 
the enrichment factor. 
Chr Position Ref Var AA Change 
Normal Tumor Cancer 
Type MAF AI FDR AI Status Ref Var VAF Ref Var VAF 
17 41245233 A G p.V772A 231 230 49.78 25 267 91.44 OV 0.033 1.3E-32 S 
17 41201181 C A p.G1788V 35 46 56.79 4 213 98.16 OV 0.004 2.1E-17 S 
17 41201187 A G p.L1786P 142 121 45.66 37 197 84.19 BRCA 0.004 4.1E-17 S 
17 41258495 A C p.C64G 56 54 49.09 5 130 96.3 OV 0.009 3.9E-17 S 
17 41223196 G C p.P1579A 273 239 46.5 78 264 77.19 OV 0.009 5.8E-17 S 
17 41244982 A G p.Y856H 199 198 49.75 72 236 76.62 STAD 0.033 2.5E-11 S 
17 41258504 A C p.C61G 64 42 39.62 12 73 85.88 BRCA 0.019 1.1E-09 S 
17 41258504 A C p.C61G 103 60 36.81 71 152 68.16 BRCA 0.019 8.0E-08 S 
17 41258504 A C p.C61G 67 38 36.19 8 45 84.91 BRCA 0.019 8.0E-08 S 
17 41219645 G A p.T1685I 44 28 38.89 11 64 85.33 OV 0.004 9.5E-08 S 
17 41256153 C T p.E143K 99 80 44.44 42 128 74.85 STAD 0.004 2.3E-07 S 
17 41247892 T C p.D214G 63 44 41.12 7 45 86.54 OV 0.014 4.3E-07 S 
17 41245233 A G p.V772A 130 106 44.92 72 169 70.12 LUAD 0.033 1.2E-06 S 
17 41251803 T C p.Y179C 82 56 40.58 30 83 73.45 HNSC 0.038 6.1E-06 S 
17 41215948 G A p.R1699W 42 30 41.67 17 64 79.01 OV 0.014 4.4E-05 S 
17 41246092 A G p.F486L 64 40 38.46 27 68 71.58 HNSC 0.038 7.8E-05 S 
17 41245714 T C p.R612G 65 74 53.24 31 93 75 OV 0.004 0.00290 S 
17 41223021 G A p.P1637L 37 43 53.75 10 43 81.13 OV 0.004 0.00739 S 
17 41223048 A G p.M1628T 32 40 55.56 18 71 79.78 BRCA 0.056 0.00758 S 
17 41246164 C T p.G462R 88 82 48.24 199 346 63.25 LUSC 0.009 0.00774 S 
17 41223048 A G p.M1628T 46 38 45.24 81 163 66.8 BRCA 0.056 0.00872 S 
17 41251803 T C p.Y179C 130 84 39.07 125 136 52.11 BRCA 0.038 0.08128 NS 
17 41245546 G A p.L668F 45 35 43.75 17 32 65.31 OV 0.004 0.14731 NS 
17 41251893 T G p.E149A 69 49 41.53 75 90 54.55 STAD 0.004 0.27013 NS 
17 41223048 A G p.M1628T 82 58 41.43 369 388 51.05 LUSC 0.056 0.29012 NS 
17 41223048 A G p.M1628T 57 36 38.71 36 42 53.85 STAD 0.056 0.37041 NS 
17 41244952 G A p.R866C 66 54 45 67 86 56.21 HNSC 0.004 0.40519 NS 
17 41246092 A G p.F486L 172 125 42.09 188 183 49.33 KIRC 0.038 0.41902 NS 
17 41258504 A C p.C61G 39 32 43.84 36 50 58.14 BRCA 0.019 0.51012 NS 
17 41246566 A G p.C328R 128 98 43.17 92 98 51.58 LUAD 0.004 0.52505 NS 
17 41246662 T C p.R296G 98 125 56.05 62 104 62.65 KIRC 0.004 0.59230 NS 
17 41223048 A G p.M1628T 58 37 38.95 70 67 48.91 LGG 0.056 0.68186 NS 
17 41201196 A G p.M1783T 129 93 41.7 54 54 50 UCEC 0.042 0.72804 NS 
17 41246092 A G p.F486L 132 121 47.83 81 95 53.98 BRCA 0.038 0.74465 NS 
17 41234517 G A p.H1421Y 134 123 47.86 125 132 51.16 KIRC 0.004 1 NS 
17 41223048 A G p.M1628T 104 98 48.51 122 133 51.95 STAD 0.056 1 NS 
17 41243512 C T p.E1346K 81 72 47.06 78 82 50.93 KIRC 0.009 1 NS 
17 41244982 A G p.Y856H 81 77 48.73 61 68 52.71 STAD 0.033 1 NS 
17 41246215 C G p.E445Q 108 98 47.34 285 287 50.09 BRCA 0.009 1 NS 
17 41223240 A G p.L1564P 37 31 45.59 45 47 51.09 UCEC 0.038 1 NS 
17 41246584 C G p.A322P 168 127 43.05 237 199 45.64 KIRC 0.004 1 NS 
17 41245233 A G p.V772A 98 88 47.31 88 89 50 HNSC 0.033 1 NS 
17 41245071 G T p.T826K 92 65 41.4 39 33 45.83 UCEC 0.023 1 NS 






17 41245233 A G p.V772A 87 83 48.82 106 110 50.93 HNSC 0.033 1 NS 
17 41226387 C A p.D1546Y 38 36 48.65 49 52 51.49 KIRC 0.004 1 NS 
17 41246092 A G p.F486L 104 79 43.17 188 149 44.21 KIRC 0.038 1 NS 
17 41245425 G T p.S708Y 65 63 49.22 71 66 48.18 BRCA 0.009 1 NS 
17 41245465 C T p.D695N 108 129 54.2 57 62 52.1 BRCA 0.004 1 NS 
17 41223240 A G p.L1564P 41 29 41.43 36 26 41.94 UCEC 0.038 1 NS 
17 41244982 A G p.Y856H 60 57 48.72 72 64 47.06 STAD 0.033 1 NS 
17 41251803 T C p.Y179C 145 138 48.76 226 204 47.22 KIRC 0.038 1 NS 
17 41243487 T G p.N1354T 255 257 50.2 209 192 47.88 BRCA 0.004 1 NS 
17 41246215 C G p.E445Q 31 55 63.95 63 71 52.99 BRCA 0.009 1 NS 
17 41245900 T G p.N550H 76 61 44.53 94 69 42.33 KIRC 0.038 1 NS 
17 41251803 T C p.Y179C 147 165 52.88 211 192 47.64 KIRC 0.038 1 NS 
17 41215920 G A p.A1708V 134 129 49.05 194 157 44.6 KIRC 0.019 1 NS 
17 41245425 G T p.S708Y 104 115 52.51 262 227 46.42 BRCA 0.009 1 NS 
17 41201142 C T p.G1801D 79 78 49.68 41 31 43.06 BRCA 0.004 1 NS 
17 41245900 T G p.N550H 83 106 56.08 82 72 46.75 BRCA 0.038 1 NS 
17 41201211 T C p.D1778G 34 37 52.11 41 31 43.06 GBM 0.004 1 NS 
17 41244982 A G p.Y856H 43 62 58.49 79 67 45.89 BRCA 0.033 1 NS 
17 41246014 G C p.L512V 81 65 44.52 139 88 38.77 BRCA 0.004 1 NS 
17 41243891 C G p.E1219D 93 72 43.64 96 58 37.66 KIRC 0.009 1 NS 
17 41245132 C T p.A806T 49 76 60.8 187 134 41.74 KIRC 0.004 1 NS 
17 41223048 A G p.M1628T 59 64 52.03 80 52 39.39 LUAD 0.056 1 NS 
17 41244664 C T p.E962K 75 92 55.09 98 65 39.88 LUAD 0.004 1 NS 
17 41244982 A G p.Y856H 29 44 60.27 88 58 39.73 STAD 0.033 1 NS 
17 41244982 A G p.Y856H 66 67 50.38 67 40 37.38 BRCA 0.033 1 NS 
17 41243809 C T p.V1247I 80 67 45.27 89 50 35.97 LUAD 0.009 1 NS 
17 41223048 A G p.M1628T 66 63 48.46 176 101 36.46 UCEC 0.056 1 NS 
17 41243835 G A p.P1238L 198 184 48.04 267 145 35.19 BRCA 0.014 1 NS 
17 41228562 T G p.K1476T 63 54 46.15 58 28 32.56 PRAD 0.004 1 NS 
17 41249283 C T p.V191I 45 37 45.12 60 23 27.71 STAD 0.033 1 NS 
17 41244094 C T p.D1152N 77 76 49.67 95 35 26.92 BRCA 0.004 1 NS 
17 41246602 T C p.S316G 34 29 46.03 68 18 20.93 BRCA 0.014 1 NS 
17 41244493 T C p.I1019V 164 151 47.94 144 16 10 BRCA 0.004 1 NS 
17 41219694 C A p.A1669S 57 30 34.48 54 6 10 OV 0.014 1 NS 
17 41243835 G A p.P1238L 53 48 47.52 838 88 9.44 LUSC 0.014 1 NS 
17 41197711 G C p.P1859R 23 28 54.9 59 6 9.23 BRCA 0.009 1 NS 
17 41245233 A G p.V772A 218 226 50.79 299 30 9.12 LUSC 0.033 1 NS 
17 41246670 G C p.T293S 93 66 41.51 148 14 8.59 OV 0.004 1 NS 
17 41249283 C T p.V191I 48 56 53.85 38 3 7.32 BRCA 0.033 1 NS 
17 41234513 C T p.G1422E 446 435 49.04 746 33 4.23 OV 0.004 1 NS 
17 41219694 C A p.A1669S 30 28 48.28 64 1 1.54 BRCA 0.014 1 NS 
[179] 
 
Supplementary Table 2.24: Rare germline missense variants overlapping with recurrent 
somatic mutations.  
Gene Annotation Cancer Type Chr Position 
Reference 
Allele Variant Allele Transcript (Ensembl) 
ABCC2 p.E943K LUAD 10 101590552 G A ENST00000370449 
ATM p.R2691C BRCA 11 108205756 C T ENST00000278616 
ATP5B p.S375L LUSC 12 57033894 G A ENST00000552919 
BARD1 p.K140N PRAD 2 215646178 C A ENST00000260947 
BRCA2 p.E2020K GBM 13 32914550 G A ENST00000380152 
CARD11 p.R423Q STAD 7 2976744 C T ENST00000396946 
CDH1 p.R224H PRAD 16 68842735 G A ENST00000261769 
CDH12 p.D674N KIRC 5 21752211 C T ENST00000382254 
CYP2D6 p.H352R BRCA 22 42523567 T C ENST00000360608 
CYP2D6 p.H352R BRCA 22 42523567 T C ENST00000360608 
CYP2D6 p.H352R BRCA 22 42523567 T C ENST00000360608 
DDX11 p.E201K BRCA 12 31238023 G A ENST00000407793 
EPHB2 p.G874S LUAD 1 23236992 G A ENST00000400191 
EPHB2 p.R392H BRCA 1 23191577 G A ENST00000400191 
FANCA p.R1084C BRCA 16 89815165 G A ENST00000389301 
FAT1 p.R806H UCEC 4 187628565 C T ENST00000441802 
FGF14 p.T229M LGG 13 102375254 G A ENST00000376131 
FLT3 p.R387Q HNSC 13 28622457 C T ENST00000380982 
LRP2 p.R3043C PRAD 2 170044681 G A ENST00000263816 
LRP2 p.R682C BRCA 2 170115593 G A ENST00000443831 
MED12 p.V1588M HNSC X 70354597 G A ENST00000333646 
MORC4 p.R224C BRCA X 106228330 G A ENST00000355610 
NOTCH4 p.T684M LGG 6 32182003 G A ENST00000375023 
PARP1 p.A625T BRCA 1 226564877 C T ENST00000366794 
PARP1 p.A625T STAD 1 226564877 C T ENST00000366794 
PDGFRB p.S650L STAD 5 149503887 G A ENST00000261799 
RICTOR p.S1101L BRCA 5 38950648 G A ENST00000296782 
SETD2 p.E639K PRAD 3 47164211 C T ENST00000409792 
TP53 p.R110H GBM 17 7579358 C T ENST00000269305 
TP53 p.R158C GBM 17 7578458 G A ENST00000269305 
TP53 p.R267Q LUAD 17 7577138 C T ENST00000359597 
TP53 p.R175C GBM 17 7578407 G A ENST00000269305 
TP53 p.R175C BRCA 17 7578407 G A ENST00000359597 









Supplementary Figure 3.1: Distribution of blood-specific mutations in DNMT3A, TET2, 
JAK2, ASXL1, SF3B1, GNAS, and all 31 genes across different age groups. The 91 sites 
include 77 detected by our processing pipeline and 14 low VAF sites (2 to 10%) identified by 
read count-based analysis. The total includes all blood-specific mutations in 556 cancer 




Supplementary Figure 3.2: Distinct and common connections among normal blood 
samples, MPN, MDS, CLL, and AML cases. A combination of precursor, initiating mutations 
in the normal blood samples may rarely collaborate with subsequent, progression mutations to 





Supplementary Table 3.1: Sample IDs for the 2,728 TCGA cases included in this study. 









Supplementary Table 3.2: Samples included in the study and their clinical characteristics. 
Cancer 
Type 
Case          
(N) Age    (Years) 
Gender Vital Status 
Female     
(%) 






NA              
(N) 
BRCA 673 57.9 ± 12.9 99 1 632 41 0 
GBM 230 59.5 ± 14.2 37 63 75 155 0 
HNSC 243 61.6 ± 12.1 28.3 71.7 131 95 17 
KIRC 57 59.5 ± 12.1 38.6 61.4 55 2 0 
LGG 210 42.8 ± 13.4 42.4 57.6 163 47 0 
LUAD 266 64.4 ± 9.7 51.7 48.3 222 37 7 
LUSC 89 67.5 ± 9.4 19.5 80.5 70 17 2 
OV 314 59.3 ± 11.6 100 0 151 162 1 
PRAD 153 60.1 ± 7.2 0 100 133 1 19 
STAD 262 65.6 ± 10.5 39 61 235 16 11 
UCEC 231 62.6 ± 10.8 100 0 214 17 0 

















Pacific Islander     
(N) 
NA              
(N) 
BRCA 504 48 46 1 0 74 
GBM 205 4 17 0 0 4 
HNSC 189 6 21 1 0 26 
KIRC 50 0 7 0 0 0 
LGG 199 0 9 0 0 2 
LUAD 191 3 17 0 0 55 
LUSC 75 0 3 0 0 11 
OV 271 13 13 2 0 15 
PRAD 111 2 6 0 0 34 
STAD 148 76 1 0 0 37 
UCEC 178 13 23 3 7 7 




Supplementary Table 3.3: The distribution of germline variants across 2,728 TCGA samples. 












shift Indel Nonstop 
Splice 
site Silent  
BRCA 14070932 426975 255541 4730 5979 5068 272 2863 152522 
GBM 4444472 140874 85491 1655 1612 1285 98 978 49755 
HNSC 4970133 149952 89998 1712 1715 1410 90 898 54129 
KIRC 1166946 45309 27417 651 694 571 33 371 15572 
LGG 4167463 113441 68999 1318 1387 1064 59 696 39918 
LUAD 5366256 162782 98330 1822 1903 1447 88 954 58238 
LUSC 1791732 45243 27868 558 591 405 22 261 15538 
OV NA 137664 131640 2749 1369 NA NA 1518 388 
PRAD 3143264 92097 54992 1046 1118 899 65 539 33438 
STAD 5366040 157380 95915 1709 1905 1595 84 961 55211 
UCEC 4829789 150768 89441 1713 2002 1764 115 937 54796 





Supplementary Table 3.4: Somatic mutations in 2,241 TCGA tumor samples included in the 
study. Somatic mutation data are unavailable for a subset of samples. 





Supplementary Table 3.5: Somatic mutations in 3,355 TCGA tumor samples from 12 cancer 
types used for identifying recurrent mutations. 






Supplementary Table 3.6: Recurrent somatic mutations from 12 TCGA cancer types used for 
hotspot analysis. 






Supplementary Table 3.7: 556 cancer-associated genes used in this study. 
ABCB1 ABCC2 ABCC4 ABCG2 ABL1 ABL2 ACO1 ACVR1B ACVR2A ACVR2B 
ADNP APOL2 ASXL3 B4GALT3 BCR CASP8 CD79B CDKN2A CIC CTNNB1 
AJUBA AR ATM BACH1 BLM CBFB CDC27 CDKN2B CNBD1 CUL4A 
AKT1 AKT2 AKT3 ALK ALKBH6 ALOX12B ALPK2 AMER1 APC APCDD1 
ARAF ARFRP1 ARHGAP35 ARID1A ARID1B ARID2 ARID5B ARL11 ASXL1 ASXL2 
ATP5B ATR ATRX AURKA AURKB AXIN1 AXIN2 AXL AZGP1 B2M 
BAK1 BAP1 BARD1 BCL2 BCL2L11 BCL2L2 BCL6 BCLAF1 BCOR BCORL1 
BRAF BRCA1 BRCA2 BRE BRIP1 BRWD3 BTG1 BTK CAP2 CARD11 
CBL CBLB CBLC CCND1 CCND2 CCND3 CCNE1 CD1D CD70 CD79A 
CDC73 CDH1 CDH12 CDH18 CDK12 CDK4 CDK6 CDK8 CDKN1A CDKN1B 
CDKN2C CEBPA CENPL CEP76 CERS2 CHD4 CHD8 CHEK1 CHEK2 CHUK 
CNKSR1 COMT CRBN CREBBP CRIPAK CRKL CRLF2 CSF1R CTCF CTNNA1 
CUL4B CUX1 CYLD CYP17A1 CYP1B1 CYP2C19 CYP2C8 CYP2D6 CYP3A4 CYP3A5 
DAXX DNMT1 EML4 ERBB4 EZH2 FANCM FGF3 FOXA1 GNA13 H3F3C 
DCAF6 DNMT3A EMSY ERCC2 EZR FAT1 FGF4 FOXA2 GNAQ HAUS3 
DDR1 DDR2 DDX11 DDX3X DDX5 DIAPH1 DIDO1 DIS3 DLC1 DNER 
DOT1L DPYD ECSCR EGFR EGR3 EIF2S2 EIF3A EIF4A2 ELF3 EME2 
EP300 EPHA2 EPHA3 EPHA5 EPHB1 EPHB2 EPHB6 EPPK1 ERBB2 ERBB3 
ERG ESR1 ESR2 ETV1 ETV4 ETV5 ETV6 EWSR1 EXT1 EZH1 
FAM129B FAM46C FANCA FANCC FANCD2 FANCE FANCF FANCG FANCI FANCL 
FAT3 FBXW7 FCGR1A FCGR2A FCGR3A FGF10 FGF12 FGF14 FGF19 FGF23 
FGF6 FGF7 FGFBP1 FGFR1 FGFR2 FGFR3 FGFR4 FLT1 FLT3 FLT4 
FOXL2 FOXQ1 FUBP1 FZD1 GAB2 GATA1 GATA2 GATA3 GID4C GNA11 
GNAS GNB1 GPR124 GPS2 GRIN2A GRM3 GSK3B GSTP1 GUCY1A2 H3F3A 
HDAC4 HGF HIF1A HIST1H1C HIST1H1E HIST1H2BD HIST1H3B HIST1H4E HLA-A HLA-B 
HLA-G ING1 JUN KMT2C MAP2K4 MDM4 MNDA MYCL1 NFE2L2 NTN4 
HNF1A INHA KDM5A KMT2D MAP3K1 MECOM MORC4 MYCN NFKBIA NTRK1 
HRAS HSP90AB1 IDH1 IDH2 IGF1 IGF1R IGF2 IKBKE IKZF1 IL7R 
INHBA INPPL1 IPO7 IRF4 IRS2 ITGAV ITPA JAK1 JAK2 JAK3 
KDM5C KDM6A KDR KEAP1 KIF5B KIT KLF4 KLHL6 KMT2A KMT2B 
KRAS LIFR LMO1 LRP1B LRP2 LRRK2 MALAT1 MAN1B1 MAP2K1 MAP2K2 
MAP3K13 MAP3K15 MAP4K1 MAP4K3 MAPK1 MAPK8IP1 MBD1 MC1R MCL1 MDM2 
MED12 MED23 MEF2A MEF2B MEN1 MET MGA MIR142 MITF MLH1 
MPL MRE11A MSH2 MSH6 MTHFR MTOR MUTYH MXRA5 MYB MYC 
MYD88 MYLK MYST3 NAV3 NBN NBPF1 NCOR1 NEIL1 NF1 NF2 
NKX2-1 NOTCH1 NOTCH2 NOTCH3 NOTCH4 NPM1 NQO1 NRAS NRP2 NSD1 
NTRK2 NTRK3 NUP93 ODAM OTUD7A PAK3 PAK7 PALB2 PAPD5 PARP1 
PARP2 PDSS2 POLD1 PRLR RAD50 RBM10 RPL22 SDHC SIRT4 SMO 
PARP3 PHF6 POLE PRPF40B RAD51 RBMX RPL5 SDHD SLC19A1 SNX25 
PARP4 PAX5 PBRM1 PCBP1 PCDH10 PDAP1 PDCD2L PDGFRA PDGFRB PDK1 
PIK3C2G PIK3C3 PIK3CA PIK3CG PIK3R1 PIK3R2 PLCG2 PML PMS2 PNRC1 
POLQ PORCN POU2AF1 POU2F2 PPM1D PPP2R1A PPP6C PRDM1 PRKAR1A PRKDC 
PRSS8 PTCH1 PTEN PTPN11 PTPRC PTPRD QKI RAB40A RAC1 RAD21 
RAD51B RAD51C RAD51D RAD52 RAD54L RAF1 RALY RARA RASA1 RB1 
REL RET RHBDF2 RHEB RHOA RICTOR RIT1 RNF43 ROS1 RPA1 
RPS14 RPS15 RPS2 RPTOR RUNX1 RUNX1T1 RUNX3 RXRA SDHAF2 SDHB 
SRC SZRD1C TLK2 TRAF7 UMPS XRCC3 SRSF2 TAF1 TLR4 TRRAP 
SERPINB13 SETBP1 SETD2 SETDB1 SF1 SF3B1 SGK1 SH2B3 SIN3A SIRPA 
SLC22A2 SLCO1B3 SMAD2 SMAD3 SMAD4 SMARCA4 SMARCB1 SMARCD1 SMC1A SMC3 
SOCS1 SOD2 SOS1 SOX10 SOX17 SOX2 SOX9 SPEN SPOP SPRY4 
STAG2 STAT4 STK11 STK19 STK38 STX2 SUFU SULT1A1 SUZ12 SYK 
TBC1D12 TBL1XR1 TBX3 TCEB1 TCF7L2 TET2 TFG TGFBR2 TIMM17A TIPARP 
TMPRSS2 TNF TNFAIP3 TNFRSF14 TOP1 TP53 TP53BP1 TPMT TPX2 TRAF3 
TSC1 TSC2 TSHR TSHZ2 TSHZ3 TYMS TYR U2AF1 U2AF65 UGT1A1 
USP9X VANGL2 VEZF1 VHL WAC WASF3 WISP3 WNK1 WT1 XPO1 
XRCC2 ZFHX3 ZNF217 ZNF703 ZRANB3 ZRSR2         
[189] 
 
Supplementary Table 3.8: 77 blood-specific events detected in 2,728 cases using our standard 
discovery pipeline. 
Gene Case Cancer Type 
Age 
(years) Group Mutation 
Blood Sample Tumor Sample 
Ref  Var  VAF CNV Ref  Var  VAF CNV 
ASXL1 TCGA-05-4403 LUAD 76 AML p.R548fs 128 69 35.0 2.0 229 10 4.2 2.0 
ASXL1 TCGA-37-4130 LUSC 56 AML p.Y591fs 142 60 29.7 2.0 247 15 5.7 3.1 
ASXL1 TCGA-86-8281 LUAD 75 AML p.Q575* 108 27 20.0 2.0 179 6 3.2 2.0 
ASXL1 TCGA-97-8179 LUAD 72 AML p.Q733* 36 6 14.3 2.0 52 0 0.0 2.4 
ASXL1 TCGA-A5-A0R8 UCEC 81 AML p.Q733fs 16 6 27.3 2.0 48 4 7.7 2.0 
ASXL1 TCGA-BR-8373 STAD 65 AML p.Y591* 124 27 17.9 2.0 125 2 1.6 2.4 
ASXL2 TCGA-DU-6400 LGG 66 AML e12-2 138 29 17.4 2.0 167 1 0.6 2.2 
ATM TCGA-52-7812 LUSC 68 notAML p.R337C 51 12 19.1 2.0 46 1 2.1 2.1 
AXL TCGA-97-8174 LUAD 67 AML p.G517D 161 20 11.1 2.0 75 0 0.0 2.3 
BCORL1 TCGA-95-8494 LUAD null AML p.G883E 20 4 16.7 null 101 0 0.0 null 
BCORL1 TCGA-EJ-5526 PRAD 56 AML p.S264* 114 33 22.5 null 128 0 0.0 null 
CBL TCGA-CR-7376 HNSC 83 AML p.R540* 111 26 19.0 2.0 111 7 5.9 2.0 
CDKN2A TCGA-97-8174 LUAD 67 AML p.E120* 58 16 21.6 2.0 42 0 0.0 1.8 
CREBBP TCGA-97-8179 LUAD 72 AML p.A259S 171 24 12.3 2.0 128 0 0.0 2.4 
DIDO1 TCGA-97-8174 LUAD 67 notAML p.H1557R 100 21 17.4 2.0 75 0 0.0 1.9 
DNMT3A TCGA-06-0142 GBM 81 AML p.R882C 64 12 15.8 2.0 89 3 3.3 2.0 
DNMT3A TCGA-06-2558 GBM 75 AML p.Y584fs 31 19 38.0 2.0 24 1 4.0 2.1 
DNMT3A TCGA-06-2563 GBM 72 AML p.E469* 185 48 20.6 2.0 229 2 0.9 2.0 
DNMT3A TCGA-12-3649 GBM 76 AML e21-2 112 15 11.8 2.0 69 0 0.0 2.1 
DNMT3A TCGA-21-5783 LUSC 76 AML p.R882H 32 15 31.9 2.0 76 4 5.0 2.7 
DNMT3A TCGA-46-6025 LUSC 71 AML p.N516fs 98 49 33.3 2.0 132 8 5.7 2.6 
DNMT3A TCGA-55-7815 LUAD 76 AML e13+1 72 9 11.1 2.0 53 1 1.9 2.0 
DNMT3A TCGA-81-5910 GBM 64 AML p.R882H 29 16 35.6 2.0 51 1 1.9 2.0 
DNMT3A TCGA-AX-A060 UCEC 77 AML e22-1 43 22 33.9 null 34 0 0.0 2.0 
DNMT3A TCGA-B2-5636 KIRC 79 AML e13+1 58 11 15.9 2.0 52 0 0.0 2.0 
DNMT3A 
TCGA-BH-
A0DL BRCA 64 AML p.F851fs 252 135 34.9 2.0 465 46 9.0 2.1 
DNMT3A TCGA-BR-7197 STAD 69 AML p.R882C 101 14 12.2 2.0 62 0 0.0 1.9 
DNMT3A 
TCGA-BR-
A4QL STAD 75 AML p.S770* 131 25 16.0 2.0 130 0 0.0 2.0 
DNMT3A TCGA-CR-7370 HNSC 72 AML p.K577fs 22 7 24.1 2.0 23 0 0.0 1.9 
DNMT3A TCGA-D1-A16G UCEC 74 AML p.W314* 106 30 22.1 2.0 165 10 5.7 2.5 
DNMT3A TCGA-D7-A4Z0 STAD 60 AML p.R882C 67 15 18.3 null 75 5 6.3 2.0 
DNMT3A TCGA-E9-A1RG BRCA 62 AML p.R882H 22 6 21.4 2.0 23 0 0.0 2.2 
DNMT3A TCGA-G9-6356 PRAD 60 AML e12-1 61 34 35.8 2.0 78 3 3.7 2.0 
GNAS TCGA-19-2625 GBM 76 AML p.R202H 77 13 14.4 2.0 214 1 0.5 2.2 
GNAS TCGA-67-4679 LUAD 69 AML p.R202H 77 21 21.4 2.0 84 0 0.0 2.0 
GNAS TCGA-D6-A4Z9 HNSC 59 AML p.R202H 69 9 11.5 2.0 68 1 1.5 2.1 
GUCY1A2 TCGA-97-7938 LUAD 76 notAML p.K643N 15 7 31.8 2.0 27 0 0.0 2.0 
HDAC4 TCGA-26-5135 GBM 72 notAML p.P412R 40 9 18.0 2.0 68 1 1.5 2.0 
IDH2 TCGA-D7-8574 STAD 72 AML p.R140Q 29 18 38.3 2.0 41 0 0.0 2.0 
JAK2 TCGA-05-4403 LUAD 76 AML p.V617F 108 77 41.6 2.0 88 6 6.4 2.0 
JAK2 TCGA-06-0240 GBM 57 AML p.V617F 186 51 21.5 2.0 114 1 0.9 2.0 
JAK2 TCGA-26-5135 GBM 72 AML p.V617F 58 160 73.4 2.0 275 2 0.7 2.0 
JAK2 TCGA-99-8025 LUAD 72 AML p.V617F 76 29 27.6 2.0 139 4 2.8 1.8 
JAK2 TCGA-AP-A0LQ UCEC 59 AML p.V617F 75 42 35.9 2.0 160 9 5.3 2.0 
JAK2 TCGA-B4-5834 KIRC 59 AML p.V617F 75 30 28.6 2.0 202 3 1.5 2.0 
JAK2 TCGA-BK-A139 UCEC 74 AML p.V617F 124 94 42.9 2.0 156 15 8.8 1.6 
JAK2 TCGA-HW-7495 LGG 45 AML p.V617F 53 10 15.9 2.0 113 0 0.0 2.0 
MBD1 TCGA-97-8174 LUAD 67 notAML p.S63N 102 12 10.5 2.0 66 0 0.0 1.9 
MECOM TCGA-13-0919 OV 52 notAML p.T982N 56 9 13.9 2.0 82 1 1.2 2.3 
MYLK TCGA-AX-A05T UCEC 82 AML p.Q1392* 59 14 19.2 null 70 0 0.0 2.0 




PPM1D TCGA-A7-A0CH BRCA 79 notAML p.Q520* 124 68 35.4 null 230 5 2.1 2.0 
PPM1D TCGA-D1-A16D UCEC 49 notAML p.S468* 115 31 21.2 2.0 146 5 3.3 2.0 
PRKDC TCGA-26-5135 GBM 72 notAML p.Q1389R 61 35 36.5 2.0 93 1 1.1 2.0 
RICTOR 
TCGA-BH-
A0DS BRCA 71 notAML e9-1 38 9 18.8 2.0 74 0 0.0 2.0 
SETBP1 TCGA-26-5135 GBM 72 AML p.E603A 87 39 31.0 2.0 144 1 0.7 2.0 
SF1 TCGA-95-7043 LUAD 63 AML p.G407V 30 4 11.8 2.0 42 0 0.0 2.5 
SF3B1 TCGA-41-2571 GBM 89 AML p.K700E 87 14 13.9 2.0 175 0 0.0 2.0 
SF3B1 TCGA-B0-5698 KIRC 77 AML p.K700E 45 34 43.0 2.0 90 10 10.0 2.0 
SH2B3 TCGA-BH-A0B1 BRCA 66 AML e3+1 104 30 22.4 2.0 51 3 5.6 null 
SNX25 TCGA-13-0919 OV 52 notAML p.A745T 42 6 12.2 2.0 44 0 0.0 1.9 
SOS1 TCGA-95-7043 LUAD 63 notAML p.G414W 28 4 12.5 2.0 47 0 0.0 2.2 
TET2 TCGA-06-2558 GBM 75 AML p.Q764fs 69 34 33.0 2.0 234 5 2.1 2.1 
TET2 TCGA-06-2559 GBM 83 AML p.F381fs 91 91 50.0 2.0 321 9 2.7 2.0 
TET2 TCGA-06-2559 GBM 83 AML p.Q888* 82 21 20.4 2.0 127 1 0.8 2.0 
TET2 TCGA-26-5135 GBM 72 AML p.T229fs 102 24 19.1 2.0 126 1 0.8 2.0 
TET2 TCGA-36-2543 OV 85 AML p.K889* 135 24 15.1 2.0 132 8 5.7 1.6 
TET2 TCGA-69-7764 LUAD 75 AML p.Q831fs 39 14 26.4 2.0 33 0 0.0 1.5 
TET2 TCGA-81-5910 GBM 64 AML p.H863fs 53 7 11.7 2.0 75 0 0.0 2.1 
TET2 TCGA-97-7938 LUAD 76 AML p.R550* 67 13 16.3 2.0 106 4 3.6 2.0 
TET2 TCGA-AK-3433 KIRC 48 AML p.Q531* 37 5 11.9 2.0 35 0 0.0 2.7 
TET2 
TCGA-BG-
A0W1 UCEC 89 AML p.Q644* 251 51 16.8 2.0 107 1 0.9 1.9 
TP53 TCGA-13-0919 OV 52 AML p.C275Y 42 7 14.3 2.0 42 0 0.0 1.5 
TP53 TCGA-50-5049 LUAD 70 AML p.R273L 17 9 34.6 2.0 28 2 6.7 1.7 
TP53 TCGA-95-8494 LUAD null AML p.Q136* 79 18 18.0 2.0 49 0 0.0 1.5 
TP53 TCGA-D7-A6F2 STAD 62 AML p.Q144* 79 15 16.0 null 37 2 5.1 null 






Supplementary Table 3.9: Low-level blood-specific events detected in DNMT3A, JAK2, 
SF3B1, GNAS, and IDH2 in TCGA samples. 














DNMT3A R882C TCGA-A2-A1G1 0.00595 0.02234 44 6 12 30 3 9.09 
DNMT3A R882C TCGA-BR-8081 0.00722 0.02167 95 10 9.52 46 0 0 
DNMT3A R882C TCGA-85-7698 0.02635 0.06586 90 7 7.22 83 0 0 
DNMT3A R882C TCGA-B2-4098 0.05886 0.12616 81 5 5.75 51 1 1.92 
DNMT3A R882C TCGA-24-1469 0.07955 0.14918 70 4 5.41 102 0 0 
DNMT3A R882H TCGA-D1-A17H 0.02256 0.10716 57 4 6.56 64 0 0 
DNMT3A R882H TCGA-FG-7634 0.02542 0.09660 60 4 6.25 63 0 0 
DNMT3A R882H TCGA-CR-7376 0.06276 0.19875 60 3 4.76 62 2 3.12 
IDH2 R140Q TCGA-09-2053 0.05230 0.18308 102 4 3.77 102 0 0 
JAK2 V617F TCGA-24-1603 0.00376 0.00919 87 8 8.42 126 0 0 
JAK2 V617F TCGA-EJ-5521 0.00606 0.01335 242 16 6.2 197 0 0 
JAK2 V617F TCGA-06-2563 0.01005 0.02011 269 16 5.59 233 0 0 
JAK2 V617F TCGA-AP-A0LD 0.05020 0.09203 96 5 4.95 89 0 0 





Supplementary Table 3.10: Deep-sequencing based validation of low-level blood-specific 
events detected in DNMT3A, JAK2, and SF3B1 in TCGA samples. 
Type Gene Mut-ation Case 
Normal Tumor Validation Normal Validation Tumor 
Ref  Var  VAF (%)  Ref  Var  
VAF 
(%)  Ref  Var  
VAF 
(%) Ref  Var  
VAF 
(%) 
Group1 DNMT3A R882C TCGA-A2-A1G1 44 6 12 30 3 9.09 525630 65588 
11.0
9 663050 15657 2.31 
Group1 DNMT3A R882C TCGA-24-1469 70 4 5.41 102 0 0 693053 19627 2.75 677489 1123 0.17 
Group1 DNMT3A R882H TCGA-D1-A17H 57 4 6.56 64 0 0 403096 16067 3.83 538616 2068 0.38 
Group1 JAK2 V617F TCGA-AP-A0LD 96 5 4.95 89 0 0 622088 23727 3.67 701514 424 0.06 
Group1 SF3B1 K700E TCGA-D1-A0ZS 127 10 7.3 128 6 4.48 1413 120 7.83 382 0 0 
Group2 DNMT3A R882C TCGA-A2-A0CW 117 0 0 78 0 0 667273 185 0.03 627418 141 0.02 
Group2 DNMT3A R882H TCGA-A7-A13D 103 0 0 163 0 0 663423 1301 0.2 667017 1101 0.16 
Group2 JAK2 V617F TCGA-A2-A04N 122 0 0 75 0 0 616831 755 0.12 680609 1047 0.15 
Group2 SF3B1 K700E TCGA-A8-A06Z 133 0 0 187 0 0 32263 2 0.01 102124 6 0.01 
Group3 DNMT3A F851fs TCGA-BH-A0DL 252 135 34.9 465 46 9 7110 4021 36.1 27942 2828 9.19 
Group2 DNMT3A W314* TCGA-D1-A16G 106 30 22.1 165 10 5.71 582397 160832 21.6 517920 43311 7.71 
Group2 DNMT3A R882H TCGA-E9-A1RG 22 6 21.4 23 0 0 375747 43963 10.5 538566 3035 0.56 
Group2 JAK2 V617F TCGA-BK-A139 124 94 42.9 156 15 8.77 364000 332335 47.7 591804 82373 12.22 
Group2 SF3B1 K700E TCGA-41-2571 87 14 13.9 175 0 0 34723 8830 20.3 62472 10 0.02 
 
*Group1: candidate variants  
*Group2: positive variants  






Supplementary Table 3.11: Truncation and hotspot variants in four prominent genes 
(DNMT3A, TET2, JAK2, and ASXL1) involved in HSPC clonal expansion in 6,503 ESP samples. 
RareTruncationVariants 









2 25458593 C T DNMT3A Nonsense p.W860* 0 0.0227 0.0077 rs376830288 
2 25459834 C A DNMT3A Nonsense p.E817* 0.0116 0 0.0077 rs373873045 
2 25464505 0 G DNMT3A Frame Shift Ins p.I669fs 0 0.0234 0.008 NA 
2 25466831 T 0 DNMT3A Frame Shift Del p.P625fs 0.0123 0.0239 0.0163 NA 
2 25467468 G C DNMT3A Nonsense p.Y536* 0.0116 0 0.0077 rs370376334 
2 25468163 C A DNMT3A Nonsense p.E505* 0.0116 0 0.0077 rs373860660 
2 25469488 C T DNMT3A Splice Site e9+1 0.0117 0 0.0077 rs374440649 
2 25469922 G A DNMT3A Nonsense p.Q374* 0 0.0227 0.0077 rs369109129 
4 106156279 G 0 TET2 Frame Shift Del p.A394fs 0.0121 0 0.008 NA 
4 106156313 TTCT 0 TET2 Frame Shift Del p.S407fs 0 0.0234 0.008 NA 
4 106156687 C T TET2 Nonsense p.Q530* 0.0116 0 0.0077 rs377382567 
4 106157505 C 0 TET2 Frame Shift Del p.Q803fs 0.0121 0 0.008 NA 
4 106157506 C T TET2 Nonsense p.Q803* 0.0116 0 0.0077 rs368508787 
4 106157653 G T TET2 Nonsense p.E852* 0.0116 0 0.0077 rs374928350 
4 106157700 T G TET2 Nonsense p.Y867* 0.0116 0 0.0077 rs145844118 
4 106157808 C 0 TET2 Frame Shift Del p.Q904fs 0.0363 0 0.024 NA 
4 106158114 G 0 TET2 Frame Shift Del p.V1006fs 0.0121 0 0.008 NA 
4 106158157 C T TET2 Nonsense p.Q1020* 0.0116 0 0.0077 rs375539032 
4 106196213 C T TET2 Nonsense p.R1516* 0.0314 0 0.0219 rs370735654 
4 106196220 C 0 TET2 Frame Shift Del p.S1518fs 0.0159 0 0.0106 NA 
4 106197161 C 0 TET2 Frame Shift Del p.L1832fs 0 0.0367 0.0131 NA 
9 5022113 T G JAK2 Nonsense p.Y42* 0.0116 0 0.0077 rs369748023 
20 31021211 C T ASXL1 Nonsense p.R404* 0 0.0454 0.0154 rs373145711 
20 31021250 C T ASXL1 Nonsense p.R417* 0.0116 0 0.0077 rs375215583 
20 31021332 C G ASXL1 Nonsense p.S444* 0.0116 0 0.0077 rs373126831 
20 31022233 A G ASXL1 Splice Site e13-2 0.0116 0 0.0077 rs376029425 
20 31022288 C G ASXL1 Nonsense p.Y591* 0.0116 0 0.0077 rs371369583 
20 31022592 C T ASXL1 Nonsense p.R693* 0 0.0227 0.0077 rs373221034 
20 31022783 C 0 ASXL1 Frame Shift Del p.Q757fs 0.0121 0 0.008 NA 
KnownHotSpotVariants 









2 25457242 C T DNMT3A Missense p.R882H 0.0581 0.0908 0.0692 rs147001633 
2 25457243 G A DNMT3A Missense p.R882C 0.0465 0 0.0308 rs377577594 







Supplementary Table 3.12: Rare truncation variants and known hotspot variants detected in 
DNMT3A, TET2, ASXL1, GNAS, JAK2, SF3B1, IDH1, and IDH2 in 557 WHISP samples. 
Sample_ID Chr Start Ref Var Gene Type Annotation 
dbGaP-298170-361467 20 31022288 C G ASXL1 Nonsense p.Y591* 
dbGaP-295088-361485 2 25457242 C T DNMT3A Missense p.R882H 
dbGaP-295464-361677 2 25457242 C T DNMT3A Missense p.R882H 
dbGaP-298112-361837 2 25457242 C T DNMT3A Missense p.R882H 
dbGaP-353698-437130 2 25457242 C T DNMT3A Missense p.R882H 
dbGaP-353485-437074 2 25459834 C A DNMT3A Nonsense p.E817* 
dbGaP-353587-436912 2 25457243 G A DNMT3A Missense p.R882C 
dbGaP-294968-360378 2 25457243 G A DNMT3A Missense p.R882C 
dbGaP-295037-360660 2 25457243 G A DNMT3A Missense p.R882C 
dbGaP-295149-361236 20 57428858 C T GNAS Nonsense p.Q180* 
dbGaP-295493-361708 20 57484421 G A GNAS Missense R202H 
dbGaP-294874-361374 9 5073770 G T JAK2 Missense p.V617F 
dbGaP-298062-361478 9 5073770 G T JAK2 Missense p.V617F 
dbGaP-295219-361137 9 5073770 G T JAK2 Missense p.V617F 
dbGap-390083-851772 2 198266834 T C SF3B1 Missense p.K700E 
dbGaP-297986-360566 2 198266834 T C SF3B1 Missense p.K700E 



























BRCA 88.6 +/- 4.4 75.7 +/- 2.6 71.7 +/- 2.9 68.6 +/- 3.7 65.7 +/- 4.7 96.8 +/- 44.3 
GBM 97.0 +/- 3.4 93.6 +/- 6.1 90.9 +/- 7.3 88.6 +/- 8.0 86.4 +/- 8.6 139.4 +/- 41.9 
HNSC 98.9 +/- 0.2 96.9 +/- 0.5 94.5 +/- 1.1 92.0 +/- 1.6 89.5 +/- 2.1 89.5 +/- 19.7 
KIRC 86.4 +/- 6.5 75.3 +/- 3.3 71.3 +/- 2.8 68.7 +/- 3.3 66.3 +/- 4.0 119.7 +/- 57.7 
LGG 98.9 +/- 0.2 96.9 +/- 0.6 94.4 +/- 1.2 92.0 +/- 1.9 89.5 +/- 2.5 99.9 +/- 24.9 
LUAD 79.1 +/- 2.2 73.6 +/- 0.8 70.9 +/- 1.2 68.4 +/- 1.7 66.0 +/- 2.2 77.9 +/- 21.1 
LUSC 78.7 +/- 1.3 73.8 +/- 0.6 71.2 +/- 1.1 68.8 +/- 1.5 66.6 +/- 2.0 80.5 +/- 26.4 
OV 95.3 +/- 3.6 89.0 +/- 6.7 85.3 +/- 7.0 82.5 +/- 7.3 79.9 +/- 7.8 150.2 +/- 70.0 
PRAD 79.8 +/- 2.9 74.2 +/- 0.8 71.8 +/- 1.0 69.7 +/- 1.4 67.7 +/- 1.8 95.1 +/- 25.0 
STAD 99.1 +/- 0.3 97.2 +/- 0.8 95.0 +/- 1.5 92.6 +/- 2.4 90.2 +/- 3.4 106.3 +/- 27.8 
UCEC 86.7 +/- 3.1 75.4 +/- 2.3 72.0 +/- 3.1 69.4 +/- 3.9 67.1 +/- 4.8 128.2 +/- 47.5 











Supplementary Figure 4.1: Read-depth of the 4 most recurrently mutated genes in the 
normal blood sample. Violin plot shows the distribution of read depth on each exon across all 




Supplementary Table 4.1: AML hotspot mutations in normal blood samples  
Chr Start End Reference Variant Gene Mutation Sample 
1 115256528 115256528 T A NRAS p.Q61H TCGA-A2-A04R 
1 115258744 115258744 C T NRAS p.G13D TCGA-F7-A622 
1 115258747 115258747 C T NRAS p.G12D TCGA-36-1581 
1 115258747 115258747 C T NRAS p.G12D TCGA-91-A4BD 
2 25457242 25457242 C T DNMT3A p.R882H TCGA-DK-A1AD 
2 25457242 25457242 C T DNMT3A p.R882H TCGA-81-5910 
2 25457242 25457242 C T DNMT3A p.R882H TCGA-21-5783 
2 25457242 25457242 C T DNMT3A p.R882H TCGA-AK-3425 
2 25457242 25457242 C T DNMT3A p.R882H TCGA-E9-A1RG 
2 25457242 25457242 C T DNMT3A p.R882H TCGA-27-2526 
2 25457242 25457242 C T DNMT3A p.R882H TCGA-E8-A44K 
2 25457242 25457242 C T DNMT3A p.R882H TCGA-BJ-A28S 
2 25457242 25457242 C T DNMT3A p.R882H TCGA-DJ-A2QB 
2 25457242 25457242 C T DNMT3A p.R882H TCGA-B1-A654 
2 25457242 25457242 C T DNMT3A p.R882H TCGA-SL-A6JA 
2 25457242 25457242 C T DNMT3A p.R882H TCGA-FS-A4FC 
2 25457242 25457242 C T DNMT3A p.R882H TCGA-D1-A17H 
2 25457242 25457242 C T DNMT3A p.R882H TCGA-FD-A6TK 
2 25457242 25457242 C T DNMT3A p.R882H TCGA-FG-7634 
2 25457242 25457242 C T DNMT3A p.R882H TCGA-24-2280 
2 25457242 25457242 C T DNMT3A p.R882H TCGA-DX-A6BB 
2 25457243 25457243 G A DNMT3A p.R882C TCGA-GF-A3OT 
2 25457243 25457243 G A DNMT3A p.R882C TCGA-BR-7197 
2 25457243 25457243 G A DNMT3A p.R882C TCGA-A2-A1G1 
2 25457243 25457243 G A DNMT3A p.R882C TCGA-BR-8081 
2 25457243 25457243 G A DNMT3A p.R882C TCGA-RP-A690 
2 25457243 25457243 G A DNMT3A p.R882C TCGA-85-7698 
2 25457243 25457243 G A DNMT3A p.R882C TCGA-B2-4098 
2 25457243 25457243 G A DNMT3A p.R882C TCGA-B5-A1MZ 
2 25457243 25457243 G A DNMT3A p.R882C TCGA-24-1469 
2 25457243 25457243 G A DNMT3A p.R882C TCGA-D5-6931 
2 25457243 25457243 G A DNMT3A p.R882C TCGA-EY-A1GS 
2 198266834 198266834 T C SF3B1 p.K700E TCGA-B0-5698 
2 198266834 198266834 T C SF3B1 p.K700E TCGA-41-2571 
2 198266834 198266834 T C SF3B1 p.K700E TCGA-AK-3447 
2 198266834 198266834 T C SF3B1 p.K700E TCGA-D1-A0ZS 
2 198266834 198266834 T C SF3B1 p.K700E TCGA-LL-A5YM 
2 198266834 198266834 T C SF3B1 p.K700E TCGA-EE-A29V 
9 5073770 5073770 G T JAK2 p.V617F TCGA-26-5135 
9 5073770 5073770 G T JAK2 p.V617F TCGA-EY-A1G8 
9 5073770 5073770 G T JAK2 p.V617F TCGA-DJ-A2Q2 
9 5073770 5073770 G T JAK2 p.V617F TCGA-05-4403 
9 5073770 5073770 G T JAK2 p.V617F TCGA-BK-A139 
9 5073770 5073770 G T JAK2 p.V617F TCGA-AP-A0LQ 
9 5073770 5073770 G T JAK2 p.V617F TCGA-BM-6198 
9 5073770 5073770 G T JAK2 p.V617F TCGA-B4-5834 
9 5073770 5073770 G T JAK2 p.V617F TCGA-99-8025 
9 5073770 5073770 G T JAK2 p.V617F TCGA-06-0240 
9 5073770 5073770 G T JAK2 p.V617F TCGA-A6-2686 
9 5073770 5073770 G T JAK2 p.V617F TCGA-TQ-A7RQ 
9 5073770 5073770 G T JAK2 p.V617F TCGA-HW-7495 
9 5073770 5073770 G T JAK2 p.V617F TCGA-24-1603 
9 5073770 5073770 G T JAK2 p.V617F TCGA-EJ-5521 
9 5073770 5073770 G T JAK2 p.V617F TCGA-06-2563 
[198] 
 
9 5073770 5073770 G T JAK2 p.V617F TCGA-CV-A6JD 
9 5073770 5073770 G T JAK2 p.V617F TCGA-J9-A8CP 
9 5073770 5073770 G T JAK2 p.V617F TCGA-AP-A0LD 
15 90631934 90631934 C T IDH2 p.R140Q TCGA-AU-3779 
15 90631934 90631934 C T IDH2 p.R140Q TCGA-D7-8574 
15 90631934 90631934 C T IDH2 p.R140Q TCGA-B5-A11L 
15 90631934 90631934 C T IDH2 p.R140Q TCGA-ER-A194 
15 90631934 90631934 C T IDH2 p.R140Q TCGA-23-1109 
15 90631934 90631934 C T IDH2 p.R140Q TCGA-B5-A3F9 
15 90631934 90631934 C T IDH2 p.R140Q TCGA-EE-A2ML 
15 90631934 90631934 C T IDH2 p.R140Q TCGA-09-2053 
15 90631934 90631934 C T IDH2 p.R140Q TCGA-A6-4105 
15 90631934 90631934 C T IDH2 p.R140Q TCGA-EE-A2MK 
15 90631934 90631934 C T IDH2 p.R140Q TCGA-IR-A3LA 
20 57484421 57484421 G A GNAS p.R202H TCGA-67-4679 
20 57484421 57484421 G A GNAS p.R202H TCGA-19-2625 
20 57484421 57484421 G A GNAS p.R202H TCGA-EY-A1GU 
20 57484421 57484421 G A GNAS p.R202H TCGA-D6-A4Z9 
20 57484421 57484421 G A GNAS p.R202H TCGA-HC-A6AN 





Supplementary Table 4.2: Blood-specific somatic mutation identified in cancer or AML-
associated genes 
Chr Start End Reference Alteration Gene Mutation Sample Gene Type 
1 12921594 12921594 C G PRAMEF2 p.S462* TCGA-13-1412 AML 
1 17256459 17256459 G A CROCC p.R157H TCGA-13-2065 AML 
1 17264170 17264170 G C CROCC p.E410Q TCGA-99-8025 AML 
1 17275365 17275365 G A CROCC p.R927Q TCGA-KM-8442 AML 
1 24384031 24384031 G T MYOM3 p.D1382E TCGA-85-A5B5 AML 
1 24389994 24389994 C T MYOM3 p.G1220S TCGA-24-0968 AML 
1 24409143 24409143 C T MYOM3 p.E679K TCGA-CI-6620 AML 
1 24417427 24417427 C T MYOM3 p.R432Q TCGA-C8-A278 AML 
1 33134591 33134591 A G RBBP4 p.I207V TCGA-BR-8686 AML 
1 33138072 33138072 G A RBBP4 p.E330K TCGA-37-4130 AML 
1 35250428 35250428 G A GJB3 p.R22H TCGA-95-7043 AML 
1 35250691 35250691 G A GJB3 p.G110R TCGA-AX-A2H7 AML 
1 36752630 36752630 C A THRAP3 p.P267T TCGA-62-8394 AML 
1 151263210 151263210 G A ZNF687 p.R1080H TCGA-86-6851 AML 
1 152281645 152281645 G T FLG p.S1906* TCGA-BR-A4J1 AML 
1 152281645 152281645 G T FLG p.S1906* TCGA-UY-A78M AML 
1 154938191 154938191 C T SHC1 p.R485Q TCGA-CI-6620 AML 
1 154938931 154938931 T G SHC1 p.Y349S TCGA-12-0773 AML 
1 181547003 181547003 C T CACNA1E p.P205L TCGA-EP-A2KB AML 
1 181700330 181700330 C T CACNA1E p.H754Y TCGA-BS-A0TC AML 
1 181731716 181731716 T C CACNA1E p.F1538L TCGA-AK-3428 AML 
1 185878613 185878613 C T HMCN1 p.P256S TCGA-CR-7370 AML 
1 185891583 185891583 C T HMCN1 p.R325* TCGA-CI-6620 AML 
1 185891589 185891589 C T HMCN1 p.P327S TCGA-12-1095 AML 
1 185934959 185934959 G C HMCN1 p.Q708H TCGA-05-4403 AML 
1 185963964 185963964 C G HMCN1 p.R1175G TCGA-29-1776 AML 
1 185969187 185969187 A C HMCN1 p.K1295N TCGA-AG-3598 AML 
1 186030998 186030998 G A HMCN1 p.R2443Q TCGA-04-1542 AML 
1 186055509 186055509 A T HMCN1 p.K3006* TCGA-86-8359 AML 
1 186062355 186062355 G A HMCN1 p.G3326E TCGA-GV-A3JW AML 
1 186107069 186107069 T C HMCN1 p.V4630A TCGA-C8-A1HJ AML 
1 186134259 186134259 G C HMCN1 p.Q5091H TCGA-97-8175 AML 
1 190068155 190068155 G T FAM5C p.Q432K TCGA-DD-A115 AML 
1 190129872 190129872 C G FAM5C p.Q370H TCGA-13-0717 AML 
1 190129876 190129876 G A FAM5C p.A369V TCGA-AG-3583 AML 
1 190129930 190129930 A T FAM5C p.F351Y TCGA-13-1408 AML 
1 190423789 190423789 A G FAM5C p.Y78H TCGA-IA-A40Y AML 
1 201772790 201772790 G T NAV1 p.S1196I TCGA-AG-3598 AML 
1 201781732 201781732 C G NAV1 p.L1722V TCGA-AF-2689 AML 
2 21227444 21227444 A T APOB p.Y3964* TCGA-AG-3584 AML 
2 21233706 21233706 G A APOB p.R2012* TCGA-D6-A6EM AML 
2 21249752 21249752 C T APOB p.A718T TCGA-36-1580 AML 
2 21249752 21249752 C T APOB p.A718T TCGA-AA-3561 AML 
2 21255274 21255274 T G APOB p.D435A TCGA-25-1317 AML 
2 54120852 54120852 C T PSME4 p.G1333R TCGA-13-0717 AML 
2 54120852 54120852 C T PSME4 p.G1333R TCGA-AA-3538 AML 
2 54120852 54120852 C T PSME4 p.G1333R TCGA-AA-3549 AML 
2 54125056 54125056 A G PSME4 p.I1186T TCGA-32-1970 AML 
2 54135476 54135476 T C PSME4 p.K922R TCGA-EL-A3GQ AML 
2 54150219 54150219 G T PSME4 p.H649N TCGA-AA-A01G AML 
2 54164535 54164535 C T PSME4 p.G230S TCGA-D8-A143 AML 
2 71742787 71742787 C T DYSF p.P264L TCGA-EK-A2PG AML 
2 71797819 71797819 G T DYSF p.R1072L TCGA-F7-A61W AML 
[200] 
 
2 71801350 71801350 G C DYSF p.G1097A TCGA-97-7546 AML 
2 71801350 71801350 G C DYSF p.G1097A TCGA-EM-A4FO AML 
2 71817373 71817373 T C DYSF p.Y1190H TCGA-AA-3514 AML 
2 71838638 71838638 C G DYSF p.A1381G TCGA-AA-A00R AML 
2 71839796 71839797 - C DYSF p.I1432fs TCGA-AA-3955 AML 
2 71894538 71894538 C T DYSF p.P1776S TCGA-36-1570 AML 
2 71906190 71906190 C T DYSF p.S1955F TCGA-29-1774 AML 
2 71906190 71906190 C T DYSF p.S1955F TCGA-CI-6620 AML 
2 166912980 166912980 A C SCN1A p.I138M TCGA-13-1408 AML 
2 166930064 166930064 G A SCN1A p.A23V TCGA-29-1702 AML 
2 210559124 210559124 G A MAP2 p.D744N TCGA-13-1497 AML 
2 210560193 210560193 A C MAP2 p.K1100T TCGA-AA-A00W AML 
2 210570439 210570439 C T MAP2 p.R1574W TCGA-CL-5917 AML 
2 220342509 220342509 T G SPEG NULL TCGA-A5-A0GB AML 
2 233613710 233613710 T C GIGYF2 p.L62P TCGA-AA-A00D AML 
2 233620934 233620934 G A GIGYF2 p.R90K TCGA-19-0955 AML 
2 233626138 233626138 A C GIGYF2 p.K175T TCGA-19-0955 AML 
3 48678907 48678907 C T CELSR3 p.E2964K TCGA-CI-6620 AML 
3 48683549 48683549 G C CELSR3 p.I2484M TCGA-AK-3461 AML 
3 49694232 49694232 G A BSN p.E2415K TCGA-D5-6540 AML 
3 49698124 49698124 G A BSN p.R2949Q TCGA-GC-A3I6 AML 
3 54913412 54913412 T A CACNA2D3 p.Y606* TCGA-06-6694 AML 
3 62484842 62484842 C T CADPS p.A901T TCGA-56-7223 AML 
3 62518612 62518612 G A CADPS p.A742V TCGA-25-1625 AML 
3 62522124 62522124 C A CADPS p.C700F TCGA-09-1667 AML 
3 62522128 62522128 A T CADPS p.S699T TCGA-23-1109 AML 
3 62522128 62522128 A T CADPS p.S699T TCGA-36-1570 AML 
3 62636542 62636542 C T CADPS p.V395M TCGA-EY-A1GR AML 
3 71026813 71026813 T C FOXP1 p.Y472C TCGA-CV-7437 AML 
3 85851258 85851258 T G CADM2 p.I43M TCGA-AG-3605 AML 
3 86010627 86010627 C A CADM2 p.P260H TCGA-24-2030 AML 
3 86010704 86010704 C A CADM2 p.L286I TCGA-AA-3846 AML 
3 121725954 121725954 A G ILDR1 p.F38S TCGA-AA-3514 AML 
3 121725954 121725954 A G ILDR1 p.F38S TCGA-AA-A00K AML 
3 123010193 123010193 G T ADCY5 p.L690M TCGA-X6-A7WB AML 
3 123014956 123014956 C T ADCY5 p.R671H TCGA-D5-6538 AML 
3 164716417 164716417 C T SI p.R1484H TCGA-DX-A7EF AML 
3 185644503 185644503 C T TRA2B p.R19K TCGA-CI-6620 AML 
4 36115858 36115858 T A ARAP2 p.K1364* TCGA-24-1548 AML 
4 36148928 36148928 C G ARAP2 p.E1085Q TCGA-AG-3608 AML 
4 36150079 36150079 A G ARAP2 p.F983S TCGA-14-0783 AML 
4 48523085 48523085 C T FRYL p.A2557T TCGA-ER-A19H AML 
4 48621344 48621344 C T FRYL p.D120N TCGA-85-8355 AML 
4 48636332 48636332 A C FRYL p.I32M TCGA-13-0761 AML 
4 89013415 89013415 T G ABCG2 p.K647Q TCGA-AA-3534 AML 
4 89022391 89022391 T C ABCG2 p.K453R TCGA-AG-A016 AML 
4 114117617 114117617 A T ANK2 p.T94S TCGA-AG-3578 AML 
4 114195805 114195805 G T ANK2 p.K561N TCGA-AK-3434 AML 
4 114203861 114203861 A G ANK2 p.K638E TCGA-13-1408 AML 
4 151203760 151203760 A C LRBA p.L2731V TCGA-AA-A00W AML 
4 151231390 151231390 T C LRBA p.T2625A TCGA-61-1998 AML 
4 151236754 151236754 T G LRBA p.D2551A TCGA-B5-A0K1 AML 
4 151520191 151520191 G A LRBA p.P2005L TCGA-AX-A062 AML 
4 151749573 151749573 G C LRBA p.L1644V TCGA-LI-A67I AML 
4 151850215 151850215 C A LRBA p.L73F TCGA-AK-3428 AML 
4 155156529 155156529 C G DCHS2 p.S2637T TCGA-AA-A00J AML 
4 155157548 155157548 A C DCHS2 p.F2297L TCGA-B2-4101 AML 
4 155241767 155241767 T C DCHS2 p.N1140S TCGA-16-1055 AML 
[201] 
 
4 155241767 155241767 T C DCHS2 p.N1140S TCGA-AG-A016 AML 
5 13721312 13721312 C T DNAH5 p.E4026K TCGA-CI-6620 AML 
5 13727662 13727662 C T DNAH5 p.R3996H TCGA-DM-A1D6 AML 
5 13776574 13776574 C T DNAH5 p.R3116Q TCGA-CI-6620 AML 
5 13814934 13814934 A C DNAH5 p.L2337R TCGA-A8-A094 AML 
5 13820505 13820505 C T DNAH5 p.S2264N TCGA-B2-4101 AML 
5 13820573 13820573 C A DNAH5 p.W2241C TCGA-62-8394 AML 
5 13870998 13870998 C T DNAH5 p.E1238K TCGA-CI-6620 AML 
5 13928265 13928265 A C DNAH5 p.F72C TCGA-25-1324 AML 
5 71493821 71493821 G T MAP1B p.E1547* TCGA-04-1364 AML 
5 79031579 79031579 G A CMYA5 p.E2331K TCGA-B5-A0JN AML 
5 83476279 83476279 C T EDIL3 p.R96Q TCGA-CI-6620 AML 
5 137722143 137722144 - T KDM3B p.E405fs TCGA-AX-A06F AML 
5 137727689 137727689 C T KDM3B p.P790S TCGA-CI-6620 AML 
5 140263648 140263648 G A PCDHA13 p.A599T TCGA-A8-A06Y AML 
5 149786745 149786745 G T CD74 p.L90M TCGA-DX-A6YT AML 
5 151775137 151775137 C T NMUR2 p.V274I TCGA-AQ-A54N AML 
5 160029624 160029624 C T ATP10B p.R1108H TCGA-13-0761 AML 
5 169116314 169116314 A G DOCK2 p.N274D TCGA-AA-3514 AML 
5 169125401 169125401 A G DOCK2 p.K335E TCGA-AA-A00W AML 
5 169507174 169507174 G T DOCK2 p.R1217M TCGA-AK-3461 AML 
5 172750262 172750262 T A STC2 p.I156L TCGA-AG-3598 AML 
5 172750273 172750273 T C STC2 p.N152S TCGA-24-1105 AML 
6 12125879 12125879 A G HIVEP1 p.K1951E TCGA-DU-7309 AML 
6 12719019 12719019 G A PHACTR1 p.A15T TCGA-13-0725 AML 
6 13287299 13287299 C T PHACTR1 p.H142Y TCGA-CI-6620 AML 
6 30884672 30884672 G C VARS2 p.C260S TCGA-AG-A016 AML 
6 33633644 33633644 T G ITPR3 p.F481C TCGA-AA-3514 AML 
6 33639851 33639851 C G ITPR3 p.S925C TCGA-AK-3428 AML 
6 33655931 33655931 C T ITPR3 p.T2121M TCGA-GV-A3JX AML 
6 42819837 42819837 A G KIAA0240 p.K616R TCGA-13-1408 AML 
6 43221065 43221065 G A TTBK1 p.R47K TCGA-A6-2681 AML 
6 56335969 56335969 C T DST p.R7388K TCGA-B5-A3F9 AML 
6 56391358 56391358 T G DST p.K5946T TCGA-13-0801 AML 
6 56417676 56417676 T G DST p.Q5274P TCGA-AK-3460 AML 
6 56425105 56425105 C G DST p.M4778I TCGA-EB-A42Y AML 
6 56473368 56473368 T G DST p.T1987P TCGA-B2-4101 AML 
6 56480676 56480676 G T DST p.P2530H TCGA-AA-3534 AML 
6 56481996 56481996 T C DST p.Q2090R TCGA-09-1666 AML 
6 56482951 56482951 G C DST p.Q1961E TCGA-26-1440 AML 
6 56489323 56489323 A - DST p.I1108fs TCGA-97-7938 AML 
6 56492043 56492043 C T DST p.E1024K TCGA-CI-6620 AML 
6 56496073 56496073 C A DST p.E823* TCGA-AX-A063 AML 
6 56499010 56499010 G A DST p.H644Y TCGA-86-8281 AML 
6 56505044 56505044 C T DST p.R259Q TCGA-KV-A6GD AML 
6 56707877 56707877 C T DST p.E23K TCGA-CI-6620 AML 
6 72957796 72957796 A G RIMS1 p.K736R TCGA-B2-4101 AML 
6 72960057 72960057 G A RIMS1 p.G756R TCGA-EJ-5531 AML 
6 73100438 73100438 A G RIMS1 p.N1351S TCGA-24-1105 AML 
6 75839883 75839883 C T COL12A1 p.W2045* TCGA-41-2571 AML 
6 75899528 75899528 C T COL12A1 p.C133Y TCGA-68-8251 AML 
6 79655838 79655838 C T PHIP p.V1504I TCGA-AA-A00R AML 
6 79688334 79688334 G A PHIP p.P955L TCGA-AA-3514 AML 
6 79697925 79697925 C T PHIP e21+1 TCGA-06-0188 AML 
6 79711697 79711697 A G PHIP p.S600P TCGA-A6-2676 AML 
6 79711697 79711697 A G PHIP p.S600P TCGA-AG-3609 AML 
6 79711697 79711697 A G PHIP p.S600P TCGA-AK-3428 AML 
6 79711781 79711781 A T PHIP p.F572I TCGA-AA-3529 AML 
[202] 
 
6 79725417 79725417 A G PHIP p.I440T TCGA-B2-4101 AML 
6 79735858 79735858 T G PHIP p.K208N TCGA-13-1408 AML 
6 79787752 79787752 G A PHIP p.R12* TCGA-CR-7379 AML 
6 102307352 102307352 G A GRIK2 p.R503H TCGA-06-0142 AML 
6 155126538 155126538 T G SCAF8 p.F366C TCGA-AA-3534 AML 
6 155145471 155145471 C T SCAF8 p.P743L TCGA-19-0962 AML 
7 34086018 34086018 G T BMPER e7+1 TCGA-86-8359 AML 
7 34125436 34125436 C A BMPER p.L493I TCGA-DY-A1DD AML 
7 34192817 34192817 C T BMPER p.H664Y TCGA-06-2565 AML 
7 43540317 43540317 C T HECW1 p.R1153W TCGA-HI-7170 AML 
7 77649126 77649126 G A MAGI2 p.H1292Y TCGA-FJ-A3ZF AML 
7 77830478 77830478 C A MAGI2 e11+1 TCGA-AA-A01F AML 
7 83606460 83606460 C G SEMA3A p.D569H TCGA-13-0792 AML 
7 83634817 83634817 T C SEMA3A p.I400V TCGA-E2-A574 AML 
7 83739800 83739800 C T SEMA3A p.G147R TCGA-AK-3433 AML 
7 113517786 113517786 T C PPP1R3A p.K1121E TCGA-12-1098 AML 
7 113558612 113558612 C T PPP1R3A p.R147Q TCGA-CG-5717 AML 
7 126086275 126086275 G T GRM8 p.T861K TCGA-25-1625 AML 
7 126249534 126249534 A T GRM8 p.V459D TCGA-CH-5750 AML 
7 126882877 126882877 C G GRM8 p.A128P TCGA-K4-A4AC AML 
7 150643964 150643964 C T KCNH2 e14+1 TCGA-AK-3447 AML 
7 150647322 150647322 C T KCNH2 p.A778T TCGA-F5-6810 AML 
7 150647343 150647343 G A KCNH2 p.H771Y TCGA-AX-A05T AML 
7 151842344 151842344 G A MLL3 p.R4747* TCGA-CD-A48A AML 
7 151851121 151851121 T G MLL3 p.I4141L TCGA-13-0765 AML 
7 151856102 151856102 T C MLL3 p.K3839R TCGA-25-1324 AML 
7 151873387 151873387 G C MLL3 p.Q3051E TCGA-A6-2676 AML 
7 151873410 151873410 T G MLL3 p.E3043A TCGA-AA-A00K AML 
7 151873423 151873423 G C MLL3 p.Q3039E TCGA-AA-A00K AML 
7 151921520 151921520 C A MLL3 p.W1053L TCGA-EE-A2MH AML 
7 151927049 151927049 G A MLL3 p.Q979* TCGA-AR-A24V AML 
7 151927058 151927058 C T MLL3 p.A976T TCGA-06-0157 AML 
7 151945038 151945038 T A MLL3 p.K827N TCGA-F4-6459 AML 
7 151962135 151962135 C T MLL3 p.C391Y TCGA-EY-A4KR AML 
7 151962265 151962265 C T MLL3 p.D348N TCGA-BR-6801 AML 
7 151962265 151962265 C T MLL3 p.D348N TCGA-ER-A194 AML 
8 3165912 3165912 C T CSMD1 p.A1250T TCGA-13-0793 AML 
8 75898242 75898242 A C CRISPLD1 p.E7A TCGA-23-1024 AML 
8 110457104 110457104 G A PKHD1L1 p.G1669E TCGA-BR-A4QL AML 
8 110457292 110457292 C T PKHD1L1 p.P1732S TCGA-86-8280 AML 
8 110477081 110477081 G A PKHD1L1 p.V2674M TCGA-B6-A408 AML 
8 110477426 110477426 C T PKHD1L1 p.R2789C TCGA-CI-6620 AML 
8 110523026 110523026 T G PKHD1L1 p.C3806G TCGA-AP-A05H AML 
8 113259329 113259329 T G CSMD3 p.K3381T TCGA-13-0889 AML 
8 113275940 113275940 C T CSMD3 p.E3264K TCGA-06-6698 AML 
8 113293406 113293406 T C CSMD3 p.T3169A TCGA-D5-5538 AML 
8 113299440 113299440 G A CSMD3 p.P3062S TCGA-DQ-7596 AML 
8 113349873 113349873 G C CSMD3 p.S2247* TCGA-AG-3598 AML 
8 113364731 113364731 T C CSMD3 p.T2057A TCGA-AA-A00J AML 
8 113516069 113516069 A G CSMD3 p.F1678S TCGA-16-1055 AML 
8 113529278 113529278 G T CSMD3 p.P1581T TCGA-FD-A6TC AML 
8 113562996 113562996 T G CSMD3 p.I1490L TCGA-24-1105 AML 
8 113697710 113697710 T C CSMD3 p.N803D TCGA-24-1548 AML 
8 113841948 113841948 C T CSMD3 p.G609D TCGA-CR-5247 AML 
8 113960037 113960037 C A CSMD3 p.R497I TCGA-BK-A4ZD AML 
8 114326942 114326942 T A CSMD3 p.N87Y TCGA-AA-A00W AML 
9 34485158 34485158 G A DNAI1 p.E34K TCGA-30-1853 AML 
9 73151464 73151464 A C TRPM3 p.F1537C TCGA-25-1324 AML 
[203] 
 
9 73442787 73442787 T C TRPM3 p.I164V TCGA-A4-7584 AML 
9 86589485 86589485 C G HNRNPK p.D93H TCGA-25-1627 AML 
9 117803337 117803337 C T TNC p.G1759R TCGA-CL-5917 AML 
9 117825447 117825447 T G TNC p.N1261T TCGA-AG-A016 AML 
9 117848674 117848674 G C TNC p.R446G TCGA-36-1577 AML 
9 123797174 123797174 T C C5 e5-2 TCGA-AA-A00W AML 
9 138667190 138667190 A G KCNT1 p.I719V TCGA-AA-A00K AML 
9 138667233 138667233 C T KCNT1 p.A733V TCGA-MF-A522 AML 
9 138683984 138683984 A G KCNT1 p.T1209A TCGA-K4-A4AB AML 
9 140772671 140772671 T C CACNA1B e1+1 TCGA-PJ-A5Z8 AML 
9 140773504 140773504 A C CACNA1B e2-1 TCGA-E2-A158 AML 
9 140880870 140880870 G T CACNA1B p.W593L TCGA-23-1120 AML 
9 140952560 140952560 G A CACNA1B p.R1390H TCGA-FS-A1ZC AML 
9 141010071 141010071 G A CACNA1B p.R1907Q TCGA-24-1845 AML 
9 141016381 141016381 C T CACNA1B p.T2318I TCGA-E1-A7YI AML 
10 46965806 46965806 A C SYT15 p.L297R TCGA-FS-A4FD AML 
10 73044507 73044507 T C UNC5B p.V112A TCGA-AA-3514 AML 
11 1261446 1261446 C T MUC5B p.Q1274* TCGA-QH-A6CX AML 
11 11400736 11400736 C T GALNTL4 p.R224H TCGA-62-8394 AML 
11 19258879 19258879 C T E2F8 p.E145K TCGA-CI-6620 AML 
11 30032436 30032436 A G KCNA4 p.F597S TCGA-23-1028 AML 
11 30033309 30033309 G A KCNA4 p.A306V TCGA-A4-A48D AML 
11 30034149 30034149 C T KCNA4 p.R26Q TCGA-FG-7637 AML 
11 85977208 85977208 G T EED p.M270I TCGA-AG-A016 AML 
11 100221518 100221518 G C CNTN5 p.G1039A TCGA-50-8460 AML 
11 102984369 102984369 T C DYNC2H1 p.M100T TCGA-IR-A3LA AML 
11 102987372 102987372 A G DYNC2H1 p.D232G TCGA-AK-3460 AML 
11 103026079 103026079 A G DYNC2H1 p.K1198R TCGA-13-0802 AML 
11 103026079 103026079 A G DYNC2H1 p.K1198R TCGA-13-1408 AML 
11 103026079 103026079 A G DYNC2H1 p.K1198R TCGA-24-1604 AML 
11 103091352 103091352 C G DYNC2H1 p.P2983A TCGA-95-7567 AML 
11 103124071 103124071 G A DYNC2H1 p.R3374H TCGA-CF-A3MH AML 
11 113281549 113281549 A C DRD2 p.F413C TCGA-24-1548 AML 
11 120833197 120833197 G T GRIK4 p.W691C TCGA-AG-A016 AML 
11 120833341 120833341 G C GRIK4 p.Q739H TCGA-B2-4101 AML 
12 118298112 118298112 C T KSR2 p.R102H TCGA-CH-5753 AML 
12 125284776 125284776 A G SCARB1 p.F287S TCGA-AA-3514 AML 
13 29933477 29933477 G T MTUS2 p.R1005L TCGA-86-8359 AML 
13 30003025 30003025 G A MTUS2 p.D16N TCGA-EY-A3L3 AML 
13 36428682 36428682 G A DCLK1 p.S330L TCGA-36-2547 AML 
13 36700129 36700129 G A DCLK1 p.T49M TCGA-D1-A17H AML 
13 39261852 39261852 C T FREM2 p.P124L TCGA-AK-3444 AML 
13 39263661 39263661 G A FREM2 p.R727H TCGA-G2-A3VY AML 
13 39264192 39264192 A G FREM2 p.H904R TCGA-AA-A00R AML 
13 39450473 39450473 A G FREM2 p.N2833S TCGA-A6-6782 AML 
13 39452990 39452990 A - FREM2 p.A2962fs TCGA-A2-A04U AML 
13 39454448 39454448 C T FREM2 p.H3012Y TCGA-AA-3514 AML 
13 101714442 101714442 G A NALCN p.R1545W TCGA-BF-A3DL AML 
13 101721047 101721047 C A NALCN p.A1444S TCGA-EE-A2MK AML 
13 101728228 101728228 T G NALCN p.K1317T TCGA-13-0761 AML 
13 101735528 101735528 T C NALCN p.K1202R TCGA-B2-4101 AML 
13 101944681 101944681 T G NALCN p.Q279P TCGA-AG-3598 AML 
13 102047560 102047560 T A NALCN p.K89* TCGA-19-1392 AML 
13 102051404 102051404 G A NALCN p.S25L TCGA-DJ-A2Q2 AML 
13 114498193 114498193 T C FAM70B p.F109L TCGA-AA-A00K AML 
13 114530118 114530118 C T GAS6 p.G486D TCGA-16-1055 AML 
14 68040028 68040028 G A PLEKHH1 p.M588I TCGA-24-2019 AML 
14 79432521 79432521 A C NRXN3 p.K839T TCGA-13-1408 AML 
[204] 
 
14 86089561 86089561 A C FLRT2 p.K568T TCGA-AF-3400 AML 
14 90650986 90650986 G T KCNK13 p.W289L TCGA-AJ-A3TW AML 
15 33925206 33925206 T C RYR3 p.L975P TCGA-AP-A051 AML 
15 33952554 33952554 C T RYR3 p.R1518C TCGA-B6-A0IM AML 
15 34016358 34016358 G A RYR3 p.R2298H TCGA-04-1530 AML 
15 34042369 34042369 G A RYR3 p.G2761S TCGA-A5-A0GA AML 
15 34135707 34135707 T G RYR3 p.F4410V TCGA-13-0802 AML 
15 85382266 85382266 C A ALPK3 p.Y322* TCGA-09-1662 AML 
15 85382266 85382266 C A ALPK3 p.Y322* TCGA-AG-3598 AML 
15 86259127 86259127 A G AKAP13 p.K1907R TCGA-AA-A00R AML 
15 86266458 86266458 A G AKAP13 p.S2222G TCGA-AR-A2LK AML 
15 86270642 86270642 T G AKAP13 p.S2349R TCGA-AA-3538 AML 
16 18849461 18849461 C T SMG1 p.E2430K TCGA-CI-6620 AML 
16 18866161 18866161 T C SMG1 p.K1434E TCGA-13-0802 AML 
16 18866161 18866161 T C SMG1 p.K1434E TCGA-13-1407 AML 
16 56947306 56947306 T A SLC12A3 p.Y1028N TCGA-AG-A016 AML 
16 67575671 67575671 G T FAM65A p.E376* TCGA-CN-5367 AML 
16 67579728 67579728 C T FAM65A p.R1138W TCGA-24-1469 AML 
16 70935052 70935052 C T HYDIN p.W2968* TCGA-DU-8161 AML 
16 71101200 71101200 T C HYDIN p.T690A TCGA-C8-A1HF AML 
16 88653039 88653039 A T ZC3H18 p.D212V TCGA-AA-3514 AML 
16 88653062 88653062 C T ZC3H18 p.P220S TCGA-B2-4101 AML 
16 88677735 88677735 G C ZC3H18 p.E422D TCGA-F5-6465 AML 
16 88690371 88690371 G A ZC3H18 p.R600Q TCGA-C8-A27A AML 
17 1562014 1562014 G A PRPF8 p.Q1728* TCGA-25-1324 AML 
17 1563288 1563288 T G PRPF8 p.D1598A TCGA-06-2563 AML 
17 1565026 1565026 C T PRPF8 p.E1361K TCGA-CI-6620 AML 
17 10346811 10346811 G A MYH4 p.R1901C TCGA-S9-A6WO AML 
17 10351240 10351240 C A MYH4 p.K1620N TCGA-14-3477 AML 
17 10351424 10351424 T C MYH4 p.E1559G TCGA-EY-A1GJ AML 
17 10354132 10354132 T C MYH4 p.I1316V TCGA-BB-7870 AML 
17 10354748 10354748 G A MYH4 p.R1254C TCGA-29-1703 AML 
17 10355280 10355280 A G MYH4 p.M1239T TCGA-AF-2689 AML 
17 10357189 10357189 A G MYH4 p.L902S TCGA-A6-6652 AML 
17 10358009 10358009 C G MYH4 p.E852Q TCGA-55-8094 AML 
17 10358324 10358324 G A MYH4 p.T790M TCGA-23-1032 AML 
17 10358358 10358358 C T MYH4 p.E779K TCGA-MP-A5C7 AML 
17 10358529 10358529 A G MYH4 p.I753T TCGA-S9-A7QX AML 
17 10366661 10366661 C - MYH4 p.E267fs TCGA-29-1703 AML 
17 10366663 10366663 A T MYH4 p.I266N TCGA-29-1703 AML 
17 10370010 10370010 C T MYH4 p.R18Q TCGA-CI-6620 AML 
17 11573101 11573101 G A DNAH9 p.V1115I TCGA-50-5946 AML 
17 11583084 11583084 C A DNAH9 p.L1122M TCGA-A6-2676 AML 
17 11593492 11593492 T A DNAH9 p.Y1451* TCGA-16-1055 AML 
17 11597310 11597310 G C DNAH9 p.Q1580H TCGA-CS-4942 AML 
17 11603144 11603144 T C DNAH9 p.Y1657H TCGA-13-0901 AML 
17 11642317 11642317 C T DNAH9 p.R1979C TCGA-ER-A3ET AML 
17 11650904 11650904 G A DNAH9 p.R2144Q TCGA-HU-8243 AML 
17 11687618 11687618 G A DNAH9 p.R2608H TCGA-R8-A6YH AML 
17 11711062 11711062 C T DNAH9 p.R2812C TCGA-EJ-7794 AML 
17 11711083 11711083 G T DNAH9 p.G2819* TCGA-AA-A00Q AML 
17 11784633 11784633 C T DNAH9 p.A3570V TCGA-76-6283 AML 
17 11786984 11786984 G T DNAH9 p.A3630S TCGA-JV-A5VF AML 
17 11790227 11790227 A G DNAH9 p.Y3686C TCGA-06-0238 AML 
17 11790227 11790227 A G DNAH9 p.Y3686C TCGA-DU-7015 AML 
17 11835380 11835380 T C DNAH9 p.F4052S TCGA-AK-3461 AML 
17 11837316 11837316 G A DNAH9 p.M4139I TCGA-FD-A5BZ AML 
17 11865389 11865389 T C DNAH9 p.F4350S TCGA-AP-A3K1 AML 
[205] 
 
17 39680397 39680397 T C KRT19 p.M316V TCGA-AO-A0JL AML 
17 48646625 48646625 T G CACNA1G p.W152G TCGA-13-0906 AML 
17 48699055 48699055 C A CACNA1G p.T1987K TCGA-23-1031 AML 
17 51901154 51901154 G T KIF2B p.D254Y TCGA-06-2569 AML 
17 72786363 72786363 A G TMEM104 p.T105A TCGA-A5-A1OG AML 
17 72832629 72832629 G A TMEM104 p.G432S TCGA-AQ-A54N AML 
17 78310077 78310077 C A RNF213 p.L1476I TCGA-AK-3428 AML 
18 47365663 47365663 C T MYO5B p.G138D TCGA-GU-A42P AML 
18 47389641 47389641 C A MYO5B p.Q1300H TCGA-62-8394 AML 
19 8962375 8962375 C A MUC16 p.E14442* TCGA-A2-A25F AML 
19 10071461 10071461 T A COL5A3 p.N1653Y TCGA-AA-A00R AML 
19 10108812 10108812 T C COL5A3 p.K375R TCGA-25-1632 AML 
19 13054627 13054628 - TTGTC CALR p.K29fs TCGA-AN-A0XR AML 
19 38935242 38935242 G A RYR1 p.G186R TCGA-D7-A6F2 AML 
19 38943518 38943518 T G RYR1 p.L435R TCGA-AA-A00K AML 
19 38957009 38957009 A G RYR1 p.Y1050C TCGA-AG-3609 AML 
19 38997019 38997019 T G RYR1 e55+2 TCGA-A8-A08O AML 
19 39001379 39001379 G C RYR1 p.S3027T TCGA-25-1634 AML 
19 39008281 39008281 T C RYR1 p.I3323T TCGA-AG-A016 AML 
19 40367854 40367854 C T FCGBP p.C4369Y TCGA-B5-A11L AML 
19 40411637 40411637 C T FCGBP e7+1 TCGA-24-1552 AML 
19 42840990 42840990 T C MEGF8 p.F426L TCGA-25-1317 AML 
19 42854495 42854495 C T MEGF8 p.P899S TCGA-25-1317 AML 
20 31388652 31388652 G A DNMT3B p.W639* TCGA-16-1055 AML 
20 40709527 40709527 A C PTPRT p.S1462A TCGA-A2-A04T AML 
20 40944473 40944473 G T PTPRT p.Q677K TCGA-FD-A3SN AML 
20 41100967 41100967 C A PTPRT p.L463F TCGA-29-1774 AML 
20 41408885 41408885 C T PTPRT p.E181K TCGA-CI-6620 AML 
21 41452078 41452078 C T DSCAM e25+1 TCGA-19-1388 AML 
21 41516603 41516603 C T DSCAM p.R1025Q TCGA-CI-6620 AML 
21 41725552 41725552 C T DSCAM p.W258* TCGA-AX-A06J AML 
X 34148760 34148760 C A FAM47A p.E546* TCGA-AA-3864 AML 
X 63445321 63445321 C A MTMR8 p.W445C TCGA-13-1407 AML 
X 63555969 63555969 A G MTMR8 p.F381L TCGA-25-1321 AML 
X 119388243 119388243 A T ZBTB33 p.K325* TCGA-DJ-A1QH AML 
X 119388836 119388836 T G ZBTB33 p.Y522* TCGA-M7-A721 AML 
X 135482269 135482269 G A GPR112 p.G2857S TCGA-D1-A0ZZ AML 
X 152811567 152811567 T C ATP2B3 p.M313T TCGA-FW-A3I3 AML 
X 152814194 152814194 C T ATP2B3 p.T407M TCGA-DE-A4MC AML 
X 152825260 152825260 C G ATP2B3 p.A900G TCGA-36-1577 AML 
X 152830557 152830557 C T ATP2B3 p.T1113M TCGA-A6-2684 AML 
1 16203071 16203071 G A SPEN p.S260N TCGA-CD-5804 Cancer/AML 
1 16256414 16256414 A G SPEN p.K1227E TCGA-13-0717 Cancer/AML 
1 162731130 162731130 C A DDR2 p.P329T TCGA-AG-A016 Cancer/AML 
2 25457176 25457176 G A DNMT3A p.P904L TCGA-MH-A561 Cancer/AML 
2 25457176 25457176 G A DNMT3A p.P904L TCGA-VP-A879 Cancer/AML 
2 25457192 25457192 G A DNMT3A p.R899C TCGA-06-6694 Cancer/AML 
2 25457231 25457231 G A DNMT3A p.Q886* TCGA-G3-A5SL Cancer/AML 
2 25457243 25457243 G A DNMT3A p.R882C TCGA-06-0142 Cancer/AML 
2 25457243 25457243 G A DNMT3A p.R882C TCGA-D1-A179 Cancer/AML 
2 25457243 25457243 G A DNMT3A p.R882C TCGA-D7-A4Z0 Cancer/AML 
2 25457243 25457243 G A DNMT3A p.R882C TCGA-EO-A3KX Cancer/AML 
2 25457243 25457243 G A DNMT3A p.R882C TCGA-G9-6339 Cancer/AML 
2 25457290 25457290 C A DNMT3A e22-1 TCGA-AX-A060 Cancer/AML 
2 25457290 25457290 C A DNMT3A e22-1 TCGA-DA-A1I8 Cancer/AML 
2 25457291 25457291 T C DNMT3A e22-2 TCGA-EL-A3CR Cancer/AML 
2 25458648 25458648 T C DNMT3A p.Q842R TCGA-E7-A519 Cancer/AML 
2 25458696 25458696 T C DNMT3A e21-2 TCGA-12-3649 Cancer/AML 
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2 25462006 25462006 T C DNMT3A p.M801V TCGA-E5-A4TZ Cancer/AML 
2 25462006 25462006 T G DNMT3A p.M801L TCGA-78-7158 Cancer/AML 
2 25462068 25462068 A G DNMT3A p.I780T TCGA-CM-6171 Cancer/AML 
2 25462068 25462068 A G DNMT3A p.I780T TCGA-NH-A50T Cancer/AML 
2 25462085 25462085 C T DNMT3A e19-1 TCGA-A7-A3RF Cancer/AML 
2 25463184 25463184 G T DNMT3A p.S770* TCGA-BR-A4QL Cancer/AML 
2 25463232 25463232 A C DNMT3A p.L754R TCGA-B2-3924 Cancer/AML 
2 25463234 25463234 C T DNMT3A p.W753* TCGA-EM-A2OV Cancer/AML 
2 25463235 25463235 C G DNMT3A p.W753S TCGA-CG-4441 Cancer/AML 
2 25463242 25463242 A T DNMT3A p.F751I TCGA-K4-A5RI Cancer/AML 
2 25463247 25463247 C A DNMT3A p.R749L TCGA-55-6712 Cancer/AML 
2 25463265 25463265 G C DNMT3A p.P743R TCGA-QK-A6VB Cancer/AML 
2 25463266 25463266 G A DNMT3A p.P743S TCGA-DX-A3LT Cancer/AML 
2 25463280 25463280 A T DNMT3A p.L738Q TCGA-HW-A5KL Cancer/AML 
2 25463283 25463283 A C DNMT3A p.L737R TCGA-CV-A45X Cancer/AML 
2 25463287 25463287 G A DNMT3A p.R736C TCGA-C5-A1BE Cancer/AML 
2 25463289 25463289 T C DNMT3A p.Y735C TCGA-EJ-A65F Cancer/AML 
2 25463308 25463308 G A DNMT3A p.R729W TCGA-CN-A6V6 Cancer/AML 
2 25463321 25463321 T C DNMT3A e18-2 TCGA-85-A5B5 Cancer/AML 
2 25463541 25463541 G C DNMT3A p.S714C TCGA-VN-A88Q Cancer/AML 
2 25464439 25464439 G A DNMT3A p.Q692* TCGA-BF-A3DN Cancer/AML 
2 25464460 25464460 C T DNMT3A p.G685R TCGA-B5-A0JX Cancer/AML 
2 25464460 25464460 C T DNMT3A p.G685R TCGA-G9-6367 Cancer/AML 
2 25464490 25464490 C T DNMT3A p.V675M TCGA-20-0996 Cancer/AML 
2 25464534 25464534 T C DNMT3A p.Y660C TCGA-85-7844 Cancer/AML 
2 25464537 25464537 C T DNMT3A p.R659H TCGA-26-5139 Cancer/AML 
2 25466796 25466796 A C DNMT3A p.V636G TCGA-E9-A1QZ Cancer/AML 
2 25466797 25466797 C A DNMT3A p.V636L TCGA-EK-A2PG Cancer/AML 
2 25467125 25467125 A - DNMT3A p.Y584fs TCGA-06-2558 Cancer/AML 
2 25467145 25467145 T - DNMT3A p.K577fs TCGA-CR-7370 Cancer/AML 
2 25467199 25467199 C T DNMT3A p.C559Y TCGA-DM-A28G Cancer/AML 
2 25467408 25467408 C A DNMT3A e13+1 TCGA-55-7815 Cancer/AML 
2 25467408 25467408 C T DNMT3A e13+1 TCGA-S9-A6WP Cancer/AML 
2 25467475 25467475 T G DNMT3A p.Q534P TCGA-X6-A7WD Cancer/AML 
2 25467519 25467519 G - DNMT3A p.C520fs TCGA-CV-7248 Cancer/AML 
2 25468129 25468129 T - DNMT3A p.N516fs TCGA-46-6025 Cancer/AML 
2 25468202 25468202 C G DNMT3A e12-1 TCGA-G9-6356 Cancer/AML 
2 25469053 25469053 C A DNMT3A p.E469* TCGA-06-2563 Cancer/AML 
2 25469083 25469083 T A DNMT3A p.K459* TCGA-HW-A5KJ Cancer/AML 
2 25469633 25469633 G A DNMT3A p.R379C TCGA-23-2643 Cancer/AML 
2 25469646 25469646 C A DNMT3A e9-1 TCGA-85-A4JB Cancer/AML 
2 25469924 25469924 A C DNMT3A p.L373R TCGA-53-A4EZ Cancer/AML 
2 25470464 25470464 G A DNMT3A p.S337L TCGA-06-0126 Cancer/AML 
2 25470464 25470464 G C DNMT3A p.S337* TCGA-AC-A3W6 Cancer/AML 
2 25470480 25470480 C T DNMT3A p.G332R TCGA-62-A46U Cancer/AML 
2 25470480 25470480 C T DNMT3A p.G332R TCGA-A5-A0GB Cancer/AML 
2 25470498 25470498 G A DNMT3A p.R326C TCGA-B6-A0IH Cancer/AML 
2 25470516 25470516 G A DNMT3A p.R320* TCGA-E8-A3X7 Cancer/AML 
2 25470516 25470516 G A DNMT3A p.R320* TCGA-EK-A2PI Cancer/AML 
2 25470533 25470533 C T DNMT3A p.W314* TCGA-D1-A16G Cancer/AML 
2 25470588 25470588 C T DNMT3A p.V296M TCGA-19-1789 Cancer/AML 
2 25470588 25470588 C T DNMT3A p.V296M TCGA-C8-A278 Cancer/AML 
2 25470920 25470920 C A DNMT3A p.E281* TCGA-BJ-A0YZ Cancer/AML 
2 25470993 25470996 GGGG - DNMT3A p.P256fs TCGA-D3-A5GO Cancer/AML 
2 141200153 141200153 G T LRP1B p.T3445N TCGA-BG-A0YV Cancer/AML 
2 141259439 141259439 C G LRP1B p.Q2889H TCGA-AF-2691 Cancer/AML 
2 141356297 141356297 T C LRP1B p.N2366S TCGA-19-1388 Cancer/AML 
2 141528569 141528569 T A LRP1B p.N1836I TCGA-55-8620 Cancer/AML 
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2 141641524 141641524 C G LRP1B p.W1344S TCGA-AA-A00W Cancer/AML 
2 141643883 141643883 A T LRP1B p.I1263N TCGA-C8-A278 Cancer/AML 
2 141665548 141665548 T C LRP1B p.K1140E TCGA-09-1667 Cancer/AML 
2 141680678 141680678 G T LRP1B p.Q1059K TCGA-AA-3514 Cancer/AML 
2 141680681 141680681 A T LRP1B p.F1058I TCGA-13-0801 Cancer/AML 
2 141680681 141680681 A T LRP1B p.F1058I TCGA-AA-3529 Cancer/AML 
2 141773398 141773398 C A LRP1B p.R686L TCGA-DU-6393 Cancer/AML 
2 141819834 141819834 A T LRP1B p.F341Y TCGA-13-0901 Cancer/AML 
2 198266176 198266176 A C SF3B1 p.F815C TCGA-AA-3518 Cancer/AML 
2 198266176 198266176 A C SF3B1 p.F815C TCGA-AA-3534 Cancer/AML 
2 198266834 198266834 T C SF3B1 p.K700E TCGA-KU-A66S Cancer/AML 
2 198267359 198267359 C A SF3B1 p.K666N TCGA-DM-A28C Cancer/AML 
2 198267359 198267359 C G SF3B1 p.K666N TCGA-A6-2681 Cancer/AML 
2 198267360 198267360 T C SF3B1 p.K666R TCGA-AP-A0LQ Cancer/AML 
2 198267371 198267371 G C SF3B1 p.H662Q TCGA-F7-A622 Cancer/AML 
2 198267371 198267371 G T SF3B1 p.H662Q TCGA-24-2030 Cancer/AML 
2 198267480 198267480 T G SF3B1 p.N626T TCGA-A6-6653 Cancer/AML 
2 198273167 198273167 C T SF3B1 p.G348E TCGA-CI-6620 Cancer/AML 
2 198273233 198273233 G A SF3B1 p.T326I TCGA-AX-A05S Cancer/AML 
3 128200669 128200669 A T GATA2 p.L379Q TCGA-FD-A3SM Cancer/AML 
3 128200771 128200771 G T GATA2 p.A345D TCGA-X6-A7WB Cancer/AML 
3 128204642 128204642 G A GATA2 p.P267S TCGA-AK-3461 Cancer/AML 
4 55589839 55589839 T G KIT p.Y441D TCGA-AX-A05T Cancer/AML 
4 55602715 55602715 T C KIT p.Y846H TCGA-AA-3517 Cancer/AML 
4 106155310 106155310 A - TET2 p.N92fs TCGA-85-8664 Cancer/AML 
4 106156242 106156242 C - TET2 p.F402fs TCGA-06-2559 Cancer/AML 
4 106156654 106156655 - A TET2 p.F540fs TCGA-UF-A71B Cancer/AML 
4 106156690 106156690 C T TET2 p.Q552* TCGA-AK-3433 Cancer/AML 
4 106156747 106156747 C T TET2 p.R571* TCGA-97-7938 Cancer/AML 
4 106156747 106156747 C T TET2 p.R571* TCGA-AM-5820 Cancer/AML 
4 106157029 106157029 C T TET2 p.Q665* TCGA-BG-A0W1 Cancer/AML 
4 106157053 106157053 C T TET2 p.Q673* TCGA-DY-A1DC Cancer/AML 
4 106157384 106157385 - C TET2 p.Q785fs TCGA-06-2558 Cancer/AML 
4 106157588 106157589 - A TET2 p.Q852fs TCGA-69-7764 Cancer/AML 
4 106157764 106157764 A T TET2 p.K910* TCGA-36-2543 Cancer/AML 
4 106157824 106157824 C T TET2 p.Q930* TCGA-F7-A624 Cancer/AML 
4 106157971 106157971 C T TET2 p.Q979* TCGA-95-A4VN Cancer/AML 
4 106158431 106158431 T A TET2 p.L1132* TCGA-KU-A66S Cancer/AML 
4 106158510 106158510 T G TET2 e2+2 TCGA-MP-A4TC Cancer/AML 
4 106164793 106164793 T C TET2 p.C1242R TCGA-BH-A0WA Cancer/AML 
4 106164917 106164917 G C TET2 p.R1283P TCGA-CI-6619 Cancer/AML 
4 106164929 106164929 A G TET2 p.N1287S TCGA-D8-A1XS Cancer/AML 
4 106193995 106193995 C G TET2 p.S1507* TCGA-CA-6715 Cancer/AML 
7 55211032 55211032 C T EGFR p.A92V TCGA-NC-A5HD Cancer/AML 
7 55221845 55221845 C T EGFR p.R252C TCGA-16-0861 Cancer/AML 
7 55233043 55233043 G T EGFR p.G553V TCGA-DU-7290 Cancer/AML 
7 55259466 55259466 A C EGFR p.N797H TCGA-AG-A016 Cancer/AML 
7 55273147 55273147 G T EGFR p.W1157L TCGA-AG-A016 Cancer/AML 
7 86415889 86415889 C T GRM3 p.R261* TCGA-D9-A6EA Cancer/AML 
7 86493647 86493647 C T GRM3 p.R517* TCGA-CI-6620 Cancer/AML 
7 148504789 148504789 C A EZH2 p.Q735H TCGA-A6-2681 Cancer/AML 
7 148507431 148507431 T G EZH2 p.N675H TCGA-AG-3598 Cancer/AML 
7 148512038 148512038 A C EZH2 p.F547C TCGA-AG-3578 Cancer/AML 
7 148524323 148524323 C A EZH2 p.D221Y TCGA-AA-3520 Cancer/AML 
7 148526832 148526832 G T EZH2 p.H158N TCGA-AA-3514 Cancer/AML 
8 12957122 12957122 G C DLC1 p.D505E TCGA-AA-3534 Cancer/AML 
8 13259044 13259044 C T DLC1 p.E370K TCGA-CI-6620 Cancer/AML 
8 93017486 93017486 C A RUNX1T1 p.A163S TCGA-24-1550 Cancer/AML 
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8 117864273 117864273 T C RAD21 p.N7D TCGA-24-0968 Cancer/AML 
8 117869536 117869536 A G RAD21 p.F220L TCGA-13-0717 Cancer/AML 
8 117878848 117878848 C A RAD21 p.V41L TCGA-AU-6004 Cancer/AML 
8 128750924 128750924 C T MYC p.S139L TCGA-CI-6620 Cancer/AML 
8 144940317 144940317 C G EPPK1 p.D2369H TCGA-A1-A0SQ Cancer/AML 
8 144940347 144940347 C T EPPK1 p.V2359M TCGA-AR-A0TW Cancer/AML 
8 144940488 144940488 C T EPPK1 p.D2312N TCGA-C8-A1HJ Cancer/AML 
8 144940506 144940506 C T EPPK1 p.A2306T TCGA-QG-A5Z1 Cancer/AML 
8 144940508 144940508 C T EPPK1 p.R2305H TCGA-EW-A3E8 Cancer/AML 
8 144940509 144940509 G A EPPK1 p.R2305C TCGA-E5-A4TZ Cancer/AML 
8 144940517 144940517 G A EPPK1 p.S2302L TCGA-J1-A4AH Cancer/AML 
8 144940602 144940602 C T EPPK1 p.D2274N TCGA-FD-A5BU Cancer/AML 
8 144942354 144942354 T C EPPK1 p.I1690V TCGA-G9-6369 Cancer/AML 
8 144945092 144945092 G A EPPK1 p.T777M TCGA-K4-A6MB Cancer/AML 
9 5050744 5050744 A C JAK2 p.E176A TCGA-24-0968 Cancer/AML 
9 5066760 5066760 A C JAK2 p.N433H TCGA-13-1408 Cancer/AML 
9 98224152 98224152 T C PTCH1 p.I897V TCGA-EO-A3KW Cancer/AML 
9 98231259 98231259 T C PTCH1 p.Y675C TCGA-AA-A00K Cancer/AML 
9 98232132 98232132 C T PTCH1 p.E604K TCGA-CI-6620 Cancer/AML 
9 98240434 98240434 T G PTCH1 p.Q417P TCGA-AK-3460 Cancer/AML 
9 98242767 98242767 T G PTCH1 p.K284Q TCGA-AG-A016 Cancer/AML 
10 28900784 28900784 C T WAC p.T457I TCGA-23-1021 Cancer/AML 
10 112342324 112342324 C T SMC3 p.S243F TCGA-CI-6620 Cancer/AML 
10 112349676 112349676 A C SMC3 p.E479A TCGA-AA-3514 Cancer/AML 
11 119148966 119148966 T C CBL p.C396R TCGA-23-1029 Cancer/AML 
11 119149334 119149334 G A CBL p.E448K TCGA-B2-4101 Cancer/AML 
11 119155953 119155953 C T CBL p.R540* TCGA-CR-7376 Cancer/AML 
12 6682257 6682257 T G CHD4 p.N1875T TCGA-AK-3460 Cancer/AML 
12 6690263 6690263 T C CHD4 p.E1647G TCGA-AA-3514 Cancer/AML 
12 6701173 6701173 C T CHD4 p.R1000Q TCGA-CI-6620 Cancer/AML 
12 6702646 6702646 C T CHD4 p.R817Q TCGA-J4-A67S Cancer/AML 
12 6704562 6704562 T G CHD4 p.K687Q TCGA-AG-A016 Cancer/AML 
12 6705266 6705266 A C CHD4 p.W644G TCGA-09-1666 Cancer/AML 
12 6711550 6711550 T A CHD4 p.K72* TCGA-14-0783 Cancer/AML 
12 31244669 31244669 A G DDX11 p.Y369C TCGA-MU-A5YI Cancer/AML 
12 31247713 31247713 A G DDX11 p.D480G TCGA-CV-7252 Cancer/AML 
12 112891058 112891058 A G PTPN11 p.K131R TCGA-09-0367 Cancer/AML 
12 112910785 112910785 G A PTPN11 p.R265Q TCGA-13-0803 Cancer/AML 
12 112926851 112926851 C T PTPN11 p.P491S TCGA-A4-7996 Cancer/AML 
12 112926926 112926926 A G PTPN11 p.M516V TCGA-G3-A25S Cancer/AML 
13 28592699 28592699 T A FLT3 p.N816Y TCGA-AA-3538 Cancer/AML 
13 28623571 28623571 G T FLT3 p.T329N TCGA-ER-A19E Cancer/AML 
13 28636128 28636128 C A FLT3 p.E82* TCGA-24-1560 Cancer/AML 
13 28895703 28895703 G T FLT1 p.A1024E TCGA-AX-A3FX Cancer/AML 
13 73335542 73335542 C T DIS3 p.E877K TCGA-AA-3514 Cancer/AML 
13 73351629 73351629 C A DIS3 p.E195* TCGA-AX-A3FW Cancer/AML 
15 88476304 88476304 C A NTRK3 p.G610W TCGA-DA-A1I8 Cancer/AML 
15 88669507 88669507 A T NTRK3 p.M464K TCGA-13-0802 Cancer/AML 
15 88799240 88799240 C G NTRK3 p.D49H TCGA-AG-A016 Cancer/AML 
17 7577538 7577538 C T TP53 p.R248Q TCGA-AX-A2H7 Cancer/AML 
17 7577538 7577538 C T TP53 p.R248Q TCGA-DK-A1AD Cancer/AML 
17 7577539 7577539 G A TP53 p.R248W TCGA-F5-6702 Cancer/AML 
17 7577548 7577548 C T TP53 p.G245S TCGA-QK-A6VB Cancer/AML 
17 7578500 7578500 G A TP53 p.Q144* TCGA-D7-A6F2 Cancer/AML 
17 7578524 7578524 G A TP53 p.Q136* TCGA-95-8494 Cancer/AML 
17 29496994 29496994 A C NF1 p.K189Q TCGA-AA-3558 Cancer/AML 
17 29550515 29550515 G A NF1 p.S592N TCGA-28-5216 Cancer/AML 
17 29560209 29560209 A G NF1 p.N1229S TCGA-44-A47F Cancer/AML 
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17 29562948 29562948 A G NF1 p.T1295A TCGA-14-0871 Cancer/AML 
17 29665822 29665822 A G NF1 p.K2307R TCGA-C8-A12X Cancer/AML 
17 30315382 30315382 A C SUZ12 p.Q356P TCGA-DU-7292 Cancer/AML 
17 30325762 30325762 C T SUZ12 p.R654* TCGA-68-8251 Cancer/AML 
17 74732454 74732454 C T SRSF2 p.R152H TCGA-24-2288 Cancer/AML 
18 42281637 42281637 C T SETBP1 p.T109I TCGA-CQ-A4CE Cancer/AML 
18 42531113 42531113 A C SETBP1 p.E603A TCGA-26-5135 Cancer/AML 
18 42531913 42531913 G A SETBP1 p.G870S TCGA-29-1761 Cancer/AML 
19 17943490 17943490 G A JAK3 p.R840C TCGA-06-1805 Cancer/AML 
20 31021086 31021086 G T ASXL1 e12-1 TCGA-EB-A5KH Cancer/AML 
20 31021250 31021250 C T ASXL1 p.R417* TCGA-CV-7437 Cancer/AML 
20 31021295 31021295 C T ASXL1 p.Q432* TCGA-77-A5GH Cancer/AML 
20 31021535 31021535 C T ASXL1 p.Q512* TCGA-EE-A2GC Cancer/AML 
20 31021535 31021535 C T ASXL1 p.Q512* TCGA-NC-A5HD Cancer/AML 
20 31021642 31021643 - T ASXL1 p.R548fs TCGA-05-4403 Cancer/AML 
20 31022238 31022238 C T ASXL1 p.Q575* TCGA-86-8281 Cancer/AML 
20 31022263 31022263 G A ASXL1 p.W583* TCGA-A6-3808 Cancer/AML 
20 31022285 31022286 TT - ASXL1 p.Y591fs TCGA-37-4130 Cancer/AML 
20 31022288 31022288 C A ASXL1 p.Y591* TCGA-BR-8373 Cancer/AML 
20 31022288 31022288 C A ASXL1 p.Y591* TCGA-EE-A2MC Cancer/AML 
20 31022288 31022288 C G ASXL1 p.Y591* TCGA-EC-A1QX Cancer/AML 
20 31022670 31022670 G - ASXL1 p.E719fs TCGA-MN-A4N1 Cancer/AML 
20 31022712 31022712 C T ASXL1 p.Q733* TCGA-97-8179 Cancer/AML 
20 31022784 31022784 C T ASXL1 p.Q757* TCGA-77-8144 Cancer/AML 
20 31022784 31022784 C T ASXL1 p.Q757* TCGA-CF-A3MH Cancer/AML 
20 31022817 31022817 C T ASXL1 p.Q768* TCGA-EM-A3O3 Cancer/AML 
20 31023159 31023159 C T ASXL1 p.Q882* TCGA-85-8584 Cancer/AML 
20 31023209 31023209 G A ASXL1 p.W898* TCGA-NK-A5CX Cancer/AML 
20 31023249 31023249 A T ASXL1 p.K912* TCGA-ER-A194 Cancer/AML 
20 31024563 31024563 C T ASXL1 p.Q1350* TCGA-EK-A2RA Cancer/AML 
21 44514777 44514777 T G U2AF1 p.Q157P TCGA-DD-A1EE Cancer/AML 
21 44514777 44514777 T G U2AF1 p.Q157P TCGA-EE-A29D Cancer/AML 
22 22314813 22314813 C T TOP3B p.A512T TCGA-AK-3434 Cancer/AML 
22 22318590 22318590 G T TOP3B p.N347K TCGA-BR-A4CR Cancer/AML 
X 39933976 39933976 T G BCOR p.D208A TCGA-24-1548 Cancer/AML 
X 40996183 40996183 A G USP9X p.N188D TCGA-EU-5907 Cancer/AML 
X 41010259 41010259 A C USP9X p.K571T TCGA-13-0906 Cancer/AML 
X 41088588 41088588 A T USP9X p.K2382* TCGA-B2-4101 Cancer/AML 
X 44879860 44879860 T A KDM6A p.I150N TCGA-24-1545 Cancer/AML 
X 44922836 44922836 C A KDM6A p.P573H TCGA-AA-A01G Cancer/AML 
X 44923034 44923034 G C KDM6A p.W639S TCGA-AA-A00K Cancer/AML 
X 44945197 44945197 G T KDM6A p.W1181L TCGA-50-5946 Cancer/AML 
X 53407567 53407567 C T SMC1A p.E1198K TCGA-CI-6620 Cancer/AML 
X 53436117 53436117 T G SMC1A p.N474T TCGA-AA-3534 Cancer/AML 
X 53436124 53436124 C T SMC1A p.E472K TCGA-CI-6620 Cancer/AML 
X 53438775 53438775 T C SMC1A p.N397S TCGA-16-0861 Cancer/AML 
X 53449458 53449458 A G SMC1A p.I31T TCGA-63-7022 Cancer/AML 
X 70346862 70346862 A G MED12 p.K910R TCGA-41-3393 Cancer/AML 
X 70346871 70346871 A G MED12 p.D913G TCGA-23-1024 Cancer/AML 
X 70354234 70354234 C T MED12 p.R1549C TCGA-23-1109 Cancer/AML 
X 123164976 123164976 G A STAG2 e3+1 TCGA-CC-A5UD Cancer/AML 
X 133547968 133547968 A T PHF6 p.K235M TCGA-AA-3520 Cancer/AML 
X 133547985 133547985 T C PHF6 p.Y241H TCGA-04-1530 Cancer/AML 
1 1747227 1747227 C A GNB1 p.K57N TCGA-DA-A1I0 Cancer 
1 1747227 1747227 C A GNB1 p.K57N TCGA-J4-A67O Cancer 
1 1747229 1747229 T C GNB1 p.K57E TCGA-19-4068 Cancer 
1 1747229 1747229 T C GNB1 p.K57E TCGA-A1-A0SE Cancer 
1 1747229 1747229 T C GNB1 p.K57E TCGA-A8-A08A Cancer 
[210] 
 
1 1747229 1747229 T C GNB1 p.K57E TCGA-AK-3444 Cancer 
1 1747229 1747229 T C GNB1 p.K57E TCGA-EJ-5497 Cancer 
1 11259403 11259403 T C MTOR p.K1389E TCGA-AA-3514 Cancer 
1 11272439 11272439 T C MTOR p.D1164G TCGA-06-0219 Cancer 
1 11288784 11288784 G C MTOR p.P991A TCGA-14-1825 Cancer 
1 11308124 11308124 T A MTOR p.T290S TCGA-EB-A41B Cancer 
1 11851367 11851367 T C MTHFR p.N591S TCGA-13-0801 Cancer 
1 11861365 11861365 T A MTHFR p.M151L TCGA-09-1668 Cancer 
1 16459810 16459810 C A EPHA2 p.E640* TCGA-EE-A2ML Cancer 
1 16474936 16474936 G T EPHA2 p.L254M TCGA-X6-A7WB Cancer 
1 17359566 17359566 G C SDHB p.S92* TCGA-13-0714 Cancer 
1 23222016 23222016 C T EPHB2 p.S548L TCGA-CI-6620 Cancer 
1 23232579 23232579 A C EPHB2 p.K622T TCGA-13-0717 Cancer 
1 23232579 23232579 A G EPHB2 p.K622R TCGA-12-1095 Cancer 
1 23232580 23232580 A C EPHB2 p.K622N TCGA-13-1407 Cancer 
1 23232580 23232580 A C EPHB2 p.K622N TCGA-AA-3561 Cancer 
1 23232580 23232580 A C EPHB2 p.K622N TCGA-AA-A00Q Cancer 
1 23233400 23233400 A T EPHB2 p.M696L TCGA-25-1625 Cancer 
1 23239064 23239064 T A EPHB2 p.F942I TCGA-A6-2676 Cancer 
1 23239065 23239065 T G EPHB2 p.F942C TCGA-AF-2691 Cancer 
1 23239996 23239996 A C EPHB2 p.K965T TCGA-AF-2691 Cancer 
1 25254220 25254220 A C RUNX3 p.V109G TCGA-A8-A08O Cancer 
1 27094387 27094387 A G ARID1A p.E1032G TCGA-AA-A00A Cancer 
1 27106589 27106589 T A ARID1A p.I2067N TCGA-36-1576 Cancer 
1 28240894 28240895 - A RPA2 p.S20fs TCGA-B5-A3S1 Cancer 
1 46725690 46725690 T C RAD54L p.L109P TCGA-A6-2678 Cancer 
1 46725690 46725690 T C RAD54L p.L109P TCGA-AK-3460 Cancer 
1 46726639 46726639 C T RAD54L p.P240S TCGA-25-1324 Cancer 
1 78422299 78422299 C T FUBP1 p.A576T TCGA-AG-A016 Cancer 
1 78429830 78429830 C T FUBP1 p.E341K TCGA-CI-6620 Cancer 
1 93301904 93301904 G T RPL5 p.G161V TCGA-FC-7961 Cancer 
1 97700536 97700536 G T DPYD p.P772T TCGA-AX-A06J Cancer 
1 120510805 120510805 C A NOTCH2 p.G387W TCGA-25-1634 Cancer 
1 150923098 150923098 G C SETDB1 p.C582S TCGA-13-0793 Cancer 
1 150923310 150923310 C G SETDB1 p.L653V TCGA-GU-A762 Cancer 
1 155210420 155210420 C T GBA e2+1 TCGA-EB-A44R Cancer 
1 155874261 155874261 C G RIT1 p.M107I TCGA-CN-5367 Cancer 
1 156841502 156841502 A C NTRK1 p.N269H TCGA-AG-A016 Cancer 
1 156845995 156845995 C T NTRK1 p.A542V TCGA-AA-3514 Cancer 
1 158152713 158152713 G A CD1D p.G218D TCGA-A1-A0SO Cancer 
1 160389236 160389236 C T VANGL2 p.Q213* TCGA-24-1105 Cancer 
1 161141691 161141691 C T B4GALT3 p.R366H TCGA-H4-A2HQ Cancer 
1 168034877 168034877 A T DCAF6 p.D830V TCGA-12-1098 Cancer 
1 173769598 173769598 A T CENPL p.F387L TCGA-AA-3534 Cancer 
1 179089370 179089370 C T ABL2 p.A334T TCGA-DK-A6B0 Cancer 
1 198711080 198711080 A T PTPRC p.H829L TCGA-16-1055 Cancer 
1 198711080 198711080 A T PTPRC p.H829L TCGA-AG-A016 Cancer 
1 198719708 198719708 A C PTPRC p.K1054Q TCGA-13-0717 Cancer 
1 204515995 204515995 T C MDM4 p.V298A TCGA-AA-3514 Cancer 
1 206650051 206650051 C T IKBKE p.R191* TCGA-CI-6620 Cancer 
1 241663886 241663886 T C FH p.K414R TCGA-19-1392 Cancer 
1 241676920 241676920 T A FH p.M121L TCGA-24-1553 Cancer 
1 241676968 241676968 C T FH p.E105K TCGA-23-1024 Cancer 
1 242035571 242035571 C T EXO1 p.T502I TCGA-A6-2686 Cancer 
1 243778439 243778439 C T AKT3 p.E196K TCGA-CI-6620 Cancer 
1 243801011 243801011 C A AKT3 p.G155C TCGA-EE-A3AB Cancer 
2 25973025 25973025 G T ASXL2 p.S467* TCGA-CN-4729 Cancer 
2 25973284 25973284 T C ASXL2 e12-2 TCGA-DU-6400 Cancer 
[211] 
 
2 29436851 29436851 G A ALK p.R1248* TCGA-06-5858 Cancer 
2 29450539 29450539 C A ALK e17-1 TCGA-24-1548 Cancer 
2 29551287 29551287 A T ALK p.V448D TCGA-DX-A6YV Cancer 
2 39281948 39281948 A T SOS1 p.F176Y TCGA-AA-3514 Cancer 
2 39514099 39514099 C T MAP4K3 p.G410E TCGA-AA-3520 Cancer 
2 42522542 42522542 G C EML4 p.V459L TCGA-23-1124 Cancer 
2 47698199 47698199 C A MSH2 p.S586* TCGA-B2-4101 Cancer 
2 47702411 47702411 T C MSH2 e12+2 TCGA-A6-2676 Cancer 
2 48027233 48027233 C G MSH6 p.A704G TCGA-DM-A28K Cancer 
2 48030696 48030696 T C MSH6 p.F1104L TCGA-13-0802 Cancer 
2 58386920 58386920 T C FANCL p.M375V TCGA-AG-3608 Cancer 
2 70314915 70314915 C T PCBP1 p.L14F TCGA-CI-6620 Cancer 
2 96920586 96920586 C T TMEM127 p.A48T TCGA-FY-A3NP Cancer 
2 96920631 96920631 C T TMEM127 p.G33R TCGA-AA-3553 Cancer 
2 111881618 111881618 T G BCL2L11 p.F99C TCGA-AK-3460 Cancer 
2 128028917 128028917 T C ERCC3 p.K647R TCGA-13-0802 Cancer 
2 128028917 128028917 T C ERCC3 p.K647R TCGA-19-0960 Cancer 
2 128028917 128028917 T C ERCC3 p.K647R TCGA-AG-3581 Cancer 
2 135975075 135975075 C T ZRANB3 p.E819K TCGA-CI-6620 Cancer 
2 135985387 135985387 C T ZRANB3 e13+1 TCGA-25-1317 Cancer 
2 148657107 148657107 C G ACVR2A p.S115C TCGA-AG-3584 Cancer 
2 169780307 169780307 G T ABCB11 p.A1264D TCGA-DX-A6YS Cancer 
2 169788945 169788945 A C ABCB11 p.F1052C TCGA-13-0717 Cancer 
2 170026301 170026301 A C LRP2 p.F3803C TCGA-36-1578 Cancer 
2 170026302 170026302 A G LRP2 p.F3803L TCGA-AA-3534 Cancer 
2 170063244 170063244 A C LRP2 p.F2329C TCGA-16-1055 Cancer 
2 170063244 170063244 A C LRP2 p.F2329C TCGA-23-1028 Cancer 
2 170068628 170068628 C T LRP2 p.A2044T TCGA-23-1027 Cancer 
2 170093754 170093754 T C LRP2 p.D1517G TCGA-AA-3514 Cancer 
2 170093754 170093754 T C LRP2 p.D1517G TCGA-AF-2689 Cancer 
2 170094807 170094807 C T LRP2 p.E1434K TCGA-CI-6620 Cancer 
2 170135894 170135894 T C LRP2 p.D518G TCGA-04-1364 Cancer 
2 187466767 187466767 G A ITGAV p.G69R TCGA-AG-3583 Cancer 
2 187466776 187466776 A G ITGAV p.K72E TCGA-25-1633 Cancer 
2 187466779 187466779 G C ITGAV p.A73P TCGA-04-1364 Cancer 
2 187529366 187529366 G A ITGAV p.E691K TCGA-25-1626 Cancer 
2 187534504 187534504 G A ITGAV p.R890Q TCGA-CH-5753 Cancer 
2 202149806 202149806 T A CASP8 p.I416N TCGA-12-1095 Cancer 
2 206610555 206610555 A T NRP2 p.E576V TCGA-AA-A00R Cancer 
2 206617580 206617580 C T NRP2 p.S642L TCGA-CI-6620 Cancer 
2 206641006 206641006 A T NRP2 p.D826V TCGA-AG-3598 Cancer 
2 212295728 212295728 A G ERBB4 p.F862S TCGA-13-0801 Cancer 
2 212295786 212295786 C T ERBB4 p.D843N TCGA-FD-A5BV Cancer 
2 212522537 212522537 T C ERBB4 p.S630G TCGA-AG-3608 Cancer 
2 212522549 212522549 T C ERBB4 p.N626D TCGA-AG-A016 Cancer 
2 212566779 212566779 A G ERBB4 p.Y468H TCGA-AG-A016 Cancer 
2 212652803 212652803 C T ERBB4 p.R168Q TCGA-CN-6992 Cancer 
2 233001226 233001226 C T DIS3L2 p.A269V TCGA-FS-A1ZM Cancer 
2 233164812 233164812 G T DIS3L2 p.E574D TCGA-AR-A24H Cancer 
2 234669075 234669075 C T UGT1A1 p.Q48* TCGA-A6-2678 Cancer 
2 240111555 240111555 C T HDAC4 p.E105K TCGA-CI-6620 Cancer 
3 3192694 3192694 G T CRBN p.A395E TCGA-A4-7584 Cancer 
3 10106076 10106076 G T FANCD2 p.D662Y TCGA-AN-A0FX Cancer 
3 10115047 10115047 G A FANCD2 e27+1 TCGA-42-2591 Cancer 
3 12641731 12641731 C T RAF1 p.G324S TCGA-A6-2683 Cancer 
3 12660036 12660036 A G RAF1 p.L62S TCGA-23-1026 Cancer 
3 12660133 12660133 G A RAF1 p.P30S TCGA-50-8459 Cancer 
3 30732960 30732960 C A TGFBR2 p.P550T TCGA-09-1662 Cancer 
[212] 
 
3 37061893 37061893 T C MLH1 p.V85A TCGA-62-A46O Cancer 
3 37092125 37092125 A G MLH1 p.K510R TCGA-64-1678 Cancer 
3 38182641 38182641 T C MYD88 p.L273P TCGA-DY-A1H8 Cancer 
3 38182761 38182761 C T MYD88 p.A313V TCGA-36-1568 Cancer 
3 39104605 39104605 T A WDR48 p.L38Q TCGA-12-1098 Cancer 
3 39104605 39104605 T C WDR48 p.L38P TCGA-24-1556 Cancer 
3 39104610 39104610 C T WDR48 p.P40S TCGA-24-1556 Cancer 
3 39136144 39136144 G T WDR48 p.L648F TCGA-B2-4101 Cancer 
3 39136154 39136154 A T WDR48 p.M652L TCGA-36-1577 Cancer 
3 41267225 41267225 A G CTNNB1 p.K263R TCGA-12-1095 Cancer 
3 41275222 41275222 C A CTNNB1 p.P456H TCGA-AA-A00R Cancer 
3 41278078 41278078 G T CTNNB1 e11-1 TCGA-DX-A6YT Cancer 
3 47125727 47125727 G A SETD2 p.T1848I TCGA-AA-A00R Cancer 
3 47155460 47155460 T G SETD2 p.N1541H TCGA-DJ-A1QE Cancer 
3 47162630 47162630 C G SETD2 p.D1166H TCGA-AJ-A3OK Cancer 
3 49399957 49399957 G A RHOA p.Q87* TCGA-13-0801 Cancer 
3 49399957 49399957 G A RHOA p.Q87* TCGA-25-1627 Cancer 
3 52438565 52438565 C T BAP1 p.R385Q TCGA-CI-6620 Cancer 
3 52439212 52439212 T A BAP1 p.N344Y TCGA-AF-2689 Cancer 
3 52442566 52442566 C G BAP1 p.R60P TCGA-AF-2689 Cancer 
3 52584823 52584823 G C PBRM1 p.N1540K TCGA-29-2431 Cancer 
3 52588862 52588862 G C PBRM1 p.P1496R TCGA-AA-A01G Cancer 
3 52613181 52613181 C A PBRM1 p.G1141V TCGA-AX-A06F Cancer 
3 69987136 69987136 C G MITF p.P173R TCGA-36-1581 Cancer 
3 69987136 69987136 C G MITF p.P173R TCGA-AG-3578 Cancer 
3 70000970 70000970 T G MITF p.I296M TCGA-AA-A00K Cancer 
3 89259331 89259331 G A EPHA3 p.D159N TCGA-A6-2676 Cancer 
3 89259331 89259331 G A EPHA3 p.D159N TCGA-AA-A00K Cancer 
3 89259331 89259331 G A EPHA3 p.D159N TCGA-AF-2689 Cancer 
3 100432602 100432602 C T TFG p.P25S TCGA-AG-A016 Cancer 
3 105397340 105397340 T C CBLB p.H50R TCGA-06-5858 Cancer 
3 119562134 119562134 G A GSK3B p.A401V TCGA-AG-A016 Cancer 
3 119595291 119595291 A T GSK3B p.F293Y TCGA-AA-3529 Cancer 
3 119631592 119631592 G A GSK3B p.P225L TCGA-AK-3444 Cancer 
3 121190975 121190975 G A POLQ p.P2194S TCGA-13-0901 Cancer 
3 121215661 121215661 A C POLQ p.Y758D TCGA-24-0968 Cancer 
3 121238888 121238888 C G POLQ p.R433P TCGA-AK-3434 Cancer 
3 121263625 121263625 C T POLQ p.E98K TCGA-CI-6620 Cancer 
3 123348330 123348330 T A MYLK p.K1702I TCGA-24-1548 Cancer 
3 123376087 123376087 G A MYLK p.Q1392* TCGA-AX-A05T Cancer 
3 123401120 123401120 C T MYLK p.M1201I TCGA-CI-6620 Cancer 
3 123427591 123427591 C A MYLK p.W698C TCGA-09-1662 Cancer 
3 124462883 124462883 G C UMPS p.M465I TCGA-13-1408 Cancer 
3 142176450 142176450 T C ATR p.M2551V TCGA-CQ-A4CI Cancer 
3 142188181 142188181 T G ATR p.K2184Q TCGA-AK-3431 Cancer 
3 142215256 142215256 C T ATR p.E1949K TCGA-EO-A2CH Cancer 
3 142215300 142215300 G T ATR p.A1934D TCGA-X6-A7WA Cancer 
3 142217487 142217487 G C ATR p.A1837G TCGA-24-0968 Cancer 
3 142269008 142269008 A G ATR p.V981A TCGA-25-1317 Cancer 
3 156395548 156395548 A G TIPARP p.D21G TCGA-29-1784 Cancer 
3 156396160 156396160 A T TIPARP p.E225V TCGA-25-1317 Cancer 
3 168810807 168810807 T A MECOM p.I838F TCGA-HU-A4GU Cancer 
3 168812911 168812911 G T MECOM p.T794N TCGA-13-0793 Cancer 
3 168812911 168812911 G T MECOM p.T794N TCGA-13-0801 Cancer 
3 168812911 168812911 G T MECOM p.T794N TCGA-24-1553 Cancer 
3 168833978 168833978 G A MECOM p.P373L TCGA-36-1578 Cancer 
3 168834045 168834045 G T MECOM p.Q351K TCGA-BH-A0B8 Cancer 
3 168834242 168834242 T C MECOM p.N285S TCGA-14-0783 Cancer 
[213] 
 
3 168834252 168834252 A C MECOM p.F282V TCGA-AA-3534 Cancer 
3 168834317 168834317 G C MECOM p.T260S TCGA-A7-A5ZV Cancer 
3 168838970 168838970 G A MECOM p.R148W TCGA-B5-A0JN Cancer 
3 169099094 169099094 T C MECOM p.N86D TCGA-13-1407 Cancer 
3 183212063 183212063 T G KLHL6 p.K385T TCGA-AA-A00D Cancer 
3 183273381 183273381 C T KLHL6 p.E21K TCGA-25-1318 Cancer 
3 186502802 186502802 T A EIF4A2 p.F88Y TCGA-25-1627 Cancer 
3 187443369 187443369 G T BCL6 p.P586Q TCGA-25-1634 Cancer 
4 1803393 1803393 C T FGFR3 p.S221L TCGA-CI-6620 Cancer 
4 55133516 55133516 A T PDGFRA p.T274S TCGA-BG-A0M2 Cancer 
4 55152092 55152092 G C PDGFRA p.D842H TCGA-AG-3601 Cancer 
4 55161371 55161371 G A PDGFRA p.E1068K TCGA-AF-3911 Cancer 
4 66286259 66286259 T G EPHA5 p.K476T TCGA-AG-3581 Cancer 
4 66509098 66509098 C A EPHA5 p.A77S TCGA-36-2547 Cancer 
4 134072199 134072199 G C PCDH10 p.G302R TCGA-13-1497 Cancer 
4 134072730 134072730 G A PCDH10 p.G479S TCGA-AA-3514 Cancer 
4 153250903 153250903 C T FBXW7 p.C386Y TCGA-24-1604 Cancer 
4 153253796 153253796 T G FBXW7 p.I313L TCGA-AA-A01Q Cancer 
4 153332525 153332525 G C FBXW7 p.T144R TCGA-95-7043 Cancer 
4 153332853 153332853 G A FBXW7 p.R35C TCGA-A2-A1FV Cancer 
4 186272686 186272686 G A SNX25 p.V633M TCGA-ER-A19H Cancer 
4 187517765 187517765 G A FAT1 p.P4310L TCGA-DJ-A13U Cancer 
4 187517870 187517870 C A FAT1 p.G4275V TCGA-B2-4101 Cancer 
4 187517879 187517879 G C FAT1 p.S4272C TCGA-98-8023 Cancer 
4 187517919 187517919 T A FAT1 p.S4259C TCGA-CV-6943 Cancer 
4 187521264 187521264 C T FAT1 p.G3964E TCGA-BG-A0VZ Cancer 
4 187540142 187540142 T A FAT1 p.N2533I TCGA-L9-A444 Cancer 
4 187630170 187630170 G A FAT1 p.P271L TCGA-G9-6367 Cancer 
4 187630461 187630461 G A FAT1 p.T174M TCGA-PQ-A6FN Cancer 
5 1268706 1268706 G A TERT p.L777F TCGA-55-8299 Cancer 
5 19571756 19571756 A T CDH18 p.N395K TCGA-AG-3587 Cancer 
5 21817166 21817166 T G CDH12 p.D297A TCGA-AA-A00R Cancer 
5 21817167 21817167 C G CDH12 p.D297H TCGA-24-1604 Cancer 
5 21975325 21975325 A T CDH12 p.I134K TCGA-BH-A0HN Cancer 
5 38954903 38954903 T G RICTOR p.K890N TCGA-13-0793 Cancer 
5 38959887 38959887 A C RICTOR p.F682C TCGA-23-1024 Cancer 
5 39021206 39021206 T C RICTOR p.N44D TCGA-12-1094 Cancer 
5 44388784 44388784 T C FGF10 p.M1V TCGA-AG-3605 Cancer 
5 56155570 56155570 A T MAP3K1 p.D221V TCGA-21-5783 Cancer 
5 56168705 56168705 A T MAP3K1 p.Q520L TCGA-FS-A4F2 Cancer 
5 56178062 56178062 G T MAP3K1 p.C1012F TCGA-24-0968 Cancer 
5 74848352 74848352 T C POLK p.I64T TCGA-06-1805 Cancer 
5 86658429 86658429 G A RASA1 p.R299H TCGA-CU-A3QU Cancer 
5 86675579 86675579 G A RASA1 p.E673K TCGA-25-1324 Cancer 
5 112163683 112163683 G A APC p.E536K TCGA-BB-8601 Cancer 
5 131939181 131939181 G C RAD50 p.Q799H TCGA-A6-5659 Cancer 
5 138253552 138253552 A G CTNNA1 p.D504G TCGA-E2-A10B Cancer 
5 138268282 138268282 T C CTNNA1 p.C772R TCGA-36-1571 Cancer 
5 140960326 140960326 G A DIAPH1 p.P270L TCGA-AX-A05T Cancer 
5 149439275 149439275 T C CSF1R p.K707R TCGA-AA-3561 Cancer 
5 149439275 149439275 T C CSF1R p.K707R TCGA-AG-3583 Cancer 
5 149499120 149499120 G A PDGFRB p.P903L TCGA-06-0939 Cancer 
5 149505037 149505037 C T PDGFRB p.W593* TCGA-AF-2689 Cancer 
5 149509531 149509531 C A PDGFRB p.R456S TCGA-E1-5304 Cancer 
5 176517975 176517975 A G FGFR4 p.K158R TCGA-12-1095 Cancer 
5 176517975 176517975 A G FGFR4 p.K158R TCGA-AA-3514 Cancer 
5 176517975 176517975 A G FGFR4 p.K158R TCGA-AG-3583 Cancer 
5 176520465 176520465 G A FGFR4 p.R437H TCGA-AQ-A54N Cancer 
[214] 
 
5 176562545 176562545 G T NSD1 p.K147N TCGA-24-1105 Cancer 
5 176637463 176637463 G T NSD1 p.R688M TCGA-36-1570 Cancer 
5 176684134 176684134 A C NSD1 p.N1650H TCGA-E2-A15G Cancer 
5 176696799 176696799 T A NSD1 p.Y1834N TCGA-24-1548 Cancer 
5 176709529 176709529 C T NSD1 p.R1986C TCGA-23-1122 Cancer 
5 176719079 176719079 G T NSD1 p.G2128V TCGA-19-0955 Cancer 
5 176722279 176722279 G A NSD1 p.W2637* TCGA-E2-A1IH Cancer 
5 180041155 180041155 C T FLT4 p.A1082T TCGA-AA-3534 Cancer 
5 180057056 180057056 C T FLT4 p.R188Q TCGA-DK-A2I6 Cancer 
6 401729 401729 G A IRF4 p.E351K TCGA-A2-A0EY Cancer 
6 17507959 17507959 T C CAP2 e5+2 TCGA-AA-3514 Cancer 
6 18130961 18130961 G A TPMT p.R226* TCGA-CD-8533 Cancer 
6 26032033 26032033 G C HIST1H3B p.Q86E TCGA-AA-3514 Cancer 
6 26056198 26056198 T G HIST1H1C p.K153N TCGA-KM-8443 Cancer 
6 26056365 26056365 C G HIST1H1C p.G98R TCGA-13-0901 Cancer 
6 31324465 31324465 C T HLA-B p.G115R TCGA-62-A46O Cancer 
6 31545193 31545193 T A TNF p.I194N TCGA-H7-8502 Cancer 
6 33288275 33288275 T C DAXX p.K378R TCGA-13-0802 Cancer 
6 35425351 35425351 C A FANCE p.Q292K TCGA-AG-A016 Cancer 
6 41904412 41904412 G A CCND3 p.P149L TCGA-CG-4449 Cancer 
6 44216418 44216418 C T HSP90AB1 p.Q18* TCGA-CI-6620 Cancer 
6 44220960 44220960 C T HSP90AB1 p.T637M TCGA-63-A5MU Cancer 
6 44221316 44221316 G A HSP90AB1 p.R719H TCGA-EE-A2MR Cancer 
6 106552908 106552908 G T PRDM1 p.M291I TCGA-AA-3514 Cancer 
6 106553435 106553435 C T PRDM1 p.P467L TCGA-HU-8249 Cancer 
6 106554918 106554918 C T PRDM1 p.R679C TCGA-16-1055 Cancer 
6 111636543 111636543 A G REV3L p.F2798S TCGA-AG-3601 Cancer 
6 111688498 111688498 T A REV3L p.K2165* TCGA-25-1634 Cancer 
6 111695842 111695842 A T REV3L p.V1239D TCGA-D1-A179 Cancer 
6 111696278 111696278 C T REV3L p.A1094T TCGA-GV-A3JX Cancer 
6 111697819 111697819 T G REV3L p.K580T TCGA-AA-A00K Cancer 
6 111710413 111710413 G T REV3L p.A253D TCGA-X6-A7WA Cancer 
6 111714106 111714106 A C REV3L p.F212C TCGA-13-0761 Cancer 
6 111714106 111714106 A C REV3L p.F212C TCGA-AG-3600 Cancer 
6 117630001 117630001 T G ROS1 p.Q2175H TCGA-24-1548 Cancer 
6 117641140 117641140 T C ROS1 p.K1944R TCGA-AG-3608 Cancer 
6 131912498 131912498 G T MED23 p.A1220D TCGA-A2-A0EQ Cancer 
6 131915340 131915340 A G MED23 p.L1050P TCGA-AA-3514 Cancer 
6 134495180 134495180 T C SGK1 p.Q159R TCGA-AA-3514 Cancer 
6 134495661 134495661 T A SGK1 p.Y142F TCGA-FG-7637 Cancer 
6 135510953 135510953 C T MYB p.H80Y TCGA-25-1634 Cancer 
6 136588182 136588182 G T BCLAF1 p.S843R TCGA-AG-3608 Cancer 
6 136596792 136596792 T C BCLAF1 p.H577R TCGA-06-1801 Cancer 
6 136599108 136599108 G A BCLAF1 p.T304I TCGA-BR-8286 Cancer 
6 136600941 136600941 G A BCLAF1 p.R22* TCGA-BF-A1PU Cancer 
6 136600997 136600997 C T BCLAF1 p.R3H TCGA-C8-A12T Cancer 
6 138195999 138195999 A G TNFAIP3 p.M105V TCGA-AA-A00W Cancer 
6 152332878 152332878 C T ESR1 p.S395F TCGA-AA-3517 Cancer 
6 157431662 157431662 G A ARID1B p.A767T TCGA-AO-A124 Cancer 
6 160103611 160103611 T A SOD2 p.N149Y TCGA-AA-3529 Cancer 
6 163987758 163987758 G T QKI p.V314L TCGA-GF-A2C7 Cancer 
7 6026386 6026390 TTACC - PMS2 p.S669fs TCGA-M7-A725 Cancer 
7 81331970 81331970 A C HGF p.I705S TCGA-AA-3534 Cancer 
7 90895939 90895940 - AA FZD1 p.P582fs TCGA-23-1021 Cancer 
7 95761141 95761141 G T SLC25A13 p.P503Q TCGA-EE-A2MH Cancer 
7 95761187 95761187 T G SLC25A13 p.K488Q TCGA-AA-3534 Cancer 
7 95799417 95799417 A C SLC25A13 p.D418E TCGA-16-1055 Cancer 
7 95818962 95818962 T C SLC25A13 p.K260R TCGA-12-1095 Cancer 
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7 98509802 98509802 C T TRRAP p.S722F TCGA-ER-A42L Cancer 
7 98601827 98601827 G A TRRAP p.V3428I TCGA-EE-A2MS Cancer 
7 98609871 98609871 C T TRRAP p.L3825F TCGA-62-8398 Cancer 
7 99359784 99359784 T C CYP3A4 p.K378R TCGA-AG-3608 Cancer 
7 101459313 101459313 G A CUX1 p.M1I TCGA-EE-A29S Cancer 
7 106509078 106509078 G T PIK3CG p.D358Y TCGA-DM-A1D0 Cancer 
7 116340189 116340189 C A MET p.P351T TCGA-AG-4009 Cancer 
7 140500174 140500174 G A BRAF p.S323L TCGA-06-2565 Cancer 
8 37697744 37697744 G A GPR124 p.E873K TCGA-25-1632 Cancer 
8 37698301 37698301 T C GPR124 p.I894T TCGA-AA-3518 Cancer 
8 37698364 37698364 C A GPR124 p.P915H TCGA-AK-3461 Cancer 
8 38282218 38282218 C G FGFR1 e6-1 TCGA-95-8494 Cancer 
8 41790240 41790240 G C KAT6A p.S1833C TCGA-AG-A016 Cancer 
8 41790454 41790454 T C KAT6A p.T1762A TCGA-76-6280 Cancer 
8 41791498 41791498 C T KAT6A p.E1414K TCGA-CI-6620 Cancer 
8 41836185 41836185 T G KAT6A p.N340H TCGA-13-0793 Cancer 
8 48690378 48690378 T A PRKDC p.M3970L TCGA-F4-6703 Cancer 
8 48769761 48769761 T A PRKDC p.I2188L TCGA-B2-4101 Cancer 
8 48775016 48775016 T C PRKDC p.N1945S TCGA-SI-A71Q Cancer 
8 48866386 48866386 A T PRKDC p.L201Q TCGA-AK-3428 Cancer 
8 55371005 55371005 G T SOX17 p.G103C TCGA-AG-3598 Cancer 
8 118812120 118812120 C T EXT1 p.R691H TCGA-A8-A08Z Cancer 
8 118831937 118831937 G T EXT1 p.A505D TCGA-13-0792 Cancer 
8 118831940 118831940 G T EXT1 p.A504E TCGA-36-1571 Cancer 
8 118831946 118831946 A T EXT1 p.V502E TCGA-36-1581 Cancer 
8 119122623 119122623 G C EXT1 p.I221M TCGA-AA-3514 Cancer 
9 328039 328039 C G DOCK8 p.H236Q TCGA-09-1666 Cancer 
9 328039 328039 C G DOCK8 p.H236Q TCGA-A6-2678 Cancer 
9 328039 328039 C G DOCK8 p.H236Q TCGA-AA-A01F Cancer 
9 328039 328039 C G DOCK8 p.H236Q TCGA-AG-3609 Cancer 
9 377046 377046 G A DOCK8 p.V691M TCGA-FS-A1ZD Cancer 
9 382560 382560 C A DOCK8 p.R817S TCGA-MP-A4SV Cancer 
9 390549 390549 T C DOCK8 p.F885L TCGA-E7-A5KE Cancer 
9 429741 429741 T G DOCK8 p.F1405V TCGA-AK-3434 Cancer 
9 434893 434893 T C DOCK8 p.V1566A TCGA-AA-3514 Cancer 
9 441358 441358 C T DOCK8 p.R1666W TCGA-BA-6869 Cancer 
9 8341773 8341773 T C PTPRD p.R1623G TCGA-DU-7302 Cancer 
9 8376030 8376030 C G PTPRD p.G1523R TCGA-25-1626 Cancer 
9 8376030 8376030 C G PTPRD p.G1523R TCGA-36-1575 Cancer 
9 8376030 8376030 C G PTPRD p.G1523R TCGA-B2-4101 Cancer 
9 8484252 8484252 C T PTPRD p.G1094R TCGA-AA-3514 Cancer 
9 8485885 8485885 T C PTPRD p.T978A TCGA-62-A46O Cancer 
9 8492883 8492883 G C PTPRD p.L816V TCGA-D1-A16N Cancer 
9 8521421 8521421 C T PTPRD p.A273T TCGA-BR-8289 Cancer 
9 21854709 21854709 T C MTAP p.F177S TCGA-AA-3514 Cancer 
9 21854709 21854709 T C MTAP p.F177S TCGA-AA-3549 Cancer 
9 21854709 21854709 T C MTAP p.F177S TCGA-AA-A00K Cancer 
9 21854709 21854709 T C MTAP p.F177S TCGA-AG-A016 Cancer 
9 21854823 21854823 T C MTAP p.I215T TCGA-13-0714 Cancer 
9 21971000 21971000 C A CDKN2A p.E120* TCGA-97-8174 Cancer 
9 32429452 32429452 T G ACO1 p.I507S TCGA-91-8499 Cancer 
9 32430482 32430482 A C ACO1 p.T546P TCGA-AG-A016 Cancer 
9 87356844 87356844 T C NTRK2 e9+2 TCGA-CV-A6JO Cancer 
9 93641155 93641155 T - SYK p.L501fs TCGA-CN-A63T Cancer 
9 98002969 98002969 G T FANCC p.Q103K TCGA-AG-A016 Cancer 
9 101891211 101891211 G C TGFBR1 p.V58L TCGA-16-1055 Cancer 
9 101894946 101894946 G A TGFBR1 p.D98N TCGA-19-1392 Cancer 
9 127933374 127933374 A G PPP6C p.I91T TCGA-AA-3514 Cancer 
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9 130270257 130270257 C T FAM129B p.E515K TCGA-CI-6620 Cancer 
9 130271277 130271277 C T FAM129B p.R432Q TCGA-HR-A2OG Cancer 
9 130286093 130286093 G T FAM129B p.L152I TCGA-DQ-7596 Cancer 
9 133730245 133730245 C A ABL1 p.T123N TCGA-AK-3460 Cancer 
9 133738305 133738305 G T ABL1 p.W254C TCGA-AG-3578 Cancer 
9 133759443 133759443 G A ABL1 p.R608H TCGA-DK-A2I1 Cancer 
9 133760339 133760339 G T ABL1 p.D907Y TCGA-FG-7637 Cancer 
9 135781005 135781005 G C TSC1 p.Q654E TCGA-CF-A3MI Cancer 
9 137300061 137300061 G A RXRA p.V116I TCGA-A7-A5ZV Cancer 
9 139390560 139390560 T C NOTCH1 p.Q2544R TCGA-K6-A3WQ Cancer 
9 139407901 139407901 C G NOTCH1 p.G766R TCGA-DK-A3X2 Cancer 
10 32307297 32307297 A C KIF5B p.L796V TCGA-AF-2689 Cancer 
10 32310198 32310198 C T KIF5B p.E684K TCGA-AA-A00K Cancer 
10 32310204 32310204 C T KIF5B p.E682K TCGA-CI-6620 Cancer 
10 43617434 43617434 T G RET p.F924C TCGA-AA-3520 Cancer 
10 43619174 43619174 C T RET p.P953S TCGA-AK-3460 Cancer 
10 88676981 88676981 G A BMPR1A p.E256K TCGA-DK-A6B0 Cancer 
10 90770573 90770573 G A FAS e6+1 TCGA-13-1410 Cancer 
10 96281821 96281821 T G TBC1D12 p.F624C TCGA-13-0802 Cancer 
10 96281821 96281821 T G TBC1D12 p.F624C TCGA-23-1028 Cancer 
10 96281821 96281821 T G TBC1D12 p.F624C TCGA-24-1553 Cancer 
10 96612671 96612671 A G CYP2C19 p.*491W TCGA-36-1577 Cancer 
10 101558976 101558976 A C ABCC2 p.K294Q TCGA-AA-A01Q Cancer 
10 101559128 101559128 G C ABCC2 e8+1 TCGA-AG-A016 Cancer 
10 101567937 101567937 T C ABCC2 p.L589P TCGA-DX-A6YV Cancer 
10 101569918 101569918 A G ABCC2 p.K615E TCGA-13-0717 Cancer 
10 101954183 101954183 T C CHUK p.S609G TCGA-36-1577 Cancer 
10 101981904 101981904 T C CHUK p.K117R TCGA-24-1544 Cancer 
10 101981905 101981905 T C CHUK p.K117E TCGA-36-1571 Cancer 
10 104359222 104359222 G A SUFU p.G315R TCGA-EX-A1H5 Cancer 
10 104595083 104595083 G A CYP17A1 p.Q122* TCGA-AX-A06J Cancer 
10 120809315 120809315 T C EIF3A p.K886E TCGA-25-1633 Cancer 
10 120816340 120816340 C G EIF3A p.R703P TCGA-AA-A00D Cancer 
10 120816341 120816341 G C EIF3A p.R703G TCGA-AA-A00U Cancer 
10 123256084 123256084 G T FGFR2 p.Q610K TCGA-24-1548 Cancer 
10 123274681 123274681 G T FGFR2 p.P414T TCGA-AG-3598 Cancer 
11 534250 534250 G T HRAS p.Q25K TCGA-EE-A2GR Cancer 
11 9450599 9450599 T G IPO7 p.F483V TCGA-AK-3428 Cancer 
11 9452479 9452479 A T IPO7 p.K604* TCGA-AA-3514 Cancer 
11 44129500 44129500 C G EXT2 p.R113G TCGA-24-1614 Cancer 
11 44129650 44129650 T C EXT2 p.Y163H TCGA-AA-A00D Cancer 
11 44129650 44129650 T C EXT2 p.Y163H TCGA-AF-2689 Cancer 
11 64540948 64540948 T C SF1 p.K189E TCGA-AA-A00K Cancer 
11 77931484 77931484 G T GAB2 p.P590T TCGA-12-1091 Cancer 
11 88924547 88924547 G A TYR p.D333N TCGA-AF-2689 Cancer 
11 92495335 92495335 C T FAT3 p.T1328M TCGA-HU-8245 Cancer 
11 92507249 92507249 G T FAT3 p.G1413V TCGA-23-1026 Cancer 
11 92507249 92507249 G T FAT3 p.G1413V TCGA-25-1324 Cancer 
11 92577800 92577800 G A FAT3 p.G91D TCGA-GM-A2DH Cancer 
11 92623878 92623878 G T FAT3 p.E760* TCGA-86-8359 Cancer 
11 106558328 106558328 T C GUCY1A2 p.K747E TCGA-AA-3518 Cancer 
11 106579331 106579331 C T GUCY1A2 p.R664H TCGA-AA-A00K Cancer 
11 106680775 106680775 G C GUCY1A2 p.L546V TCGA-AA-A00D Cancer 
11 106681104 106681104 C T GUCY1A2 p.R436Q TCGA-CI-6620 Cancer 
11 106810299 106810299 C T GUCY1A2 p.E365K TCGA-97-7552 Cancer 
11 108117691 108117691 G T ATM p.G301V TCGA-BG-A0VZ Cancer 
11 108117798 108117798 C T ATM p.R337C TCGA-52-7812 Cancer 
11 108141790 108141790 G C ATM e18-1 TCGA-A2-A0CS Cancer 
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11 108142001 108142001 G A ATM p.R982H TCGA-AK-3456 Cancer 
11 108173700 108173700 T G ATM p.L1814V TCGA-26-1440 Cancer 
11 108186639 108186639 G A ATM NULL TCGA-CV-7101 Cancer 
11 108192065 108192065 G A ATM p.E2164K TCGA-GU-A767 Cancer 
11 108201099 108201099 C T ATM p.S2489F TCGA-85-8351 Cancer 
11 108213988 108213988 T G ATM p.C2770G TCGA-78-8655 Cancer 
11 108216546 108216546 G A ATM p.R2832H TCGA-AO-A0J3 Cancer 
11 108218084 108218084 T C ATM p.I2888T TCGA-G2-A2EC Cancer 
11 111228223 111228223 C A POU2AF1 p.G135W TCGA-25-1634 Cancer 
12 402089 402089 C T KDM5A p.A1568T TCGA-AK-3434 Cancer 
12 936232 936232 G A WNK1 p.M319I TCGA-D1-A103 Cancer 
12 974498 974498 C T WNK1 p.R788C TCGA-GM-A3XL Cancer 
12 977270 977270 A G WNK1 p.N878S TCGA-EI-6881 Cancer 
12 994511 994511 C T WNK1 p.S2012F TCGA-CI-6620 Cancer 
12 995105 995105 C T WNK1 p.P2210L TCGA-06-2569 Cancer 
12 1025575 1025575 T G RAD52 p.Q267P TCGA-25-1317 Cancer 
12 18719891 18719891 A C PIK3C2G p.H1304P TCGA-13-0802 Cancer 
12 18719891 18719891 A C PIK3C2G p.H1304P TCGA-25-1324 Cancer 
12 40702988 40702988 G A LRRK2 p.G1424R TCGA-12-1098 Cancer 
12 40714859 40714859 T G LRRK2 p.I1680R TCGA-AG-3574 Cancer 
12 40734202 40734202 G A LRRK2 p.G2019S TCGA-09-0369 Cancer 
12 46211492 46211492 A T ARID2 p.N153I TCGA-AA-3555 Cancer 
12 46298778 46298778 T C ARID2 p.S1809P TCGA-09-1662 Cancer 
12 50029249 50029249 A G PRPF40B p.K401R TCGA-AG-3594 Cancer 
12 52387811 52387811 G A ACVR1B p.A479T TCGA-AG-3608 Cancer 
12 56487605 56487605 G A ERBB3 p.G513D TCGA-14-0867 Cancer 
12 56490607 56490607 C G ERBB3 p.Q751E TCGA-AA-3534 Cancer 
12 56492290 56492290 A C ERBB3 p.I116L TCGA-AA-A00Q Cancer 
12 56492296 56492296 T A ERBB3 p.W118R TCGA-13-0717 Cancer 
12 56492296 56492296 T A ERBB3 p.W118R TCGA-13-0793 Cancer 
12 56493451 56493451 C G ERBB3 p.N194K TCGA-04-1525 Cancer 
12 56495474 56495474 T C ERBB3 p.Y463H TCGA-AA-A00K Cancer 
12 57033003 57033003 T G ATP5B p.K448T TCGA-24-1614 Cancer 
12 57033003 57033003 T G ATP5B p.K448T TCGA-AA-A00D Cancer 
12 78392238 78392238 G A NAV3 p.A288T TCGA-FW-A5DX Cancer 
12 78415643 78415643 G A NAV3 e9+1 TCGA-FI-A2EY Cancer 
12 78515866 78515866 G C NAV3 p.G1299A TCGA-AX-A063 Cancer 
12 96131740 96131740 G C NTN4 p.F219L TCGA-24-1548 Cancer 
12 111884838 111884838 G A SH2B3 e3+1 TCGA-BH-A0B1 Cancer 
12 133202357 133202357 C G POLE e9-1 TCGA-23-2078 Cancer 
12 133250183 133250183 C T POLE p.R457Q TCGA-HB-A3YV Cancer 
13 20763395 20763408 
CCCTTGAT
GAACTT - GJB2 p.K105fs TCGA-D7-A6EV Cancer 
13 25016729 25016729 C T PARP4 p.R1181K TCGA-AX-A3GI Cancer 
13 25021323 25021323 A C PARP4 p.I1039R TCGA-MN-A4N1 Cancer 
13 26911726 26911726 T A CDK8 p.L51I TCGA-AA-A00K Cancer 
13 26975712 26975712 T C CDK8 p.V407A TCGA-AQ-A54N Cancer 
13 27216449 27216449 C A WASF3 p.C14* TCGA-12-1098 Cancer 
13 27246071 27246071 A G WASF3 p.K162R TCGA-AA-3517 Cancer 
13 103506156 103506156 C T ERCC5 p.T105M TCGA-13-0751 Cancer 
13 103519132 103519132 A T ERCC5 p.N824Y TCGA-AA-3514 Cancer 
14 21863247 21863247 G C CHD8 p.F1738L TCGA-12-0773 Cancer 
14 21867802 21867802 C T CHD8 p.S1627N TCGA-AP-A05H Cancer 
14 21869607 21869607 C A CHD8 p.K1376N TCGA-13-0901 Cancer 
14 21869607 21869607 C A CHD8 p.K1376N TCGA-AK-3433 Cancer 
14 21882512 21882512 T C CHD8 p.K697R TCGA-23-1026 Cancer 
14 62194229 62194229 G A HIF1A p.C234Y TCGA-86-8054 Cancer 
14 64716307 64716307 G C ESR2 p.H394Q TCGA-FI-A2F9 Cancer 
14 65543274 65543274 C T MAX p.D72N TCGA-AP-A0LL Cancer 
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14 95556866 95556866 T C DICER1 p.K811R TCGA-KQ-A41R Cancer 
14 95557596 95557596 C A DICER1 p.G722V TCGA-AR-A0TP Cancer 
14 95570161 95570161 A T DICER1 p.L89* TCGA-24-0968 Cancer 
14 95577701 95577701 G C DICER1 p.P737A TCGA-ER-A194 Cancer 
14 103342756 103342756 A C TRAF3 p.E155A TCGA-AG-3578 Cancer 
15 31795960 31795960 C T OTUD7A p.A319T TCGA-FI-A3PV Cancer 
15 40488922 40488922 T C BUB1B p.F426S TCGA-AA-3514 Cancer 
15 41961438 41961438 G C MGA p.D116H TCGA-25-1318 Cancer 
15 41961453 41961453 T G MGA p.Y121D TCGA-24-0968 Cancer 
15 41999973 41999973 A G MGA p.K746E TCGA-62-8395 Cancer 
15 42002979 42002979 A G MGA p.E839G TCGA-D5-6540 Cancer 
15 43701940 43701940 C T TP53BP1 e25-1 TCGA-19-0960 Cancer 
15 43738687 43738687 A G TP53BP1 p.S980P TCGA-AA-3561 Cancer 
15 43748399 43748399 C A TP53BP1 p.A803S TCGA-06-2569 Cancer 
15 66727463 66727463 T G MAP2K1 p.V60G TCGA-A8-A08O Cancer 
15 67462920 67462920 G A SMAD3 p.M212I TCGA-13-1498 Cancer 
15 75644493 75644493 G A NEIL1 p.R159Q TCGA-CL-5917 Cancer 
15 75682073 75682073 C T SIN3A p.D981N TCGA-AX-A06F Cancer 
15 75705208 75705208 G T SIN3A p.P218T TCGA-X6-A7WA Cancer 
15 75722679 75722679 T C SIN3A p.Y13C TCGA-HT-A74K Cancer 
15 80450402 80450402 C G FAH p.P28A TCGA-50-5946 Cancer 
15 89811667 89811667 C T FANCI p.R265C TCGA-CI-6620 Cancer 
15 89826432 89826432 T G FANCI p.L550* TCGA-19-0962 Cancer 
15 91333927 91333927 G A BLM p.V958M TCGA-HE-A5NI Cancer 
15 91346838 91346838 T A BLM p.L1149Q TCGA-AF-3400 Cancer 
15 99459339 99459339 C T IGF1R p.R659W TCGA-62-8395 Cancer 
15 99491888 99491888 G A IGF1R p.V1225I TCGA-BG-A0VT Cancer 
15 99500663 99500663 A C IGF1R p.T1366P TCGA-24-1419 Cancer 
16 2012148 2012149 - C RPS2 p.T278fs TCGA-AX-A06J Cancer 
16 2134230 2134230 C T TSC2 p.S1280L TCGA-NH-A50T Cancer 
16 3807376 3807376 T A CREBBP p.Y1204F TCGA-24-1463 Cancer 
16 3843590 3843590 T G CREBBP p.Q338P TCGA-AG-A016 Cancer 
16 3860609 3860609 T G CREBBP p.N324H TCGA-AA-3529 Cancer 
16 9857058 9857058 C G GRIN2A p.C1448S TCGA-A2-A04T Cancer 
16 9923491 9923491 A G GRIN2A p.F599S TCGA-19-1392 Cancer 
16 9928022 9928022 C G GRIN2A p.V573L TCGA-29-1761 Cancer 
16 14015889 14015889 A G ERCC4 p.E70G TCGA-AA-3514 Cancer 
16 14015897 14015897 A G ERCC4 p.I73V TCGA-55-8094 Cancer 
16 14029464 14029464 G A ERCC4 p.G559S TCGA-13-0802 Cancer 
16 50261778 50261778 C T PAPD5 p.P485L TCGA-24-1469 Cancer 
16 50820790 50820790 A C CYLD p.K655N TCGA-24-1553 Cancer 
16 56862935 56862935 G T NUP93 p.A281S TCGA-AG-3583 Cancer 
16 67645910 67645910 A C CTCF p.N280H TCGA-12-1095 Cancer 
16 67645910 67645910 A C CTCF p.N280H TCGA-AG-3584 Cancer 
16 72821572 72821572 C T ZFHX3 p.E3535K TCGA-CI-6620 Cancer 
16 72827585 72827585 G C ZFHX3 p.A2999G TCGA-24-1614 Cancer 
16 72829588 72829588 T G ZFHX3 p.K2331N TCGA-25-1625 Cancer 
16 72831356 72831356 G T ZFHX3 p.A1742E TCGA-ER-A42L Cancer 
16 72831357 72831357 C G ZFHX3 p.A1742P TCGA-ER-A42L Cancer 
16 72923831 72923831 C G ZFHX3 p.G1083R TCGA-24-1548 Cancer 
16 72923831 72923831 C G ZFHX3 p.G1083R TCGA-AA-3514 Cancer 
16 72923831 72923831 C G ZFHX3 p.G1083R TCGA-AA-A00K Cancer 
16 72923831 72923831 C G ZFHX3 p.G1083R TCGA-AA-A00W Cancer 
16 72991497 72991497 G C ZFHX3 p.L850V TCGA-A6-2678 Cancer 
16 72992414 72992414 G A ZFHX3 p.S544L TCGA-24-2254 Cancer 
16 89871744 89871744 C T FANCA p.C218Y TCGA-AX-A06F Cancer 
16 89986377 89986378 - A MC1R p.G238fs TCGA-AO-A125 Cancer 
16 89986432 89986432 C T MC1R p.P256S TCGA-A5-A2K2 Cancer 
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17 7217411 7217411 G T GPS2 p.L129I TCGA-24-1548 Cancer 
17 7976585 7976585 G A ALOX12B p.P603S TCGA-AX-A05U Cancer 
17 7984061 7984061 T A ALOX12B p.N189Y TCGA-AX-A3G6 Cancer 
17 7989439 7989439 A G ALOX12B p.Y83H TCGA-AK-3461 Cancer 
17 8108584 8108584 G T AURKB p.P230T TCGA-19-0955 Cancer 
17 8108590 8108590 C T AURKB p.G228R TCGA-16-1055 Cancer 
17 8110150 8110150 A G AURKB p.L111S TCGA-CU-A3QU Cancer 
17 15989715 15989715 C T NCOR1 p.E1020K TCGA-AX-A06F Cancer 
17 16004574 16004574 C T NCOR1 p.E894K TCGA-CI-6620 Cancer 
17 16055265 16055265 G C NCOR1 p.I279M TCGA-HT-A74O Cancer 
17 18188820 18188820 G A TOP3A p.H538Y TCGA-FI-A2EW Cancer 
17 18196026 18196026 C G TOP3A p.R405P TCGA-AA-A00R Cancer 
17 33446607 33446607 C G RAD51D p.C9S TCGA-AX-A3FV Cancer 
17 37671989 37671989 T C CDK12 p.I925T TCGA-AG-3575 Cancer 
17 37687081 37687081 T C CDK12 p.S1329P TCGA-25-1623 Cancer 
17 37866713 37866713 A C ERBB2 p.S264R TCGA-AK-3428 Cancer 
17 38508209 38508209 G C RARA p.E189Q TCGA-23-2645 Cancer 
17 38508630 38508630 C G RARA p.D242E TCGA-24-1474 Cancer 
17 40478145 40478145 T A STAT3 p.I452F TCGA-AK-3431 Cancer 
17 40478177 40478177 A G STAT3 p.F441S TCGA-AA-A00K Cancer 
17 40489511 40489511 G A STAT3 p.Q247* TCGA-AX-A05S Cancer 
17 40860072 40860072 G T EZH1 p.Q452K TCGA-JV-A5VF Cancer 
17 40870492 40870492 T A EZH1 p.K234I TCGA-24-1544 Cancer 
17 40872469 40872469 T C EZH1 e4-2 TCGA-EE-A29E Cancer 
17 40880863 40880863 G A EZH1 p.Q33* TCGA-EE-A29E Cancer 
17 41219694 41219694 C A BRCA1 p.A160S TCGA-E9-A1NI Cancer 
17 41276054 41276054 T G BRCA1 p.K20N TCGA-AG-3605 Cancer 
17 41606916 41606916 A C ETV4 p.W323G TCGA-25-1634 Cancer 
17 41606916 41606916 A C ETV4 p.W323G TCGA-A6-2676 Cancer 
17 41610714 41610714 G A ETV4 p.A90V TCGA-24-1103 Cancer 
17 47684672 47684672 G T SPOP p.Y259* TCGA-09-1659 Cancer 
17 47684672 47684672 G T SPOP p.Y259* TCGA-24-0968 Cancer 
17 47684672 47684672 G T SPOP p.Y259* TCGA-AA-A00A Cancer 
17 47684672 47684672 G T SPOP p.Y259* TCGA-AK-3431 Cancer 
17 47684672 47684672 G T SPOP p.Y259* TCGA-AK-3433 Cancer 
17 47688785 47688785 C T SPOP p.G172D TCGA-12-1095 Cancer 
17 47688789 47688789 A C SPOP p.S171A TCGA-AG-3575 Cancer 
17 48453303 48453303 C A EME1 p.P245Q TCGA-EY-A3L3 Cancer 
17 48453480 48453480 G T EME1 p.E277* TCGA-AG-3609 Cancer 
17 56056645 56056645 T G VEZF1 p.K327Q TCGA-DA-A3F8 Cancer 
17 56435456 56435456 G A RNF43 p.R434W TCGA-A1-A0SK Cancer 
17 56492733 56492733 A C RNF43 p.F69C TCGA-AA-3514 Cancer 
17 56492767 56492767 T C RNF43 p.T58A TCGA-D1-A0ZP Cancer 
17 57134243 57134243 T C TRIM37 p.I398V TCGA-DF-A2KS Cancer 
17 58711254 58711254 C G PPM1D p.R248G TCGA-19-2621 Cancer 
17 58734152 58734152 C G PPM1D p.Q404E TCGA-29-1703 Cancer 
17 58734323 58734323 T G PPM1D p.*431G TCGA-24-0970 Cancer 
17 58740439 58740439 T - PPM1D p.L450fs TCGA-D3-A5GL Cancer 
17 58740498 58740498 C G PPM1D p.S468* TCGA-D1-A16D Cancer 
17 58740529 58740529 C A PPM1D p.C478* TCGA-29-2427 Cancer 
17 58740626 58740626 A C PPM1D p.K511Q TCGA-36-1571 Cancer 
17 58740653 58740653 C T PPM1D p.Q520* TCGA-A7-A0CH Cancer 
17 58740739 58740739 G - PPM1D p.K549fs TCGA-HD-A6HZ Cancer 
17 58740891 58740891 G A PPM1D p.R599K TCGA-12-0707 Cancer 
17 59858270 59858270 T G BRIP1 p.K575N TCGA-19-0955 Cancer 
17 60558565 60558565 A G TLK2 p.K27E TCGA-AG-A016 Cancer 
17 63010560 63010560 G C GNA13 p.H222D TCGA-09-1662 Cancer 
17 63526198 63526198 C T AXIN2 p.D810N TCGA-06-2569 Cancer 
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17 63533601 63533601 T C AXIN2 p.Y518C TCGA-AO-A0J2 Cancer 
17 63534452 63534452 G A AXIN2 p.R357C TCGA-77-A5GH Cancer 
17 66519018 66519018 T C PRKAR1A p.I100T TCGA-24-1558 Cancer 
17 78681694 78681694 C A RPTOR p.C134* TCGA-25-1632 Cancer 
17 78923324 78923324 C T RPTOR p.S1116L TCGA-CI-6620 Cancer 
18 10471569 10471569 C A APCDD1 p.Y95* TCGA-BG-A18C Cancer 
18 10487664 10487664 G A APCDD1 p.A392T TCGA-FG-7634 Cancer 
18 12686307 12686307 T C CEP76 p.K359R TCGA-AA-A00K Cancer 
18 31251726 31251726 A C ASXL3 p.N204T TCGA-04-1530 Cancer 
18 31323321 31323321 A G ASXL3 p.N1170S TCGA-EJ-A65F Cancer 
18 39576644 39576644 G T PIK3C3 p.E312* TCGA-B2-4101 Cancer 
18 48593472 48593472 T G SMAD4 p.F408C TCGA-AA-3534 Cancer 
18 48604664 48604664 C T SMAD4 p.R496C TCGA-CI-6620 Cancer 
18 56246661 56246661 A C ALPK2 p.Y449* TCGA-AA-A00K Cancer 
19 1440165 1440165 C G RPS15 p.H86Q TCGA-EE-A29N Cancer 
19 10599903 10599903 C T KEAP1 p.G558E TCGA-86-8359 Cancer 
19 11123688 11123688 G A SMARCA4 p.E780K TCGA-25-1318 Cancer 
19 11123688 11123688 G A SMARCA4 p.E780K TCGA-25-1625 Cancer 
19 11132584 11132584 A G SMARCA4 p.K934E TCGA-AK-3461 Cancer 
19 11138599 11138599 C T SMARCA4 p.R1119C TCGA-CI-6620 Cancer 
19 11169476 11169476 A G SMARCA4 p.N1548D TCGA-AR-A0U3 Cancer 
19 15273355 15273355 C T NOTCH3 p.W1945* TCGA-G9-6339 Cancer 
19 15276741 15276741 C T NOTCH3 p.A1842T TCGA-AX-A06J Cancer 
19 15276834 15276834 C T NOTCH3 p.D1811N TCGA-AF-2689 Cancer 
19 15290896 15290896 C G NOTCH3 p.G1105A TCGA-AQ-A54N Cancer 
19 15302421 15302421 C T NOTCH3 p.A284T TCGA-BR-A4QL Cancer 
19 18273902 18273902 A G PIK3R2 p.Q412R TCGA-23-1021 Cancer 
19 30312631 30312631 A C CCNE1 p.E189D TCGA-13-0889 Cancer 
19 30314634 30314634 A C CCNE1 p.T380P TCGA-AX-A1CC Cancer 
19 31770488 31770488 C T TSHZ3 p.E71K TCGA-CI-6620 Cancer 
19 36503951 36503951 T C ALKBH6 p.K60R TCGA-13-0717 Cancer 
19 36503951 36503951 T C ALKBH6 p.K60R TCGA-AG-3608 Cancer 
19 40746019 40746019 T C AKT2 e4-2 TCGA-AA-3821 Cancer 
19 40771132 40771132 G A AKT2 p.R15C TCGA-13-0792 Cancer 
19 41754431 41754431 G A AXL p.G249D TCGA-97-8174 Cancer 
19 41758288 41758288 T C AXL p.F314L TCGA-25-1634 Cancer 
19 41758862 41758862 A C AXL p.D371A TCGA-AO-A129 Cancer 
19 41762429 41762429 C A AXL p.Y435* TCGA-04-1331 Cancer 
19 41762429 41762429 C A AXL p.Y435* TCGA-BH-A0E0 Cancer 
19 45858928 45858928 T A ERCC2 p.D513V TCGA-AP-A0LL Cancer 
19 45871892 45871892 G T ERCC2 p.P119H TCGA-EE-A20I Cancer 
19 45873458 45873458 G T ERCC2 p.P13Q TCGA-D3-A3C3 Cancer 
19 45917294 45917294 T C ERCC1 e7-2 TCGA-15-0742 Cancer 
19 45920082 45920082 C G ERCC1 p.W200S TCGA-AA-3514 Cancer 
19 52714694 52714694 T A PPP2R1A p.F151Y TCGA-AG-3598 Cancer 
20 9561389 9561389 A T PAK7 p.Y131* TCGA-L9-A443 Cancer 
20 30370135 30370135 G T TPX2 p.A416S TCGA-25-1625 Cancer 
20 39725965 39725965 T C TOP1 p.F279S TCGA-23-1028 Cancer 
20 39726949 39726949 G A TOP1 p.R316Q TCGA-AX-A05S Cancer 
20 49509761 49509761 T C ADNP p.Y497C TCGA-EE-A2GP Cancer 
20 57484421 57484421 G A GNAS p.R844H TCGA-67-4679 Cancer 
20 57484421 57484421 G A GNAS p.R844H TCGA-D6-A4Z9 Cancer 
20 57484421 57484421 G A GNAS p.R844H TCGA-EY-A1GU Cancer 
20 57484739 57484739 A G GNAS p.D883G TCGA-CU-A72E Cancer 
20 61537287 61537287 C T DIDO1 p.V514I TCGA-AX-A064 Cancer 
20 61541236 61541236 C A DIDO1 p.D326Y TCGA-AK-3433 Cancer 
20 62331866 62331866 C T ARFRP1 p.G179S TCGA-62-8398 Cancer 
21 30693746 30693746 C T BACH1 p.R49W TCGA-AA-3518 Cancer 
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21 39763607 39763607 T G ERG p.K289T TCGA-14-0783 Cancer 
22 21288357 21288357 C A CRKL p.P201Q TCGA-AA-A01G Cancer 
22 22127223 22127223 A G MAPK1 p.I302T TCGA-FS-A1ZC Cancer 
22 22142564 22142564 G T MAPK1 p.P280T TCGA-36-1568 Cancer 
22 22142564 22142564 G T MAPK1 p.P280T TCGA-36-1578 Cancer 
22 22142591 22142591 T G MAPK1 p.N271H TCGA-23-1028 Cancer 
22 22142591 22142591 T G MAPK1 p.N271H TCGA-36-1578 Cancer 
22 29106018 29106019 - A CHEK2 p.E318fs TCGA-UF-A7JF Cancer 
22 29695627 29695627 G T EWSR1 p.G578* TCGA-BR-A4J2 Cancer 
22 29696113 29696113 G T EWSR1 p.G650C TCGA-12-0707 Cancer 
22 29696120 29696120 A G EWSR1 p.H652R TCGA-AA-3514 Cancer 
22 30050686 30050686 T C NF2 p.L163S TCGA-AA-3514 Cancer 
22 41531828 41531828 A G EP300 p.M514V TCGA-42-2593 Cancer 
22 41568555 41568555 C T EP300 p.P1502L TCGA-13-0717 Cancer 
22 41573538 41573538 G T EP300 p.Q1941H TCGA-AG-A016 Cancer 
22 42522940 42522940 C T CYP2D6 p.E410K TCGA-BG-A0M6 Cancer 
22 42526656 42526657 - A CYP2D6 p.L47fs TCGA-C8-A1HO Cancer 
X 15833799 15833799 G A ZRSR2 e8-1 TCGA-EJ-7330 Cancer 
X 15836711 15836711 T A ZRSR2 p.V258D TCGA-D9-A1JW Cancer 
X 15836766 15836766 G C ZRSR2 e9+1 TCGA-D7-8574 Cancer 
X 15840902 15840902 T C ZRSR2 p.L329P TCGA-CD-5798 Cancer 
X 19389468 19389468 C T MAP3K15 p.D929N TCGA-A1-A0SO Cancer 
X 19418771 19418771 A C MAP3K15 p.L451V TCGA-12-1095 Cancer 
X 41205637 41205637 A G DDX3X p.K491E TCGA-CQ-6218 Cancer 
X 41205659 41205659 C A DDX3X p.T498K TCGA-AO-A129 Cancer 
X 47028716 47028716 G A RBM10 p.G7D TCGA-AA-3514 Cancer 
X 48549524 48549524 G T WAS p.E494* TCGA-A6-2676 Cancer 
X 48650377 48650377 C T GATA1 p.S116F TCGA-CI-6620 Cancer 
X 53222394 53222394 T C KDM5C p.K1480E TCGA-24-1548 Cancer 
X 53222723 53222723 C T KDM5C p.E1405K TCGA-DM-A1HB Cancer 
X 53225129 53225129 C A KDM5C p.R1030L TCGA-24-1548 Cancer 
X 66941763 66941763 C A AR p.Q803K TCGA-B2-4101 Cancer 
X 70603001 70603001 A C TAF1 p.K644T TCGA-13-0793 Cancer 
X 70603001 70603001 A C TAF1 p.K644T TCGA-36-1578 Cancer 
X 70683864 70683864 G C TAF1 p.A1897P TCGA-AG-A016 Cancer 
X 76912120 76912120 A G ATRX p.S1382P TCGA-AG-A016 Cancer 
X 76938973 76938973 G T ATRX p.P592H TCGA-25-1329 Cancer 
X 79948443 79948443 C T BRWD3 p.V1087I TCGA-AJ-A2QO Cancer 
X 79955530 79955530 C A BRWD3 p.V957F TCGA-12-1098 Cancer 
X 79973218 79973218 G T BRWD3 p.N695K TCGA-AA-3549 Cancer 
X 100611209 100611209 T A BTK p.K466M TCGA-36-1568 Cancer 
X 100613379 100613379 G T BTK p.Q341K TCGA-AG-3598 Cancer 
X 102755278 102755278 A C RAB40A p.V136G TCGA-AR-A0TZ Cancer 
X 106221416 106221416 C T MORC4 p.R317K TCGA-CI-6620 Cancer 
X 106224209 106224209 A G MORC4 p.I283T TCGA-13-0761 Cancer 
X 110406153 110406153 C G PAK3 p.T196R TCGA-AF-2691 Cancer 
X 110439743 110439743 T G PAK3 p.W464G TCGA-25-1324 Cancer 
X 119666287 119666287 A C CUL4B p.M828R TCGA-A6-2678 Cancer 
X 119673152 119673152 T G CUL4B p.K589T TCGA-13-1408 Cancer 
X 129147539 129147539 C G BCORL1 p.S264* TCGA-EJ-5526 Cancer 
X 129148664 129148664 G A BCORL1 p.R639H TCGA-DD-A4NJ Cancer 
X 129171468 129171468 C T BCORL1 p.H1552Y TCGA-A7-A3J0 Cancer 
X 132795817 132795817 T C GPC3 p.M475V TCGA-13-0717 Cancer 
X 132795817 132795817 T C GPC3 p.M475V TCGA-AA-3561 Cancer 
X 132887636 132887636 G T GPC3 p.S302Y TCGA-26-5135 Cancer 
X 153993198 153993198 A G DKC1 p.K14R TCGA-JW-A5VK Cancer 




Supplementary Table 4.3: 26 significantly mutated genes identified in normal blood samples  












LRT FDR CT 
DNMT3A 5 86 91 8.40 0 0 0 0 0 0 
JAK2 0 17 17 1.68 0 0 6.76E-21 5.71E-11 0 8.15E-17 
ASXL1 3 18 21 1.58 0 0 3.54E-20 4.15E-11 0 2.85E-16 
TET2 5 17 22 0.80 0 1.15E-12 3.93E-17 6.01E-09 5.57E-09 2.37E-13 
IDH2 0 10 10 2.96 0 0 4.23E-15 4.70E-07 0 2.04E-11 
PPM1D 2 8 10 2.41 0 6.21E-10 4.49E-12 8.78E-05 1.87E-06 1.81E-08 
SF3B1 0 17 17 1.42 0 1.28E-10 1.25E-11 8.78E-05 4.40E-07 4.31E-08 
ZNF318 0 16 16 1.05 0 2.37E-07 4.73E-09 0.0076 0.0003 1.42E-05 
MYH4 1 13 14 0.99 0 1.15E-06 5.82E-09 0.0090 0.0010 1.56E-05 
PCMTD1 0 7 7 1.17 0 5.71E-09 1.88E-08 0.0400 1.38E-05 4.54E-05 
PTN 0 6 6 4.80 0 7.34E-08 5.11E-08 0.1549 0.0001 0.0001 
FRG1B 0 8 8 2.50 0 6.06E-08 6.45E-08 0.1080 0.0001 0.0001 
GNB1 0 7 7 2.30 0 3.50E-09 8.49E-08 0.1094 9.38E-06 0.0002 
EMID2 0 6 6 1.98 0 1.24E-08 3.07E-07 0.2707 2.49E-05 0.0005 
TIE1 0 10 10 0.52 0 1.00E-10 3.97E-07 0.3141 4.02E-07 0.0006 
EPHB2 0 10 10 0.88 0 8.23E-08 8.06E-07 0.2707 0.0001 0.0011 
FRG1 0 8 8 1.85 0 7.49E-06 1.14E-06 0.5440 0.0042 0.0015 
ASH1L 0 16 16 0.71 0 3.08E-06 1.23E-06 0.2707 0.0022 0.0016 
ZKSCAN4 0 6 6 1.47 0 6.40E-09 2.69E-06 0.9941 1.40E-05 0.0031 
TMC1 0 8 8 1.06 0 5.50E-06 2.59E-06 0.6894 0.0035 0.0031 
EPPK1 0 10 10 0.78 0 2.94E-07 2.96E-06 0.6894 0.0003 0.0031 
SPOP 0 7 7 1.53 0 1.29E-06 2.95E-06 0.9420 0.0011 0.0031 
SLC9A4 0 7 7 1.22 0 1.35E-07 4.65E-06 1.0000 0.0002 0.0047 
MORC2 0 9 9 0.85 0 1.33E-07 6.99E-06 1.0000 0.0002 0.0066 
GBAS 0 7 7 1.75 0 8.27E-06 9.38E-06 1.0000 0.0045 0.0084 






Supplementary Table 4.4:  58 cancer-associated genes overlapped with blood specific somatic 
CNVs 
 Chr CNV Type Sample Genotype:QualityScore Gene Position Gene Name Blood Control 
1:120351324-120461178 Deletion TCGA-D3-A2JA 1:66 0:94,65 1:120457927-120612022 NOTCH2 
1:120460286-120502127 Deletion TCGA-AO-A03O 1:99 0:99,78 1:120457927-120612022 NOTCH2 
1:120461027-120471837 Deletion TCGA-GN-A268 1:99 0:84,99 1:120457927-120612022 NOTCH2 
1:120464857-120480635 Deletion TCGA-EE-A3AH 1:99 0:92,92 1:120457927-120612022 NOTCH2 
1:120464857-120480635 Deletion TCGA-ER-A19B 1:99 0:97,80 1:120457927-120612022 NOTCH2 
1:120483176-120484379 Deletion TCGA-D3-A1Q5 1:71 0:99,69 1:120457927-120612022 NOTCH2 
1:120506195-120509114 Deletion TCGA-99-8028 1:99 0:99,74 1:120457927-120612022 NOTCH2 
1:120506195-120509114 Deletion TCGA-DK-A3IK 1:64 0:92,84 1:120457927-120612022 NOTCH2 
1:120510698-120548213 Deletion TCGA-D3-A2JC 1:90 0:61,82 1:120457927-120612022 NOTCH2 
2:47635538-47705660 Deletion TCGA-AG-3906 1:76 0:72,97 2:47630329-47789452 MSH2 
2:48025748-48036407 Deletion TCGA-13-1498 1:75 0:95,90 2:48010307-48034001 MSH6 
2:48025748-48036407 Deletion TCGA-A8-A08Z 1:64 0:68,76 2:48010307-48034001 MSH6 
2:48025748-48046219 Deletion TCGA-13-1405 1:99 0:86,86 2:48010307-48034001 MSH6 
2:48025748-48046219 Deletion TCGA-A8-A06P 1:66 0:87,83 2:48010307-48034001 MSH6 
2:48025748-48049444 Deletion TCGA-13-1509 1:99 0:70,97 2:48010307-48034001 MSH6 
2:202122840-202123107 Deletion TCGA-41-3392 1:98 0:63,99 2:202098186-202151319 CASP8 
2:202136237-202153506 Deletion TCGA-A5-A0GJ 1:98 0:60,77 2:202098186-202151319 CASP8 
2:202136237-202154579 Deletion TCGA-BH-A0HX 1:99 0:63,95 2:202098186-202151319 CASP8 
2:202136237-202173975 Deletion TCGA-BH-A0HY 1:98 0:63,95 2:202098186-202151319 CASP8 
2:202137359-202150042 Deletion TCGA-A8-A07I 1:98 0:70,98 2:202098186-202151319 CASP8 
2:202137359-202172347 Deletion TCGA-13-0760 1:89 0:75,88 2:202098186-202151319 CASP8 
2:202151180-202195247 Deletion TCGA-B6-A0I8 1:89 0:87,69 2:202098186-202151319 CASP8 
5:56152425-56189509 Deletion TCGA-A6-2678 1:97 0:82,76 5:56111399-56189509 MAP3K1 
7:151876917-151884934 Deletion TCGA-A2-A0CX 1:81 0:83,93 7:151833915-152132873 MLL3 
7:151884345-152027829 Deletion TCGA-23-1809 1:93 0:70,91 7:151833915-152132873 MLL3 
7:151919656-151945707 Deletion TCGA-G4-6315 1:86 0:82,91 7:151833915-152132873 MLL3 
7:151970788-152027829 Deletion TCGA-19-1385 1:76 0:87,77 7:151833915-152132873 MLL3 
9:98221880-98718297 Deletion TCGA-97-8179 1:93 0:71,87 9:98209192-98279104 PTCH1 
9:135762754-135778176 Deletion TCGA-CN-5366 1:93 0:89,90 9:135771620-135820010 TSC1 
12:49436342-49460317 Deletion TCGA-09-1669 1:85 0:86,83 12:49415561-49449109 MLL2 
12:49444667-49448811 Deletion TCGA-25-1314 1:94 0:95,71 12:49415561-49449109 MLL2 
12:49444667-49449109 Deletion TCGA-13-0794 1:94 0:66,84 12:49415561-49449109 MLL2 
12:49446345-49449109 Deletion TCGA-36-1580 1:71 0:82,94 12:49415561-49449109 MLL2 
12:49446696-49460486 Deletion TCGA-BH-A0GZ 1:94 0:92,84 12:49415561-49449109 MLL2 
12:52369047-52374985 Deletion TCGA-13-0764 1:94 0:95,71 12:52345526-52387896 ACVR1B 
12:52385645-52407987 Deletion TCGA-09-1662 1:94 0:94,79 12:52345526-52387896 ACVR1B 
13:32928996-32945239 Deletion TCGA-20-0996 1:89 0:88,85 13:32890596-32972909 BRCA2 
13:48985523-49037973 Deletion TCGA-09-1668 1:87 0:94,75 13:48878047-49054785 RB1 
13:49033822-49281996 Deletion TCGA-DK-A6B0 1:95 0:85,80 13:48878047-49054785 RB1 
16:3786035-3860782 Deletion TCGA-A5-A0RA 1:97 0:84,79 16:3777717-3929919 CREBBP 
17:15965417-16220149 Deletion TCGA-UE-A6QU 1:98 0:68,93 17:15935608-16118717 NCOR1 
17:41243450-41256975 Deletion TCGA-C5-A1MQ 1:98 0:69,98 17:41197693-41277204 BRCA1 
18:45368196-45423129 Deletion TCGA-BH-A18I 1:98 0:90,90 18:45368196-45423129 SMAD2 
19:11105502-11123790 Deletion TCGA-13-0764 1:99 0:97,76 19:11094826-11175879 SMARCA4 
19:11105502-11123790 Deletion TCGA-13-0794 1:94 0:88,93 19:11094826-11175879 SMARCA4 
20:30816064-31294564 Deletion TCGA-DM-A1D6 1:66 0:94,64 20:30946577-31025143 ASXL1 
1:43806056-43818445 Duplication TCGA-A8-A08L 2:76 0:99,74 1:43803518-43818445 MPL 
1:65301077-65309900 Duplication TCGA-13-0794 2:99 0:80,99 1:65300243-65351949 JAK1 
1:226173001-226259182 Duplication TCGA-A6-2678 2:99 0:91,86 1:226252051-226259182 H3F3A 
2:178081229-178097313 Duplication TCGA-BH-A0GZ 2:62 0:97,60 2:178092632-178175735 NFE2L2 
2:198260778-198262842 Duplication TCGA-AX-A05S 2:78 0:84,98 2:198257025-198299725 SF3B1 
3:41268697-41277336 Duplication TCGA-09-0366 2:67 0:92,94 3:41265558-41301589 CTNNB1 
3:41274830-41280847 Duplication TCGA-AX-A06F 2:98 0:80,96 3:41265558-41301589 CTNNB1 
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3:41274830-41504746 Duplication TCGA-13-0794 2:85 0:85,87 3:41265558-41301589 CTNNB1 
3:178525125-178947232 Duplication TCGA-13-1497 2:96 0:75,87 3:178916612-178952154 PIK3CA 
3:178742803-178947232 Duplication TCGA-AX-A0J1 2:96 0:83,69 3:178916612-178952154 PIK3CA 
3:178742803-178957854 Duplication TCGA-BG-A0VT 2:98 0:69,93 3:178916612-178952154 PIK3CA 
3:178742803-178968780 Duplication TCGA-AG-3906 2:96 0:79,86 3:178916612-178952154 PIK3CA 
3:178745432-178957854 Duplication TCGA-AX-A0IW 2:97 0:79,77 3:178916612-178952154 PIK3CA 
4:1719877-1804881 Duplication TCGA-B6-A402 2:97 0:96,65 4:1795660-1809017 FGFR3 
4:55133454-55133910 Duplication TCGA-AX-A06F 2:97 .:62,97 4:55106218-55161441 PDGFRA 
4:55561676-55604725 Duplication TCGA-30-1891 2:97 0:93,68 4:55524180-55604725 KIT 
4:55561676-55604725 Duplication TCGA-32-2616 2:97 0:92,81 4:55524180-55604725 KIT 
5:149420309-149441233 Duplication TCGA-B6-A0IB 2:74 0:81,94 5:149433630-149465992 CSF1R 
7:2946270-2968334 Duplication TCGA-09-1661 2:95 0:88,89 7:2946270-2998142 CARD11 
7:54610422-55755619 Duplication TCGA-D1-A3DG 2:94 0:88,76 7:55086822-55273312 EGFR 
7:54820102-55273312 Duplication TCGA-DU-7290 2:94 0:88,74 7:55086822-55273312 EGFR 
7:55209977-55242515 Duplication TCGA-A8-A07U 2:71 0:87,78 7:55086822-55273312 EGFR 
7:55209977-55268108 Duplication TCGA-B5-A3S1 2:94 0:85,97 7:55086822-55273312 EGFR 
7:55209977-55496142 Duplication TCGA-D7-8576 2:94 0:89,88 7:55086822-55273312 EGFR 
7:55214297-55268108 Duplication TCGA-AP-A1E0 2:60 0:89,72 7:55086822-55273312 EGFR 
7:55214297-55863787 Duplication TCGA-AJ-A3NC 2:94 0:66,74 7:55086822-55273312 EGFR 
7:116339123-116436180 Duplication TCGA-09-1668 2:84 0:85,89 7:116335809-116436180 MET 
7:116380002-116403324 Duplication TCGA-S9-A6WE 2:94 0:79,91 7:116335809-116436180 MET 
9:5078304-5090913 Duplication TCGA-23-1029 2:62 0:73,93 9:4985031-5126976 JAK2 
9:5078304-5090913 Duplication TCGA-24-1842 2:94 0:94,67 9:4985031-5126976 JAK2 
9:5078304-5090913 Duplication TCGA-30-1855 2:94 0:92,85 9:4985031-5126976 JAK2 
9:5080227-5090913 Duplication TCGA-23-1111 2:63 0:84,93 9:4985031-5126976 JAK2 
9:5123002-5185604 Duplication TCGA-23-2081 2:94 0:60,93 9:4985031-5126976 JAK2 
10:123239563-123247629 Duplication TCGA-13-0794 2:70 0:77,95 10:123237876-123357588 FGFR2 
13:28608217-28608546 Duplication TCGA-AX-A064 2:83 0:86,95 13:28578082-28674649 FLT3 
13:28608217-28608546 Duplication TCGA-AX-A06B 2:95 0:76,95 13:28578082-28674649 FLT3 
13:28610070-28624361 Duplication TCGA-24-1843 2:95 0:92,66 13:28578082-28674649 FLT3 
14:81606021-81610699 Duplication TCGA-13-0794 2:68 0:91,95 14:81421331-81610699 TSHR 
15:90610368-90634878 Duplication TCGA-HU-A4GY 2:97 0:83,69 15:90627496-90645624 IDH2 
17:37783644-38080458 Duplication TCGA-62-8398 2:98 0:65,85 17:37855811-37886681 ERBB2 
17:37814656-37868302 Duplication TCGA-55-A493 2:98 0:82,79 17:37855811-37886681 ERBB2 
17:37880977-38027880 Duplication TCGA-DK-A2I2 2:98 0:63,91 17:37855811-37886681 ERBB2 
17:74729373-74739540 Duplication TCGA-DA-A1IA 2:82 0:86,97 17:74732241-74733244 SRSF2 
19:3114940-3121319 Duplication TCGA-CR-7389 2:97 0:98,84 19:3094645-3121434 GNA11 
19:10251455-10291563 Duplication TCGA-76-4928 2:99 0:86,80 19:10244025-10311561 DNMT1 
19:52671309-52705289 Duplication TCGA-AX-A05U 2:99 0:85,99 19:52693348-52729236 PPP2R1A 








Supplementary Table 4.5: Rare PPM1D truncation mutations in ExAC database  
Chr Start ID Reference Alternate Mutation Annotation Allele Frequency 
17 58734163 . T A p.Cys407Ter Nonsense 0.00000824 
17 58740432 . C G p.Ser446Ter Nonsense 0.00001648 
17 58740438 . T - p.Leu450Ter Frame-Shift 0.000008238 
17 58740467 . C T p.Arg458Ter Nonsense 0.00001648 
17 58740498 . C G p.Ser468Ter Nonsense 0.00000824 
17 58740529 rs146477590 C A p.Cys478Ter Nonsense 0.00003297 
17 58740532 . - A p.Ala481SerfsTer8 Frame-Shift 0.000008243 
17 58740532 . A - p.Ala481ProfsTer2 Frame-Shift 0.00001649 
17 58740601 . - A p.Ser503IlefsTer25 Frame-Shift 0.000008252 
17 58740623 . - A p.Asn512LysfsTer16 Frame-Shift 0.000008259 
17 58740623 . A - p.Asn512IlefsTer2 Frame-Shift 0.00002478 
17 58740653 . C T p.Gln520Ter Nonsense 0.000008261 
17 58740674 . G T p.Glu527Ter Nonsense 0.000008262 
17 58740676 . AG - p.Arg528AsnfsTer7 Frame-Shift 0.000008261 
17 58740713 rs138670032 G T p.Glu540Ter Nonsense 0.000008256 
17 58740749 . C T p.Arg552Ter Nonsense 0.000008249 
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